UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
10-K
|
|
|
þ
|
|
ANNUAL
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
For
the
fiscal year ended December 31, 2007
OR
|
|
|
o
|
|
TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF
1934
|
Commission
file number 000-26648
OPKO
HEALTH, INC.
(Exact
Name of Registrant as Specified in Its Charter)
|
|
|
DELAWARE
|
|
75-2402409
|
(State
or Other Jurisdiction of Incorporation or Organization)
|
|
(I.R.S.
Employer Identification No.)
|
4400
Biscayne Blvd., Suite 1180, Miami, FL 33137
(Address
of Principal Executive Offices, Zip Code)
Registrant’s
Telephone Number, Including Area Code: (305) 575-4138
Securities
registered pursuant to section 12(b) of the Act:
Title
of Each Class
|
|
Name
of Each Exchange on Which Registered
|
Common
Stock, $.01 par value per
share
|
|
American
Stock Exchange
|
Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined
in
Rule 405 of the Securities Act. Yes
¨
No
þ
Indicate
by check mark if the registrant is not required to file reports pursuant to
Section 13 or Section 15(d) of the Act. Yes
¨
No
þ
Indicate
by check mark whether the Registrant (1) has filed all reports required to
be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the
Registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. Yes
¨
No
þ
Indicate
by check mark if disclosures of delinquent filers pursuant to Item 405 of
Regulation S-K is not contained herein, and will not be contained, to the best
of registrant’s knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this Form 10-K or any amendment to
this Form 10-K.
¨
Indicate
by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company
(as
defined in Rule 12b-2 of the Exchange Act).
Large
Accelerated filer
¨
|
|
Accelerated
filer
¨
|
|
Non-Accelerated
filer
þ
|
|
Smaller
Reporting Company
¨
|
Indicate
by check mark whether the registrant is a shell company (as defined in
Rule 12b-2 Act). Yes
¨
No
þ
The
aggregate market value of the voting and non-voting common equity held by
non-affiliates computed by reference to the price at which the common equity
was
last sold, as of the last business day of the Registrant’s most recently
completed second fiscal quarter was: $236,986,298.
As
of
March 21, 2008 the registrant had 182,150,969 shares of common stock
outstanding.
Documents
Incorporated by Reference
Portions
of the registrant’s definitive proxy statement for its 2008 Annual Meeting of
Stockholders are incorporated by reference in Items 10, 11, 12, 13, and 14
of
Part III of this Annual Report on Form 10-K.
|
|
|
Page
|
Part
I.
|
|
|
|
|
|
|
|
Item
1.
|
Business
|
|
6
|
|
|
|
|
Item
1A.
|
Risk
Factors
|
|
23
|
|
|
|
|
Item
1B.
|
Unresolved
Staff Comments
|
|
39
|
|
|
|
|
Item
2.
|
Properties
|
|
39
|
|
|
|
|
Item
3.
|
Legal
Proceedings
|
|
39
|
|
|
|
|
Item
4.
|
Submission
of Matters to a Vote of Security Holders
|
|
39
|
|
|
|
|
Part
II.
|
|
|
|
|
|
|
|
Item
5.
|
Market
for Registrant’s Common Equity, Related Stockholder Matters and Issuer
Purchases of Equity Securities
|
|
41
|
|
|
|
|
Item
6.
|
Selected
Financial Data
|
|
42
|
|
|
|
|
Item
7.
|
Management’s
Discussion and Analysis of Financial Condition and Results of
Operations
|
|
43
|
|
|
|
|
Item
7A.
|
Quantitative
and Qualitative Disclosures about Market Risk
|
|
49
|
|
|
|
|
Item
8.
|
Financial
Statements and Supplementary Data
|
|
50
|
|
|
|
|
Item
9.
|
Changes
in and Disagreements with Accountants on Accounting and Financial
Disclosure
|
|
73
|
|
|
|
|
Item
9A(T).
|
Controls
and Procedures
|
|
73
|
|
|
|
|
Item
9B.
|
Other
Information
|
|
74
|
|
|
|
|
Part
III.
|
|
|
|
|
|
|
|
Item
10.
|
Directors,
Executive Officers and Corporate Governance
|
|
|
|
|
|
|
Item
11.
|
Executive
Compensation
|
|
|
|
|
|
|
Item
12.
|
Security
Ownership of Certain Beneficial Owners and Management and Related
Stockholder Matters
|
|
|
|
|
|
|
Item
13.
|
Certain
Relationships and Related Transactions, and Director
Independence
|
|
|
|
|
|
|
Item
14.
|
Principal
Accountants Fees and Services
|
|
|
|
|
|
|
Part
IV.
|
|
|
|
|
|
|
|
Item
15.
|
Exhibits,
Financial Statement Schedules
|
|
76
|
|
|
|
Signatures
|
|
78
|
|
|
|
Certifications
|
|
|
CAUTIONARY
STATEMENTS REGARDING FORWARD-LOOKING STATEMENTS
This
Annual Report on Form 10-K contains “forward-looking statements,” as that term
is defined under the Private Securities Reform Act of 1995, or PSLRA, Section
27A of the Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. Forward-looking statements include statements
about our expectations, beliefs or intentions regarding our product development
efforts, business, financial condition, results of operations, strategies or
prospects. You can identify forward-looking statements by the fact that these
statements do not relate strictly to historical or current matters. Rather,
forward-looking statements relate to anticipated or expected events, activities,
trends or results as of the date they are made. Because forward-looking
statements relate to matters that have not yet occurred, these statements are
inherently subject to risks and uncertainties that could cause our actual
results to differ materially from any future results expressed or implied by
the
forward-looking statements. Many factors could cause our actual activities
or
results to differ materially from the activities and results anticipated in
forward-looking statements. These factors include those described below and
in
“Item 1A-Risk Factors” of this Annual Report on Form 10-K. We do not undertake
any obligation to update forward-looking statements. We intend that all
forward-looking statements be subject to the safe-harbor provisions of the
PSLRA. These forward-looking statements are only predictions and reflect our
views as of the date they are made with respect to future events and financial
performance.
Risks
and
uncertainties, the occurrence of which could adversely affect our business,
include the following:
|
·
|
We
have a history of operating losses and we do not expect to become
profitable in the near future.
|
|
·
|
Our
technologies are in an early stage of development and are
unproven.
|
|
·
|
Our
drug research and development activities may not result in commercially
viable products.
|
|
·
|
We
are highly dependent on the success of our lead product candidate,
bevasiranib, and we cannot give any assurance that it will receive
regulatory approval or be successfully
commercialized.
|
|
·
|
The
results of previous clinical trials may not be predictive of future
results, and our current and planned clinical trials may not satisfy
the
requirements of the FDA or other non-United States regulatory
authorities.
|
|
·
|
We
will require substantial additional funding, which may not be available
to
us on acceptable terms, or at all.
|
|
·
|
If
our competitors develop and market products that are more effective,
safer
or less expensive than our future product candidates, our commercial
opportunities will be negatively
impacted.
|
|
·
|
The
regulatory approval process is expensive, time consuming and uncertain
and
may prevent us or our collaboration partners from obtaining approvals
for
the commercialization of some or all of our product
candidates.
|
|
·
|
Failure
to recruit and enroll patients for clinical trials may cause the
development of our product candidates to be
delayed.
|
|
·
|
Even
if we obtain regulatory approvals for our product candidates, the
terms of
approvals and ongoing regulation of our products may limit how we
manufacture and market our product candidates, which could materially
impair our ability to generate anticipated
revenues.
|
|
·
|
We
may not meet regulatory quality standards applicable to our manufacturing
and quality processes.
|
|
·
|
We
may be unable to resolve issues relating to an FDA warning letter
in a
timely manner.
|
|
·
|
Even
if we receive regulatory approval to market our product candidates,
the
market may not be receptive to our
products.
|
|
·
|
If
we fail to attract and retain key management and scientific personnel,
we
may be unable to successfully develop or commercialize our product
candidates.
|
|
·
|
As
we evolve from a company primarily involved in development to a company
also involved in commercialization, we may encounter difficulties
in
managing our growth and expanding our operations
successfully.
|
|
·
|
If
we fail to acquire and develop other products or product candidates
at all
or on commercially reasonable terms, we may be unable to diversify
or grow
our business.
|
|
·
|
We
have no experience manufacturing our pharmaceutical product candidates
and
we therefore rely on third parties to manufacture and supply our
pharmaceutical product candidates, and would need to meet various
standards necessary to satisfy FDA regulations when we commence
manufacturing.
|
|
·
|
We
currently have no pharmaceutical marketing, sales or distribution
organization. If we are unable to develop our sales and marketing
and
distribution capability on our own or through collaborations with
marketing partners, we will not be successful in commercializing
our
pharmaceutical product candidates.
|
|
·
|
Independent
clinical investigators and contract research organizations that we
engage
to conduct our clinical trials may not be diligent, careful or
timely.
|
|
·
|
The
success of our business may be dependent on the actions of our
collaborative partners.
|
|
·
|
If
we are unable to obtain and enforce patent protection for our products,
our business could be materially
harmed.
|
|
·
|
If
we are unable to protect the confidentiality of our proprietary
information and know-how, the value of our technology and products
could
be adversely affected.
|
|
·
|
We
will rely heavily on licenses from third
parties.
|
|
·
|
We
license patent rights to certain of our technology from third-party
owners. If such owners do not properly maintain or enforce the patents
underlying such licenses, our competitive position and business prospects
will be harmed.
|
|
·
|
Our
commercial success depends significantly on our ability to operate
without
infringing the patents and other proprietary rights of third
parties.
|
|
·
|
Medicare
prescription drug coverage legislation and future legislative or
regulatory reform of the health care system may affect our ability
to sell
our products profitably.
|
|
·
|
Failure
to obtain regulatory approval outside the United States will prevent
us
from marketing our product candidates
abroad.
|
|
·
|
Acquisitions
may disrupt our business, distract our management and may not proceed
as
planned; and we may encounter difficulties in integrating acquired
businesses.
|
|
·
|
Non-United
States governments often impose strict price controls, which may
adversely
affect our future profitability.
|
|
·
|
Our
business may become subject to economic, political, regulatory and
other
risks associated with international
operations.
|
|
·
|
The
market price of our common stock may fluctuate
significantly.
|
|
·
|
Directors,
executive officers, principal stockholders and affiliated entities
own a
significant percentage of our capital stock, and they may make decisions
that you do not consider to be in your best interests or in the best
interests of our stockholders.
|
|
·
|
Compliance
with changing regulations concerning corporate governance and public
disclosure may result in additional
expenses.
|
|
·
|
If
we are unable to satisfy the requirements of Section 404 of the
Sarbanes-Oxley Act of 2002, as they apply to us, or our internal
controls
over financial reporting are not effective, the reliability of our
financial statements may be questioned and our common stock price
may
suffer.
|
|
·
|
We
may be unable to maintain our listing on the American Stock Exchange,
which could cause our stock price to fall and decrease the liquidity
of
our common stock.
|
|
·
|
Future
issuances of common stock and hedging activities may depress the
trading
price of our common stock.
|
|
·
|
Provisions
in our charter documents and Delaware law could discourage an acquisition
of us by a third party, even if the acquisition would be favorable
to
you.
|
|
·
|
We
do not intend to pay cash dividends on our common stock in the foreseeable
future.
|
PART
I
Unless
the context otherwise requires, all references in this Annual Report on Form
10-K to the “Company”, “OPKO”, “we”, “our”, “ours”, and “us” refers to OPKO
Health, Inc., a Delaware corporation, including our wholly-owned
subsidiaries.
OVERVIEW
We
are a
specialty healthcare company focused on the discovery, development and
commercialization of proprietary pharmaceuticals, drug delivery technologies,
diagnostic systems, and instruments for the treatment, diagnosis and management
of ophthalmic disorders. Our business presently consists of the development
of
ophthalmic pharmaceuticals and the development, commercialization and sale
of
ophthalmic diagnostic and imaging systems and instrumentation products. Our
objective is to establish industry-leading positions in large and rapidly
growing segments of ophthalmology by leveraging our preclinical and development
expertise and our novel and proprietary technologies. We actively explore
opportunities to acquire complementary pharmaceuticals, compounds, and
technologies, which could, individually or in the aggregate, materially increase
the scale of our business. We also intend to explore strategic opportunities
in
other medical markets that would allow us to benefit from our business and
global distribution expertise, and which have operational characteristics that
are similar to ophthalmology, such as dermatology. We intend to expand under
the
following strategic objectives.
Leverage
R&D strengths to develop our pharmaceutical product
pipeline
.
We plan
to leverage our strengths in siRNA drug development, RNAi technology, and all
phases of pharmaceutical research and development to further develop and
commercialize a pipeline of pharmaceutical products used in the treatment of
ophthalmic disorders with unmet medical needs, such as Age-Related Macular
Degeneration, or AMD, glaucoma, diabetic retinopathy, and dry eye, among others.
Develop
novel diagnostic and disease management technologies
.
We plan
to invest in and develop novel technologies and products to diagnose ophthalmic
disorders at the earliest stages and to monitor the disease state and track
the
impact of intervention over time and during the course of treatment. We believe
these technologies will improve our understanding of disease processes, help
individualize treatment options, improve clinical decision making and enhance
clinical outcomes and quality of life for patients with a variety of ocular
disorders, including AMD, diabetic retinopathy and glaucoma.
Utilize
expertise and resources to develop other ophthalmic products
.
We also
plan to use our expertise and resources to develop and commercialize other
types
of ophthalmic products beyond pharmaceutical products and diagnostic and imaging
systems, including without limitation, drug delivery systems and other
ophthalmic devices which aid in the management of ocular disorders.
Acquire
additional ophthalmic businesses, therapies and technologies and expand into
complementary businesses
.
We
continue to seek to expand our current operations by acquiring additional
ophthalmic businesses and therapeutic and diagnostic technologies. We also
intend to explore strategic opportunities in other medical markets that would
allow us to benefit from our business and global distribution expertise, and
which have operational characteristics that are similar to ophthalmology, such
as dermatology. While we have not yet made any definitive plans to acquire
any
dermatology-related businesses, we believe that there are opportunities to
apply
our expertise to this field.
Utilize
expertise and resources to enhance our competitive position
.
We
intend to utilize our wide-ranging technological innovation and proprietary
position to enhance our competitive position in the ophthalmic products market.
For example, we intend to utilize our diagnostic and instrumentation products
to
measure disease progression and treatment outcomes of our pharmaceutical
products in clinical trials.
Key
elements of our strategy are to:
|
·
|
Obtain
regulatory approval for our lead product candidate, bevasiranib,
for Wet
AMD;
|
|
·
|
Develop
a focused commercialization capability in the United
States;
|
|
·
|
Strategically
utilize our R&D resources to advance our product
pipeline;
|
|
·
|
Develop
and grow our instrumentation business beyond diagnostic and imaging
systems to include drug delivery devices and other therapeutic devices
and
technologies;
|
|
·
|
Utilize
our ophthalmic expertise to identify and acquire companies with innovative
ophthalmic technologies; and
|
|
·
|
Expand
into other medical markets, including dermatology, which we believe
are
complementary to and synergistic with our ophthalmology
business.
|
Corporate
Information
We
were
originally incorporated in Delaware in October 1991 under the name Cytoclonal
Pharmaceutics, Inc., which was later changed to eXegenics, Inc. On March
27, 2007, we were part of a three-way merger with Froptix Corporation, or
Froptix, a research and development company, and Acuity Pharmaceuticals,
Inc., or Acuity, a research and development company. This transaction was
accounted for as a reverse merger between Froptix and eXegenics, with the
combined company then acquiring Acuity. eXegenics was previously involved in
the
research, creation, and development of drugs for the treatment and/or prevention
of cancer and infectious diseases; however, eXegenics had been a public shell
company without any operations since 2003. On June 8, 2007, we changed our
name
to OPKO Health, Inc.
On
November 28, 2007, we acquired Ophthalmic Technologies, Inc., or OTI, an Ontario
corporation pursuant to a definitive share purchase agreement with OTI and
its
shareholders. As a result of this agreement, we have entered into the ophthalmic
instrumentation market and have begun generating revenue from this
business.
Our
shares are publicly traded on the American Stock Exchange under the ticker
“OPK”. Our principal executive offices are located in Miami, Florida. Our
clinical operations are based in Morristown, New Jersey. OTI has offices in
Toronto, Ontario, Canada, with a research and development branch office in
Kingston, Ontario, Canada. OTI also maintains a research and development office
in the United Kingdom at the University of Kent. We maintain a website at
www.OPKO.com.
BUSINESS
We
presently have eight compounds and technologies in research and development
for
the ophthalmic pharmaceutical market. Our most advanced drug candidate is
bevasiranib, which we are developing for the treatment of Wet AMD. In July
2007,
we initiated the first of two required pivotal Phase III trials for bevasiranib.
Bevasiranib is the first therapy in late stage clinical development based on
the
Nobel Prize-winning RNA interference, or RNAi technology, and we believe it
is
the most advanced siRNA-based drug currently in development. Bevasiranib is
administered locally to the eye through an intravitreal injection, and is
designed to require administration every eight to 12 weeks. Lucentis®, an FDA
approved treatment for the treatment of Wet AMD currently on the market, is
recommended to be administered through intravitreal injection every four weeks.
We are also researching and developing several novel pharmaceutical products
for
ophthalmic disorders, including Dry AMD, diabetic retinopathy and Diabetic
Macular Edema, or DME, dry eye, viral conjunctivitis, and prevention of ocular
infection. The following table lists our most advanced pharmaceutical product
candidates, the initial indications that we plan to address through their
development, and their development stage.
Product
Candidate
|
|
Initial
Indication
|
|
Development
Stage
|
Bevasiranib
|
|
Wet
AMD
|
|
Phase
III
|
|
|
|
|
|
Bevasiranib
|
|
Diabetic
Retinopathy/DME
|
|
Phase
I / II
|
|
|
|
|
|
Civamide
|
|
Dry
Eye
|
|
Phase
I/II
|
|
|
|
|
|
ACU-HHY-011
|
|
Wet
AMD, Diabetic Retinopathy/DME
|
|
Pre-Clinical
|
|
|
|
|
|
ACU-XSP-001
|
|
Allergy
and Inflammation
|
|
Pre-Clinical
|
|
|
|
|
|
Wound
Dressing
|
|
Post-surgical
Wound Healing
|
|
Late
Stage Research
|
|
|
|
|
|
ACU-HTR-028
|
|
Wound-Healing-Antifibrotic
|
|
Pre-Clinical
|
|
|
|
|
|
Dry-AMD
Compound
|
|
AMD
|
|
Pre-Clinical
|
|
|
|
|
|
N-Chlorotaurine
|
|
Viral
Conjunctivitis
|
|
Late
Stage Research
|
In
April
2007, we acquired 33% of Ophthalmic Technologies, Inc., or OTI, and in November
2007, we acquired the remaining 67% of OTI. Through OTI, we presently market
four ophthalmic diagnostic systems and instrumentation products in over 60
countries worldwide. We offer innovative systems with advanced imaging
capabilities and tools designed to meet the needs of eye care
professionals.
We
offer
a full line of advanced imaging products and ultrasound used by eye care
professionals for both routine and specialized care. These technologically
advanced systems are routinely used in the screening and management of major
eye
diseases, provide key information for treatment decisions, and complement our
therapeutic products. In the future, for example, we expect that patient
outcomes will be significantly optimized by the use of our instrumentation
products in individualizing treatment as well as monitoring and tracking disease
progression and treatment outcomes. We believe our OCT / SLO system is an
innovative product offering significant advantages over current technology
and
providing a flexible platform that can process a wide variety of diagnostic
tests. OTI has offices in Canada and the United Kingdom, and a growing
distributor network that currently covers more than 60 countries.
OPHTHALMIC
PHARMACEUTICAL MARKET
In
the
developed world, major vision threatening disorders include cataracts, glaucoma,
AMD, and diabetic retinopathy/DME. To date, we have primarily focused our
resources on developing drugs to prevent and treat AMD, as well as diabetic
retinopathy/DME.
The
ophthalmic pharmaceutical market in the developed world is driven
by:
|
·
|
An
aging population and increased life
expectancy;
|
|
·
|
Increased
incidence of chronic and age-related disorders with vision destroying
characteristics, such as Diabetes (Type I and II), and other metabolic
syndromes;
|
|
·
|
Better
understanding of the pathophysiology of
diseases;
|
|
·
|
Emerging
technologies to diagnose, treat and manage ophthalmic diseases;
and
|
|
·
|
Improved
access to medical care.
|
Age
Related Macular Degeneration (“AMD”)
AMD
is a
back-of-the-eye disease involving the retina, macula and fovea, which is
characterized by loss of central visual acuity. AMD affects the central part
of
the retina, known as the macula. The extent of vision loss is dependent on
the
degree to which the center of the macula, the fovea, is affected. The fovea
is
responsible for vision acuity. The rest of the retina outside of the macular
area is responsible for peripheral vision, which is usually unaffected in AMD
patients. Untreated AMD can significantly impact an affected individual’s
quality of life.
AMD
accounts for approximately 55% of blindness in the United States. Direct and
indirect costs attributed to the treatment of AMD in the United States are
approximately $30 to $40 billion annually, according to the National Eye
Institute, a division of the National Institutes of Health. Age is the primary
risk factor for AMD, and the number of cases of AMD is expected to increase
significantly as the population ages. AMD afflicts approximately 9 million
Americans, and the current Wet AMD treatment market is approaching 2 million
patients in the United States. There are two forms of AMD, Dry and Wet. Wet
AMD
is the result of the formation of new, leaky, poorly organized blood vessels
under the retina, which is known as neovascularization. The blood vessels are
delicate and break easily, causing bleeding, swelling and the formation of
scar
tissue, which results in visual impairment and/or blindness. Although more
common than Wet AMD, Dry AMD typically results in a less severe, more gradual
loss of vision.
Wet
AMD
is considered a more serious disease, with clinically demonstrated vision loss
occurring within three to six months of diagnosis.
Currently
there is no known proven pharmaceutical therapy for Dry AMD.
Diabetic
Retinopathy/Diabetic Macular Edema
Diabetic
retinopathy is the most common diabetic eye disease. It is caused by damage
to blood vessels in the retina. Diabetic Macular Edema, or DME, a medical
condition which occurs when the damaged blood vessels leak fluid and lipids
onto
the macula, the portion of the retina that allows us to see detail, is present
in approximately 25% of all diabetic retinopathy cases. DME can occur at any
stage in diabetic retinopathy development, and it is possible for advanced
diabetic retinopathy and DME to occur simultaneously in the same patient. DME
is
the leading cause of visual impairment for people with diabetic retinopathy,
and
the population suffering from DME is expected to grow as a result of an
increasing incidence of Type II diabetes in the United States.
OPHTHALMIC
PHARMACEUTICAL BUSINESS
We
have
concentrated significant resources to address ophthalmic disease in large and
growing markets by employing a powerful and rapidly progressing technology,
known as RNAi, to develop our lead product candidate, bevasiranib. In October
2006, the Nobel prize in Medicine was awarded to the two individuals who
discovered RNAi. We have taken advantage of this major scientific breakthrough
by inventing and developing siRNAs that shut down the production of proteins
that cause ophthalmic diseases. We believe we are a pioneer in this area as
we
conducted the first clinical trials ever with an siRNA and obtained the first
clinical proof of concept with a siRNA. We intend to market bevasiranib, which
is our most advanced therapeutic compound, as a treatment for Wet AMD.
Bevasiranib is a first in class siRNA drug designed to silence the genes that
cause vascular endothelial growth factor, or VEGF, which is believed to be
largely responsible for the vision loss associated with Wet AMD and other
related ocular conditions. We believe that bevasiranib is the most advanced
siRNA-based drug currently in development. We believe that RNA-interference
based drugs have the potential to be a significant advancement over the VEGF
inhibitors presently on the market because they block the synthesis of VEGF
as
opposed to merely neutralizing existing VEGF. In addition, RNA-interference
based drugs should require less frequent administration than VEGF inhibitors
and
have a better safety profile.
We
have
utilized our expertise in ophthalmology and RNAi technology to take bevasiranib
from the laboratory through animal models into clinical trials. We have
completed two Phase II clinical trials studying the use of bevasiranib as a
treatment for Wet AMD and DME. Bevasiranib demonstrated safety and potential
to
show efficacy in our Phase II clinical trial for Wet AMD in 129 patients.
Results showed bevasiranib to be safe and well-tolerated, with a dose-related
effect evident across multiple endpoints including near vision, choroidal
neovascularization, or CNV, size and time to rescue.
In
July
2007, we commenced our pivotal multi-national Phase III COBALT, or Combining
Bevasiranib And Lucentis® Therapy, clinical trial of bevasiranib for the
treatment of Wet AMD. The trial will include more than 330 Wet AMD patients
and
will assess whether bevasiranib administered every eight or 12 weeks is safe
and
has equivalent efficacy in preventing vision loss as Lucentis® administered
every four weeks. Interim analysis of safety and efficacy will be made at week
60.
We
believe that bevasiranib will be an improvement over existing and anticipated
therapies for Wet AMD as it addresses the underlying source of VEGF production,
rather than merely neutralizing existing VEGF. Currently marketed drugs for
the
treatment of Wet AMD are antagonist-based and are only designed to neutralize
existing VEGF. We also believe bevasiranib has a better safety profile than
VEGF
inhibitors in that we do not believe it has the serious systemic side effects
associated with VEGF inhibitors in some patients.
We
are
also developing product candidates for additional ophthalmic disorders,
including the treatment of dry eye, diabetic retinopathy and DME, complications
of ocular surgery, viral conjunctivitis, and the fibrotic component of Wet
AMD
and Dry AMD. In order to treat these disorders, we are using compounds that
induce lacrimation, are anti-angiogenic, anti-inflammatory, anti-fibrotic and
anti-Drusen. These products address eye diseases with large markets and major
unmet medical needs, and range in developmental stage from clinical to
preclinical.
Bevasiranib
Commercial Potential
We
have
an exclusive license to commercialize bevasiranib. We believe there are three
primary potential therapeutic profiles for bevasiranib in the marketplace:
maintenance therapy, primary therapy and preventative treatment.
Maintenance
Therapy
.
We
anticipate that bevasiranib will be used by itself as a maintenance therapy
to
inhibit VEGF production following an initiation therapy with an approved VEGF
antagonist drug. After the antagonist has absorbed extracellular VEGF,
bevasiranib could be used to suppress the formation of new VEGF and maintain
a
patient’s vision.
Primary
Therapy
.
It is
possible that not all patients will require the VEGF antagonist initiation
regimen due to low VEGF load at time of diagnosis. These patients may get the
full benefit from bevasiranib alone. Additionally, not all patients respond
favorably to the currently marketed VEGF antagonist. Finally, when used in
combination with other therapies bevasiranib’s sustained VEGF suppression may
add to the antagonist’s activity and provide a better outcome than that of the
VEGF antagonist alone.
Preventative
Therapy
.
Certain
patients who do not yet have the wet form of AMD may be determined to be at
high-risk for progressing to the wet form. Bevasiranib may prevent these
high-risk patients from progressing to Wet AMD. The current VEGF antagonist
products will not likely provide any benefit to this type of patient because
of
the lack of any VEGF to absorb.
Clinical
Results and Program Status of Bevasiranib
The
following table summarizes the status of our material clinical trials of
bevasiranib to date:
Indication
|
|
Trial
Name
|
|
Phase
|
|
Objectives
|
|
Number
of Patients
|
|
Enrollment
Status
|
Wet
AMD
|
|
CARBON
study
|
|
Phase
III
|
|
Dose
ranging, Safety and Efficacy
|
|
~500
|
|
Initiation
planned for 2009
|
Wet
AMD
|
|
COBALT
study
|
|
Phase
III
|
|
Safety
and Efficacy
|
|
~330
|
|
Initiated
July 2007
|
Wet
AMD
|
|
CARE
Trial
|
|
Phase
II
|
|
Safety
/ Dosage / Efficacy
|
|
129
|
|
Complete
|
Wet
AMD
|
|
NA
|
|
Phase
I
|
|
Safety
|
|
15
|
|
Complete
|
DME
|
|
RACE
Trial
|
|
Phase
II
|
|
Safety
/ Dosage / Efficacy
|
|
48
|
|
Complete
|
Clinical
Trials for the Treatment of Wet AMD
The
COBALT Study.
In
July
2007, we initiated this pivotal Phase III study of bevasiranib for the treatment
of Wet AMD. The multi-national COBALT study is currently open and enrolling
patients. The trial will include approximately 330 wet AMD patients and will
assess whether bevasiranib administered every eight or 12 weeks is safe and
has
equivalent efficacy in preventing vision loss as Lucentis® administered every
four weeks. This study has been designed to show that bevasiranib is safe and
efficacious for the treatment of wet AMD following an initiation with Lucentis®.
Additionally, the study has been designed to demonstrate that in patients that
receive an initiation therapy with Lucentis®, a less frequent administration of
bevasiranib is equivalent or superior to monthly treatments of
Lucentis®.
We
currently anticipate initiating a second Phase III clinical trial of bevasiranib
in or around 2009. This clinical trial of bevasiranib for the treatment of
Wet
AMD will be referred to as the CARBON study. The trial will include more than
~500 Wet AMD patients and will compare the safety and efficacy of three doses
of
bevasiranib administered every eight weeks to Lucentis®, an approved treatment
for Wet AMD, administered every four weeks.
The
CARE™ Trial, a Phase II Clinical Trial for Wet AMD
.
The
“Cand5 Anti-VEGF RNAi Evaluation, or CARE study,” a 129 patient Phase II
clinical study in patients with predominantly and minimally classic Wet AMD,
was
completed successfully. The results of the CARE study demonstrated that
bevasiranib is safe and well-tolerated for doses up to 3.0 mg/eye. An important
measure of Wet AMD is choroidal neovascularization, or CNV. In the CARE study,
bevasiranib was shown to inhibit the growth of CNV, and demonstrated the effects
of RNA interference-based VEGF suppression.
Phase
I Clinical Trial for Wet AMD
.
This
Phase I trial was an open label, dose escalation study that included 15 patients
and tested five dose levels administered by intravitreal injection at six-week
intervals. Bevasiranib was shown to be safe and well-tolerated following
repeated administration of escalating doses, up to 3.0 mg per eye. Further,
this
study indicated that the study drug was below the limit of detection in the
peripheral blood at any of the doses tested. The absence of systemic exposure
to
bevasiranib is significant because anti-VEGF agents have been shown to have
serious systemic side effects in some patients.
Clinical
Trials for the Treatment of DME
The
R.A.C.E.™ Trial
,
a Pilot
Phase II Clinical Trial for DME. The RNAi Assessment of bevasiranib in Diabetic
Macular Edema, or R.A.C.E. trial, was a pilot phase II investigation of the
safety and preliminary efficacy of bevasiranib in patients with DME. This 48
patient multi-center, double-masked and randomized trial studied three dose
levels of bevasiranib.
In
this
pilot study, there was a trend showing a decrease in macular thickness between
weeks eight and twelve, where the higher doses result in a larger reduction
in
thickness than the lowest dose. This trial also showed no detectable levels
of
bevasiranib in patients at all doses and time-points. These results further
support the findings of the CARE study and serve as a confirmation of the safety
and biologic activity in a second VEGF-driven ocular condition.
ACU-HHY-011
for the Treatment of Wet AMD
We
have a
worldwide exclusive license to commercialize ACU-HHY-011, which is an siRNA
targeting HIF-1α, believed to be the most important transcription factor
involved in the cellular response to hypoxia, a key step in the
neovascularization process which occurs in Wet AMD. HIF-1α is upstream of the
target for bevasiranib and preclinical data suggests that targeting HIF-1α may
have advantages over other approaches to treating Wet AMD. HIF-1α modulates the
expression of more than 60 genes, including multiple angiogenic factors under
hypoxic conditions, such as VEGF, angiopoietin-1, angiopoietin-2, placental
growth factor, and platelet-derived growth facto
r-B.
ACU-HTR-028
for the Treatment of Fibrosis
We
have a
worldwide exclusive license to commercialize siRNAs targeting transforming
growth factor-b receptor Type II, or TbRII, which is an important mediator
of
wound healing and has been shown to play a significant causative role in ocular
inflammation and scarring. This compound may have a therapeutic application
as
an eye drop to prevent complications from ocular surgery, and will also be
developed as an adjunct therapy to bevasiranib or ACU-HHY-011 in Wet AMD
patients to reduce the damage caused by the fibrotic component of Wet
AMD.
Compounds
for the Treatment of Dry AMD
We
have
worldwide exclusive licenses to commercialize compounds from the University
of
Florida Research Foundation which have potential to treat Dry AMD by eliminating
disease-causing accumulations of protein molecules at the back of the eye.
Proteins must fold into their correct three-dimensional conformation to achieve
their biological function. The loss of vision associated with Dry AMD is thought
to be caused by the destructive effects of the misfolded protein and debris
aggregates likes lipofuscin. Autophagy is a cellular process by which cellular
protein aggregates and dysfunctional organelles like mitochondria are degraded.
If methods for increasing autophagy were available, they might enhance the
elimination of misfolded proteins, and eliminate the destructive effects
associated with their accumulation. These compounds may mitigate retinal
degeneration by causing the elimination or reduction of drusen in patients
with
Dry AMD.
Civamide
for the Treatment of Dry Eye
In
September 2007, we acquired worldwide rights to
commercialize products containing civamide for the treatment of ophthalmic
conditions in humans, particularly dry eye. There is only one FDA approved
prescription product available for dry eye. Dry eye syndrome is caused by a
variety of conditions, such as insufficient tear production. Nine million
Americans are estimated to suffer from moderate to severe dry eye. An additional
20 to 30 million people may have a mild form of the condition. Dry eye syndrome
is more common with advancing age and the incidence appears to be increasing
with our aging population and the increasing popularity of procedures that
can
cause dry eye, such as vision-correction surgery and cosmetic eyelid surgery.
Wound Dressing
In
October 2007, we acquired worldwide rights to commercialize an ocular product
for use following invasive retinal procedures to prevent the development of
endophthalmitis, a devastating complication that can lead to blindness and
loss
of the affected eye. There are estimated to be over 1.5 million invasive retinal
procedures, including both surgeries and intravitreal injections, being
currently performed in the U.S. alone. While most patients suffer no adverse
effects from intravitreal injections, all patients who receive invasive retinal
procedures are at risk of developing endophthalmitis. The product is in
late-stage research.
N-chlorotaurine
In
April
2006, we entered into a license agreement with Pathogenics, Inc. (“Pathogenics”)
under which we were granted an exclusive, irrevocable license, with the right
to
sublicense, under Pathogenics intellectual property to make, have made, use,
sell, offer for sale, import, or otherwise commercialize N-chlorotaurine and
licensed products for the treatment of ophthalmic disease or infection in any
territory. We were also granted non-exclusive rights to all data resulting
from
a phase I clinical trial with N-chlorotaurine in Austria. We are obligated
to
use commercially reasonable efforts to develop and commercialize the licensed
product, including commercially reasonable efforts to initiate pre-clinical
activities necessary to file an IND with the FDA to initiate a phase I clinical
trial for N-chlorotaurine for an ophthalmic indication. Pathogenics will have
a
non-exclusive right to such information for the treatment of non-ophthalmic
diseases or infections.
OPHTHALMIC
INSTRUMENTATION MARKET
The
market for ophthalmic instrumentation, including imaging systems and other
devices, is approximately $1.5 billion and growing at a rate of approximately
10% annually. This growth is primarily driven by an aging patient population,
technological innovation and improvement in treatment options, as well as
improved awareness in patients actively seeking treatment. Ophthalmic
instruments, imaging products, and other medical devices are sold to a variety
of eye care practitioners, including retinal and glaucoma specialists,
ophthalmologists, optometrists, retail optometry chain outlets, teaching
institutions, and military hospitals.
OPHTHALMIC
INSTRUMENTATION BUSINESS
Our
instrumentation business consists of the development, commercialization and
sale
of ophthalmic diagnostic and imaging systems and instrumentation products.
Currently, the instrumentation business is primarily based on the technology
platform established by Ophthalmic Technologies, Inc. (OTI), which offers
innovative systems with advanced diagnostic imaging capabilities and tools
that
meet the needs of eye care professionals. We continue to build our presence
in
the international marketplace currently covering more than 60 countries using
the distributor network built by OTI. Additionally, we are developing our own
direct sales force in the United States to sell our products primarily to
retinal and glaucoma specialists and ophthalmologists.
We
plan
to utilize our expertise and resources to expand our business to include other
types of ophthalmic products. These efforts may lead to our acquiring or
developing products which aid in the prevention, diagnosis, treatment, and
management of ocular disorders. The product types may include diagnostic and
imaging instruments, other instrumentation products, and drug delivery systems
and technologies.
We
plan
to develop and sell novel technologies utilized to diagnose ophthalmic diseases
at the earliest stages and track them for change over time, and during the
course of treatment. We expect these technologies to improve physician treatment
decisions and enhance outcomes for a variety of ocular disorders, including
AMD,
diabetic retinopathy, and glaucoma, among others.
Optical
Coherence Tomography / Confocal Scanning
Ophthalmoscopy
We
have
developed a spectral imaging system which combines Spectral Optical Coherence
Tomography, together with a Confocal Scanning Ophthalmoscope, or OCT / SLO,
in a
single platform that is used in the diagnosis of a variety of ocular disorders.
We believe this is an innovative product that offers significant advantages
over
current technology in resolution and functionality. OCT technology is being
rapidly adopted by the eye care community for diagnosing AMD and diabetic
retinopathy and also tracking the course of treatment. The OCT / SLO is unique
in that it offers microperimetry capability, which provides the physician with
the ability to correlate loss of visual function with abnormalities in the
retina. Additionally, the OCT / SLO diagnostic platform offers a foundation
upon which to build a multitude of diagnostic tests. In the future, we plan
to
incorporate a number of imaging and other diagnostic test modalities into the
OCT / SLO platform.
Ultrasound
We
develop, manufacture, market and sell a full line of advanced ophthalmic
ultrasound systems used by eye care professionals for both routine and
specialized care. Our ultrasound systems include A-scans, B-scans, and
Ultrasound Bio-microscope, or UBM, high frequency B-scan systems. A-scan
technology is principally used for eye axial length measurement in the
calculation of the power for an intraocular lens implant. These systems are
routinely used prior to cataract surgery.
The
B-scan system displays internal structures of the eye, often when these
structures are not visible by traditional light-based imaging methods. This
system has the ability to pass through opacities and reveal internal
structures.
The
UBM
system is a high frequency ultrasound device that provides detailed structural
assessment of the anterior segment of the eye and is typically used in glaucoma
evaluation and certain refractive surgeries that require precise positioning
of
lens implantation.
Research
and development program expenses
To
date,
the majority of our research and development expenses have been incurred to
develop our bevasiranib programs. During 2006, our research and development
expenses of $0.5 million reflect the sponsored research between Froptix and
the
University of Florida. During 2007, we incurred $10.9 million in research and
development expenses, a majority of which reflects costs to develop bevasiranib.
In addition, during 2007 we recorded $243.8 million for acquired in process
research and development related to our acquisition of Acuity.
INTELLECTUAL
PROPERTY
We
believe that technology innovation is driving breakthroughs in vision
healthcare. We have adopted a comprehensive intellectual property strategy
which
blends the efforts to innovate in a focused manner with the efforts of our
business development activities to strategically in-license intellectual
property rights. We develop, protect, and defend our own intellectual property
rights as dictated by the developing competitive environment. We value our
intellectual property assets and believe we have benefited from early and
insightful efforts at understanding the disease and the molecular basis of
potential pharmaceutical intervention.
We actively
seek, when appropriate and available, protection for our products and
proprietary information by means of United States and foreign patents,
trademarks, trade secrets, copyrights, and contractual arrangements. Patent
protection in the pharmaceutical field, however, can involve complex legal
and
factual issues. Moreover, broad patent protection for new formulations or new
methods of use of existing chemical entities is sometimes difficult to obtain,
primarily because the active ingredient and many of the formulation techniques
have been known for some time. Consequently, some patents claiming new
formulations or new methods of use for old drugs may not provide meaningful
protection against competition. There can be no assurance that any steps taken
to protect such proprietary information will be effective.
We
own or
have exclusively licensed more than eight issued patents in the United States
and five foreign patents, as well as more than 100 United States and foreign
patent applications. Our acquisition of OTI has given us access to an additional
seven
U.S.
patents in the field of ophthalmic instrumentation, as well as
ten
U.S.
patent applications and
18
foreign
patent applications.
We
have
exclusively licensed technology, patents, and patent applications from the
University of Pennsylvania related to siRNA directed to specific mRNA targets
for therapeutic use. These applications include targeting VEGF,
HIF-1α,
and intracellular adhesion molecules, or ICAM, among other therapeutic targets.
In particular, we have exclusively licensed two issued U.S. patents that cover
bevasiranib and methods of using bevasiranib.
In
addition, we have exclusively licensed technology, patents, and patent
applications related to (i) the treatment of ophthalmic disorders characterized
by excessive neovascularization, angiogenesis or leakage, (ii) siRNA targeting
TGF-bRI; and (iii) compounds or technologies to treat a variety of ocular
disorders, including without limitation, Dry AMD and retinitis pigmentosa,
viral
conjunctivitis, dry eye, and ocular infection. See “Licenses and Collaborative
Relationships”.
LICENSES
AND COLLABORATIVE RELATIONSHIPS
Our
strategy is to develop a portfolio of product candidates through a combination
of internal development and external partnerships. Collaborations are key to
our
strategy and we continue to build relationships and forge partnerships with
companies both inside and outside of ophthalmology. We have completed strategic
deals with the Trustees of the University of Pennsylvania, the University of
Illinois, the University of Florida Research Foundation, Pathogenics, Inc.,
and
Intradigm Corporation, among others.
The
Trustees of the University of Pennsylvania
In
March
2003, we entered into two world-wide exclusive license agreements with The
Trustees of the University of Pennsylvania to commercialize siRNA targeting
VEGF, HIF-1α, ICAM, and other therapeutic targets. In consideration
for
the
licenses, we are obligated to make certain milestone payments to the University
of Pennsylvania. We also agreed to pay the University of Pennsylvania earned
royalties based on the number of products we sell that use the inventions
claimed in the licensed patents. We agreed to use commercially reasonable
efforts to develop, commercialize, market, and sell such products covered by
the
license agreements.
The
term
of the agreements is for the later of the expiration or abandonment of the
last
patent or ten years after the first commercial sale of the first licensed
product. We may terminate either of the agreements upon 60 days’ prior written
notice. The University of Pennsylvania may terminate either of the agreements
if
we are more than 90 days late in a payment owed to the University of
Pennsylvania, we breach the agreements and do not cure within 90 days after
receiving written notice from the University of Pennsylvania, if we become
insolvent or we are involved in bankruptcy proceedings.
Intradigm
Corporation
In
June
2005, we entered into a license and collaboration agreement with Intradigm
Corporation, or Intradigm, for intellectual property covering the treatment
of
ophthalmic diseases characterized by excessive neovascularization, angiogenesis,
or leakage. Under the terms of the agreement, we have agreed to jointly develop
a topical siRNA compound. After selection the topical siRNA compound, we are
obligated to use commercially reasonable efforts to market, distribute, and
sell
the topical siRNA in the United States and any selected foreign country. We
have
agreed to pay to Intradigm certain milestone payments upon the achievement
of
specified milestones and royalty payments on all net sales of the topical siRNA
and other licensed products.
The
term
of the agreement is 20 years, unless earlier terminated in accordance with
the
agreement. Either party may terminate upon mutual written consent, upon written
notice by a party if the other party dissolves or enters into bankruptcy or
insolvency proceedings, or upon 90 days prior written notice of a material
breach of the agreement without cure.
The
Board of Trustees of the University of Illinois
In
August
2006, we entered into an exclusive worldwide license agreement with The Board
of
Trustees of the University of Illinois to commercialize intellectual property
related to ophthalmic siRNA targeting TGF-bRII for the treatment of ophthalmic
disease. In September 2007, the license was amended to include all other fields
of use beyond the treatment of ophthalmic disease. The license agreement
obligates us to pay to the University of Illinois certain milestone payments
and
royalty payments on all net sales of licensed products and an annual license
fee
payment.
University
of Florida Research Foundation
In
April
2006, we entered into three world-wide exclusive license agreements with the
University of Florida Research Foundation. The license agreements obligate
us to
pay to University of Florida Research Foundation royalty payments on all net
sales of licensed products. We agreed to use our commercially reasonable
activities to commercialize products. The technology licensed from the
University of Florida Research Foundation includes autophagy inducing compounds
which are designed to enhance the elimination of misfolded proteins, and
eliminate the destructive effects associated with their accumulation, compounds
that affect important intracellular pathways which lead to the accumulation
of
properly folded mutant proteins, and potential drug candidates that are designed
to recruit stem cells which may aid in delaying or reversing the damage at
the
back of the eye associated with several retinal diseases including Dry AMD
and
retinitis pigmentosa. The term of each of the agreements is for the earlier
of
the date that no licensed patent remains an enforceable patent or the payment
of
earned royalties under the agreement once begun, ceases for more than two
calendar quarters. We may terminate any of the agreements upon 60 days’ prior
written notice. The University of Florida Research Foundation may terminate
any
of the agreements if we are more than 60 days late, after written demand, for
a
payment owed to the University of Florida Research Foundation, if we breach
the
agreements and do not cure within 60 days after receiving written notice from
the University of Florida Research Foundation, or if we become involved in
bankruptcy proceedings.
Civamide
License
In
September 2007, we entered into an exclusive worldwide license to commercialize
intellectual property related to pharmaceutical compositions or preparations
containing civamide for the treatment of ophthalmic conditions in humans,
particularly dry eye. The license agreement obligates us to pay the licensor
certain milestone payments and royalty payments on all net sales of licensed
products thereunder and all costs of research and development necessary to
obtain marketing authorizations for such licensed products. There is only one
FDA approved prescription product available for dry eye. Dry eye syndrome is
caused by a variety of conditions, such as insufficient tear production. Nine
million Americans are estimated to suffer from moderate to severe dry eye.
An
additional 20 to 30 million people may have a mild form of the condition. Dry
eye syndrome is more common with advancing age and the incidence appears to
be
increasing with our aging population and the increasing popularity of procedures
that can cause dry eye, such as vision-correction surgery and cosmetic eyelid
surgery. We intend to evaluate the safety and efficacy of civamide in patients
with moderate to severe dry eye. A Phase I/II proof of principal study in
moderate to severe dry eye is being planned in 2008.
Theta
Research Consultants
In
October 2007, we entered into an exclusive worldwide license to commercialize
intellectual property related to an ocular product for use following invasive
retinal procedures to prevent the development of endophthalmitis, a devastating
complication that can lead to blindness and loss of the affected eye. The
license agreement obligates us to make royalty payments on all net sales of
licensed products thereunder and all costs of research and development necessary
to obtain marketing authorizations for such licensed products. Experts believe
that the incidence of endophthalmitis is growing as a result of the rising
number of ocular surgeries being performed, the widespread adoption of
sutureless surgical techniques, and a significant increase in the number of
intravitreal injections. While most patients suffer no adverse effects from
intravitreal injections, all patients who receive invasive retinal procedures
are at risk of developing endophthalmitis.
Pathogenics
In
April
2006, we entered into a license agreement with Pathogenics under which we were
granted an exclusive, irrevocable license, with the right to sublicense, under
Pathogenics’ intellectual property to make, have made, use, sell, offer for
sale, import, or otherwise commercialize N-chlorotaurine and licensed products
for the treatment of ophthalmic disease or infection in any territory. We were
also granted non-exclusive rights to all data resulting from a phase I clinical
trial with N-chlorotaurine in Austria. We are obligated to use commercially
reasonable efforts to develop and commercialize the licensed product, including
commercially reasonable efforts to initiate pre-clinical activities necessary
to
file an IND with the FDA to initiate a phase I clinical trial for
N-chlorotaurine for an ophthalmic indication. Pathogenics will have a
non-exclusive right to such information for the treatment of non-ophthalmic
diseases or infections.
We
are
obligated to pay to Pathogenics certain milestone payments upon the achievement
of specified milestones and royalty payments on all net sales of licensed
products. We are also obligated to pay Pathogenics an annual minimum payment
if
the total payments made for such year are less than a specified minimum amount.
The term of the agreement is for the shorter of twenty years or the last to
expire of the Pathogenics intellectual property. We may terminate the agreement
for any reason upon written notice. The agreement may be terminated upon mutual
written consent of the parties, by either party upon written notice if either
party dissolves or is involved in a bankruptcy or insolvency proceeding or
upon
ninety days prior written notice if the other party is in material breach and
fails to cure.
COMPETITION
Wet
AMD
The
Wet
AMD treatment market is highly competitive with each competitive company eager
to expand market share. Several pharmaceutical and biotechnology companies
are
actively engaged in research and development related to new treatments for
Wet
AMD. We intend to leverage our technological innovation and proprietary position
utilizing RNAi and other platform technologies to effectively compete in the
ophthalmic drug market. Additionally, we intend to couple diagnostic tests
together with therapeutics in clinical trials to further enhance our competitive
position.
Genentech,
Allergan, Alcon Laboratories, Novartis, Alnylam, Regeneron and QLT all have
products or development programs for Wet AMD. For Wet AMD, we
currently believe that Genentech and Allergan are or will be our primary
competitors. Genentech’s Lucentis® and Avastin® products are both based on
antibody technology to block VEGF protein after it is produced. While both
of
the drugs provide most patients with an effective treatment, we believe that
bevasiranib has distinct advantages over these approaches, which will result
in
its use and contribute to a significant market share.
Lucentis®
and Avastin® block VEGF protein only after it is produced. Additionally,
Lucentis® and Avastin® are designed to require monthly injections for optimal
effectiveness and include cautions about potential arterial thromboembolic
events. Bevasiranib is designed to reduce injection frequency to bi-monthly
or
quarterly, and we do not believe it has the systemic side effect risks
associated with anti-VEGF antibodies. By using siRNA and stopping the production
of VEGF, we believe bevasiranib will provide a Wet AMD patient with a
longer-lasting and safer maintenance treatment following an initiation therapy
with either Lucentis® or Avastin®.
Allergan
is presently developing an siRNA based therapy with a product licensed from
Merck (formerly Sirna). This siRNA based therapy targets a particular VEGF
receptor and due to the fact that there are multiple receptors for VEGF, it
is
unclear whether that approach will yield a clinical benefit in Wet AMD.
Additionally this program is at an earlier stage than our bevasiranib program.
Diabetic
Retinopathy
We
believe that the primary competitors in the diabetic retinopathy/DME market
include Bausch & Lomb with its Fluocinolone acetonide product, Allergan with
its Dexamethasone product, Surmodics with its Triamcinolone acetonide product,
and Psividia/Alimeira Sciences with its Fluocinolone acetonide product. Many
of
these competitors have significantly greater financial resources than we do
to
fund further research and development.
Optical
Coherence Tomography
We
have
several competitors located in the United States and abroad. These include
companies with a far more diverse product offering than ours with significantly
greater market presence. Our primary competition for medical devices include
Carl Zeiss Meditec, Topcon Corporation, and Heidelberg Engineering. There are
a
number of competitors and smaller start-up companies that may also have
competing technologies and products.
The
ophthalmic device market is highly competitive. We intend to leverage our
technological innovations to effectively compete in the ophthalmic device
market. We differentiate our products on the basis of scan quality, precise
image registration, software functionality, and on a diagnostic test known
as
microperimetry. Microperimetry allows the clinician to obtain both structure
and
function from a single device. Additionally, in the future we intend to utilize
diagnostic tests to further refine and guide therapeutic treatments in clinical
trials in order to further enhance our competitive position.
GOVERNMENT
REGULATION OF OUR DRUG AND DEVICE DEVELOPMENT ACTIVITIES
The
United States federal government regulates healthcare through various agencies,
including but not limited to the following: (i) the FDA, which administers
the
FDCA, as well as other relevant laws; (ii) the Centers for Medicare &
Medicaid Services, or CMS, which administers the Medicare and Medicaid programs;
(iii) the Office of Inspector General, or OIG, which enforces various laws
aimed
at curtailing fraudulent or abusive practices, including by way of example,
the
Anti-Kickback Law, the Anti-Physician Referral Law, commonly referred to as
the
Stark law, the Anti-Inducement Law, the Civil Money Penalty Law, and the laws
that authorize the OIG to exclude healthcare providers and others from
participating in federal healthcare programs; and (iv) the Office of Civil
Rights, which administers the privacy aspects of the Health Insurance
Portability and Accountability Act of 1996 (HIPAA). All of the aforementioned
are agencies within the Department of Health and Human Services (HHS).
Healthcare is also provided or regulated, as the case may be, by the Department
of Defense through its TriCare program, the Department of Veterans Affairs,
especially through the Veterans Health Care Act of 1992, the Public Health
Service within HHS under Public Health Service Act § 340B (42 U.S.C. § 256b),
the Department of Justice through the Federal False Claims Act and various
criminal statutes, and state governments under the Medicaid and other state
sponsored or funded programs and their internal laws regulating all healthcare
activities.
The
testing, manufacture, distribution, advertising, and marketing of drug products
and medical devices are subject to extensive regulation by federal, state,
and
local governmental authorities in the United States, including the FDA, and
by
similar agencies in other countries. Any product that we develop must receive
all relevant regulatory approvals or clearances, as the case may be, before
it
may be marketed in a particular country. The PMA clearance processes for drugs
differ from those for devices.
The
regulatory process, which includes overseeing preclinical studies and clinical
trials of each pharmaceutical compound to establish its safety and efficacy
and
confirmation by the FDA that good laboratory, clinical, and manufacturing
practices were maintained during testing and manufacturing, can take many years,
requires the expenditure of substantial resources, and gives larger companies
with greater financial resources a competitive advantage over us. Delays or
terminations of clinical trials that we undertake would likely impair our
development of product candidates. Delays or terminations could result from
a
number of factors, including stringent enrollment criteria, slow rate of
enrollment, size of patient population, having to compete with other clinical
trials for eligible patients, geographical considerations, and
others.
The
FDA
review processes can be lengthy and unpredictable, and we may encounter delays
or rejections of our applications when submitted. Generally, in order to gain
FDA approval, we must first conduct preclinical studies in a laboratory and
in
animal models to obtain preliminary information on a compound and to identify
any safety problems. The results of these studies are submitted as part of
an
IND application that the FDA must review before human clinical trials of an
investigational drug can commence.
Clinical
trials are normally done in three sequential phases and generally take two
to
five years or longer to complete. Phase I consists of testing the drug product
in a small number of humans, normally healthy volunteers, to determine
preliminary safety and tolerable dose range. Phase II usually involves studies
in a limited patient population to evaluate the effectiveness of the drug
product in humans having the disease or medical condition for which the product
is indicated, determine dosage tolerance and optimal dosage, and identify
possible common adverse effects and safety risks. Phase III consists of
additional controlled testing at multiple clinical sites to establish clinical
safety and effectiveness in an expanded patient population of geographically
dispersed test sites to evaluate the overall benefit-risk relationship for
administering the product and to provide an adequate basis for product labeling.
Phase IV clinical trials may be conducted after approval to gain additional
experience from the treatment of patients in the intended therapeutic
indication.
After
completion of clinical trials of a new drug product, FDA and foreign regulatory
authority marketing approval must be obtained. Assuming that the clinical data
support the product’s safety and effectiveness for its intended use, an NDA is
submitted to the FDA for its review. Generally, it takes one to three years
to
obtain approval. If questions arise during the FDA review process, approval
may
take a significantly longer period of time. The testing and approval processes
require substantial time and effort and we may not receive approval on a timely
basis, if at all, or the approval that we receive may be for a narrower
indication than we had originally sought, potentially undermining the commercial
viability of the product. Even if regulatory approvals are obtained, a marketed
product is subject to continual review, and later discovery of previously
unknown problems or failure to comply with the applicable regulatory
requirements may result in restrictions on the marketing of a product or
withdrawal of the product from the market as well as possible civil or criminal
sanctions. For marketing outside the United States, we also will be subject
to
foreign regulatory requirements governing human clinical trials and marketing
approval for pharmaceutical products. The requirements governing the conduct
of
clinical trials, product licensing, pricing, and reimbursement vary widely
from
country to country.
None
of
our pharmaceutical products under development has been approved for marketing
in
the United States or elsewhere. We may not be able to obtain regulatory approval
for any such products under development in a timely manner, if at all. Failure
to obtain requisite governmental approvals or failure to obtain approvals of
the
scope requested will delay or preclude us, or our licensees or marketing
partners, from marketing our products, or limit the commercial use of our
products, and thereby would have a material adverse effect on our business,
financial condition, and results of operations. See “Risk Factors—The results of
previous clinical trials may not be predictive of future results, and our
current and planned clinical trials may not satisfy the requirements of the
FDA
or other non-United States regulatory authorities.”
Devices
are subject to varying levels of premarket regulatory control, the most
comprehensive of which requires that a clinical evaluation be conducted before
a
device receives approval for commercial distribution. The FDA classifies medical
devices into one of three classes: Class I devices are relatively simple and
can
be manufactured and distributed with general controls; Class II devices are
somewhat more complex and require greater scrutiny; Class III devices are new
and frequently help sustain life.
In
the
United States, a company generally can obtain permission to distribute a new
device in one of two ways. The first applies to any device that is substantially
equivalent to a device first marketed prior to May 1976, or to another device
marketed after that date, but which was substantially equivalent to a pre-May
1976 device. These devices are either Class I or Class II devices. To obtain
FDA
permission to distribute the device, the company generally must submit a section
510(k) submission, and receive an FDA order finding substantial equivalence
to a
predicate device (pre-May 1976 or post-May 1976 device that was substantially
equivalent to a pre-May 1976 device) and permitting commercial distribution
of
that device for its intended use. A 510(k) submission must provide information
supporting a claim of substantial equivalence to the predicate device. If
clinical data from human experience are required to support the 510(k)
submission, these data must be gathered in compliance with investigational
device exemption, or IDE, regulations for investigations performed in the United
States. The 510(k) process is normally used for products of the type that the
Company proposes distributing. The FDA review process for premarket
notifications submitted pursuant to section 510(k) takes, on average, about
90
days, but it can take substantially longer if the FDA has concerns, and there
is
no guarantee that the FDA will “clear” the device for marketing, in which case
the device cannot be distributed in the United States. There is also no
guarantee that the FDA will deem the applicable device subject to the 510(k)
process, as opposed to the more time-consuming, resource-intensive and
problematic, PMA process described below.
The
second, more comprehensive, approval process applies to a new device that is
not
substantially equivalent to a pre-1976 product or that is to be used in
supporting or sustaining life or preventing impairment. These devices are
normally Class III devices. For example, most implantable devices are subject
to
the approval process. Two steps of FDA approval are generally required before
a
company can market a product in the United States that is subject to approval,
as opposed to clearance. First, a company must comply with IDE regulations
in
connection with any human clinical investigation of the device. These
regulations permit a company to undertake a clinical study of a “non-significant
risk” device without formal FDA approval. Prior express FDA approval is required
if the device is a significant risk device. Second, the FDA must review the
company’s PMA application, which contains, among other things, clinical
information acquired under the IDE. The FDA will approve the PMA application
if
it finds there is reasonable assurance that the device is safe and effective
for
its intended use. The PMA process takes substantially longer than the 510(k)
process and it is conceivable that the FDA would not agree with our assessment
that a device that we propose to distribute should be a Class I or Class II
device. If that were to occur we would be required to undertake the more complex
and costly PMA process. However, for either the 510(k) or the PMA process,
the
FDA could require us to run clinical trials, which would pose all of the same
risks and uncertainties associated with the clinical trials of drugs, described
above.
Even
when
a clinical study has been approved by the FDA or deemed approved, the study
is
subject to factors beyond a manufacturer’s control, including, but not limited
to the fact that the institutional review board at a given clinical site might
not approve the study, might decline to renew approval which is required
annually, or might suspend or terminate the study before the study has been
completed. Also, the interim results of a study may not be satisfactory; leading
the sponsor to terminate or suspend the study on its own initiative or the
FDA
may terminate or suspend the study. There is no assurance that a clinical study
at any given site will progress as anticipated; there may be an insufficient
number of patients who qualify for the study or who agree to participate in
the
study or the investigator at the site may have priorities other than the study.
Also, there can be no assurance that the clinical study will provide sufficient
evidence to assure the FDA that the product is safe and effective, a
prerequisite for FDA approval of a PMA, or substantially equivalent in terms
of
safety and effectiveness to a predicate device, a prerequisite for clearance
under 510(k). Even if the FDA approves or clears a device, it may limit its
intended uses in such a way that manufacturing and distributing the device
may
not be commercially feasible.
After
clearance or approval to market is given, the FDA and foreign regulatory
agencies, upon the occurrence of certain events, are authorized under various
circumstances to withdraw the clearance or approval or require changes to a
device, its manufacturing process or its labeling or additional proof that
regulatory requirements have been met.
A
manufacturer of a device approved through the PMA is not permitted to make
changes to the device which affect its safety or effectiveness without first
submitting a supplement application to its PMA and obtaining FDA approval for
that supplement. In some instances, the FDA may require clinical trials to
support a supplement application. A manufacturer of a device cleared through
the
510(k) process must submit another premarket notification if it intends to
make a change or modification in the device that could significantly affect
the
safety or effectiveness of the device, such as a significant change or
modification in design, material, chemical composition, energy source or
manufacturing process. Any change in the intended uses of a PMA device or a
510(k) device requires an approval supplement or cleared premarket notification.
Exported devices are subject to the regulatory requirements of each country
to
which the device is exported, as well as certain FDA export requirements.
A
company
that intends to manufacture medical devices is required to register with the
FDA
before it begins to manufacture the device for commercial distribution. As
a
result, we and any entity that manufactures products on our behalf will be
subject to periodic inspection by the FDA for compliance with the FDA’s Quality
System Regulation requirements and other regulations. In the European Community,
we will be required to maintain certain International Organization for
Standardization (“ISO”) certifications in order to sell products and we or our
manufacturers undergo periodic inspections by notified bodies to obtain and
maintain these certifications. These regulations require us or our manufacturers
to manufacture products and maintain documents in a prescribed manner with
respect to design, manufacturing, testing and control activities. Further,
we
are required to comply with various FDA and other agency requirements for
labeling and promotion. The Medical Device Reporting regulations require that
we
provide information to the FDA whenever there is evidence to reasonably suggest
that a device may have caused or contributed to a death or serious injury or,
if
a malfunction were to occur, could cause or contribute to a death or serious
injury. In addition, the FDA prohibits us from promoting a medical device for
unapproved indications.
The
FDA
in the course of enforcing the FD&C Act may subject a company to various
sanctions for violating FDA regulations or provisions of the Act, including
requiring recalls, issuing Warning Letters, seeking to impose civil money
penalties, seizing devices that the agency believes are non-compliant, seeking
to enjoin distribution of a specific type of device or other product, seeking
to
revoke a clearance or approval, seeking disgorgement of profits and seeking
to
criminally prosecute a company and its officers and other responsible parties.
The
levels of revenues and profitability of biopharmaceutical companies may be
affected by the continuing efforts of government and third party payers to
contain or reduce the costs of health care through various means. For example,
in certain foreign markets, pricing or profitability of therapeutic and other
pharmaceutical products is subject to governmental control. In the United
States, there have been, and we expect that there will continue to be, a number
of federal and state proposals to implement similar governmental control. In
addition, in the United States and elsewhere, sales of therapeutic and other
pharmaceutical products are dependent in part on the availability and adequacy
of reimbursement from third party payers, such as the government or private
insurance plans. Third party payers are increasingly challenging established
prices, and new products that are more expensive than existing treatments may
have difficulty finding ready acceptance unless there is a clear therapeutic
benefit. We cannot assure you that any of our products will be considered cost
effective, or that reimbursement will be available or sufficient to allow us
to
sell them competitively and profitably.
Our
instrumentation products are subject to regulation by the FDA and similar
international health authorities. We also have an obligation to adhere to
the
FDA’s cGMP regulations. Additionally, we are subject to periodic FDA
inspections, quality control procedures, and other detailed validation
procedures. If the FDA finds deficiencies in the validation of our manufacturing
and quality control practices, they may impose restrictions on marketing
specific products until corrected.
On
March
25, 2008, OTI received a warning letter in connection with an inspection
of
OTI
’
s
facilities. The warning letter cited several deficiencies in OTI’s quality
systems. We intend to fully cooperate with the FDA and have immediately begun
to
take corrective actions to remedy these deficiencies. See
“Manufacturing
and
Quality
”
below
.
We
are
also subject to various federal, state, and international laws pertaining to
health care “fraud and abuse,” including anti-kickback laws and false claims
laws. Anti-kickback laws make it illegal to solicit, offer, receive or pay
any
remuneration in exchange for, or to induce, the referral of business, including
the purchase or prescription of a particular drug or the use of a service or
device. Federal and state false claims laws prohibit anyone from knowingly
and
willingly presenting, or causing to be presented for payment to third-party
payors (including Medicare and Medicaid), claims for reimbursed drugs or
services that are false or fraudulent, claims for items or services not provided
as claimed, or claims for medically unnecessary items or services. If the
government were to allege against or convict us of violating these laws, there
could be a material adverse effect on us, including our stock price. Even an
unsuccessful challenge could cause adverse publicity and be costly to respond
to, which could have a materially adverse effect on our business, results of
operations and financial condition. We will consult counsel concerning the
potential application of these and other laws to our business and our sales,
marketing and other activities and will make good faith efforts to comply with
them. However, given their broad reach and the increasing attention given by
law
enforcement authorities, we cannot assure you that some of our activities will
not be challenged or deemed to violate some of these laws.
MANUFACTURING
AND QUALITY
We
currently have no pharmaceutical manufacturing facilities. We have entered
into
agreements with various third parties for the formulation and manufacture of
our
pharmaceutical clinical supplies. These suppliers and their manufacturing
facilities must comply with FDA regulations, current good laboratory practices,
or cGLPs, and current good manufacturing practices, or cGMPs. We plan to
outsource the manufacturing and formulation of our clinical
supplies.
OTI
has an instrumentation manufacturing facility in Toronto, Canada which
predominantly performs high level assembly. Certain of OTI’s components and
optical subsystems are produced by sub-contracted vendors that specialize in
optical device manufacturing.
On
March
25, 2008, OTI received a warning letter in connection with a FDA inspection
of
OTI’s facilities in July and August of 2007. The warning letter cited several
deficiencies in OTI’s quality, record keeping, and reporting systems relating to
certain of OTI’s products, including the OTI Scan 1000, OTI Scan 2000, and OTI
OCT/SLO combination imaging system. Based upon the observations noted in
the
warning letter, OTI is not currently in compliance with cGMP. The FDA indicated
that it has issued an Import Alert and may refuse admission of these products.
As a result, we will not be permitted to sell these devices in the United
States, and the pre-market approval application for the Company’s OCT/SLO
product will be delayed until the violations have been corrected.
We
plan
to cooperate fully with the FDA, and upon receipt of the warning letter,
we
immediately began to take corrective action to address the FDA’s concerns and to
assure the quality of OTI’s products. We are committed to providing high quality
products to our customers, and we plan to meet this commitment by working
diligently to remedy these deficiencies and to implement updated and improved
quality systems and concepts throughout the OTI organization.
SALES
& MARKETING
We
currently do not have pharmaceutical sales or marketing personnel. In order
to
commercialize any pharmaceutical products that are approved for commercial
sale,
we must either build a sales and marketing infrastructure or collaborate with
third parties with sales and marketing experience.
Our
instrumentation division presently has an eight-person sales and marketing
staff, including three salespersons calling on retinal specialists and
ophthalmologists, that is beginning to market our OTI products. OTI has offices
in Canada, the United States and the United Kingdom and a growing distributor
network that currently covers more than 60 countries. Our strategy is to
increase sales of existing products through expansion of our sales channel
in
the United States and to provide additional marketing resources to our
international distributor network.
SERVICE
& SUPPORT
We
currently offer service and telephone support for all of our marketed
instrumentation products. Warranties are given on all products against defects
and performance for a period of one year. Extended Service Contracts are
available for purchase. Product repairs are performed at our Toronto facility.
EMPLOYEES
As
of
December 31, 2007, we have 57 full-time employees. We plan to add to our
headcount in key functional areas that will allow us to further the development
of our product candidates. None of our employees are represented by a collective
bargaining agreement.
MANAGEMENT
Executive
Officers
The
following table sets forth information concerning our current executive
officers, including their ages:
Name
|
|
Age
|
|
Title
|
Phillip
Frost, M.D.
|
|
71
|
|
Chief
Executive Officer and Chairman of the Board
|
|
|
|
|
|
Jane
H. Hsiao, Ph.D., MBA
|
|
60
|
|
Chief
Technical Officer and Vice Chairman
|
|
|
|
|
|
Steven
D. Rubin
|
|
47
|
|
Executive
Vice President - Administration and Director
|
|
|
|
|
|
Rao
Uppaluri, Ph.D.
|
|
58
|
|
Senior
Vice President and Chief Financial Officer
|
|
|
|
|
|
Naveed
K. Shams, M.D., Ph.D.
|
|
51
|
|
Senior
Vice President - Research and Development and Chief Medical
Officer
|
Phillip
Frost, M.D.
Dr.
Frost
became the CEO and Chairman of OPKO Health, Inc. upon the consummation of the
merger of Acuity Pharmaceuticals Inc., Froptix Corporation and eXegenics, Inc.
on March 27, 2007 (referred to as the “Acquisition”). Dr. Frost was named
the Vice Chairman of the Board of Teva Pharmaceutical Industries, Limited,
or
Teva, in January 2006 when Teva acquired IVAX Corporation, or IVAX. Dr. Frost
had served as Chairman of the Board of Directors and Chief Executive Officer
of
IVAX Corporation since 1987. He was Chairman of the Department of Dermatology
at
Mt. Sinai Medical Center of Greater Miami, Miami Beach, Florida from 1972 to
1986. Dr. Frost was Chairman of the Board of Directors of Key Pharmaceuticals,
Inc. from 1972 until the acquisition of Key Pharmaceuticals by Schering Plough
Corporation in 1986. Dr. Frost was named Chairman of the Board of Ladenburg
Thalmann Financial Services Inc., an investment banking, asset management,
and
securities brokerage firm providing services through its principal operating
subsidiary, Ladenburg Thalmann & Co. Inc., in July 2006 and has been a
director of Ladenburg Thalmann since March 2005. Dr. Frost also serves as
Chairman of the Board of Directors of Ideation Acquisition Corp., a special
purpose acquisition company formed for the purpose of acquiring businesses
in
digital media, and Modigene Inc., a development stage biopharmaceutical company.
He serves on the Board of Regents of the Smithsonian Institution, a member
of
the Board of Trustees of the University of Miami, a Trustee of each of the
Scripps Research Institutes, the Miami Jewish Home for the Aged, and the Mount
Sinai Medical Center and is Co-Vice Chairman of the Board of Governors of the
American Stock Exchange. Dr. Frost is also a director of Continucare
Corporation, a provider of outpatient healthcare and home healthcare services,
and Northrop Grumman Corp., a global defense and aerospace company.
Jane
H. Hsiao, Ph.D., MBA.
Dr.
Hsiao
has served as Vice-Chairman and Chief Technical Officer of the Company since
May
2007. Dr. Hsiao served as the Vice Chairman-Technical Affairs of IVAX from
1995
to January 2006, when Teva acquired IVAX. Dr. Hsiao served as IVAX’s Chief
Technical Officer since 1996, and as Chairman, Chief Executive Officer and
President of IVAX Animal Health, IVAX’s veterinary products subsidiary, since
1998. From 1992 until 1995, Dr. Hsiao served as IVAX’s Chief Regulatory Officer
and Assistant to the Chairman. Dr. Hsiao has served as Chairman of the Board
of
Safestitch Medical, Inc., a medical device company, since September 2007. Dr.
Hsiao is also a director of Modigene, Inc., a development stage
biopharmaceutical company.
Steven
D. Rubin.
Mr.
Rubin
has served as Executive Vice President - Administration since May 2007 and
a
director of the Company since February 2007. Mr. Rubin served as the Senior
Vice
President, General Counsel and Secretary of IVAX from August 2001 until
September 2006. Prior to joining IVAX, Mr. Rubin was Senior Vice President,
General Counsel and Secretary with privately-held Telergy, Inc., a provider
of
business telecommunications and diverse optical network solutions, from early
2000 to August 2001. In addition, he was with the Miami law firm of Stearns
Weaver Miller Weissler Alhadeff & Sitterson from 1986 to 2000, in the
Corporate and Securities Department. Mr. Rubin had been a shareholder of that
firm since 1991 and a director since 1998. Mr. Rubin currently serves on the
board of directors of Dreams, Inc., a vertically integrated sports licensing
and
products company, Safestitch Medical, Inc., a medical device company, Ideation
Acquisition Corp., a special purpose acquisition company formed for the purpose
of acquiring businesses in digital media,
Modigene,
Inc., a development stage biopharmaceutical company, and Longfoot Communications
Corp., a public shell company seeking to identify a merger or business
combination candidate
.
Rao
Uppaluri, Ph.D.
Dr.
Uppaluri has served as our Senior Vice President and Chief Financial Officer
since May, 2007. Dr. Uppaluri served as the Vice President, Strategic Planning
and Treasurer of IVAX from 1997 until December 2006. Before joining IVAX,
from 1987 to August 1996, Dr. Uppaluri was Senior Vice President, Senior
Financial Officer and Chief Investment Officer with Intercontinental Bank,
a
publicly traded commercial bank in Florida. In addition, he served in various
positions, including Senior Vice President, Chief Investment Officer and
Controller, at Peninsula Federal Savings & Loan Association, a publicly
traded Florida S&L, from October 1983 to 1987. His prior employment, during
1974 to 1983, included engineering, marketing and research positions with
multinational companies and research institutes in India and the United States.
Dr. Uppaluri currently serves on the board of directors of Ideation Acquisition
Corp., a special purpose acquisition company formed for the purpose of acquiring
businesses in digital media,
and
Longfoot Communications Corp., a public shell company seeking to identify a
merger or business combination candidate
.
Naveed
Shams, M.D., Ph.D
.
Dr.
Shams has served as Chief Medical Officer and Senior Vice President of Research
and Development since January 2008. Prior to joining the Company, Dr. Shams
served from September 2003 through November 2007 as Senior Medical Director,
Head Ophthalmic Medical Affairs and Post-Marketing Team Leader at Genentech,
Inc., a pharmaceutical company, where he led the clinical team responsible
for
launching Lucentis®. Previously, Dr. Shams was also a Director, Clinical Science
for Novartis Ophthalmics, Inc. from April 1998 through September 2003, and
Senior Scientist and Glaucoma Group Leader-Discovery for Storz Ophthalmics
from
January 1995 through March 1998. Before joining industry, Dr. Shams was a member
of the Research Faculty at the Schepen’s Eye Research Institute and Department
of Ophthalmology at Harvard Medical School.
Code
of Ethics
We
have
adopted a Code of Business Conduct and Ethics. We require all employees,
including our principal executive officer and principal accounting officer
and
other senior officers and our employee directors, to read and to adhere to
the
Code of Business Conduct and Ethics in discharging their work-related
responsibilities. Employees are required to report any conduct that they
believe
in good faith to be an actual or apparent violation of the Code of Business
Conduct and Ethics. The Code of Business Conduct and Ethics is available
on our
website at http://www.OPKO.com.
You
should carefully consider the risks described below, as well as other
information contained in this report, including the consolidated financial
statements and the notes thereto and “Management’s Discussion and Analysis of
Financial Condition and results of operations.” The occurrence of any of the
events discussed below could significantly and adversely affect our business,
prospects, results of operations, financial condition, and cash flows.
RISKS
RELATED TO OUR BUSINESS
The
occurrence of any of the events discussed below could significantly and
adversely affect our business, prospects, results of operations, financial
condition, and cash flows:
We
have a history of operating losses and we do not expect to become profitable
in
the near future.
We
are a
specialty healthcare company with a limited operating history. We are not
profitable and have incurred losses since our inception. We do not anticipate
that we will generate revenue from the sale of pharmaceutical products for
the
foreseeable future and we have generated limited revenue from our ophthalmic
instrumentation business. We have not yet submitted any pharmaceutical products
for approval or clearance by regulatory authorities and we do not currently
have
rights to any pharmaceutical product candidates that have been approved for
marketing. We continue to incur research and development and general and
administrative expenses related to our operations and, to date, we have devoted
most of our financial resources to research and development, including our
pre-clinical development activities and clinical trials. We expect to continue
to incur losses from our operations for the foreseeable future, and we expect
these losses to increase as we continue our research activities and conduct
development of, and seek regulatory approvals and clearances for, our product
candidates, and prepare for and begin to commercialize any approved or cleared
products. If our product candidates fail in clinical trials or do not gain
regulatory approval or clearance, or if our product candidates do not achieve
market acceptance, we may never become profitable. In addition, if we are
required by the U.S. Food and Drug Administration, or the FDA, to perform
studies in addition to those we currently anticipate, our expenses will increase
beyond expectations and the timing of any potential product approval may be
delayed. Even if we achieve profitability in the future, we may not be able
to
sustain profitability in subsequent periods.
Our
technologies are in an early stage of development and are
unproven.
We
are
engaged in the research and development of pharmaceutical products, drug
delivery technologies, and diagnostic systems and instruments for the treatment
and prevention of ophthalmic diseases. The effectiveness of our technologies
is
not well-known in, or accepted generally by, the clinical medical community.
There can be no assurance that we will be able to successfully employ our
technologies as therapeutic, diagnostic, or preventative solutions for any
ophthalmic disease. Our failure to establish the efficacy or safety of our
technologies would have a material adverse effect on our business.
In
addition, we have a limited operating history. Our operations to date have
been
primarily limited to organizing and staffing our company, developing our
technology, and undertaking pre-clinical studies and clinical trials of our
product candidates. We have not yet obtained regulatory approvals for any of
our
pharmaceutical product candidates. Consequently, any predictions you make about
our future success or viability may not be as accurate as they could be if
we
had a longer operating history.
Our
product research and development activities may not result in commercially
viable products.
Most
of
our product candidates are in the very early stages of development and are
prone
to the risks of failure inherent in drug and medical device product development.
We will likely be required to complete and undertake significant additional
clinical trials to demonstrate to the FDA that our product candidates are safe
and effective to the satisfaction of the FDA and other non-United States
regulatory authorities or for their intended uses, or are substantially
equivalent in terms of safety and effectiveness to an existing, lawfully
marketed non-premarket approved device. Clinical trials are expensive and
uncertain processes that often take years to complete. Failure can occur at
any
stage of the process, and successful early positive results do not ensure that
the entire clinical trial or later clinical trials will be successful. Product
candidates in clinical-stage trials may fail to show desired efficacy and safety
traits despite early promising results.
We
are highly dependent on the success of our lead product candidate, bevasiranib,
and our failure to commercialize bevasiranib, or the experience of significant
delays in doing so, would have a material adverse effect on our business,
results of operation, and financial condition.
We
have
invested a significant portion of our efforts and financial resources in the
development of bevasiranib. Bevasiranib has been studied in a Phase II clinical
drug trial for the treatment of Wet AMD, and we are presently studying
bevasiranib in Phase III clinical trials. Our Phase III clinical trials may
not
be successful, and bevasiranib may never receive regulatory approval or be
successfully commercialized. Our clinical development program for bevasiranib
may not receive regulatory approval if we fail to demonstrate that it is safe
and effective in clinical trials and, consequently, fail to obtain necessary
approvals from the FDA, or similar non-United States regulatory agencies, or
if
we have inadequate financial or other resources to advance bevasiranib through
the clinical trial process. Even if bevasiranib receives regulatory approval,
its approved labeling may be insufficient to permit adequate marketing. We
may
not be successful in marketing it for a number of other reasons, including
the
introduction by our competitors of more clinically-effective or cost-effective
alternatives or failure in our sales and marketing efforts. Any failure to
obtain approval of bevasiranib and successfully commercialize it would have
a
material and adverse impact on our business.
The
results of pre-clinical trials and previous clinical trials may not be
predictive of future results, and our current and planned clinical trials may
not satisfy the requirements of the FDA or other non-United States regulatory
authorities.
Positive
results from pre-clinical studies and early clinical trial experience should
not
be relied upon as evidence that later-stage or large-scale clinical trials
will
succeed. We will be required to demonstrate with substantial evidence through
well-controlled clinical trials that our product candidates either (i) are
safe
and effective for use in a diverse population of their intended uses or (ii)
with respect to Class I or Class II devices only, are substantially equivalent
in terms of safety and effectiveness to devices that are already marketed under
section 510(k) of the Food, Drug and Cosmetic Act. Success in early clinical
trials does not mean that future clinical trials will be successful because
product candidates in later-stage clinical trials may fail to demonstrate
sufficient safety and efficacy to the satisfaction of the FDA and other
non-United States regulatory authorities despite having progressed through
initial clinical trials.
Further,
our drug candidates may not be approved or cleared even if they achieve their
primary endpoints in Phase III clinical trials or registration trials nor may
our device candidates be approved or cleared, as the case may be, even though
clinical or other data are, in our view, adequate to support a device approval
or clearance. The FDA or other non-United States regulatory authorities may
disagree with our trial design and our interpretation of data from pre-clinical
studies and clinical trials. In addition, any of these regulatory authorities
may change requirements for the approval or clearance of a product candidate
even after reviewing and providing comment on a protocol for a pivotal clinical
trial that has the potential to result in FDA approval. In addition, any of
these regulatory authorities may also approve or clear a product candidate
for
fewer or more limited indications or uses than we request or may grant approval
or clearance contingent on the performance of costly post-marketing clinical
trials. In addition, the FDA or other non-United States regulatory authorities
may not approve the labeling claims necessary or desirable for the successful
commercialization of our product candidates.
In
addition, the results of our clinical trials may show that our product
candidates may cause undesirable side effects, which could interrupt, delay
or
halt clinical trials, resulting in the denial of regulatory approval by the
FDA
and other regulatory authorities.
In
light
of widely publicized events concerning the safety risk of certain drug products,
regulatory authorities, members of Congress, the Government Accounting Office,
medical professionals, and the general public have raised concerns about
potential drug safety issues. These events have resulted in the withdrawal
of
drug products, revisions to drug labeling that further limit use of the drug
products, and establishment of risk management programs that may, for instance,
restrict distribution of drug products. The increased attention to drug safety
issues may result in a more cautious approach by the FDA to clinical trials.
Data from clinical trials may receive greater scrutiny with respect to safety,
which may make the FDA or other regulatory authorities more likely to terminate
clinical trials before completion, or require longer or additional clinical
trials that may result in substantial additional expense and a delay or failure
in obtaining approval or approval for a more limited indication than originally
sought.
We
will require substantial additional funding, which may not be available to
us on
acceptable terms, or at all.
We
are
advancing and intend to continue to advance multiple product candidates through
clinical and pre-clinical development. We believe that our existing cash and
cash equivalents and short-term investments will be sufficient to enable us
to
fund our operating expenses and capital expenditure requirements at least for
the next twelve months. We have based this estimate on assumptions that may
prove to be wrong or subject to change, and we may be required to use our
available capital resources sooner than we currently expect. Because of the
numerous risks and uncertainties associated with the development and
commercialization of our product candidates, we are unable to estimate the
amounts of increased capital outlays and operating expenditures associated
with
our current and anticipated clinical trials. Our future capital requirements
will depend on a number of factors, including the continued progress of our
research and development of product candidates, the timing and outcome of
clinical trials and regulatory approvals, the costs involved in preparing,
filing, prosecuting, maintaining, defending, and enforcing patent claims and
other intellectual property rights, the status of competitive products, the
availability of financing, and our success in developing markets for our product
candidates.
We
will
need to raise substantial additional capital to engage in and continue our
clinical and pre-clinical development, and commercialization activities. Until
we can generate a sufficient amount of product revenue to finance our cash
requirements, which we may never do, we expect to finance future cash needs
primarily through public or private equity offerings, debt financings, or
strategic collaborations. We do not know whether additional funding will be
available on acceptable terms, or at all. If we are not able to secure
additional funding when needed, we may have to delay, reduce the scope of,
or
eliminate one or more of our clinical trials or research and development
programs. To the extent that we raise additional funds by issuing equity
securities, our stockholders may experience additional significant dilution,
and
debt financing, if available, may involve restrictive covenants. To the extent
that we raise additional funds through collaboration and licensing arrangements,
it may be necessary to relinquish some rights to our technologies or our product
candidates or grant licenses on terms that may not be favorable to us. We may
seek to access the public or private capital markets whenever conditions are
favorable, even if we do not have an immediate need for additional capital
at
that time.
If
our competitors develop and market products that are more effective, safer
or
less expensive than our future product candidates, our commercial opportunities
will be negatively impacted.
The
life
sciences industry is highly competitive, and we face significant competition
from many pharmaceutical, biopharmaceutical, biotechnology, and medical device
companies that are researching and marketing products designed to address AMD
and other ophthalmic diseases and conditions our products are designed to
diagnose, treat, or prevent. We are currently developing therapeutic,
diagnostic, and preventative products that will compete with other drugs,
therapies, and medical devices that currently exist or are being developed.
Products we may develop in the future are also likely to face competition from
other drugs, therapies, and medical devices. Many of our competitors have
significantly greater financial, manufacturing, marketing, and drug development
resources than we do. Large pharmaceutical companies, in particular, have
extensive experience in clinical testing and in obtaining regulatory approvals
or clearances for drugs or medical devices. These companies also have
significantly greater research and marketing capabilities than we do. Some
of
the pharmaceutical companies we expect to compete with include Genentech,
Allergan, Alcon Laboratories, Regeneron, QLT, Pfizer, Alnylam, and Bausch &
Lomb. In addition, many universities and private and public research
institutions may become active in ophthalmic disease research. Compared to
us,
many of our potential competitors have substantially greater capital resources,
development resources, including personnel and technology, clinical trial
experience, regulatory experience, expertise in prosecution of intellectual
property rights, manufacturing and distribution experience, and sales and
marketing experience. The development of other promising drugs for the treatment
of Dry AMD, which in certain patients is the precursor to Wet AMD, could
materially adversely affect the prospects for bevasiranib and other treatments
for Wet AMD.
We
believe that our ability to successfully compete will depend on, among other
things:
|
·
|
the
results of our clinical trials;
|
|
·
|
our
ability to recruit and enroll patients for our clinical
trials;
|
|
·
|
the
efficacy, safety and reliability of our product
candidates;
|
|
·
|
the
speed at which we develop our product
candidates;
|
|
·
|
our
ability to commercialize and market any of our product candidates
that may
receive regulatory approval or
clearance;
|
|
·
|
our
ability to design and successfully execute appropriate clinical
trials;
|
|
·
|
the
timing and scope of regulatory approvals or
clearances;
|
|
·
|
appropriate
coverage and adequate levels of reimbursement under private and
governmental health insurance plans, including
Medicare;
|
|
·
|
our
ability to protect intellectual property rights related to our
products;
|
|
·
|
our
ability to have our partners manufacture and sell commercial quantities
of
any approved products to the market;
and
|
|
·
|
acceptance
of future product candidates by physicians and other health care
providers.
|
If
our
competitors market products that are more effective, safer, easier to use or
less expensive than our future product candidates, if any, or that reach the
market sooner than our future product candidates, if any, we may not achieve
commercial success. In addition, both the biopharmaceutical and medical device
industries are characterized by rapid technological change. Because our research
approach integrates many technologies, it may be difficult for us to stay
abreast of the rapid changes in each technology. If we fail to stay at the
forefront of technological change, we may be unable to compete effectively.
Technological advances or products developed by our competitors may render
our
technologies or product candidates obsolete or less competitive.
Our
product development activities could be delayed or
stopped.
We
do not
know whether our planned clinical trials will be completed on schedule, or
at
all, and we cannot guarantee that our planned clinical trials will begin on
time
or at all. The commencement of our planned clinical trials could be
substantially delayed or prevented by several factors, including:
|
·
|
a
limited number of, and competition for, suitable patients with the
particular types of ophthalmic disease required for enrollment in
our
clinical trials or that otherwise meet the protocol’s inclusion criteria
and do not meet any of the exclusion
criteria;
|
|
·
|
a
limited number of, and competition for, suitable sites to conduct
our
clinical trials;
|
|
·
|
delay
or failure to obtain FDA approval or agreement to commence a clinical
trial;
|
|
·
|
delay
or failure to obtain sufficient supplies of the product candidate
for our
clinical trials;
|
|
·
|
requirements
to provide the drugs or medical devices required in our clinical
trial
protocols or clinical trials at no cost or cost, which may require
significant expenditures that we are unable or unwilling to
make;
|
|
·
|
delay
or failure to reach agreement on acceptable clinical trial agreement
terms
or clinical trial protocols with prospective sites or investigators;
and
|
|
·
|
delay
or failure to obtain institutional review board, or IRB, approval
to
conduct or renew a clinical trial at a prospective or accruing
site.
|
The
completion of our clinical trials could also be substantially delayed or
prevented by several factors, including:
|
·
|
slower
than expected rates of patient recruitment and
enrollment;
|
|
·
|
failure
of patients to complete the clinical
trial;
|
|
·
|
unforeseen
safety issues;
|
|
·
|
lack
of efficacy evidenced during clinical
trials;
|
|
·
|
termination
of our clinical trials by one or more clinical trial
sites;
|
|
·
|
inability
or unwillingness of patients or medical investigators to follow our
clinical trial protocols; and
|
|
·
|
inability
to monitor patients adequately during or after
treatment.
|
Our
clinical trials may be suspended or terminated at any time by the FDA, other
regulatory authorities, the IRB for any given site, or us. Additionally, changes
in regulatory requirements and guidance may occur and we may need to amend
clinical trial protocols to reflect these changes with appropriate regulatory
authorities. Amendments may require us to resubmit our clinical trial protocols
to IRBs for re-examination, which may impact the costs, timing, or successful
completion of a clinical trial. Any failure or significant delay in completing
clinical trials for our product candidates could materially harm our financial
results and the commercial prospects for our product candidates.
The
regulatory approval process is expensive, time consuming and uncertain and
may
prevent us or our collaboration partners from obtaining approvals for the
commercialization of some or all of our product
candidates.
The
research, testing, manufacturing, labeling, approval, selling, marketing, and
distribution of drug products or medical devices are subject to extensive
regulation by the FDA and other non-United States regulatory authorities, which
regulations differ from country to country. We are not permitted to market
our
product candidates in the United States until we receive approval of a new
drug
application, or NDA, a clearance letter under the premarket notification
process, or 510(k) process, or an approval of a pre-market approval, or PMA,
from the FDA. We have not submitted an NDA or PMA application or premarket
notification, nor have we received marketing approval or clearance for any
of
our pharmaceutical product candidates. Obtaining approval of an NDA or PMA
can
be a lengthy, expensive, and uncertain process. With respect to medical devices,
while the FDA reviews and clears a premarket notification in as little
as three months, there is no guarantee that our products will qualify for
this more expeditious regulatory process, which is reserved for Class I and
II
devices, nor is there any assurance that even if a device is reviewed under
the
510(k) process that the FDA will review it expeditiously or determine that
the
device is substantially equivalent to a lawfully marketed non-PMA device. If
the
FDA fails to make this finding, then we cannot market the device. In lieu of
acting on a premarket notification, the FDA may seek additional information
or
additional data which would further delay our ability to market the product.
Furthermore, we are not permitted to make changes to a device approved through
the PMA or 510(k) which affects the safety or efficacy of the device without
first submitting a supplement application to the PMA and obtaining FDA approval
or cleared premarket notification for that supplement. In some cases, the FDA
may require clinical trials to support a supplement application. In addition,
failure to comply with FDA, non-United States regulatory authorities, or other
applicable United States and non-United States regulatory requirements may,
either before or after product approval or clearance, if any, subject our
company to administrative or judicially imposed sanctions, including, but not
limited to the following:
|
·
|
restrictions
on the products, manufacturers, or manufacturing
process;
|
|
·
|
adverse
inspectional observations (Form 483), warning letters, or non-warning
letters incorporating inspectional
observations;
|
|
·
|
civil
and criminal penalties;
|
|
·
|
suspension
or withdrawal of regulatory approvals or
clearances;
|
|
·
|
product
seizures, detentions, or import
bans;
|
|
·
|
voluntary
or mandatory product recalls and publicity
requirements;
|
|
·
|
total
or partial suspension of
production;
|
|
·
|
imposition
of restrictions on operations, including costly new manufacturing
requirements; and
|
|
·
|
refusal
to approve or clear pending NDAs or supplements to approved NDAs,
applications or pre-market notifications.
|
Regulatory
approval of an NDA or NDA supplement, PMA, PMA supplement or clearance pursuant
to a pre-market notification is not guaranteed, and the approval or clearance
process, as the case may be, is expensive and may, especially in the case of
an
NDA or PMA application, take several years. The FDA also has substantial
discretion in the drug and medical device approval and clearance process.
Despite the time and expense exerted, failure can occur at any stage, and we
could encounter problems that cause us to abandon clinical trials or to repeat
or perform additional pre-clinical studies and clinical trials. The number
of
pre-clinical studies and clinical trials that will be required for FDA approval
or clearance varies depending on the drug or medical device candidate, the
disease or condition that the drug or medical device candidate is designed
to
address, and the regulations applicable to any particular drug or medical device
candidate. The FDA can delay, limit or deny approval or clearance of a drug
or
medical device candidate for many reasons, including:
|
·
|
a
drug candidate may not be deemed safe or
effective;
|
|
·
|
a
medical device candidate may not be deemed to be substantially equivalent
to a lawfully marketed non-PMA device, in the case of a premarket
notification.
|
|
·
|
FDA
officials may not find the data from pre-clinical studies and clinical
trials sufficient;
|
|
·
|
the
FDA might not approve our or our third-party manufacturer’s processes or
facilities; or
|
|
·
|
the
FDA may change its approval or clearance policies or adopt new
regulations.
|
The
Company may, at some future date, seek approval of one or more drugs under
the
Federal Food, Drug, and Cosmetic Act, or FDCA, § 505(b)(2) which permits a
manufacturer to submit an NDA for an existing drug compound for intended uses
that have already been approved by the FDA, but with certain different
characteristics, such as a different route of administration. Section 505(b)(2)
allows a company to reference the clinical data already collected by the NDA
of
the drug supplemented by clinical trial results that address the change (e.g.,
route of administration). The Company is not presently involved in clinical
trials for a section 505(b)(2) drug or the submission of an NDA for such a
drug,
but could be in the future. If the Company were to submit an NDA under that
section, the Company could be sued for patent infringement by the pharmaceutical
company that owns the patent on the existing approved NDA drug. Such a suit
would automatically preclude the FDA from processing our NDA for 30 months
and
possibly longer. Defending such a suit would be costly. If we were to lose
the
litigation, we could be precluded from marketing the product until the NDA
holder’s patent expires. Such an adverse result would interfere without
strategic plans and would therefore have adverse financial implications for
the
company.
Our
product candidates may have undesirable side effects and cause our approved
drugs to be taken off the market.
If
a
product candidate receives marketing approval and we or others later identify
undesirable side effects caused by such products:
|
·
|
regulatory
authorities may require the addition of labeling statements, specific
warnings, a contraindication, or field alerts to physicians and
pharmacies;
|
|
·
|
regulatory
authorities may withdraw their approval of the product and require
us to
take our approved drug off the
market;
|
|
·
|
we
may be required to change the way the product is administered, conduct
additional clinical trials, or change the labeling of the
product;
|
|
·
|
we
may have limitations on how we promote our
drugs;
|
|
·
|
sales
of products may decrease
significantly;
|
|
·
|
we
may be subject to litigation or product liability claims;
and
|
|
·
|
our
reputation may suffer.
|
Any
of
these events could prevent us from achieving or maintaining market acceptance
of
the affected product or could substantially increase our commercialization
costs
and expenses, which in turn could delay or prevent us from generating
significant revenues from its sale.
We
may be unable to resolve issues related to an FDA warning letter in a timely
manner, which could delay the production and sale of our instrumentation
products.
We
are
currently taking remedial action in response to certain deficiencies in OTI’s
quality systems as cited by the FDA in a warning letter to OTI dated March
25,
2008. The warning letter noted several deficiencies in OTI’s quality control
systems relating to certain products. As stated in the warning letter, the
FDA
issued an Import Alert and may refuse admission of OTI’s Scan 1000, Scan 2000,
and OCT/SLO combination imaging system products. As a result, we will not
permitted to sell these devices in the United States, and pre-market approval
applications for the Company’s OCT/SLO product will be delayed until the
violations have been corrected.
While
we
intend to work with the FDA to resolve these issues, this work will require
the
dedication of significant incremental internal and external resources and
will
impede our ability to sell these products in the United States. There
can be no assurances regarding the length of time or cost it will take us
to
resolve these quality issues to our satisfaction and to the satisfaction of
the FDA. If our remedial actions are not satisfactory to the FDA, we may
have to
devote additional financial and human resources to our efforts, and the FDA
may
take further regulatory actions against us including, but not limited to,
assessing civil monetary penalties or imposing a consent decree on us, which
could result in further regulatory constraints, including the governance
of our
quality system by a third party. Our inability to resolve these issues or
the
taking of further regulatory action by the FDA may weaken our competitive
position and have a material adverse effect on our operations.
We
may not meet regulatory quality standards applicable to our manufacturing
and
quality processes, which could have an adverse effect on our business, financial
condition and results of operations.
As
a
medical device manufacturer, we are required to register with the FDA and
are
subject to periodic inspection by the FDA for compliance with its Quality
System
Regulation (QSR) requirements, which require manufacturers of medical devices
to
adhere to certain regulations, including testing, quality control and
documentation procedures. Compliance with applicable regulatory requirements
is
subject to continual review and is monitored rigorously through periodic
inspections by the FDA. In addition, most international jurisdictions have
adopted regulatory approval and periodic renewal requirements for medical
devices, and we must comply with these requirements in order to market our
products in these jurisdictions. In the European Community, we are required
to
maintain certain ISO certifications in order to sell our products and must
undergo periodic inspections by notified bodies to obtain and maintain these
certifications. Further, some emerging markets rely on the FDA’s Certificate for
Foreign Government (CFG) in lieu of their own regulatory approval requirements.
Our FDA warning letter prevents our ability to obtain CFGs;
therefore, our ability to market new products or renew marketing approvals
in
countries that rely on CFGs may be impacted until the warning letter is
resolved.
If
we, or
our manufacturers, fail to adhere to quality system regulations or ISO
requirements, this could delay production of our products and lead to fines,
difficulties in obtaining regulatory clearances, recalls or other consequences,
which could, in turn, have a material adverse effect on our financial condition
or results of operations.
Even
if we obtain regulatory approvals or clearances for our product candidates,
the
terms of approvals and ongoing regulation of our products may limit how we
manufacture and market our product candidates, which could materially impair
our
ability to generate anticipated revenues.
Once
regulatory approval has been granted, the approved or cleared product and its
manufacturer are subject to continual review. Any approved or cleared product
may only be promoted for its indicated uses. In addition, if the FDA or other
non-United States regulatory authorities approve any of our product candidates,
the labeling, packaging, adverse event reporting, storage, advertising, and
promotion for the product will be subject to extensive regulatory requirements.
We and the manufacturers of our products are also required to comply with
current Good Manufacturing Practicing, or cGMP regulations, or the FDA’s QSR
regulations, which include requirements relating to quality control and quality
assurance as well as the corresponding maintenance of records and documentation.
Moreover, device manufacturers are required to report adverse events by filing
Medical Device Reports with the FDA, which reports are publicly available.
Further, regulatory agencies must approve manufacturing facilities before they
can be used to manufacture our products, and these facilities are subject to
ongoing regulatory inspection. If we fail to comply with the regulatory
requirements of the FDA and other non-United States regulatory authorities,
or
if previously unknown problems with our products, manufacturers, or
manufacturing processes are discovered, we could be subject to administrative
or
judicially imposed sanctions.
In
addition, the FDA and other non-United States regulatory authorities may change
their policies and additional regulations may be enacted that could prevent
or
delay regulatory approval or clearance of our product candidates. We cannot
predict the likelihood, nature or extent of government regulation that may
arise
from future legislation or administrative action, either in the United States
or
abroad. If we are not able to maintain regulatory compliance, we would likely
not be permitted to market our future product candidates and we may not achieve
or sustain profitability.
Even
if we receive regulatory approval or clearance to market our product candidates,
the market may not be receptive to our products.
Even
if
our product candidates obtain regulatory approval or clearance, resulting
products may not gain market acceptance among physicians, patients, health
care
payors and/or the medical community. We believe that the degree of market
acceptance will depend on a number of factors, including:
|
·
|
timing
of market introduction of competitive
products;
|
|
·
|
the
safety and efficacy of our product compared to other
products;
|
|
·
|
prevalence
and severity of any side effects;
|
|
·
|
potential
advantages or disadvantages over alternative
treatments;
|
|
·
|
strength
of marketing and distribution
support;
|
|
·
|
price
of our future product candidates, both in absolute terms and relative
to
alternative treatments;
|
|
·
|
availability
of coverage and reimbursement from government and other third-party
payors;
|
|
·
|
potential
product liability claims;
|
|
·
|
limitations
or warnings contained in a product’s FDA-approved labeling;
and
|
|
·
|
changes
in the standard of care for the targeted indications for any of our
product candidates, which could reduce the marketing impact of any
claims
that we could make following FDA
approval.
|
In
addition, our efforts to educate the medical community and health care payors
on
the benefits of our product candidates may require significant resources and
may
never be successful.
If
our future product candidates fail to achieve market acceptance, we may not
be
able to generate significant revenue or achieve or sustain
profitability.
The
coverage and reimbursement status of newly approved or cleared drugs or medical
devices is uncertain, and failure of our pharmaceutical products and procedures
using our medical devices to be adequately covered by insurance and eligible
for
adequate reimbursement could limit our ability to market any future product
candidates we may develop and decrease our ability to generate revenue from
any
of our existing and future product candidates that may be approved or
cleared.
There
is
significant uncertainty related to the third-party coverage and reimbursement
of
newly approved or cleared drugs or medical devices. Many medical devices are
not
directly covered by insurance; instead, the procedure using the device is
subject to a coverage determination by the insurer. The commercial success
of
our existing and future product candidates in both domestic and international
markets will depend in part on the availability of coverage and adequate
reimbursement from third-party payors, including government payors, such as
the
Medicare and Medicaid programs, managed care organizations, and other
third-party payors. The government and other third-party payors are increasingly
attempting to contain health care costs by limiting both insurance coverage
and
the level of reimbursement for new drugs or devices and, as a result, they
may
not cover or provide adequate payment for our existing and future product
candidates. These payors may conclude that our future product candidates are
less safe, less effective, or less cost-effective than existing or
later-introduced products. These payors may also conclude that the overall
cost
of the procedure using one of our devices exceeds the overall cost of the
competing procedure using another type of device, and third-party payors may
not
approve our future product candidates for insurance coverage and adequate
reimbursement. The failure to obtain coverage and adequate or any reimbursement
for our existing and future product candidates, or health care cost containment
initiatives that limit or restrict reimbursement for our existing and future
product candidates, may reduce any future product revenue. Even though a drug
(not administered by a physician) may be approved by the FDA, this does not
mean
that a Prescription Drug Plan, or PDP, a private insurer operating under
Medicare part D, will list that drug on its formulary or will set a
reimbursement level. PDPs are not required to make every FDA-approved drug
available on their formularies. If our drug products are not listed on
sufficient number of PDP formularies or if the PDPs’ levels of reimbursement are
inadequate, the Company could be materially adversely affected.
If
we fail to attract and retain key management and scientific personnel, we may
be
unable to successfully develop or commercialize our product
candidates.
We
will
need to expand and effectively manage our managerial, operational, financial,
development, and other resources in order to successfully pursue our research,
development, and commercialization efforts for our existing and future product
candidates. Our success depends on our continued ability to attract, retain,
and
motivate highly qualified management and pre-clinical and clinical personnel.
The loss of the services or support of any of our senior management,
particularly Dr. Phillip Frost, our Chairman of the Board and Chief Executive
Officer, could delay or prevent the development and commercialization of our
product candidates. We do not maintain “key man” insurance policies on the lives
of any of our employees. We will need to hire additional personnel as we
continue to expand our research and development activities and build a sales
and
marketing function.
We
have
scientific and clinical advisors who assist us in formulating our research,
development, and clinical strategies. These advisors are not our employees
and
may have commitments to, or consulting or advisory contracts with, other
entities that may limit their availability to us. In addition, these advisors
may have arrangements with other companies to assist those companies in
developing products or technologies that may compete with ours.
We
may
not be able to attract or retain qualified management and scientific personnel
in the future due to the intense competition for qualified personnel among
biotechnology, pharmaceutical, medical device, and other similar businesses.
If
we are unable to attract and retain the necessary personnel to accomplish our
business objectives, we may experience constraints that will impede
significantly the achievement of our research and development objectives, our
ability to raise additional capital and our ability to implement our business
strategy. In particular, if we lose any members of our senior management team,
we may not be able to find suitable replacements in a timely fashion or at
all
and our business may be harmed as a result.
As
we evolve from a company primarily involved in development to a company also
involved in commercialization, we may encounter difficulties in managing our
growth and expanding our operations successfully.
As
we
advance our product candidates through clinical trials, research, and
development we will need to expand our development, regulatory, manufacturing,
marketing, and sales capabilities or contract with third parties to provide
these capabilities for us. As our operations expand, we expect that we will
need
to manage additional relationships with such third parties, as well as
additional collaborators and suppliers. Maintaining these relationships and
managing our future growth will impose significant added responsibilities on
members of our management. We must be able to: manage our development efforts
effectively; manage our clinical trials effectively; hire, train and integrate
additional management, development, administrative and sales and marketing
personnel; improve our managerial, development, operational and finance systems;
and expand our facilities, all of which may impose a strain on our
administrative and operational infrastructure.
Furthermore,
we may acquire additional businesses, products or product candidates that
complement or augment our existing business. Integrating any newly acquired
business or product could be expensive and time-consuming. We may not be able
to
integrate any acquired business or product successfully or operate any acquired
business profitably. Our future financial performance will depend, in part,
on
our ability to manage any future growth effectively and our ability to integrate
any acquired businesses. We may not be able to accomplish these tasks, and
our
failure to accomplish any of them could prevent us from successfully growing
our
company.
If
we fail to acquire and develop other products or product candidates at all
or on
commercially reasonable terms, we may be unable to diversify or grow our
business.
We
intend
to continue to rely on acquisitions and in-licensing as the source of our
products and product candidates for development and commercialization. The
success of this strategy depends upon our ability to identify, select, and
acquire pharmaceutical products, drug delivery technologies, and medical device
product candidates. Proposing, negotiating, and implementing an economically
viable product acquisition or license is a lengthy and complex process. We
compete for partnering arrangements and license agreements with pharmaceutical,
biotechnology and medical device companies, and academic research institutions.
Our competitors may have stronger relationships with third parties with whom
we
are interested in collaborating and/or may have more established histories
of
developing and commercializing products. As a result, our competitors may have
a
competitive advantage in entering into partnering arrangements with such third
parties. In addition, even if we find promising product candidates, and generate
interest in a partnering or strategic arrangement to acquire such product
candidates, we may not be able to acquire rights to additional product
candidates or approved products on terms that we find acceptable, or at
all.
We
expect
that any product candidate to which we acquire rights will require additional
development efforts prior to commercial sale, including extensive clinical
testing and approval or clearance by the FDA and other non-United States
regulatory authorities. All product candidates are subject to the risks of
failure inherent in pharmaceutical or medical device product development,
including the possibility that the product candidate will not be shown to be
sufficiently safe and effective for approval by regulatory authorities. Even
if
the product candidates are approved or cleared, we cannot be sure that they
would be capable of economically feasible production or commercial
success.
We
have no experience or capability manufacturing large clinical-scale or
commercial-scale products and have no pharmaceutical manufacturing facility;
we
therefore rely on third parties to manufacture and supply our pharmaceutical
product candidates.
We
believe we currently have, or can access, sufficient supplies of bevasiranib
to
conduct and complete our planned Phase III clinical trials. If our manufacturing
partners are unable to produce bevasiranib or our other products in the amounts
that we require, we may not be able to establish a contract and obtain a
sufficient alternative supply from another supplier on a timely basis and in
the
quantities we require. We expect to continue to depend on third-party contract
manufacturers for the foreseeable future.
Our
product candidates require precise, high quality manufacturing. Any of our
contract manufacturers will be subject to ongoing periodic unannounced
inspection by the FDA and other non-United States regulatory authorities to
ensure strict compliance with QSR regulations for devices or cGMPs for drugs,
and other applicable government regulations and corresponding standards relating
to matters such as testing, quality control, and documentation procedures.
If
our contract manufacturers fail to achieve and maintain high manufacturing
standards in compliance with QSR or cGMPs, we may experience manufacturing
errors resulting in patient injury or death, product recalls or withdrawals,
delays or interruptions of production or failures in product testing or
delivery, delay or prevention of filing or approval of marketing applications
for our products, cost overruns, or other problems that could seriously harm
our
business.
Any
performance failure on the part of our contract manufacturers could delay
clinical development or regulatory approval or clearance of our product
candidates or commercialization of our future product candidates, depriving
us
of potential product revenue and resulting in additional losses. In addition,
our dependence on a third party for manufacturing may adversely affect our
future profit margins. Our ability to replace an existing manufacturer may
be
difficult because the number of potential manufacturers is limited and the
FDA
must approve any replacement manufacturer before it can begin manufacturing
our
product candidates. Such approval would result in additional non-clinical
testing and compliance inspections. It may be difficult or impossible for us
to
identify and engage a replacement manufacturer on acceptable terms in a timely
manner, or at all.
We
currently have limited marketing staff, no pharmaceutical sales or distribution
capabilities and have only recently commenced developing medical device sales
capabilities in the United States. If we are unable to develop our
pharmaceutical sales and marketing and distribution capability and our medical
device sales and marketing capabilities in the United States on our own or
through collaborations with marketing partners, we will not be successful in
commercializing our pharmaceutical product candidates or our medical device
product candidates in the United States.
We
currently have no pharmaceutical marketing, sales or distribution capabilities.
We have only recently commenced developing medical device sales capabilities
in
the United States. If our pharmaceutical product candidates are approved, we
intend to establish our sales and marketing organization with technical
expertise and supporting distribution capabilities to commercialize our product
candidates, which will be expensive and time-consuming. Any failure or delay
in
the development of any of our internal sales, marketing, and distribution
capabilities would adversely impact the commercialization of our products.
With
respect to our existing and future pharmaceutical product candidates, we may
choose to collaborate with third parties that have direct sales forces and
established distribution systems, either to augment our own sales force and
distribution systems or in lieu of our own sales force and distribution systems.
To the extent that we enter into co-promotion or other licensing arrangements,
our product revenue is likely to be lower than if we directly marketed or sold
our products. In addition, any revenue we receive will depend in whole or in
part upon the efforts of such third parties, which may not be successful and
are
generally not within our control. If we are unable to enter into such
arrangements on acceptable terms or at all, we may not be able to successfully
commercialize our existing and future product candidates. If we are not
successful in commercializing our existing and future product candidates, either
on our own or through collaborations with one or more third parties, our future
product revenue will suffer and we may incur significant additional
losses.
Independent
clinical investigators and contract research organizations that we engage to
conduct our clinical trials may not be diligent, careful or
timely.
We
depend
on independent clinical investigators to conduct our clinical trials. Contract
research organizations may also assist us in the collection and analysis of
data. These investigators and contract research organizations will not be our
employees, and we will not be able to control, other than by contract, the
amount of resources, including time, that they devote to products that we
develop. If independent investigators fail to devote sufficient resources to
the
development of product candidates or clinical trials, or if their performance
is
substandard, it will delay the approval or clearance and commercialization
of
any products that we develop. Further, the FDA requires that we comply with
standards, commonly referred to as good clinical practice, for conducting,
recording and reporting clinical trials to assure that data and reported results
are credible and accurate and that the rights, integrity, and confidentiality
of
trial subjects are protected. If our independent clinical investigators and
contract research organizations fail to comply with good clinical practice,
the
results of our clinical trials could be called into question and the clinical
development of our product candidates could be delayed. Failure of clinical
investigators or contract research organizations to meet their obligations
to us
or comply with federal regulations and good clinical practice procedures could
adversely affect the clinical development of our product candidates and harm
our
business.
The
success of our business may be dependent on the actions of our collaborative
partners.
We
expect
to enter into collaborative arrangements with established multinational
pharmaceutical and medical device companies, which will finance or otherwise
assist in the development, manufacture and marketing of products incorporating
our technology. We anticipate deriving some revenues from research and
development fees, license fees, milestone payments, and royalties from
collaborative partners. Our prospects, therefore, may depend to some extent
upon
our ability to attract and retain collaborative partners and to develop
technologies and products that meet the requirements of prospective
collaborative partners. In addition, our collaborative partners may have the
right to abandon research projects and terminate applicable agreements,
including funding obligations, prior to or upon the expiration of the
agreed-upon research terms. There can be no assurance that we will be successful
in establishing collaborative arrangements on acceptable terms or at all, that
collaborative partners will not terminate funding before completion of projects,
that our collaborative arrangements will result in successful product
commercialization, or that we will derive any revenues from such arrangements.
To the extent that we are unable to develop and maintain collaborative
arrangements, we would need substantial additional capital to undertake
research, development, and commercialization activities on our own.
If
we are unable to obtain and enforce patent protection for our products, our
business could be materially harmed.
Our
success depends, in part, on our ability to protect proprietary methods and
technologies that we develop or license under the patent and other intellectual
property laws of the United States and other countries, so that we can prevent
others from unlawfully using our inventions and proprietary information.
However, we may not hold proprietary rights to some patents required for us
to
commercialize our proposed products. Because certain United States patent
applications are confidential until patents issue, such as applications filed
prior to November 29, 2000, or applications filed after such date for which
nonpublication has been requested, third parties may have filed patent
applications for technology covered by our pending patent applications without
our being aware of those applications, and our patent applications may not
have
priority over those applications. For this and other reasons, we or our
third-party collaborators may be unable to secure desired patent rights, thereby
losing desired exclusivity. If licenses are not available to us on acceptable
terms, we may not be able to market the affected products or conduct the desired
activities, unless we challenge the validity, enforceability, or infringement
of
the third-party patent or otherwise circumvent the third-party
patent.
Our
strategy depends on our ability to rapidly identify and seek patent protection
for our discoveries. In addition, we will rely on third-party collaborators
to
file patent applications relating to proprietary technology that we develop
jointly during certain collaborations. The process of obtaining patent
protection is expensive and time-consuming. If our present or future
collaborators fail to file and prosecute all necessary and desirable patent
applications at a reasonable cost and in a timely manner, our business will
be
adversely affected. Despite our efforts and the efforts of our collaborators
to
protect our proprietary rights, unauthorized parties may be able to obtain
and
use information that we regard as proprietary.
The
issuance of a patent does not guarantee that it is valid or enforceable. Any
patents we have obtained, or obtain in the future, may be challenged,
invalidated, unenforceable, or circumvented. Moreover, the United States Patent
and Trademark Office, or USPTO, may commence interference proceedings involving
our patents or patent applications. Any challenge to, finding of
unenforceability or invalidation or circumvention of, our patents or patent
applications would be costly, would require significant time and attention
of
our management, and could have a material adverse effect on our business. In
addition, court decisions may introduce uncertainty in the enforceability or
scope of patents owned by biotechnology, pharmaceutical, and medical device
companies.
Our
pending patent applications may not result in issued patents. The patent
position of pharmaceutical, biotechnology, and medical device companies,
including ours, is generally uncertain and involves complex legal and factual
considerations. The standards that the USPTO and its foreign counterparts use
to
grant patents are not always applied predictably or uniformly and can change.
There is also no uniform, worldwide policy regarding the subject matter and
scope of claims granted or allowable in pharmaceutical, biotechnology, or
medical device patents. Accordingly, we do not know the degree of future
protection for our proprietary rights or the breadth of claims that will be
allowed in any patents issued to us or to others. The legal systems of certain
countries do not favor the aggressive enforcement of patents, and the laws
of
foreign countries may not protect our rights to the same extent as the laws
of
the United States. Therefore, the enforceability or scope of our owned or
licensed patents in the United States or in foreign countries cannot be
predicted with certainty, and, as a result, any patents that we own or license
may not provide sufficient protection against competitors. We may not be able
to
obtain or maintain patent protection for our pending patent applications, those
we may file in the future, or those we may license from third parties, including
the University of Pennsylvania, the University of Illinois, the University
of
Florida Research Foundation, Pathogenics, and Intradigm.
While
we
believe that our patent rights are enforceable, we cannot assure you that any
patents that have issued, that may issue, or that may be licensed to us will
be
enforceable or valid, or will not expire prior to the commercialization of
our
product candidates, thus allowing others to more effectively compete with us.
Therefore, any patents that we own or license may not adequately protect our
product candidates or our future products.
If
we are unable to protect the confidentiality of our proprietary information
and
know-how, the value of our technology and products could be adversely
affected.
In
addition to patent protection, we also rely on other proprietary rights,
including protection of trade secrets, know-how, and confidential and
proprietary information. To maintain the confidentiality of trade secrets and
proprietary information, we will seek to enter into confidentiality agreements
with our employees, consultants, and collaborators upon the commencement of
their relationships with us. These agreements generally require that all
confidential information developed by the individual or made known to the
individual by us during the course of the individual’s relationship with us be
kept confidential and not disclosed to third parties. Our agreements with
employees also generally provide that any inventions conceived by the individual
in the course of rendering services to us shall be our exclusive property.
However, we may not obtain these agreements in all circumstances, and
individuals with whom we have these agreements may not comply with their terms.
In the event of unauthorized use or disclosure of our trade secrets or
proprietary information, these agreements, even if obtained, may not provide
meaningful protection, particularly for our trade secrets or other confidential
information. To the extent that our employees, consultants, or contractors
use
technology or know-how owned by third parties in their work for us, disputes
may
arise between us and those third parties as to the rights in related
inventions.
Adequate
remedies may not exist in the event of unauthorized use or disclosure of our
confidential information. The disclosure of our trade secrets would impair
our
competitive position and may materially harm our business, financial condition,
and results of operations.
We
will rely heavily on licenses from third parties.
Many
of
the patents and patent applications in our patent portfolio are not owned by
us,
but are licensed from third parties. For example, we rely on technology licensed
from the University of Pennsylvania, the University of Illinois, the University
of Florida Research Foundation, Pathogenics and Intradigm. Such license
agreements give us rights for the commercial exploitation of the patents
resulting from the respective patent applications, subject to certain provisions
of the license agreements. Failure to comply with these provisions could result
in the loss of our rights under these license agreements. Our inability to
rely
on these patents and patent applications, which are the basis of our technology,
would have a material adverse effect on our business.
We
license patent rights to certain of our technology from third-party owners.
If
such owners do not properly maintain or enforce the patents underlying such
licenses, our competitive position and business prospects will be
harmed.
We
have
obtained licenses from, among others, the University of Pennsylvania, the
University of Illinois, the University of Florida Research Foundation,
Pathogenics, and Intradigm that are necessary or useful for our business. In
addition, we intend to enter into additional licenses of third-party
intellectual property in the future.
Our
success will depend in part on our ability or the ability of our licensors
to
obtain, maintain, and enforce patent protection for our licensed intellectual
property and, in particular, those patents to which we have secured exclusive
rights in our field. We or our licensors may not successfully prosecute the
patent applications which are licensed to us. Even if patents issue in respect
of these patent applications, we or our licensors may fail to maintain these
patents, may determine not to pursue litigation against other companies that
are
infringing these patents, or may pursue such litigation less aggressively than
we would. Without protection for the intellectual property we have licensed,
other companies might be able to offer substantially identical products for
sale, which could adversely affect our competitive business position and harm
our business prospects.
Some
jurisdictions may require us, or those from whom we license patents, to grant
licenses to third parties. Such compulsory licenses could be extended to include
some of our product candidates, which may limit our potential revenue
opportunities.
Many
countries, including certain countries in Europe, have compulsory licensing
laws
under which a patent owner may be compelled to grant licenses to third parties.
In addition, most countries limit the enforceability of patents against
government agencies or government contractors. In these countries, the patent
owner may be limited to monetary relief from an infringement and may be unable
to enjoin infringement, which could materially diminish the value of the
patent.
Our
commercial success depends significantly on our ability to operate without
infringing the patents and other proprietary rights of third
parties.
Other
entities may have or obtain patents or proprietary rights that could limit
our
ability to manufacture, use, sell, offer for sale or import products, or impair
our competitive position. In addition, to the extent that a third party develops
new technology that covers our products, we may be required to obtain licenses
to that technology, which licenses may not be available or may not be available
on commercially reasonable terms, if at all. If licenses are not available
to us
on acceptable terms, we will not be able to market the affected products or
conduct the desired activities, unless we challenge the validity, enforceability
or infringement of the third-party patent, or circumvent the third-party patent,
which would be costly and would require significant time and attention of our
management. Third parties may have or obtain valid and enforceable patents
or
proprietary rights that could block us from developing products using our
technology. Our failure to obtain a license to any technology that we require
may materially harm our business, financial condition, and results of
operations.
Additionally,
RNAi is a relatively new scientific technology that has generated many different
patent applications from organizations and individuals seeking to obtain
important patents in the field. These applications claim many different methods,
compositions, and processes relating to the discovery, development, and
commercialization of RNAi therapeutics. Because the field is so new, very few
of
these patent applications have been fully processed by government patent offices
around the world, and there is a great deal of uncertainty about which patents
will issue, when, to whom, and with what claims. It is likely that there will
be
significant litigation and other proceedings, such as interference and
opposition proceedings in various patent offices, relating to patent rights
in
RNAi technology. Others may attempt to invalidate our intellectual property
rights. Even if our rights are not directly challenged, disputes among third
parties could impact our intellectual property rights.
If
we become involved in patent litigation or other proceedings related to a
determination of rights, we could incur substantial costs and expenses,
substantial liability for damages or be required to stop our product development
and commercialization efforts.
Third
parties may sue us for infringing their patent rights. Likewise, we may need
to
resort to litigation to enforce a patent issued or licensed to us or to
determine the scope and validity of proprietary rights of others. In addition,
a
third-party may claim that we have improperly obtained or used its confidential
or proprietary information. Furthermore, in connection with our third-party
license agreements, we generally have agreed to indemnify the licensor for
costs
incurred in connection with litigation relating to intellectual property rights.
The cost to us of any litigation or other proceeding relating to intellectual
property rights, even if resolved in our favor, could be substantial, and the
litigation would divert our management’s efforts. Some of our competitors may be
able to sustain the costs of complex patent litigation more effectively than
we
can because they have substantially greater resources. Uncertainties resulting
from the initiation and continuation of any litigation could limit our ability
to continue our operations.
If
any
parties successfully claim that our creation or use of proprietary technologies
infringes upon their intellectual property rights, we might be forced to pay
damages, potentially including treble damages, if we are found to have willfully
infringed on such parties’ patent rights. In addition to any damages we might
have to pay, a court could require us to stop the infringing activity or obtain
a license. Any license required under any patent may not be made available
on
commercially acceptable terms, if at all. In addition, such licenses are likely
to be non-exclusive and, therefore, our competitors may have access to the
same
technology licensed to us. If we fail to obtain a required license and are
unable to design around a patent, we may be unable to effectively market some
of
our technology and products, which could limit our ability to generate revenues
or achieve profitability and possibly prevent us from generating revenue
sufficient to sustain our operations.
Medicare
legislation and future legislative or regulatory reform of the health care
system may affect our ability to sell our products
profitably.
In
the
United States, there have been a number of legislative and regulatory
initiatives, at both the federal and state government levels, to change the
healthcare system in ways that, if approved, could affect our ability to sell
our products profitably. For example, the Medicare Prescription Drug,
Improvement, and Modernization Act of 2003, or MMA, extended Medicare, effective
January 1, 2006, to cover most outpatient prescription drugs that are not
administered by physicians and modified, effective January 1, 2004, the
methodology used by Medicare to reimburse for those drugs administered by
physicians. Our business could be harmed by the MMA, by the possible effect
of
this legislation on amounts that private payors will pay, and by other
healthcare reforms that may be enacted or adopted in the future. To the extent
that our products are deemed to be durable medical equipment, they may be
subject to distribution under the new Competitive Acquisition regulations,
also
part of MMA, and this could adversely affect the amount that patients or medical
providers can seek from payors. Non-durable medical equipment devices used
in
surgical procedures are normally paid directly by the hospital or health care
provider and not reimbursed separately by third-party payors. As a result,
these
types of devices are subject to intense price competition that can place a
small
manufacturer at a competitive disadvantage.
We
are
unable to predict what additional legislation or regulation, if any, relating
to
the health care industry or third-party coverage and reimbursement may be
enacted in the future or what effect such legislation or regulation would have
on our business. Any cost containment measures or other health care system
reforms that are adopted could have a material adverse effect on our ability
to
commercialize our existing and future product candidates
successfully.
Failure
to obtain regulatory approval outside the United States will prevent us from
marketing our product candidates abroad.
We
intend
to market certain of our existing and future product candidates in non-United
States markets. In order to market our existing and future product candidates
in
the European Union and many other non-United States jurisdictions, we must
obtain separate regulatory approvals. We have had limited interactions with
non-United States regulatory authorities, the approval procedures vary among
countries and can involve additional testing, and the time required to obtain
approval may differ from that required to obtain FDA approval or clearance.
Approval or clearance by the FDA does not ensure approval by regulatory
authorities in other countries, and approval by one or more non-United States
regulatory authority does not ensure approval by other regulatory authorities
in
other countries or by the FDA. The non-United States regulatory approval process
may include all of the risks associated with obtaining FDA approval or
clearance. We may not obtain non-United States regulatory approvals on a timely
basis, if at all. We may not be able to file for non-United States regulatory
approvals and may not receive necessary approvals to commercialize our existing
and future product candidates in any market.
Acquisitions
may result in disruptions to our business or distractions of our management
and
may not proceed as planned.
We
intend
to continue to expand our business through the acquisition of companies,
technologies, products, and services. Acquisitions involve a number of special
problems and risks, including, but not limited to:
|
·
|
difficulty
integrating acquired technologies, products, services, operations,
and
personnel with the existing businesses;
|
|
·
|
diversion
of management’s attention in connection with both negotiating the
acquisitions and integrating the businesses;
|
|
·
|
strain
on managerial and operational resources as management tries to oversee
larger operations;
|
|
·
|
exposure
to unforeseen liabilities of acquired
companies;
|
|
·
|
potential
costly and time-consuming litigation, including stockholder
lawsuits;
|
|
·
|
potential
issuance of securities to equity holders of the company being acquired
with rights that are superior to the rights of holders of our common
stock, or which may have a dilutive effect on our
stockholders;
|
|
·
|
the
need to incur additional debt or use cash;
and
|
|
·
|
the
requirement to record potentially significant additional future operating
costs for the amortization of intangible
assets.
|
As
a
result of these or other problems and risks, businesses we acquire may not
produce the revenues, earnings, or business synergies that we anticipated,
and
acquired products, services, or technologies might not perform as we expected.
As a result, we may incur higher costs and realize lower revenues than we had
anticipated. We may not be able to successfully address these problems and
we
cannot assure you that the acquisitions will be successfully identified and
completed or that, if acquisitions are completed, the acquired businesses,
products, services, or technologies will generate sufficient revenue to offset
the associated costs or other harmful effects on our business.
Any
of
these risks can be greater if an acquisition is large relative to our size.
Failure to manage effectively our growth through acquisitions could adversely
affect our growth prospects, business, results of operations, and financial
condition.
Non-United
States governments often impose strict price controls, which may adversely
affect our future profitability.
We
intend
to seek approval to market certain of our existing and future product candidates
in both the United States and in non-United States jurisdictions. If we obtain
approval in one or more non-United States jurisdictions, we will be subject
to
rules and regulations in those jurisdictions relating to our product. In some
countries, particularly countries of the European Union, each of which has
developed its own rules and regulations, pricing is subject to governmental
control. In these countries, pricing negotiations with governmental authorities
can take considerable time after the receipt of marketing approval for a drug
or
medical device candidate. To obtain reimbursement or pricing approval in some
countries, we may be required to conduct a clinical trial that compares the
cost-effectiveness of our existing and future product candidates to other
available products. If reimbursement of our future product candidates is
unavailable or limited in scope or amount, or if pricing is set at
unsatisfactory levels, we may be unable to achieve or sustain
profitability.
Our
business may become subject to economic, political, regulatory and other risks
associated with international operations.
Our
business is subject to risks associated with conducting business
internationally, in part due to a number of our suppliers being located outside
the United States. Accordingly, our future results could be harmed by a variety
of factors, including:
|
·
|
difficulties
in compliance with non-United States laws and
regulations;
|
|
·
|
changes
in non-United States regulations and
customs;
|
|
·
|
changes
in non-United States currency exchange rates and currency
controls;
|
|
·
|
changes
in a specific country’s or region’s political or economic
environment;
|
|
·
|
trade
protection measures, import or export licensing requirements, or
other
restrictive actions by United States or non-United States
governments;
|
|
·
|
negative
consequences from changes in tax laws;
and
|
|
·
|
difficulties
associated with staffing and managing foreign operations, including
differing labor relations.
|
The
market price of our common stock may fluctuate
significantly.
The
market price of our common stock may fluctuate significantly in response to
numerous factors, some of which are beyond our control, such as:
|
·
|
the
announcement of new products or product enhancements by us or our
competitors;
|
|
·
|
developments
concerning intellectual property rights and regulatory
approvals;
|
|
·
|
variations
in our and our competitors’ results of
operations;
|
|
·
|
changes
in earnings estimates or recommendations by securities analysts,
if our
common stock is covered by analysts;
|
|
·
|
developments
in the biotechnology, pharmaceutical, and medical device
industry;
|
|
·
|
the
results of product liability or intellectual property
lawsuits;
|
|
·
|
future
issuances of common stock or other
securities;
|
|
·
|
the
addition or departure of key
personnel;
|
|
·
|
announcements
by us or our competitors of acquisitions, investments, or strategic
alliances; and
|
|
·
|
general
market conditions and other factors, including factors unrelated
to our
operating performance.
|
Further,
the stock market in general, and the market for biotechnology, pharmaceutical,
and medical device companies in particular, has recently experienced extreme
price and volume fluctuations. Continued market fluctuations could result in
extreme volatility in the price of our common stock, which could cause a decline
in the value of our common stock.
Trading
of our common stock is limited and restrictions imposed by securities regulation
and certain lockup agreements may further reduce our trading, making it
difficult for our stockholders to sell shares.
Our
common stock began trading on the American Stock Exchange in June 2007. To
date, the liquidity of our common stock is limited, not only in terms of the
number of shares that can be bought and sold at a given price, but also through
delays in the timing of transactions and changes in security analyst and media
coverage, if at all.
A
substantial percentage
of
the outstanding shares of our common stock (including outstanding shares of
our
preferred stock on an as converted basis) are restricted securities and/or
are subject to lockup agreements which limit sales during a two-year period
ending March 27, 2009. These factors may result in lower prices for our common
stock than might otherwise be obtained and could also result in a larger spread
between the bid and ask prices for our common stock. In addition, without a
large float, our common stock is less liquid than the stock of companies with
broader public ownership and, as a result, the trading prices of our common
stock may be more volatile. In the absence of an active public trading market,
an investor may be unable to liquidate his investment in our common stock.
Further, the limited liquidity could be an indication that the trading price
is
not reflective of the actual fair market value of our common stock. Trading
of a
relatively small volume of our common stock may have a greater impact on the
trading price of our stock than would be the case if our public float were
larger.
Future
sales of our common stock could reduce our stock
price.
Some
or
all of the “restricted” shares of our common stock issued to former stockholders
of Froptix and Acuity in connection with the acquisition or held by other of
our
stockholders may be offered from time to time in the open market pursuant to
an
effective registration statement, or after April 2, 2008, pursuant to Rule
144.
In addition, as described herein, a substantial number of our shares of common
stock are subject to lockup agreements expiring on March 27, 2009, provided
that
(i) one third of the shares subject to the lockup shall be exempt from lockup
restrictions beginning March 27, 2008, (ii) one third of the shares subject
to
lockup shall be exempt from lockup restrictions beginning September 27, 2008,
and (iii) the restrictions on the remaining shares subject to lockup shall
lapse
on March 27, 2009. Future sales of a substantial number of shares of our common
stock in the public market pursuant to Rule 144 or after the lockup agreements
lapse, or the perception that such sales could occur, could adversely affect
the
price of our common stock.
Directors,
executive officers, principal stockholders and affiliated entities own a
majority of our capital stock, and they may make decisions that you do not
consider to be in the best interests of our
stockholders.
As
of
March 21, 2008, our directors, executive officers, principal stockholders,
and
affiliated entities beneficially owned, in the aggregate a majority of our
outstanding voting securities. As a result, if some or all of them acted
together, they would have the ability to control the election of our Board
of
Directors and the outcome of issues requiring approval by our stockholders.
This
concentration of ownership may also have the effect of delaying or preventing
a
change in control of our company that may be favored by other stockholders.
This
could prevent transactions in which stockholders might otherwise recover a
premium for their shares over current market prices.
Failure
to maintain effective internal controls in accordance with Section 404 of the
Sarbanes-Oxley Act could have a material adverse effect on our business and
operating results. In addition, current and potential shareholders could lose
confidence in our financial reporting, which could have a material adverse
effect on the price of our common stock.
Effective
internal controls are necessary for us to provide reliable financial reports
and
effectively prevent fraud. If we cannot provide reliable financial reports
or
prevent fraud, our results of operation could be harmed.
Section
404 of the Sarbanes-Oxley Act of 2002 requires annual management assessments
of
the effectiveness of our internal control over financial reporting and a report
by our independent registered public accounting firm on the effectiveness of
internal control over financial reporting as of December 31, 2008. We
continuously monitor our existing internal control over financial reporting
systems to confirm that they are compliant with Section 404, and we may identify
deficiencies that we may not be able to remediate in time to meet the deadlines
imposed by the Sarbanes-Oxley Act. This process may divert internal resources
and will take a significant amount of time and effort to complete.
If,
at
any time, it is determined that we are not in compliance with Section 404,
we
may be required to implement new internal control procedures and reevaluate
our
financial reporting. We may experience higher than anticipated operating
expenses as well as increased independent auditor fees during the implementation
of these changes and thereafter. Further, we may need to hire additional
qualified personnel. If we fail to maintain the adequacy of our internal
controls, as such standards are modified, supplemented or amended from time
to
time, we may not be able to conclude on an ongoing basis that we have effective
internal control over financial reporting in accordance with Section 404 of
the
Sarbanes-Oxley Act, which could result in our being unable to obtain an
unqualified report on internal control from our independent auditors. Failure
to
maintain an effective internal control environment could also cause investors
to
lose confidence in our reported financial information, which could have a
material adverse effect on the price of our common stock.
Compliance
with changing regulations concerning corporate governance and public disclosure
may result in additional expenses.
There
have been changing laws, regulations, and standards relating to corporate
governance and public disclosure, including the Sarbanes-Oxley Act of 2002,
new
regulations promulgated by the Securities and Exchange Commission and rules
promulgated by the American Stock Exchange, the other national securities
exchanges and the NASDAQ. These new or changed laws, regulations, and standards
are subject to varying interpretations in many cases due to their lack of
specificity, and, as a result, their application in practice may evolve over
time as new guidance is provided by regulatory and governing bodies, which
could
result in continuing uncertainty regarding compliance matters and higher costs
necessitated by ongoing revisions to disclosure and governance practices. As
a
result, our efforts to comply with evolving laws, regulations, and standards
are
likely to continue to result in increased general and administrative expenses
and a diversion of management time and attention from revenue-generating
activities to compliance activities. Our board members, Chief Executive Officer,
Chief Financial Officer, and Principal Accounting Officer could face an
increased risk of personal liability in connection with the performance of
their
duties. As a result, we may have difficulty attracting and retaining qualified
board members and executive officers, which could harm our business. If our
efforts to comply with new or changed laws, regulations, and standards differ
from the activities intended by regulatory or governing bodies, we could be
subject to liability under applicable laws or our reputation may be
harmed.
|
UNRESOLVED
STAFF COMMENTS.
|
None.
Our
principal corporate office is located at 4400 Biscayne Blvd, Suite 1180, Miami,
Florida. We lease this space from Frost Real Estate Holdings, LLC, an entity
which is controlled by Dr. Phillip Frost, our Chairman of the Board and Chief
Executive Officer. Pursuant to the lease agreement with Frost Real Estate
Holdings, we lease approximately 8,300 square feet, which encompasses space
for
our corporate offices, administrative services, preclinical research and
development, project management and pharmacology. The lease is for a five-year
term and currently requires annual rent of approximately $221,000, which amount
increases by approximately 4.5% per year.
We
also
lease approximately 2,000 square feet of office space in Morristown, New Jersey,
where additional clinical research and development is performed, and an animal
research facility at Mount Sinai Hospital in Miami Beach, Florida. Our OTI
subsidiary maintains offices in Toronto, Ontario, Canada and research and
development branch offices in Kingston, Ontario, and in the United Kingdom
at
the University of Kent.
We
are
not currently a party to any material litigation. From time to time,
we may be involved in litigation arising in the ordinary course of our
business.
|
SUBMISSION
OF MATTERS TO A VOTE OF SECURITY
HOLDERS.
|
Effective
as of December 4, 2007, stockholders holding a majority of the voting power
of
our outstanding stock approved the issuance to members of The Frost Group,
LLC,
or the Frost Group, a private investment group controlled by Dr. Phillip Frost,
M.D., our Chairman and CEO, of an aggregate of 10,869,565 shares of our common
stock in exchange for a $20 million investment in the Company. Stockholder
approval was in the form of a written consent of stockholders in lieu of a
special meeting in accordance with the relevant sections of the Delaware General
Corporation Law, and included those of our stockholders holding a majority
of
the voting power of our issued and outstanding shares of common stock and
preferred stock, voting together as a group. Stockholder approval was sought
solely in order to comply with applicable rules of the American Stock Exchange,
on which our common stock is listed.
The
foregoing is merely a summary of those matters submitted to a stockholder vote
during the fourth quarter of 2007, and is qualified in its entirety by the
full
text of our Definitive Information Statement on Schedule 14C, filed with the
SEC
on January 8, 2008, which is incorporated by reference into this Item 4 to
our
Annual Report on Form 10-K.
PART
II
|
MARKET
FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER
PURCHASES OF EQUITY
SECURITIES.
|
We
changed our name from eXegenics, Inc. to OPKO Health, Inc in June 2007. Our
common stock has been traded publicly on the American Stock Exchange under
the
symbol “OPK” since June 11, 2007. Prior to June 11, 2007, our common stock
was quoted on the over-the-counter bulletin board, or the OTCBB, under the
symbol “EXEG.” Quotes on the OTCBB may have reflected inter-dealer prices
without retail markups, markdowns, or commissions and may not necessarily have
represented actual transactions. The following table sets forth, for the periods
indicated, the high and low sales prices per share of our common stock during
each of the quarters set forth below as reported on the OTCBB for the periods
from January 1, 2006 through June 8, 2007 and on the American Stock Exchange
from June 11, 2007 through December 31, 2007:
|
|
High
|
|
Low
|
|
2007
|
|
|
|
|
|
First
Quarter
|
|
$
|
4.10
|
|
$
|
0.87
|
|
Second
Quarter
|
|
|
5.50
|
|
|
3.20
|
|
April 1
- June 8, 2007
|
|
|
5.50
|
|
|
3.20
|
|
June 11,
2007 - June 30, 2007
|
|
|
4.33
|
|
|
3.42
|
|
Third
Quarter
|
|
|
4.94
|
|
|
3.36
|
|
Fourth
Quarter
|
|
|
4.53
|
|
|
2.50
|
|
|
|
|
|
|
|
|
|
2006
|
|
|
|
|
|
|
|
First
Quarter
|
|
$
|
0.46
|
|
$
|
0.39
|
|
Second
Quarter
|
|
|
0.45
|
|
|
0.38
|
|
Third
Quarter
|
|
|
1.09
|
|
|
0.38
|
|
Fourth
Quarter
|
|
|
0.99
|
|
|
0.72
|
|
As
of
March 21, 2008, there were approximately 436 holders of record of our common
stock.
The
Company has not declared or paid any cash dividends on its common stock. No
cash
dividends have been previously paid on our common stock and none are anticipated
in fiscal 2008.
Recent
Sales of Unregistered Securities
On
December 5, 2007, members of The Frost Group, LLC, a private investment group
controlled by Dr. Phillip Frost, M.D., our Chairman and CEO, made a $20 million
investment in the Company. Under the terms of the investment, we issued
10,869,565 shares of common stock, par value $.01, at $1.84 per share,
representing an approximately 40% discount to the average trading price of
the Company's stock on the American Stock Exchange for the five
trading days immediately preceding the effective date of board and stockholder
approval of the investment. The shares issued in the investment are restricted
securities, subject to a two year lockup, and no registration rights were
granted. The issuance of the shares was exempt from the registration
requirements under the Securities Act of 1933, as amended, pursuant to Section
4(2) thereof, because the transaction did not involve a public
offering.
Stock
Performance Graph
As
a
result of the reverse merger between Froptix Corporation, or Froptix and
eXegenics, Inc., or eXegenics, historical comparative results are those of
Froptix. Froptix was incorporated on June 23, 2006. The following selected
historical consolidated statement of operations data for the year ended December
31, 2007 and for the period from inception (June 23, 2006) through December
31,
2006 and the consolidated balance sheet data as of December 31, 2007 and
December 31, 2006, below are derived from our audited consolidated financial
statements and related notes thereto. The results of operations for the period
from inception (June 23, 2006) to December 31, 2006 include Froptix’s operating
results for the full period. The year ended December 31, 2007 includes the
results of operations from Froptix for the full year, the operating results
of
Acuity Pharmaceuticals, Inc., or Acuity, subsequent to our acquisition on March
27, 2007, and the operating results from Ophthalmic Technologies, Inc., or
OTI,
subsequent to our acquisition on November 28, 2007. In addition, the results
for
the 2007 period includes the minority interest loss of $0.6 million for a
portion of OTI's operating loss from the date of our investment in OTI on April
13, 2007 through the date of our acquisition on November 28, 2007.
(in
thousands, except share and per shares information)
|
|
For
the year ended
December
31, 2007
|
|
Period
from inception
(June
23, 2006) to
December
31, 2006
|
|
|
|
(unaudited)
|
|
(unaudited)
|
|
Statement
of operations data
|
|
|
|
|
|
Revenue
|
|
$
|
847
|
|
$
|
-
|
|
Cost
of goods sold
|
|
|
808
|
|
|
-
|
|
Gross
margin
|
|
|
39
|
|
|
-
|
|
Operating
expenses:
|
|
|
|
|
|
|
|
Selling,
general and administrative
|
|
|
12,466
|
|
|
375
|
|
Research
and development
|
|
|
10,850
|
|
|
508
|
|
Write-off
of acquired in-process research and development
|
|
|
243,761
|
|
|
-
|
|
Other
operating expenses; primarily amortization of intangible
assets
|
|
|
150
|
|
|
|
|
Total
operating expenses
|
|
|
267,227
|
|
|
883
|
|
Operating
loss
|
|
|
(267,188
|
)
|
|
(883
|
)
|
Other
(expense) income, net
|
|
|
(671
|
)
|
|
6
|
|
Loss
before income taxes and loss from OTI
|
|
|
(267,859
|
)
|
|
(877
|
)
|
Income
taxes
|
|
|
83
|
|
|
-
|
|
Net
loss before loss from OTI
|
|
|
(267,776
|
)
|
|
(877
|
)
|
Loss
from OTI
|
|
|
(629
|
)
|
|
-
|
|
Net
loss
|
|
|
(267,405
|
)
|
|
(877
|
)
|
Preferred
stock dividend
|
|
|
(217
|
)
|
|
-
|
|
Net
loss attributable to common shareholders
|
|
$
|
(268,622
|
)
|
$
|
(877
|
)
|
Loss
per share, basic and diluted
|
|
$
|
(2.09
|
)
|
$
|
(0.01
|
)
|
Weighted
average number of shares outstanding
-
basic and diluted
|
|
|
128,772,080
|
|
|
58,733,556
|
|
Balance
sheet data
|
|
|
|
|
|
|
|
Total
assets
|
|
$
|
39,568
|
|
$
|
116
|
|
Working
capital
|
|
$
|
19,489
|
|
$
|
21
|
|
Notes
payable, credit line with related party and capital lease obligations,
net
|
|
$
|
14,235
|
|
$
|
-
|
|
Stockholders’
equity
|
|
$
|
16,784
|
|
$
|
21
|
|
|
MANAGEMENT’S
DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATION.
|
This
Annual Report on Form 10-K contains certain forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”),
Section 27A of the Securities Act of 1933, as amended (the “Securities Act”),
and Section 21E of the Securities Exchange Act of 1934, as amended, (the
“Exchange Act”), about our expectations, beliefs, or intentions regarding our
product development efforts, business, financial condition, results of
operations, strategies, or prospects. You can identify forward-looking
statements by the fact that these statements do not relate strictly to
historical or current matters. Rather, forward-looking statements relate to
anticipated or expected events, activities, trends, or results as of the date
they are made. Because forward-looking statements relate to matters that have
not yet occurred, these statements are inherently subject to risks and
uncertainties that could cause our actual results to differ materially from
any
future results expressed or implied by the forward-looking statements. Many
factors could cause our actual activities or results to differ materially from
the activities and results anticipated in forward-looking statements. These
factors include those contained in “Item 1A - Risk Factors” of this Annual
Report on Form 10-K. We do not undertake any obligation to update
forward-looking statements. We intend that all forward-looking statements be
subject to the safeharbor provisions of PSLRA. These forward-looking statements
are only predictions and reflect our views as of the date they are made with
respect to future events and financial performance.
We
are a
specialty healthcare company focused on the discovery, development, and
commercialization of proprietary pharmaceuticals, imaging and diagnostic
systems, and instruments for the treatment, diagnosis, and management of
ophthalmic disorders. Our business presently consists of the development of
ophthalmic pharmaceuticals and the development, commercialization and sale
of
ophthalmic diagnostic and imaging systems and instrumentation products. Our
objective is to establish industry-leading positions in large and rapidly
growing segments of ophthalmology by leveraging our preclinical and development
expertise and our novel and proprietary technologies. We actively explore
opportunities to acquire complementary pharmaceuticals, compounds, and
technologies, which could, individually or in the aggregate, materially increase
the scale of our business. We also intend to explore strategic opportunities
in
other medical markets that would allow us to benefit from our business and
global distribution expertise, and which have operational characteristics that
are similar to ophthalmology, such as dermatology.
We
expect
to incur substantial losses as we continue the development of our product
candidates, particularly bevasiranib, continue our other research and
development activities, and establish a sales and marketing infrastructure
in
anticipation of the commercialization of our product candidates. We currently
have limited commercialization capabilities, and it is possible that we may
never successfully commercialize any of our pharmaceutical product candidates.
To date, we have devoted substantially all of our efforts towards research
and
development. As of December 31, 2007, we had an accumulated deficit of $269.3
million. Since we do not generate revenue from any of our pharmaceutical product
candidates and have only generated limited revenue from our instrumentation
business, we expect to continue to generate losses in connection with the
continued clinical development of bevasiranib and the research and development
activities relating to our technology and other product candidates. Such
research and development activities are budgeted to expand over time and will
require further resources if we are to be successful. As a result, we believe
that our operating losses are likely to be substantial over the next several
years. We will need to obtain additional funds to further develop our research
and development programs, and there can be no assurance that additional capital
will be available to us on acceptable terms, or at all.
On
June
8, 2007, we changed our name to OPKO Health, Inc., or OPKO, from eXegenics,
Inc., or eXegenics. On March 27, 2007, we were part of a three-way merger (the
“Mergers”) between Froptix Corporation, or Froptix, a research and development
company, eXegenics, a public shell company, and Acuity Pharmaceuticals, Inc.,
or
Acuity, a research and development company. This transaction was accounted
for
as a reverse merger between Froptix and eXegenics, with the combined company
then acquiring Acuity. eXegenics, Inc., formerly known as Cytoclonal
Pharmaceuticals Inc., was previously involved in the research, creation, and
development of drugs for the treatment and/or prevention of cancer and
infectious diseases; however, eXegenics had been a public shell company without
any operations since 2003.
On
November 28, 2007, we acquired Ophthalmic Technologies, Inc., or OTI, an Ontario
corporation pursuant to a definitive Share Purchase Agreement with OTI and
its
shareholders. As a result of this agreement, we have entered into the ophthalmic
instrumentation market and have begun generating revenue from this business.
On
March
25, 2008, OTI received a warning letter citing several deficiencies in OTI’s
quality systems relating to three of its products, including the OCT/SLO
combination imaging system. Until we resolve these deficiencies to the
satisfaction of the FDA, we will not be permitted to sell these products in
the
United States.
RESULTS
OF OPERATIONS
For
The Years Ended December 31, 2007 and From Inception (June 23, 2006) Through
December 31, 2006
The
results of operations for the period from inception (June 23, 2006) through
December 31, 2006 include only the operating results of Froptix. The results
of
operations for 2007 include those of Froptix for the full period as well as
the
results of operations of Acuity from March 27, 2007 through December 31,
2007, and of OTI from November 28, 2007 through December 31, 2007. We had
limited operating activities during the 2006 period since our inception was
on
June 23, 2006. During 2007, we increased the level of activities in our research
and development programs to include the initiation of our first of two required
Phase III clinical trials for bevasiranib, our lead compound in development
and
the most clinically advanced siRNA drug in development. Further, during 2007,
we
began to build a commercial presence in the ophthalmic instrumentation business
in the U.S. as we prepared for the acquisition of OTI, and we assumed
the operations of OTI for instrumentation sales internationally in November.
In
addition, our general and administrative expenses have increased in line with
the operations of our ophthalmic pharmaceutical and instrumentation business
as
well as incurring the costs associated with being a public company.
Revenue.
Revenue
for the year ended December 31, 2007 was $0.8 million. All revenue generated
relates to product sold after our acquisition of OTI on November 28, 2007.
Until
the acquisition of OTI, we did not generate any revenue. During 2007, all
revenue relates to products that were shipped internationally. There were no
product sales in the U.S.
Gross
margin.
Gross
margin for the year ended December 31, 2007 was $39 thousand. The gross margin
related to product sold after our acquisition of OTI on November 28, 2007.
The gross margin was negatively impacted by manufacturing costs associated
with the introduction of our new OCT / SLO model. We anticipate that our margin
will increase as we begin manufacturing more components in-house.
Selling,
General and Administrative Expense
.
Selling, general and administrative expense in 2007 was $12.5 million and
increased from $0.4 million during the 2006 period, primarily as a result of
increased personnel costs, including equity-based compensation, directors’ and
officers’ insurance, professional fees and other costs related to building
infrastructure as a public company. In addition, during 2007 we incurred
professional fees related to various business transactions, including the
acquisitions of Acuity and OTI. During 2007, we also incurred expenses related
to building a commercial presence in the ophthalmic instrumentation market
in the United States, including personnel and tradeshow costs. During the 2006
period, selling, general and administrative expense primarily included
equity-based compensation expense related to a consultant and professional
fees.
We did not have any employees during 2006.
Equity
based compensation expense for the year ended December 31, 2007 was $7.4
million, of which, $4.4 million was included in selling, general and
administrative expense and $3.0 million was included in research and development
expense. During the period from our inception (June 23, 2006) through December
31, 2006, equity based compensation expense was $0.3 million, all of which
was
recorded in selling, general and administrative expense.
Research
and Development Expense
.
Research and development expense for 2007 was $10.9 million and increased from
$0.5 million during the 2006 period, primarily as a result of the expense
related to our Phase III clinical trial for bevasiranib, which was initiated
in
July 2007. Research and development expenses for the year ended December 31,
2007 include personnel costs, including equity-based compensation and
professional fees as we initiated our Phase III clinical trial for bevasiranib.
During the third quarter of 2007, a reversal of equity-based compensation
expense of $8.1 million was recorded as a result of the termination of a
consulting agreement prior to the vesting of any of the equity based awards
issued under the consulting agreement. Originally, we accrued $0.3 million
for
this expense during 2006 and $7.8 million during the first six months of 2007.
Research and development expense during 2006 was related to our sponsored
research agreement with the University of Florida and costs related to the
prosecution of related patents.
We
anticipate that research and development expense during 2008 will primarily
relate to our bevasiranib program, including on-going costs for our initial
Phase III clinical trial. The trial was initiated in July 2007 and is expected
to last approximately 60 weeks once the trial is fully enrolled. We
currently anticipate enrollment will take approximately eighteen months. We
currently expect the total cost of this trial to be approximately $25 million,
although this estimate could vary significantly as the Phase III clinical trial
progresses.
Write-off
of Acquired In-Process Research and Development
.
On
March 27, 2007, we acquired Acuity in a stock for stock transaction. We valued
our common stock issued to Acuity shareholders at the average closing price
of
the common stock on the date of the transaction and two days prior to the
transaction. We recorded the assets and liabilities acquired at fair value.
Approximately $243.8 million of the purchase price was allocated to in-process
research and development projects, which was immediately charged to
expense. We record expense for in-process research and development
projects which have not reached technological feasibility and which have no
alternative future use. At the time of our acquisition of Acuity, Acuity’s
lead product, bevasiranib, had not begun the first of two required
Phase III clinical trials and as such, had not reached a stage of technological
feasibility and had no alternative future use.
Other
Income and Expenses
.
Other
expense was $0.7 million, net of $0.3 million of interest income for the year
ended December 31, 2007. Other expenses primarily consist of interest expense
incurred on our $4.0 million term loan and our $12.0 million line of credit,
partially offset by interest earned on our cash and cash equivalents. Other
income during the 2006 period reflected the interest earned on our cash and
cash
equivalents. We did not have any outstanding debt during that period. In
addition, the 2007 period includes the minority interest loss of $0.6 million
for a prorated portion of OTI’s operating loss from the date of our investment
in OTI on April 13, 2007 through the date of our acquisition on November 28,
2007.
Liquidity
And Capital Resources
At
December 31, 2007, we had cash and cash equivalents of approximately $23.4
million. Cash used in operations primarily reflects our net loss, offset by
our
non-cash operating expenses including the write-off of in-process research
and
development acquired in the acquisition of Acuity and equity-based compensation
expense. Since our inception, we have not generated significant revenue and
our
primary source of cash has been from the private placement of stock and through
credit facilities available to us.
In
connection with the acquisition of Acuity, we assumed the rights and obligations
under Acuity’s $4.0 million term loan ($2.4 million outstanding at December 31,
2007) with Horizon Financial Funding Company, LLC. The term loan bears interest
at 12.23% and is payable monthly. The principal is payable in 12 equal
monthly installments which commenced August 2007. On January 11, 2008, we repaid
in full all outstanding amounts and terminated all of our commitments under
the
term loan with Horizon. The total amount repaid in satisfaction of our
obligations under the term loan was $2.4 million. We realized a net savings
by
avoiding future interest charges over the remaining term of the
obligation.
We
also
assumed the rights and obligations of Acuity under the $7 million line of credit
with The Frost Group, LLC, or the Frost Group, a related party. The Frost Group
members include a trust controlled by Dr. Phillip Frost, who is the
Company’s Chief Executive Officer and Chairman of the board of directors,
Dr. Jane H. Hsiao, who is the Vice Chairman of the board of directors and
Chief Technical Officer, Steven D. Rubin who is Executive Vice President -
Administration and a director of the Company, and Rao Uppaluri who is the Chief
Financial Officer of the Company. At the time of the acquisition of Acuity,
we
amended and restated the Frost Group line of credit to provide additional
available borrowing capacity up to a total of $12 million, and we assumed
Acuity’s existing obligation to repay $4.0 million outstanding under the line of
credit. During 2007, we drew down the available amount under this credit line
of
$8.0 million for a total of $12.0 million borrowed. We are obligated to pay
interest upon maturity, capitalized quarterly, on outstanding borrowings under
the line of credit at a 10% annual rate, which is due July 11, 2009. The line
of
credit is collateralized by all of our personal property except our intellectual
property.
On
December 5, 2007, in exchange for a $20 million cash investment in the Company,
we agreed to issue 10,869,565 shares of our common stock, par value
$.01, to members of the Frost Group. The shares were issued at a price of $1.84
per share, representing an approximately 40% discount to the average trading
price of our stock on the American Stock Exchange for the five trading days
immediately preceding the date the board of directors and stockholders approved
the issuance of the shares. The shares issued in the private placement are
restricted securities, subject to a two year lockup, and no registration rights
have been granted.
We
expect
to incur losses from operations for the foreseeable future. We expect to incur
substantial research and development expenses, including expenses related to
the
hiring of personnel and additional clinical trials. We expect that selling,
general and administrative expenses will also increase as we expand our sales,
marketing and administrative staff, add infrastructure and incur additional
costs related to being a public company, including the costs of directors’ and
officers’ insurance, investor relations programs and increased professional
fees.
We
believe the cash and cash equivalents on hand at December 31, 2007 will be
sufficient to meet our anticipated cash requirements for operations and debt
service for at least the next 12 months. We based this estimate on assumptions
that may prove to be wrong or subject to change, and we may be required to
use
our available cash resources sooner than we currently expect. If we
accelerate our product development programs or initiate additional clinical
trials, we will need additional funds. Our future cash requirements will
depend on a number of factors, including the continued progress of our research
and development of product candidates, the timing and outcome of clinical trials
and regulatory approvals, the costs involved in preparing, filing, prosecuting,
maintaining, defending, and enforcing patent claims and other intellectual
property rights, the status of competitive products, the availability of
financing, and our success in developing markets for our product candidates.
If
we are not able to secure additional funding when needed, we may have to delay,
reduce the scope of, or eliminate one or more of our clinical trials or research
and development programs.
We
intend
to finance additional research and development projects, clinical trials and
our
future operations with a combination of private placements, payments from
potential strategic research and development, licensing and/or marketing
arrangements, public offerings, debt financing and revenues from future product
sales, if any. There can be no assurance, however, that additional capital
will
be available to us on acceptable terms, or at all.
The
following table provides information as of December 31, 2007 with respect to
the
amounts and timing of our known contractual obligation payments due by period.
Contractual
obligations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(in
thousands)
|
|
2008
|
|
2009
|
|
2010
|
|
2011
|
|
2012
|
|
After
2012
|
|
Total
|
|
Open
purchase orders
|
|
$
|
1,469
|
|
$
|
-
|
|
$
|
|
|
|
|
|
$
|
-
|
|
$
|
-
|
|
$
|
1,469
|
|
Operating
leases
|
|
|
333
|
|
|
351
|
|
|
338
|
|
|
350
|
|
|
226
|
|
|
-
|
|
|
1,598
|
|
Term
loan
|
|
|
2,392
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
2,392
|
|
Credit
line
|
|
|
-
|
|
|
12,000
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
12,000
|
|
Total
|
|
|
4,194
|
|
|
12,351
|
|
|
338
|
|
|
350
|
|
|
226
|
|
|
-
|
|
|
17,459
|
|
The
preceding table does not include information where the amounts of the
obligations are not currently determinable, including contractual obligations
in
connection with clinical trials, which are payable on a per-patient basis and
product license agreements that include payments upon achievement of certain
milestones. In addition to the principal balance as shown on our credit line,
we
also must pay interest upon the maturity of the credit line in July
2009.
Critical
Accounting Policies and Estimates
Accounting
Estimates
.
The
preparation of financial statements in conformity with generally accepted
accounting principles requires management to make estimates and assumptions
that
affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of sales and expenses during the reporting period. Actual
results could differ from those estimates.
Equity
Based Compensation.
As of June 23, 2006 (the date of inception), we adopted
Statement of Financial Accounting Standards, or SFAS No. 123(R). Share-Based
Payments SFAS No. 123(R) replaces SFAS No. 123, Accounting for Stock-Based
Compensation, and supersedes APB No. 25. SFAS No. 123(R) requires that all
stock-based compensation be recognized as an expense in the financial statements
and that such cost be measured at the fair value of the award. We adopted SFAS
No. 123(R) upon our inception. Equity-based compensation arrangements to
non-employees are accounted for in accordance with SFAS No. 123(R) and Emerging
Issues Task Force Issue No. 96-18 (EITF 96-18), “Accounting for Equity
Instruments That Are Issued to Other Than Employees for Acquiring, or in
Conjunction with Selling, Goods or Services,” which requires that these equity
instruments are recorded at their fair value on the measurement date. As
prescribed under SFAS 123(R), we estimate the grant-date fair value of our
stock
option grants using a valuation model known as the Black-Scholes-Merton formula
or the “Black-Scholes Model” and allocate the resulting compensation expense
over the corresponding requisite service period associated with each grant.
The
Black-Scholes Model requires the use of several variables to estimate the
grant-date fair value of stock options including expected term, expected
volatility, expected dividends and risk-free interest rate. We perform
significant analyses to calculate and select the appropriate variable
assumptions used in the Black-Scholes Model. We also perform significant
analyses to estimate forfeitures of equity-based awards as required by SFAS
123(R). We are required to adjust our forfeiture estimates on at least an annual
basis based on the number of share-based awards that ultimately vest. The
selection of assumptions and estimated forfeiture rates is subject to
significant judgment and future changes to our assumptions and estimates may
have a material impact on our Consolidated Financial Statements.
As
of
December 31, 2007, we had $15.9 million of unrecognized compensation expense
related to unvested stock options that is expected to be recognized over a
weighted average period of 3 years.
Goodwill
and Intangible Assets
.
The
allocation of the purchase price for acquisitions requires extensive use of
accounting estimates and judgments to allocate the purchase price to the
identifiable tangible and intangible assets acquired, including in-process
research and development, and liabilities assumed based on their respective
fair
values under the provisions of SFAS No. 141, Business Combinations (SFAS No.
141). Additionally, we must determine whether an acquired entity is considered
to be a business or a set of net assets, because a portion of the purchase
price
can only be allocated to goodwill in a business combination.
Appraisals
inherently require significant estimates and assumptions, including but not
limited to, determining the timing and estimated costs to complete the
in-process R&D projects, projecting regulatory approvals, estimating future
cash flows, and developing appropriate discount rates. We believe the estimated
fair values assigned to the Acuity and OTI assets acquired and liabilities
assumed are based on reasonable assumptions. However, the fair value estimates
for the purchase price allocation may change during the allowable allocation
period under SFAS No. 141, which is up to one year from the acquisition date,
if
additional information becomes available that would require changes to our
estimates.
Allowance
for Doubtful Accounts and Revenue Recognition
.
Generally,
we recognize revenue from product sales when goods are shipped and title and
risk of loss transfer to our customers.
Certain
of our products are sold directly to end-users and require that we deliver,
install and train the staff at the end-users’ facility. As a result, we do not
recognize revenue until the product is delivered, installed and training has
occurred.
Return policies in certain international markets for our
medical device products provide for stringent guidelines in accordance with
the
terms of contractual agreements with customers. Our estimates for sales returns
are based upon the historical patterns of products returned matched against
the
sales from which they originated, and management’s evaluation of specific
factors that may increase the risk of product returns. The allowance for
doubtful accounts recognized in our consolidated balance sheets at December
31,
2007 was $0.5 million. The allowance for doubtful accounts at December 31,
2007 was due to the acquired OTI medical device products.
New
Accounting Pronouncements
In
July
2006, the Financial Accounting Standards Board, or FASB, issued Interpretation
Number 48, Accounting for Uncertainty in Income Taxes, or FIN 48. FIN 48 applies
to all tax positions within the scope of SFAS 109, applies a “more likely than
not” threshold for tax benefit recognition, identifies a defined methodology for
measuring benefits, and increases the disclosure requirements for companies.
FIN
48 is mandatory for years beginning after December 15, 2006; accordingly, we
adopted FIN 48 effective January 1, 2007. As a result of our full valuation
allowance on our net deferred income tax assets, there was no impact of
adoption.
In
September 2006, the FASB issued SFAS No. 157, Fair Value Measurements, or SFAS
157. SFAS 157 defines fair value, establishes a framework for measuring fair
value in generally accepted accounting principles, and expands disclosures
about
fair value measurements. This Statement applies to other accounting
pronouncements that require or permit fair value measurements, the FASB having
previously concluded in those accounting pronouncements that fair value is
the
relevant measurement attribute. Accordingly, this Statement does not require
any
new fair value measurements. SFAS 157 is effective for fiscal years beginning
after November 15, 2007. We will adopt SFAS 157 beginning in the first quarter
of our 2008 fiscal year and do not expect the impact to be material to our
financial position or results of operations.
In
February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial
Assets and Financial Liabilities, or SFAS 159, which gives companies the option
to measure eligible financial assets, financial liabilities, and firm
commitments at fair value (i.e., the fair value option), on an
instrument-by-instrument basis, that are otherwise not permitted to be accounted
for at fair value under other accounting standards. The election to use the
fair
value option is available when an entity first recognizes a financial asset
or
financial liability or upon entering into a firm commitment. Subsequent changes
in fair value must be recorded in earnings. SFAS 159 is effective for financial
statements issued for fiscal years beginning after November 15, 2007. We will
adopt SFAS 159 beginning in the first quarter of our 2008 fiscal year and do
not
expect the impact to be material to our financial position or results of
operations.
In
June
2007, the EITF issued EITF Issue 07-03, Accounting for Advance Payments for
Goods or Services to Be Used in Future Research and Development, or EITF 07-03.
EITF 07-03 addresses the accounting for the non-refundable portion of a payment
made by a research and development entity for future research and development
activities. Under EITF 07-03, an entity would defer and capitalize
non-refundable advance payments made for research and development activities
until the related goods are delivered or the related services are performed.
EITF 07-03 is effective for fiscal years beginning after December 15, 2007.
We
plan to adopt EITF 07-03 beginning in the first quarter of our 2008 fiscal
year
and do not expect the impact to be material to our financial position or results
of operations.
In
December 2007, the FASB issued SFAS No. 141R, Business Combinations. SFAS
141R
will require, among other things, the expensing of direct transaction costs,
including deal costs and restructuring costs as incurred, acquired IPR&D
assets to be capitalized, certain contingent assets and liabilities to be
recognized at fair value and earn-our arrangements, including contingent
consideration, may be required to be measured at fair value until settled,
with
changes in fair value recognized each period into earnings. In addition,
material adjustments made to the initial acquisition purchase accounting
will be
required to be recorded back to the acquisition date. This will cause companies
to revise previously reported results when reporting comparative financial
information in subsequent filings. SFAS No. 141R is effective for the Company
on
a prospective basis for transactions occurring in 2009 and earlier adoption
is
not permitted. SFAS No. 141R may have a material impact on the Company’s
consolidated financial position, results of operations and cash flows
if we enter into material business combinations after the standard’s
effective date.
ITEM
7A
.
|
QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK.
|
In
the
normal course of doing business, we are exposed to the risks associated with
foreign currency exchange rates and changes in interest rates. We do not engage
in trading market risk sensitive instruments or purchasing hedging instruments
or “other than trading” instruments that are likely to expose us to significant
market risk, whether interest rate, foreign currency exchange, commodity price,
or equity price risk.
Our
exposure to market risk relates to our cash and investments and to our
borrowings. We maintain an investment portfolio of money market funds and
qualified purchaser funds. The securities in our investment portfolio are not
leveraged, and are, due to their very short-term nature, subject to minimal
interest rate risk. We currently do not hedge interest rate exposure. Because
of
the short-term maturities of our investments, we do not believe that a change
in
market interest rates would have a significant negative impact on the value
of
our investment portfolio except for reduced income in a low interest rate
environment. At December 31, 2007, we had cash and cash equivalents of $23.4
million. The weighted average interest rate related to our cash and cash
equivalents for the year ended December 31, 2007 was 4.9%. As of December 31,
2007, the principal value of our term loan and credit line was $14.6 million,
which bear a weighted average interest rate of 10.7%.
The
primary objective of our investment activities is to preserve principal while
at
the same time maximizing yields without significantly increasing risk. To
achieve this objective, we invest our excess cash in debt instruments of the
U.S. Government and its agencies, bank obligations, repurchase agreements and
high-quality corporate issuers, and, by policy, restrict our exposure to any
single corporate issuer by imposing concentration limits. To minimize the
exposure due to adverse shifts in interest rates, we maintain investments at
an
average maturity of generally less than one month.
ITEM
8
.
|
FINANCIAL
STATEMENTS AND SUPPLEMENTARY
DATA.
|
|
|
Page
|
|
|
|
Report
of Independent Registered Public Accounting Firm
|
|
51
|
|
|
|
Consolidated
Balance Sheets
|
|
52
|
|
|
|
Consolidated
Statements of Operations
|
|
53
|
|
|
|
Consolidated
Statement of Shareholders’ Equity
|
|
54
|
|
|
|
Consolidated
Statements of Cash Flows
|
|
55
|
|
|
|
Notes
to Consolidated Financial Statements
|
|
56
- 72
|
Report
of Independent Registered Public Accounting Firm
The
Board
of Directors and Shareholders of OPKO Health, Inc.
We
have
audited the accompanying consolidated balance sheets of OPKO Health, Inc. and
subsidiaries as of December 31, 2007 and 2006, and the related consolidated
statements of operations, shareholders' equity and cash flows for the year
ended
December 31, 2007 and for the period from inception (June 23, 2006) to December
31, 2006. These financial statements are the responsibility of the Company's
management. Our responsibility is to express an opinion on these financial
statements based on our audits.
We
conducted our audits in accordance with the standards of the Public Company
Accounting Oversight Board (United States). Those standards require that we
plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. We were not engaged to perform
an
audit of the Company's internal control over financial reporting. Our audits
included consideration of internal control over financial reporting as a basis
for designing audit procedures that are appropriate in the circumstances, but
not for the purpose of expressing an opinion on the effectiveness of the
Company's internal control over financial reporting. Accordingly, we express
no
such opinion. An audit also includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements, assessing
the accounting principles used and significant estimates made by management,
and
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.
In
our
opinion, the financial statements referred to above present fairly, in all
material respects, the consolidated financial position of OPKO Health, Inc.
and
subsidiaries at December 31, 2007 and 2006, and the consolidated results of
their operations and their cash flows for the year ended December 31, 2007
and
for the period from inception (June 23, 2006) to December 31, 2006, in
conformity with U.S. generally accepted accounting principles.
|
|
|
|
|
/s/
Ernst & Young LLP
|
|
Certified Public Accountants
|
Miami,
Florida
|
|
March
28, 2008
|
|
OPKO
Health, Inc.
CONSOLIDATED
BALANCE SHEETS
(in
thousands except share data)
|
|
December
31,
|
|
|
|
2007
|
|
2006
|
|
ASSETS
|
|
|
|
|
|
Current
assets
|
|
|
|
|
|
Cash
and cash equivalents
|
|
$
|
23,373
|
|
$
|
116
|
|
Accounts
receivable, net
|
|
|
1,689
|
|
|
-
|
|
Inventory
|
|
|
2,214
|
|
|
-
|
|
Prepaid
expenses and other current assets
|
|
|
1,936
|
|
|
-
|
|
Total
current assets
|
|
|
29,212
|
|
|
116
|
|
Property
and equipment, net
|
|
|
410
|
|
|
-
|
|
Intangible
assets, net
|
|
|
9,931
|
|
|
-
|
|
Other
assets
|
|
|
15
|
|
|
-
|
|
Total
assets
|
|
$
|
39,568
|
|
$
|
116
|
|
|
|
|
|
|
|
|
|
LIABILITIES
AND SHAREHOLDERS’ EQUITY
|
|
|
|
|
|
|
|
Current
liabilities
|
|
|
|
|
|
|
|
Accrued
expenses
|
|
$
|
|
|
$
|
|
|
Accounts
payable
|
|
|
3,319
|
|
|
-
|
|
Current
portion of notes payable, net unamortized discount of $8 and capital
lease
obligations
|
|
|
2,546
|
|
|
-
|
|
Total
current liabilities
|
|
|
9,723
|
|
|
95
|
|
Long-term
liabilities and capital lease obligations
|
|
|
1,372
|
|
|
-
|
|
Line
of credit with related party, net unamortized discount of
$311
|
|
|
11,689
|
|
|
-
|
|
Total
liabilities
|
|
|
22,784
|
|
|
95
|
|
Commitments
and contingencies
|
|
|
|
|
|
|
|
Shareholders’ equity
|
|
|
|
|
|
|
|
Series
A Preferred stock - $0.01 par value, 4,000,000 shares authorized;
954,799
and 0 shares issued and outstanding (liquidation value of $2,387
and $0)
December 31, 2007 and 2006, respectively
|
|
|
10
|
|
|
-
|
|
Series
C Preferred Stock - $0.01 par value, 500,000 shares authorized; no
shares
issued or outstanding
|
|
|
-
|
|
|
-
|
|
Common
Stock - $0.01 par value, 500,000,000 shares authorized; 178,344,608
and
61,775,002 shares issued and outstanding at December 31, 2007 and
2006,
respectively
|
|
|
1,783
|
|
|
618
|
|
Additional
paid-in-capital
|
|
|
284,273
|
|
|
280
|
|
Accumulated
deficit
|
|
|
(269,282
|
)
|
|
(877
|
)
|
Total
shareholders’ equity
|
|
|
16,784
|
|
|
21
|
|
Total
liabilities and shareholders’ equity
|
|
$
|
39,568
|
|
$
|
116
|
|
The
accompanying Notes to Consolidated Financial Statements are an integral part
of
these statements.
CONSOLIDATED
STATEMENTS OF OPERATIONS
(in
thousands except share data)
|
|
For
the year ended December 31, 2007
|
|
For
the period from inception (June 23, 2006) to
December
31, 2006
|
|
Revenue
|
|
$
|
847
|
|
$
|
-
|
|
Cost
of goods sold
|
|
|
808
|
|
|
-
|
|
Gross
margin
|
|
|
39
|
|
|
-
|
|
|
|
|
|
|
|
|
|
Operating
expenses
|
|
|
|
|
|
|
|
Selling,
general and administrative
|
|
|
12,466
|
|
|
375
|
|
Research
and development
|
|
|
10,850
|
|
|
508
|
|
Write-off
of acquired in-process research and development
|
|
|
243,761
|
|
|
-
|
|
Other
operating expenses, principally amortization of intangible
assets
|
|
|
150
|
|
|
-
|
|
Total
operating expenses
|
|
|
267,227
|
|
|
883
|
|
Operating
loss
|
|
|
(267,188
|
)
|
|
(883
|
)
|
Other
(expense) income, net
|
|
|
(671
|
)
|
|
6
|
|
Loss
before income taxes and investment loss from OTI
|
|
|
(267,859
|
)
|
|
(877
|
)
|
Income
taxes
|
|
|
83
|
|
|
-
|
|
Loss
before investment loss from OTI
|
|
|
(267,776
|
)
|
|
(877
|
)
|
Loss
from investment in OTI
|
|
|
(629
|
)
|
|
-
|
|
Net
loss
|
|
|
(268,405
|
)
|
|
(877
|
)
|
Preferred
stock dividend
|
|
|
(217
|
)
|
|
-
|
|
Net
loss attributable to common shareholders
|
|
$
|
(268,622
|
)
|
$
|
(877
|
)
|
|
|
|
|
|
|
|
|
Loss
per share, basic and diluted
|
|
$
|
(2.09
|
)
|
$
|
(0.01
|
)
|
|
|
|
|
|
|
|
|
Weighted
average number of shares outstanding,
basic
and diluted
|
|
|
128,772,080
|
|
|
58,733,556
|
|
The
accompanying Notes to Consolidated Financial Statements are an integral part
of
these statements.
OPKO
Health, Inc.
CONSOLIDATED
STATEMENTS OF SHAREHOLDERS’ EQUITY
(in
thousands except share data)
For
the
period from inception (June 23, 2006) to December 31,
2007
|
|
Series
A Preferred Stock
|
|
Series
C Preferred Stock
|
|
Common
Stock
|
|
Additional
Paid-In
|
|
Accumulated
|
|
|
|
|
|
Shares
|
|
Dollars
|
|
Shares
|
|
Dollars
|
|
Shares
|
|
Dollars
|
|
Capital
|
|
Deficit
|
|
Total
|
|
Issuance
of capital stock to founders
of
Froptix, $0.01 per share
|
|
|
-
|
|
$
|
-
|
|
|
-
|
|
$
|
-
|
|
|
61,775,002
|
|
$
|
618
|
|
$
|
20
|
|
$
|
-
|
|
$
|
638
|
|
Equity-based
compensation expense
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
260
|
|
|
-
|
|
|
260
|
|
Net
loss for the period from inception
(June
23, 2006) to December 31, 2006
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(877
|
)
|
|
(877
|
)
|
Balance
at December 31, 2006
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
61,775,002
|
|
|
618
|
|
|
280
|
|
|
(877
|
)
|
|
21
|
|
Equity-based
compensation expense
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
7,373
|
|
|
-
|
|
|
7,373
|
|
Issuance
of equity securities for net
monetary
assets at $0.43 per share
|
|
|
1,081,750
|
|
|
11
|
|
|
-
|
|
|
-
|
|
|
36,607,023
|
|
|
366
|
|
|
15,626
|
|
|
-
|
|
|
16,003
|
|
Issuance
of equity securities to acquire
Acuity
Pharmaceuticals, Inc. at $2.65
per
share
|
|
|
-
|
|
|
-
|
|
|
457,603
|
|
|
5
|
|
|
14,778,556
|
|
|
148
|
|
|
234,470
|
|
|
-
|
|
|
234,623
|
|
Issuance
of equity securities to acquire
Ophthalmic
Technologies, Inc. at
$2.57
per share
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
2,682,928
|
|
|
27
|
|
|
6,905
|
|
|
-
|
|
|
6,932
|
|
Issuance
of equity securities to acquire
software
at $3.79 per share
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
30,000
|
|
|
-
|
|
|
114
|
|
|
-
|
|
|
114
|
|
Issuance
of common stock in private
placement
to related party at $1.84
per
share
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
10,869,565
|
|
|
109
|
|
|
19,891
|
|
|
-
|
|
|
20,000
|
|
Issuance
of common stock upon
automatic
conversion of Series C
preferred
stock
|
|
|
-
|
|
|
-
|
|
|
(457,603
|
)
|
|
(5
|
)
|
|
45,760,300
|
|
|
457
|
|
|
(452
|
)
|
|
-
|
|
|
-
|
|
Conversion
of Series A preferred stock
|
|
|
(213,751
|
)
|
|
(2
|
)
|
|
-
|
|
|
-
|
|
|
213,751
|
|
|
2
|
|
|
-
|
|
|
-
|
|
|
-
|
|
Exercise
of common stock options
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
641,972
|
|
|
6
|
|
|
117
|
|
|
-
|
|
|
123
|
|
Exercise
of common warrants
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
4,985,511
|
|
|
50
|
|
|
(50
|
)
|
|
-
|
|
|
-
|
|
Preferred
stock dividend
|
|
|
86,800
|
|
|
1
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
|
)
|
|
-
|
|
|
-
|
|
Net
loss for the year ended
December
31, 2007
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
(268,405
|
)
|
|
(268,405
|
)
|
Balance
at December 31, 2007
|
|
|
954,799
|
|
$
|
10
|
|
|
-
|
|
$
|
-
|
|
|
178,344,608
|
|
$
|
1,783
|
|
$
|
284,273
|
|
$
|
(269,282
|
)
|
$
|
16,784
|
|
The
accompanying Notes to Consolidated Financial Statements are an integral part
of
these statements.
OPKO
Health, Inc.
CONSOLIDATED
STATEMENTS OF CASH FLOWS
(in
thousands)
|
|
For
the year ended December 31, 2007
|
|
For
the period from inception (June 23, 2006) to December 31,
2006
|
|
Cash
flows from operating activities
|
|
|
|
|
|
Net
loss
|
|
$
|
(268,405
|
)
|
$
|
(877
|
)
|
Adjustments
to reconcile net loss to net cash used in operating
activities:
|
|
|
|
|
|
|
|
Depreciation
and
amortization
|
|
|
184
|
|
|
-
|
|
Write-off
of acquired in-process research and development
|
|
|
243,761
|
|
|
-
|
|
Accretion
of debt discount related to notes payable
|
|
|
279
|
|
|
-
|
|
Loss
from investment in OTI
|
|
|
629
|
|
|
-
|
|
Equity
based compensation - employees and non-employees
|
|
|
7,373
|
|
|
260
|
|
Changes
in:
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
(554
|
)
|
|
-
|
|
Inventory
|
|
|
(317
|
)
|
|
-
|
|
Prepaid
expenses and other current assets
|
|
|
(789
|
)
|
|
-
|
|
Accounts
payable
|
|
|
(607
|
)
|
|
95
|
|
Accrued
expenses
|
|
|
1,497
|
|
|
-
|
|
Net
cash used in operating activities
|
|
|
(16,949
|
)
|
|
(522
|
)
|
Cash
flows from investing activities
|
|
|
|
|
|
|
|
Investment
in 33% of Ophthalmic Technologies, Inc.
|
|
|
(5,000
|
)
|
|
-
|
|
Acquisition
of businesses, net of cash
|
|
|
2,751
|
|
|
-
|
|
Capital
expenditures
|
|
|
(489
|
)
|
|
-
|
|
Net
cash used in investing activities
|
|
|
(2,738
|
)
|
|
-
|
|
Cash
flows from financing activities:
|
|
|
|
|
|
|
|
Issuance
of common stock for cash to related party
|
|
|
20,000
|
|
|
638
|
|
Issuance
of common stock
|
|
|
16,284
|
|
|
-
|
|
Borrowings
under line of credit with related party
|
|
|
8,000
|
|
|
-
|
|
Insurance
financing
|
|
|
|
|
|
-
|
|
Proceeds
from the exercise of stock options
|
|
|
123
|
|
|
-
|
|
Repayments
of notes payable and capital lease obligations
|
|
|
(1,615
|
)
|
|
-
|
|
Net
cash provided by financing activities
|
|
|
42,944
|
|
|
638
|
|
Net
change in cash and cash equivalents
|
|
|
23,257
|
|
|
116
|
|
Cash
and cash equivalents at beginning of period
|
|
|
116
|
|
|
-
|
|
Cash
and cash equivalents at end of period
|
|
$
|
23,373
|
|
$
|
116
|
|
The
accompanying Notes to Consolidated Financial Statements are an integral
part of these statements.
NOTES
TO CONSOLIDATED FINANCIAL STATEMENTS
Note
1 Business and Organization
OPKO
Health, Inc. ("we" or the "Company") is a specialty healthcare company
focused on the discovery, development, and commercialization of proprietary
pharmaceuticals, diagnostic and imaging systems and instrumentation products
for
the treatment, diagnosis and management of ophthalmic diseases. We continue
to
seek to expand our current operations by acquiring additional ophthalmic
businesses and pharmaceutical and instrumentation technologies, as well as
exploring opportunities in other medical markets that have operational
characteristics similar to ophthalmology, such as dermatology. We are a Delaware
corporation, headquartered in Miami, Florida, with instrumentation operations
in
Toronto, Ontario and our clinical operations in Morristown, New Jersey.
On
June
8, 2007, we changed our name to OPKO Health, Inc. from eXegenics, Inc. Through
March 26, 2007, eXegenics was a public shell company whose assets consisted
of
cash and nominal other assets. On February 9, 2007, eXegenics, completed the
sale of 19,440,491 shares of its common stock for $8.0 million, constituting
51%
of its issued and outstanding shares of capital stock on a fully diluted basis,
to a small group of investors led by The Frost Group, LLC, or the Frost Group,
a
related party. The Frost Group members include a trust controlled by Dr. Phillip
Frost, who is the Company’s Chief Executive Officer and Chairman of the board of
directors, Dr. Jane H. Hsiao, who is the Company's Vice Chairman of the
board of directors and Chief Technical Officer, Steven D. Rubin who is the
Company's Executive Vice President - Administration and a director, and Rao
Uppaluri who is the Company's Chief Financial Officer. On March 27, 2007,
pursuant to the terms of a Merger Agreement and Plan of Reorganization, Froptix
Corporation, or Froptix, a development stage research and development company,
controlled by the Frost Group, and Acuity Pharmaceuticals, Inc., or Acuity,
a
development stage research and development company, and eXegenics were part
of a
three-way merger. Per that agreement, eXegenics issued new capital stock to
acquire all of the issued and outstanding capital stock of Froptix and Acuity.
Per
that agreement, eXegenics issued new capital stock to acquire all of the issued
and outstanding capital stock of Froptix and Acuity.
Froptix
was
the
accounting acquirer in the three-way merger which was accounted for
as:
|
·
|
a
reverse merger between Froptix and eXegenics (a public shell company).
For
accounting purposes Froptix has been treated as the continuing registrant.
As a result, all post merger comparative historical financials statements
filed by us will be those of Froptix. Froptix was incorporated on
June 23,
2006. Further, Froptix’ historical shareholders’ equity prior to the
merger has been retroactively restated (recapitalized) for the equivalent
number of shares received in the reverse merger. Earnings and loss
per
share calculations have also been retroactively restated to give
effect to
the recapitalization for all periods presented. Lastly, the merger
between
Froptix and eXegenics has been accounted for as a capital transaction
equivalent to the issuance of capital stock by Froptix for the net
monetary assets of eXegenics.
|
|
·
|
an
asset acquisition of Acuity by Froptix. Refer to Note
2
|
As
a
result, at the closing of the Mergers, we issued (a) an aggregate of 61,775,002
shares of our common stock to the former holders of Froptix common stock, (b)
an
aggregate of 14,778,556 shares of our common stock to the former holders of
Acuity common stock and Acuity Series A preferred stock, and (c) an aggregate
45,760,300 shares of our common stock, to the former holders of Acuity Series
B
preferred stock which had converted into 457,603 shares of our Series C
preferred stock prior to the Series C preferred stock converting into our common
stock on June 23, 2007. We also granted 28,358,857 warrants to purchase shares
of our common stock to former shareholders of Froptix and Acuity and 15,810,115
options to purchase our common stock to former option holders of Froptix and
Acuity and 1,686,600 warrants to purchase our common stock, which had been
warrants to purchase our Series C preferred stock prior to our Series C
preferred stock converting to common stock on June 23, 2007. As
consideration for an increase in our credit line with the Frost Group, we
granted to the Frost Group an additional 4,000,000 warrants to purchase our
common stock in connection with the Mergers.
On
November 28, 2007, we completed the acquisition of Ophthalmic Technologies,
Inc., or OTI
and
as a
result we are no longer a development-stage company.
Refer to Note
2.
Note
2 Acquisitions
On
March
27, 2007, we acquired Acuity in a stock for stock transaction. Refer to Note
1.
We valued our common stock issued to Acuity shareholders at the average closing
price of the common stock on the date of acquisition and the two days prior
to
the transaction. Acuity’s primary focus prior to our acquisition had been on the
development of its lead compound, bevasiranib, for the treatment of Wet
Age-Related Macular Degeneration, or Wet AMD. We believe the acquisition of
Acuity was complementary to our platform of compounds for ophthalmic diseases
and that Acuity had an advanced clinical product.
On
April
13, 2007, we invested $5 million in exchange for common shares of
Ophthalmic Technologies, Inc., or OTI, equaling one-third of the outstanding
equity of OTI. On November 28, 2007, we acquired the remaining outstanding
shares of OTI and issued approximately 2.7 million shares of our common stock
based upon a purchase price of $10,000,000 and a value of $3.55 per share.
OTI
provides diagnostic and imaging systems to eye care professionals worldwide
through its distributor network which covers over 60 countries. We believe
our
acquisition of OTI will provide a complementary product line to our
pharmaceutical business that will improve physician treatment decisions and
enhance outcomes for a variety of ocular disorders. The minority interest
results in OTI from April 13, 2007 through our acquisition of OTI on November
28, 2007 have been included in our financial statements.
The
following table summarizes the estimated fair value of the net assets acquired
and liabilities assumed in the acquisition of Acuity and OTI at the dates of
acquisition:
(in
thousands)
|
|
|
|
Current
assets (including cash of $ 2,751)
|
|
$
|
6,032
|
|
Property
and equipment
|
|
|
85
|
|
In-process
research and development
|
|
|
243,761
|
|
Intangible
assets
|
|
|
8,087
|
|
Other
assets
|
|
|
602
|
|
Goodwill
|
|
|
1,732
|
|
Accounts
payable and accrued expenses
|
|
|
(6,528
|
)
|
Line
of credit and term loan
|
|
|
(7,419
|
)
|
Total
purchase price
|
|
$
|
246,352
|
|
The
portion of the purchase price allocated to in-process research and development
of $243.8 million relates to the acquisition of Acuity and was immediately
expensed. The purchase price of Acuity includes $1.5 million of costs incurred
by us to acquire Acuity, including $1.3 million of costs associated with the
issuance of warrants to the Frost Group as a result of the increase of the
credit line with Acuity. Refer to Note 5. The purchase consideration issued
and
the purchase price allocation are preliminary pending completion of related
valuation procedures and as a result, the amounts are subject to
change.
The
following table summarizes that fair value assigned to our major intangible
assets classes:
(in
thousands)
|
|
Fair
value assigned
|
|
Weighted
average amortization period
|
|
Technology
|
|
$
|
4,597
|
|
|
10
years
|
|
Customer
relationships
|
|
|
2,978
|
|
|
3
years
|
|
Covenants
not to compete
|
|
|
317
|
|
|
3
years
|
|
Tradename
|
|
|
195
|
|
|
3
years
|
|
Total
amortizing intangible assets
|
|
|
8,087
|
|
|
|
|
Goodwill
|
|
|
1,732
|
|
|
Indefinite
|
|
Total
intangible assets acquired
|
|
$
|
9,819
|
|
|
|
|
All
of
the intangible assets acquired and goodwill acquired relate to our acquisition
of OTI.
The
following table includes the pro forma results for the year ended December
31, 2007 and the period from inception (June 23, 2006) to December 31, 2006
of
the combined companies as though the acquisitions of Acuity and OTI had been
completed as of the beginning of each period, respectively.
(in
thousands, except per share amounts)
|
|
For
the year ended December 31, 2007
|
|
Period
from inception (June 23, 2006) through December 31, 2006
|
|
Revenue
|
|
$
|
12,148
|
|
$
|
5,570
|
|
Net
loss
|
|
$
|
(278,097
|
)
|
$
|
(7,577
|
)
|
Basic
and diluted loss per share
|
|
$
|
(2.06
|
)
|
$
|
(0.10
|
)
|
This
unaudited pro forma financial information is presented for informational
purposes only. The unaudited pro forma financial information may not
necessarily reflect our future results of operations or what the results of
operations would have been had we owned and operated each company as of the
beginning of the periods presented.
Note
3 Summary of Significant Accounting Policies
Basis
of Presentation
.
The
accompanying consolidated financial statements have been prepared in
accordance with accounting principles generally accepted in the United States
and with the instructions to Form 10-K and of Regulation S-X.
Use
of Estimates
.
The
preparation of financial statements in conformity with accounting principles
generally accepted in the United States of America requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date
of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those estimates.
Cash
and Cash Equivalents
.
We
consider all non-restrictive, highly liquid short-term investments purchased
with a maturity of three months or less on the date of purchase to be cash
equivalents.
Inventories
.
Inventories are valued at the lower of cost or market (net realizable value).
Cost is determined by the first-in, first-out method.
Property
and Equipment
.
Property and equipment are recorded at cost. Depreciation is provided using
the
straight-line method over the estimated useful lives of the assets, generally
five to ten years and includes amortization expense for assets capitalized
under capital leases. Expenditures for repairs and maintenance are charged
to
expense as incurred, while betterments are capitalized. Depreciation expense
for
the year ended December 31, 2007 was $35 thousand. We did not have any property
or equipment for the period from inception (June 23, 2006) to December 31,
2006 and as a result did not incur depreciation expense for that
period.
Goodwill
and Other Intangible Assets
.
Goodwill represents the difference between the purchase price and the estimated
fair value of the net assets acquired when accounted for by the purchase method
of accounting and arises from our acquisition of OTI. Refer to Note 2. In
accordance with SFAS 142, “Goodwill and Intangible Assets,” we do not amortize
goodwill. Also in accordance with FAS 142, we will perform an annual impairment
test of goodwill.
We
test
for impairment annually during the fourth quarter.
We will continue to
evaluate our goodwill for impairment annually and whenever events and changes
in
circumstances suggest that the carrying amount may not be recoverable.
We
amortize intangible assets with definite lives on a straight-line basis over
their estimated useful lives, ranging from 3 to 10 years, and review for
impairment at least annually, or sooner when events or changes in
circumstances indicate that the carrying amount of such assets may not be
recoverable. Amortization expense for the year ended December 31, 2007 was
$0.2
million. We did not have any intangible assets for the period from inception
to
December 31, 2006 and as a result did not incur amortization expense for that
period. Amortization expense for the years ended December 31, 2008, 2009, 2010,
2010 and 2011 is expected to be $1.6 million, $1.6 million, $1.5 million, $0.5
million and $0.5 million, respectively.
Impairment
of Long-Lived Assets
.
In
accordance with Statement of Financial Accounting Standards (SFAS) No. 144,
Accounting for Impairment or Disposal of Long-Lived Assets, long-lived assets,
such as property and equipment, are reviewed for impairment whenever events
or
changes in circumstances indicate that the carrying amount of an asset may
not
be recoverable. Recoverability of assets to be held and used is measured by
a
comparison of the carrying amount of an asset to estimated undiscounted future
cash flows expected to be generated by the asset. If the carrying amount of
an
asset exceeds its estimated future cash flows, then an impairment charge is
recognized by the amount by which the carrying amount of the asset exceeds
the
fair value of the asset.
Research
and Development
.
Research and development costs are charged to expense as incurred. We
record expense for in-process research and development projects acquired which
have not reached technological feasibility and which have no alternative
future use.
Income
Taxes
.
Income
taxes are accounted for under the asset-and-liability method. Deferred tax
assets and liabilities are recognized for the future tax consequences
attributable to differences between the financial statement carrying amounts
of
existing assets and liabilities and the respective tax bases and operating
loss
and tax credit carryforwards. Deferred tax assets and liabilities are measured
using enacted tax rates expected to apply to taxable income in the years in
which those temporary differences are expected to be recovered or settled.
The
effect on deferred tax assets and liabilities of a change in tax rates is
recognized in operations in the period that includes the enactment date.
We
periodically evaluate the realizability of our net deferred tax assets. Our
tax
accruals
are analyzed periodically and adjustments are made as events occur to warrant
such adjustment.
Loss
Per Common Share
.
Basic
and diluted earnings or loss per common share is based on the net loss increased
by dividends on preferred stock divided by the weighted average number of common
shares outstanding during the period. In the periods in which their effect
would
be anti-dilutive, no effect has been given to outstanding options, warrants
or
convertible preferred stock in the diluted computation. As of December 31,
2007,
we have 178,344,608 common shares outstanding, in addition, we have
options, warrants and convertible preferred stock outstanding at December 31,
2007 that, if converted or exercised would result in the issuance of an
additional 45,934,615 shares of common stock, resulting in 224,279,223 potential
common shares outstanding. The diluted loss per share does not include the
weighted average impact of the outstanding options and warrants of
30,508,179 for the year ended December 31, 2007 because their inclusion
would have been anti-dilutive.
Revenue
Recognition and Allowance for Doubtful
Accounts
. Generally,
we recognize revenue from product sales when goods are shipped and title and
risk of loss transfer to our customers.
Certain
of our products are sold directly to end-users and require that we deliver,
install and train the staff at the end-users’ facility. As a result, we do not
recognize revenue until the product is delivered, installed and training has
occurred.
Estimated
allowances for sales returns are based upon our history of product returns.
The
amount of allowance for doubtful accounts at December 31, 2007 was $0.5
million.
Equity-Based
Compensation
.
We
follow the provisions of Financial Accounting Standards Board (“FASB”) Statement
of Financial Accounting Standards (“Statement”) No. 123 (revised 2004),
Share-Based Payment (“SFAS 123R”), which requires that a company measure the
cost of employee services received in exchange for an award of equity
instruments based on the grant-date fair value of the award. That cost is
recognized in the statement of operations over the period during which an
employee is required to provide service in exchange for the award. SFAS 123R
also requires that excess tax benefits, as defined, realized from the exercise
of stock options be reported as a financing cash inflow rather than as a
reduction of taxes paid in cash flow from operations. Refer to Note 8.
Equity-based compensation arrangements to non-employees are accounted for in
accordance with SFAS No. 123R and Emerging Issues Task Force Issue No. 96-18
(EITF 96-18), “Accounting for Equity Instruments That Are Issued to Other Than
Employees for Acquiring, or in Conjunction with Selling, Goods or Services,”
which requires that these equity instruments be recorded at their fair
value on the measurement date. The measurement of equity-based compensation
is
subject to periodic adjustment as the underlying equity instruments vest.
Comprehensive
income or loss
.
Our
comprehensive loss has no components other than net loss for all periods
presented.
Segment
reporting.
Our
chief operating decision-maker (or “CODM”) is comprised of our executive
management with the oversight of our board of directors. Our CODM review our
operating results and operating plans and make resource allocation decisions
on
a company-wide or aggregate basis. Accordingly, we operate as one segment.
Our
products are being used by and developed for retina specialists,
ophthalmologists, and optometrists. During 2007, all of our instrumentation
products were sold internationally.
New
accounting pronouncements
:
In July
2006, the FASB issued Interpretation Number 48, Accounting for Uncertainty
in Income Taxes, or FIN 48. FIN 48 applies to all tax positions within the
scope
of SFAS 109, applies a “more likely than not” threshold for tax benefit
recognition, identifies a defined methodology for measuring benefits, and
increases the disclosure requirements for companies. FIN 48 is mandatory for
years beginning after December 15, 2006; accordingly, we adopted FIN 48
effective January 1, 2007. Refer to Note 9.
In
September 2006, the FASB issued SFAS No. 157, Fair Value Measurements, or SFAS
157. SFAS 157 defines fair value, establishes a framework for measuring fair
value in generally accepted accounting principles, and expands disclosures
about
fair value measurements. This Statement applies to other accounting
pronouncements that require or permit fair value measurements, the FASB having
previously concluded in those accounting pronouncements that fair value is
the
relevant measurement attribute. Accordingly, this Statement does not require
any
new fair value measurements. SFAS 157 is effective for fiscal years beginning
after November 15, 2007. We will adopt SFAS 157 beginning in the first quarter
of our 2008 fiscal year and do not expect the impact to be material to our
financial position or results of operations.
In
February 2007, the FASB issued SFAS No. 159, The Fair Value Option for Financial
Assets and Financial Liabilities, or SFAS 159, which gives companies the option
to measure eligible financial assets, financial liabilities, and firm
commitments at fair value (i.e., the fair value option), on an
instrument-by-instrument basis, that are otherwise not permitted to be accounted
for at fair value under other accounting standards. The election to use the
fair
value option is available when an entity first recognizes a financial asset
or
financial liability or upon entering into a firm commitment. Subsequent changes
in fair value must be recorded in earnings. SFAS 159 is effective for financial
statements issued for fiscal years beginning after November 15, 2007. We will
adopt SFAS 159 beginning in the first quarter of our 2008 fiscal year and do
not
expect the impact to be material to our financial position or results of
operations.
In
June
2007, the EITF issued EITF Issue 07-03, Accounting for Advance Payments for
Goods or Services to Be Used in Future Research and Development, or EITF 07-03.
EITF 07-03 addresses the accounting for the non-refundable portion of a payment
made by a research and development entity for future research and development
activities. Under EITF 07-03, an entity would defer and capitalize
non-refundable advance payments made for research and development activities
until the related goods are delivered or the related services are performed.
EITF 07-03 is effective for fiscal years beginning after December 15, 2007.
We
plan to adopt EITF 07-03 beginning in the first quarter of our 2008 fiscal
year
and do not expect the impact to be material to our financial position or results
of operations.
In
December 2007, the FASB issued SFAS No. 141R, Business Combinations. SFAS
141R
will require, among other things, the expensing of direct transaction costs,
including deal costs and restructuring costs as incurred, acquired IPR&D
assets to be capitalized, certain contingent assets and liabilities to be
recognized at fair value and earn-our arrangements, including contingent
consideration, may be required to be measured at fair value until settled,
with
changes in fair value recognized each period into earnings. In addition,
material adjustments made to the initial acquisition purchase accounting
will be
required to be recorded back to the acquisition date. This will cause companies
to revise previously reported results when reporting comparative financial
information in subsequent filings. SFAS No. 141R is effective for the Company
on
a prospective basis for transactions occurring in 2009 and earlier adoption
is
not permitted. SFAS No. 141R may have a material impact on the Company’s
consolidated financial position, results of operations and cash flows
if we enter into material business combinations after the standard’s
effective date.
Note
4 Composition of Certain Financial Statement Captions
|
|
December
31,
|
|
(in
thousands)
|
|
2007
|
|
2006
|
|
Accounts
receivable, net
|
|
|
|
|
|
Accounts
receivable
|
|
$
|
2,154
|
|
$
|
-
|
|
Less
allowance for doubtful accounts
|
|
|
(465
|
)
|
|
-
|
|
|
|
$
|
1,689
|
|
$
|
-
|
|
Inventories
|
|
|
|
|
|
|
|
Raw
materials (components)
|
|
$
|
1,913
|
|
|
-
|
|
Finished
products
|
|
|
301
|
|
|
-
|
|
Less
provision for inventory reserve
|
|
|
|
|
|
-
|
|
|
|
$
|
2,214
|
|
$
|
-
|
|
Prepaid
expenses and other current assets
|
|
|
|
|
|
|
|
Prepaid
clinical trial expenses
|
|
$
|
511
|
|
$
|
-
|
|
Prepaid
insurance
|
|
|
426
|
|
|
-
|
|
Prepaid
supplies
|
|
|
456
|
|
|
-
|
|
Canadian
tax credit recoverable
|
|
|
225
|
|
|
-
|
|
Other
|
|
|
318
|
|
|
-
|
|
|
|
$
|
1,936
|
|
$
|
-
|
|
Property
and equipment, net
|
|
|
|
|
|
|
|
Machinery
and equipment
|
|
$
|
153
|
|
$
|
-
|
|
Furniture
and fixtures
|
|
|
207
|
|
|
-
|
|
Software
|
|
|
117
|
|
|
-
|
|
Leasehold
improvements
|
|
|
27
|
|
|
-
|
|
Less
accumulated depreciation
|
|
|
(94
|
)
|
|
-
|
|
|
|
$
|
410
|
|
$
|
-
|
|
Intangible
assets
|
|
|
|
|
|
|
|
Technology
|
|
$
|
4,597
|
|
$
|
-
|
|
Customer
relationships
|
|
|
2,978
|
|
|
-
|
|
Covenants
not to compete
|
|
|
317
|
|
|
-
|
|
Tradename
|
|
|
195
|
|
|
-
|
|
Other
|
|
|
262
|
|
|
-
|
|
Less
amortization
|
|
|
(150
|
)
|
|
-
|
|
Goodwill
|
|
|
1,732
|
|
|
-
|
|
|
|
$
|
9,931
|
|
$
|
-
|
|
Accrued
expenses
|
|
|
|
|
|
|
|
Accrued
royalties
|
|
$
|
313
|
|
$
|
-
|
|
Accrued
distributor commissions
|
|
|
187
|
|
|
-
|
|
Product
warranties - medical device products
|
|
|
221
|
|
|
-
|
|
Clinical
trials
|
|
|
1,495
|
|
|
-
|
|
Customer
deposits
|
|
|
511
|
|
|
-
|
|
Other
|
|
|
1,131
|
|
|
95
|
|
|
|
$
|
3,858
|
|
$
|
95
|
|
Note
5 Debt
On
January 11, 2007, Acuity entered into an agreement with the Frost Group whereby
the Frost Group provided a subordinated secured line of credit of up to $7.0
million to Acuity. In exchange for entering into this agreement, Acuity agreed
to grant to the Frost Group a warrant to purchase Acuity Series B Preferred
Stock which after the Merger became warrants to acquire up
to 647,800 shares of our common stock at an exercise price of approximately
$0.3854 per share and warrants to acquire
Acuity
common stock which after the Merger become warrants to acquire
81,085 shares of our common stock at an exercise price of $0.0019
per share.
In
connection with the acquisition of Acuity, we assumed the rights and obligations
of Acuity under this line of credit. We also amended and restated this line
of
credit to increase the borrowing capacity to $12.0 million and
assume
Acuity’s existing obligation to repay $4.0 million outstanding under the prior
line of credit. During 2007, we drew down the remaining available funds of
$8.0
million for a total of $12.0 million borrowed. We are obligated to pay interest
upon maturity, compounded quarterly on borrowings under the line of credit
at a
10% annual rate, which is due on July 11, 2009. The line of credit is
collateralized by all of our personal property, except intellectual property.
In
connection with the assumption and amendment of the line of credit, we granted
warrants to purchase 4,000,000 shares of our common stock to the Frost Group.
The fair value of the warrants was determined to be $12.4 million using the
Black-Scholes option valuation model. Because the issuance of the warrants
and
the increase in the line of credit were conditioned upon the completion of
the
Mergers, the value of the warrants has been allocated on a relative fair value
basis to the cost of the Acuity acquisition ($1.3 million), the cost of the
reverse merger between Froptix and eXegenics ($11.0 million) and debt commitment
fee ($0.1 million).
We
also
assumed the rights and obligations of Acuity’s $4.0 million term loan ($2.4
million outstanding of December 31, 2007) with Horizon Financial, Inc., in
connection with the Mergers. The term loan bears interest at 12.23%, which
is
payable monthly. The principal is payable in 12 equal monthly
installments which began August 2007. On January 11, 2008, we
repaid in full all outstanding amounts and terminated all of our commitments
under the term loan with Horizon.
Note
6 Equity Offering
On
December 5, 2007, in exchange for a $20 million cash investment in the Company,
we issued 10,869,565 shares of our common stock, par value $.01, to members
of
the Frost Group. The shares were issued at a price of $1.84 per share,
representing an approximately 40% discount to the average trading price of
our
stock on the American Stock Exchange for the five trading days immediately
preceding the date the board of directors and stockholders approved the issuance
of the shares. The shares issued in the private placement are restricted
securities, subject to a two year lockup, and no registration rights have been
granted. Refer to Note 11.
Note
7 Stockholders’ Equity
Our
authorized capital stock consists of 500,000,000 shares of common stock, par
value $.01 per share, and 10,000,000 shares of preferred stock, par value $.01
per share.
Common
Stock
Subject
to the rights of the holders of any shares of preferred stock currently
outstanding or which may be issued in the future, the holders of the common
stock are entitled to receive dividends from our funds legally available when,
as and if declared by our board of directors, and are entitled to share ratably
in all of our assets available for distribution to holders of common stock
upon
the liquidation, dissolution or winding-up of our affairs subject to the
liquidation preference, if any, of any then outstanding shares of preferred
stock. Holders of our common stock do not have any preemptive, subscription,
redemption or conversion rights. Holders of our common stock are entitled to
one
vote per share on all matters which they are entitled to vote upon at meetings
of stockholders or upon actions taken by written consent pursuant to Delaware
corporate law. The holders of our common stock do not have cumulative voting
rights, which means that the holders of a plurality of the outstanding shares
can elect all of our directors. All of the shares of our common stock currently
issued and outstanding are fully-paid and nonassessable. No dividends have
been
paid to holders of our common stock since our incorporation, and no cash
dividends are anticipated to be declared or paid in the reasonably foreseeable
future.
In
addition to our equity-based compensation plans, we have warrants to purchase
our common stock. Refer to Note 8 for additional information on our
share-based compensation plans. The table below provides additional information
for warrants outstanding as of December 31, 2007. In connection with the
Mergers, we issued a total of:
Warrants
|
|
Number
of warrants
|
|
Weighted
average exercise price
|
|
Expiration
date
|
|
Outstanding
at December 31, 2006
|
|
|
-
|
|
|
-
|
|
|
-
|
|
Issued
to former Acuity warrant holders’
|
|
|
6,472,652
|
|
$
|
0.02
|
|
|
Various
2015-2016
|
|
Issued
to Acuity shareholders’
|
|
|
6,253,236
|
|
$
|
0.86
|
|
|
March
27, 2017
|
|
Issued
to Acuity Series B warrant holders
|
|
|
1,686,000
|
|
$
|
0.39
|
|
|
Various
2015-2017
|
|
Issued
to Froptix shareholders’
|
|
|
15,632,969
|
|
$
|
0.86
|
|
|
March
27, 2017
|
|
Issued
in conjunction with debt commitment
|
|
|
4,000,000
|
|
$
|
0.50
|
|
|
March
27, 2017
|
|
Issued
to eXegenics warrant holders
|
|
|
290,000
|
|
$
|
0.75
|
|
|
August
13, 2007 through March 5, 2008
|
|
Exercised
|
|
|
(5,537,475
|
)
|
|
|
|
|
|
|
Expired
|
|
|
(125,000
|
)
|
|
|
|
|
|
|
Outstanding
at December 31, 2007
|
|
|
28,672,382
|
|
|
|
|
|
|
|
Exercisable
at December 31, 2007
|
|
|
28,672,382
|
|
|
|
|
|
|
|
Of
the
5,537,475 warrants exercised to purchase common stock, 551,964 shares were
surrendered in lieu of a cash payment via the net exercise feature of the
warrant agreements.
Preferred
Stock
Under
our
certificate of incorporation, our board of directors has the authority, without
further action by stockholders, to designate up to 10 million shares of
preferred stock in one or more series and to fix or alter, from time to time,
the designations, powers and rights of each series of preferred stock and the
qualifications, limitations or restrictions of any series of preferred stock,
including dividend rights, dividend rate, conversion rights, voting rights,
rights and terms of redemption (including sinking fund provisions), redemption
price or prices, and the liquidation preference of any wholly issued series
of
preferred stock, any or all of which may be greater than the rights of the
common stock, and to establish the number of shares constituting any such
series.
Series
A Preferred Stock
Of
the
authorized preferred stock, 4,000,000 shares have been designated Series A
preferred stock. Dividends are payable on the Series A preferred stock in
the amount of $0.25 per share, payable annually in arrears. At the option of
our
board of directors, dividends will be paid either (i) wholly or partially in
cash or (ii) in newly issued shares of Series A preferred stock valued at $2.50
per share to the extent cash dividend is not paid.
Holders
of Series A preferred stock have the right to convert their shares, at their
option exercisable at any time, into shares of our common stock on a one-for-one
basis subject to anti-dilution adjustments. These anti-dilution adjustments
are
triggered in the event of any subdivision or combination of our outstanding
common stock, any payment by us of a stock dividend to holders of our common
stock or other occurrences specified in the certificate of designations relating
to the Series A preferred stock. We may elect to convert the Series A preferred
stock into common stock or a substantially equivalent preferred stock in the
case of a merger or consolidation in which we do not survive, a sale of all
or
substantially all of our assets or a substantial reorganization of us.
Each
share of Series A preferred stock is entitled to one vote on all matters on
which the common stock has the right to vote. Holders of Series A preferred
stock are also entitled to vote as a separate class on any proposed adverse
change in the rights, preferences or privileges of the Series A preferred stock
and any increase in the number of authorized shares of Series A preferred stock.
In the event of any liquidation or winding up of the Company, the holders of
the
Series A preferred stock will be entitled to receive $2.50 per share plus any
accrued and unpaid dividends before any distribution to the holders of the
common stock and any other class of series of preferred stock ranking junior
to
it.
We
may
redeem the outstanding shares of Series A preferred stock for $2.50 per share
(plus accrued and unpaid dividends), at any time.
Series
C Preferred Stock
Of
the
authorized preferred stock, 500,000 shares were designated Series C preferred
stock. On June 22, 2007, 457,603 Series C preferred stock were issued and
outstanding and held by 30 stockholders. Cumulative dividends were payable
on
the Series C preferred stock in the amount of $1.54 per share when declared
by
the board of directors. On June 22, 2007, all of the shares of Series C
preferred stock automatically converted into shares of common stock, on a
one-hundred-for-one basis.
Note
8 Equity-Based Compensation
We
maintain equity-based incentive compensation plans that provide for grants
of
stock options to our directors, officers, key employees and certain outside
consultants. Our 2007 Equity Incentive Plan includes all options assumed from
the companies combined in the Merger discussed in Note 1. Options granted
under the 1996 Stock Option Plan, 2000 Stock Option Plan and the plans assumed
from Froptix and Acuity are exercisable for a period of up to 10 years from
date
of grant. Options granted under the 2007 Equity Incentive Plan are exercisable
for a period up to 7 years. Vesting periods range from immediate to 4 years.
Adoption
of New Accounting Guidance and Transition
Upon
our
incorporation in June 2006, we adopted the fair value recognition provisions
of
SFAS No. 123R, which is a revision of SFAS No. 123, using the prospective
transition method.
SFAS
No.
123R requires that we classify the cash flows resulting from the tax benefit
that arises when the tax deductions exceed the compensation cost recognized
for
those options (excess tax benefits) as financing cash flows. There were no
excess tax benefits for the year ended December 31, 2007 or the period from
inception (June 23, 2006) to December 31, 2006.
Equity-based
compensation arrangements to non-employees are accounted for in accordance
with
SFAS No. 123R and Emerging Issues Task Force Issue No. 96-18 (EITF 96-18),
“Accounting for Equity Instruments That Are Issued to Other Than Employees for
Acquiring, or in Conjunction with Selling, Goods or Services,” which requires
that these equity instruments are recorded at their fair value on the
measurement date. The measurement of equity-based compensation is subject to
periodic adjustment over the waiting time of the equity
instruments.
Valuation
and Expense Information
We
recorded equity based compensation expense of $7.4 million and $0.3
million, for the year ended December 31, 2007 and the period from inception
(June 23, 2006) to December 31, 2006, respectively, all of which were
reflected as operating expense.
Of
the
$7.4 million of expense recorded during the year ended December 31, 2007, $4.4
million was included as selling, general and administration expense and $3.0
million was recorded as research and development expense.
During
the third quarter of 2007, a reversal of equity-based compensation expense
of
$8.1 million was recorded as a result of the termination of a consulting
agreement prior to the vesting of any of the equity based awards issued under
a
consulting agreement. Originally, we accrued $0.3 million for this expense
during 2006 and $7.8 million during the first six months of
2007.
During the 2006 period, all of the
equity-based compensation was recorded as selling, general and administration
expense.
As of December 31, 2007, there was $16.0 million of total
unrecognized compensation cost related to non-vested stock options, which will
be expensed over a weighted-average period of 3.0 years. We did not recognize
a
tax benefit for equity-based compensation arrangements during the year ended
December 31, 2007.
As
required by SFAS No. 123R, we estimate forfeitures of stock options and
recognize compensation cost only for those awards expected to vest. Forfeiture
rates are determined for all employees and non-employee directors based on
historical experience and our estimate of future vesting. Estimated forfeiture
rates are adjusted from time to time based on actual forfeiture experience.
Stock
Options
In
accordance with SFAS No. 123R, we estimate the fair value of each stock option
on the date of grant using a Black-Scholes option-pricing formula, applying
the
following assumptions, and amortized the fair value to expense over the
option’s vesting period using the straight-line attribution approach for
employees and non-employee directors, and the amortization method allowed by
Financial Accounting Standards Board Interpretation 28, “Accounting for Stock
Appreciation Rights and Other Variable Stock Option or Award Plans an
interpretation of APB Opinions No. 15 and 25”, for awards issued to
non-employees which allows for recognizing compensation expense on a graded
basis, with most of the compensation expense being recorded during the initial
period of vesting:
|
|
Year
Ended
|
|
|
December
31, 2007
|
|
December
31, 2006
|
Expected
term (in years)
|
|
3.5
- 9.7
|
|
9.5
|
Risk-free
interest rate
|
|
3.2%
- 5.2%
|
|
4.5%
|
Expected
volatility
|
|
73%
- 76%
|
|
35%
|
Expected
dividend yield
|
|
0%
|
|
0%
|
Expected
Term: The expected term of the stock options to employees and non-employee
directors was calculated using the shortcut method allowed by the provisions
of
SFAS No. 123R and interpreted by Staff Accounting Bulletin No. 110 (SAB 110).
We
believe this method is appropriate as our equity shares have been publicly
trade
for a limited period of time and as such we do not have sufficient historical
exercise data to provide a reasonable basis upon which to estimate expected
term. The expected term of stock options issued to non-employee
consultants is the remaining contractual life of the options
issued.
Risk-Free
Interest Rate: The risk-free interest rate is based on the rates paid on
securities issued by the U.S. Treasury with a term approximating the expected
life of the option.
Expected
Volatility: The expected volatility was based on a peer group of publicly-traded
stocks’ historical trading which we believe will be representative of the
volatility over the expected term of the options. We believe the peer group’s
historical volatility is appropriate as our equity shares have been publicly
traded for a limited period of time.
The
expected volatility for the 2006 period utilized a different peer group than
the
year ended December 31, 2007 and as a result had a lower
volatility.
Expected
Dividend Yield: We do not intend to pay dividends on common stock for the
foreseeable future. Accordingly, we used a dividend yield of zero in the
assumptions.
We
maintain incentive stock plans that provide for the grants of stock options
to
our directors, officers, employees and outside consultants. For the year ended,
December 31, 2007, there were 18,038,329 shares of common stock reserved for
issuance under our 2007 Incentive Plan. We intend to issue new shares upon
the
exercise of options. Stock options granted under these plans have been granted
at an option price equal to the closing market value of the stock on the date
of
the grant. Options granted under these plans to employees typically become
exercisable over four years in equal annual installments after the date of
grant, and to non-employee directors become exercisable in full after one-year
after the grant date, subject to, in each case, continuous service with the
Company during the applicable vesting period. The Company assumed options to
grant common stock as part of the Merger, which reflected various vesting
schedules, including monthly vesting to employees and contractors.
A
summary
of option activity under our stock plans as of December 31, 2007 and the changes
during the year is presented below:
Options
|
|
Number
of options
|
|
Weighted
average exercise price
|
|
Weighted
average remaining contractual term (years)
|
|
Aggregate
intrinsic value (in thousands)
|
|
Outstanding
at December 31, 2006
|
|
|
4,436,878
|
|
$
|
0.01
|
|
|
|
|
|
|
|
Assumed
from Acuity Pharmaceuticals
|
|
|
11,373,237
|
|
|
0.14
|
|
|
|
|
|
|
|
Assumed
from eXegenics
|
|
|
305,000
|
|
|
0.59
|
|
|
|
|
|
|
|
Granted
|
|
|
5,220,000
|
|
|
4.45
|
|
|
|
|
|
|
|
Conversion
of Series C Stock Options to Common Stock Options
|
|
|
731,700
|
|
|
0.32
|
|
|
|
|
|
|
|
Exercised
|
|
|
(654,220
|
)
|
|
0.26
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(5,103,216
|
)
|
|
0.04
|
|
|
|
|
|
|
|
Expired
|
|
|
(1,945
|
)
|
|
0.04
|
|
|
|
|
|
|
|
Outstanding
at December 31, 2007
|
|
|
16,307,434
|
|
$
|
1.53
|
|
|
6.2
|
|
$
|
29,979
|
|
Vested
and expected to vest at December 31, 2007
|
|
|
15,172,394
|
|
$
|
1.45
|
|
|
6.1
|
|
$
|
28,826
|
|
Exercisable
at December 31, 2007
|
|
|
8,529,411
|
|
$
|
0.20
|
|
|
5.2
|
|
$
|
22,571
|
|
The
amount of compensation costs recorded in 2007 related to stock options awards
is
$7.4 million and $0.3 million was recorded during 2006. As of December 31,
2007,
there was $15.9 million of unrecognized compensation cost related to the stock
options granted under our stock plans. That cost is expected to be recognized
over a weighted-average period of 3 years. The per share weighted-average
fair value of stock options granted during 2007 was $2.73. The total intrinsic
value of stock options exercised was $2.3 million during 2007. There were no
stock option exercises during 2006, our year of inception.
Note
9
Income Taxes
Income
before income taxes was taxed in the U.S. and Canada.
The
provision (benefit) for incomes taxes consists of the following:
(in
thousands)
|
|
For the Year
Ended
December 31, 2007
|
|
For the period from
inception (June 23, 2006) through
December 31,
2006
|
|
Current
|
|
|
|
|
|
|
|
Federal
|
|
$
|
-
|
|
$
|
-
|
|
State
|
|
|
-
|
|
|
-
|
|
Foreign
|
|
|
(83
|
)
|
|
-
|
|
|
|
|
(83
|
)
|
|
-
|
|
Deferred
|
|
|
|
|
|
|
|
Federal
|
|
|
(5,274
|
)
|
|
(199
|
)
|
State
|
|
|
(333
|
)
|
|
(30
|
)
|
Foreign
|
|
|
(106
|
)
|
|
-
|
|
|
|
|
(5,714
|
)
|
|
(229
|
)
|
Total
|
|
|
(5,797
|
)
|
|
(229
|
)
|
Change
in valuation allowance
|
|
|
5,714
|
|
|
229
|
|
Total,
net
|
|
$
|
(83
|
)
|
$
|
-
|
|
|
|
|
|
|
|
|
|
Deferred
income tax assets and liabilities as of December 31, 2007 and December
31, 2006
are comprised of the following:
(in
thousands)
|
|
December 31, 2007
|
|
December 31, 2006
|
|
Deferred
income tax assets
|
|
|
|
|
|
|
|
Federal
net operating loss
|
|
$
|
8,726
|
|
$
|
229
|
|
State
net operating loss
|
|
|
1,665
|
|
|
-
|
|
Foreign
net operating loss
|
|
|
509
|
|
|
|
|
Capitalized
research and development expense
|
|
|
4,916
|
|
|
|
|
Research
and development tax credit
|
|
|
781
|
|
|
-
|
|
Canadian
research and development pool
|
|
|
1,269
|
|
|
-
|
|
Amortization
and depreciation
|
|
|
304
|
|
|
-
|
|
Other
|
|
|
983
|
|
|
-
|
|
Deferred
income tax assets
|
|
|
19,153
|
|
|
229
|
|
Deferred
income tax liabilities
|
|
|
|
|
|
|
|
Intangible
assets
|
|
|
(3,090
|
)
|
|
-
|
|
Other
|
|
|
(3
|
)
|
|
-
|
|
Deferred
income tax liabilities
|
|
|
(3,093
|
)
|
|
-
|
|
Net
deferred income tax assets
|
|
|
16,060
|
|
|
229
|
|
Valuation
allowance
|
|
|
(16,924
|
)
|
|
(229
|
)
|
Net
deferred income tax liabilities
|
|
$
|
(864
|
)
|
$
|
-
|
|
|
|
|
|
|
|
|
|
The
increase in deferred income tax assets, liabilities and valuation allowances
at
December 31, 2007 reflect the acquisition of various legal entities, including
the tax attributes. The acquisitions were accounted for under U.S. GAAP
as asset
acquisitions. As of December 31, 2007, we have net operating loss carryforwards
of approximately $31.2 million that expire at various dates through 2027.
We
have research and development tax credit carryforwards of $0.8 million
that
expire in varying amounts through 2027. We have determined a full valuation
allowance is required against all of our tax assets that we do not expect
to be
utilized by the turn around of deferred income tax liabilities and recorded
a
deferred tax liability for the temporary differences arising from the
acquisition of non-deductible identifiable intangible assets of OTI that
are in
excess of OTI's tax assets.
Under
Section 382 of the Internal Revenue Code of 1986, as amended, certain
significant changes in ownership may restrict the future utilization of
our
income tax loss carryforwards and income tax credit carryforwards in the
United
States. The annual limitation is equal to the value of our stock immediately
before the ownership change, multiplied by the long-term tax-exempt rate
(i.e.,
the highest of the adjusted Federal long-term rates in effect for any month
in
the three-calendar-month period ending with the calendar month in which
the
change date occurs). This limitation may be increased under the IRC§ 338
Approach (IRS approved methodology for determining recognized Built-In
Gain). As
a result, federal net operating losses and tax credits may expire before
we are
able to fully utilize them. As we have recorded a full valuation allowance
against our net deferred income tax assets, there is no current impact
of this
limitation for financial reporting purposes. We are currently undergoing
a study
to determine what, if any limitations we have on our income tax loss carry
forwards and income tax credit carryforwards.
Adoption
of FIN 48
Prior
to
January 1, 2007, we recognized income taxes with respect to uncertain tax
positions based upon SFAS No. 5, “ Accounting for Contingencies" , or SFAS No.
5. Under SFAS No. 5, we would record a liability associated with an uncertain
tax position if the liability was both probable and estimable. Prior to January
1, 2007, the liabilities recorded under SFAS No. 5 including interest and
penalties related to income tax exposures, would have been recognized as
incurred within “income taxes” in our consolidated statements of operations. We
recorded no such liabilities in 2006.
Effective
January 1, 2007, we adopted FIN 48, "Accounting for Uncertainty in Income
Taxes.” FIN 48 clarifies the accounting for uncertainty in income taxes
recognized in financial statements in accordance with SFAS No. 109, “Accounting
for Income Taxes.” FIN 48 prescribes a recognition threshold and measurement
attribute for the financial statement recognition and measurement of a tax
position taken or expected to be taken in a tax return. FIN 48 requires that
we
determine whether the benefit of our tax positions are more likely than not
to
be sustained upon audit, based on the technical merits of the tax position.
For
tax positions that are more likely than not to be sustained upon audit, we
recognize the greatest amount of the benefit that is more likely than not
to be
sustained in our consolidated financial statements. For tax positions that
are
not more likely than not to be sustained upon audit, we do not recognize
any
portion of the benefit in our consolidated financial statements. The provisions
of FIN 48 also provide guidance on derecognition, classification, interest
and
penalties, accounting in interim periods, and disclosure.
Our
policy for interest and penalties under FIN 48, related to income tax exposures,
was not impacted as a result of the adoption of the recognition and measurement
provisions of FIN 48. Therefore, we continue to recognize interest and penalties
as incurred within “income taxes” in our consolidated statements of operations,
when applicable.
There
was
no change to our accumulated deficit as of January 1, 2007 as a result of
the
adoption of the recognition and measurement provisions of FIN 48.
Uncertain
Income Tax Positions
We
file
income tax returns in the U.S. federal jurisdiction, Canada federal jurisdiction
and with various U.S. states and the Ontario province in Canada. We are subject
to tax audits in all jurisdictions for which we file tax returns. Tax audits
by
their very nature are often complex and can require several years to complete.
There are currently no tax audits that have commenced with respect to income
returns in any jurisdiction.
U.S.
Federal: Under the tax statute of limitations applicable to the Internal
Revenue
Code, we are no longer subject to U.S. federal income tax examinations by
the
Internal Revenue Service for years before 2003. However, because we are carrying
forward income tax attributes, such as net operating losses and tax credits
from
2002 and earlier tax years, these attributes can still be audited when utilized
on returns filed in the future.
State:
Under the statutes of limitation applicable to most state income tax laws,
we
are no longer subject to state income tax examinations by tax authorities
for
years before 2003 in states in which we have filed income tax returns. Certain
states may take the position that we are subject to income tax in such states
even though we have not filed income tax returns in such states and, depending
on the varying state income tax statutes and administrative practices, the
statute of limitations in such states may extend to years before
2003.
Foreign:
Under the statutes of limitations applicable to our foreign operations,
we are
no longer subject to tax examination for years before 2003 in jurisdictions
we
have filed income tax returns.
As
a
result of our January 1, 2007 implementation of FIN 48, the total amount
of
gross tax benefits, excluding the offsetting full valuation allowance, that
became unrecognized, was approximately $0.4 million. There were no accrued
interest and penalties resulting from such unrecognized tax benefits. As
of
December 31, 2007, the total amount of gross unrecognized tax benefits was
approximately $0.9 million, and accrued interest and penalties on such
unrecognized tax benefits was $0.
The
following table reconciles the activity in our gross unrecognized income
tax
benefits.
(in
thousands)
|
|
|
|
Unrecognized
tax benefits January 1, 2007
|
|
$
|
412
|
|
Gross
increases - tax positions in prior period
|
|
|
468
|
|
Gross
decreases - tax positions in prior period
|
|
|
-
|
|
Unrecognized
tax benefits at December 31, 2007
|
|
$
|
880
|
|
The
net
unrecognized tax benefits that, if recognized, would impact the effective
tax
rate as of December 31, 2007 and December 31, 2006, were $0 and $0,
respectively.
Other
Income Tax Disclosures
The
significant elements contributing to the difference between the federal
statutory tax rate and the effective tax rate are as follows:
|
|
For
the Year Ended
|
|
For
the period from inception
(June
23, 2006) through
December
31, 2006
|
|
|
|
December 31,
2007
|
|
December 31,
2006
|
|
Federal
statutory rate
|
|
|
(35.0
|
)%
|
|
(35.0
|
)%
|
State
income taxes, net of federal benefit
|
|
|
(3.9
|
)
|
|
(3.3
|
)
|
Acquired
in-process research and development
|
|
|
35.3
|
|
|
—
|
|
Valuation
allowance
|
|
|
2.1
|
|
|
38.3
|
|
Other
|
|
|
1.5
|
|
|
—
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
0.0
|
%
|
|
—
|
%
|
We
paid
no income taxes in 2007 or 2006.
The
following table reconciles our losses before income taxes by
jurisdiction:
(in
thousands)
|
|
For the Year Ended
December 31,
2007
|
|
For the Period from
Inception
(June 23, 2006)
through
December 31,
2006
|
|
Pre-tax
loss
|
|
|
|
|
|
|
|
U.S.
|
|
$
|
(267,542
|
)
|
$
|
(877
|
)
|
Foreign
|
|
|
(317
|
)
|
|
-
|
|
Total
|
|
$
|
(267,859
|
)
|
$
|
(877
|
)
|
Note
10
Supplemental Cash Flow Information
Supplemental
cash flow information is summarized as follows:
(in
thousands)
|
|
For
the Year Ended
December
31,
2007
|
|
For
the Period From Inception
(June
23, 2006) through
December
31,
2006
|
|
Interest
paid
|
|
$
|
370
|
|
$
|
-
|
|
Non-cash
financing
|
|
|
|
|
|
|
|
Issuance
of capital stock to acquire Acuity
|
|
$
|
243,623
|
|
$
|
-
|
|
Issuance
of capital stock to acquire OTI
|
|
|
6,932
|
|
|
-
|
|
Issuance
of capital stock to acquire other
|
|
|
114
|
|
|
-
|
|
Total
non-cash financing
|
|
$
|
250,669
|
|
$
|
-
|
|
Note
11 Related Party Transactions
In
June
2007, we paid the $125,000 filing fee to the Federal Trade Commission in
connection with filings made by us and Dr. Frost, our Chairman and Chief
Executive Officer, under the Hart-Scott-Rodino Antitrust Improvements Act of
1976 (“HSR”). The filings permitted Dr. Frost and his affiliates to acquire
additional shares of our common stock upon expiration of the HSR
waiting period on July 12, 2007.
In
November 2007, we entered into an office lease with Frost Real Estate Holdings,
LLC, an entity affiliated with Dr. Frost, the Company's Chairman of the
Board and Chief Executive Officer. The lease is for approximately 8,300 square
feet of space in an office building in Miami, Florida, where the Company's
principal executive offices are located. We had previously been leasing this
space from Frost Real Estate Holdings on a month-to-month basis while the
parties were negotiating the lease. The lease provides for payments of
approximately $18,000 per month in the first year increasing annually to $24,000
per month in the fifth year, plus applicable sales tax. The rent is inclusive
of
operating expenses, property taxes and parking. The rent for the first year
has
been reduced to reflect a $30,000 credit for the costs of tenant
improvements.
On
December 5, 2007, we issued 10,869,565 shares of the our common stock, par
value
$.01, to members of the Frost Group in exchange for a $20 million cash
investment, or $1.84 per share, representing an approximately 40% discount
to
the average trading price of our stock on the American Stock Exchange for the
five days preceding the date our board of directors and stockholders approved
the issuance of the shares. The shares issued in the private placement were
restricted securities, subject to a two year lockup, and no registration rights
have been granted.
As
part
of the Mergers, we assumed a line of credit with the Frost Group from Acuity
and
amended and restated that line of credit to increase borrowing availability.
In
connection with the increase of the borrowing availability, we issued 4,000,000
warrants to the Frost Group.
Refer to Note 5.
Note
12 Employee Benefit Plans
Effective
January 1, 2007, the OPKO Health Savings and Retirement Plan, or the Plan,
permits employees to contribute up to 50% of qualified pre-tax annual
compensation up to annual statutory limitations. The discretionary company
match
for employee contributions to the Plan is 100% of up to the first 4% of the
participant’s earnings contributed to the Plan. Our matching contributions to
the plan were approximately $0.1 million in 2007.
Note
13 Commitments and Contingencies
We
have
agreed to indemnify one of our former employees for damages or losses incurred
by such employee in connection with a lawsuit by the employee’s previous
employer for alleged breach of fiduciary duty and tortious interference with
contractual relationships and prospective business. The plaintiff in this matter
has also sought leave to amend its complaint to add the Company and the Frost
Group, LLC as defendants. We are opposing this motion, and intend to vigorously
defend the matter in the event we are named as a defendant. It is too early
to
assess the probability of a favorable or unfavorable outcome, or the loss or
range of loss or indemnification obligation, if any, and therefore, no amounts
have been accrued relating to this action.
We
are a
party to litigation in the ordinary course of business. We do not believe that
any such litigation will have a material adverse effect on our business,
financial condition, or results of operations.
Note
14 Strategic Alliances
Our
strategy is to develop a portfolio of product candidates through a combination
of internal development and external partnerships. We have completed strategic
deals with the Trustees of the University of Pennsylvania, the University of
Illinois, the University of Florida Research Foundation, Pathogenics, Inc.,
and
Intradigm Corporation, among others.
The
Trustees of the University of Pennsylvania
In
March
2003, we entered into two world-wide exclusive license agreements with The
Trustees of the University of Pennsylvania to comm
ercialize
siRNA targeting VEGF, HIF-1α, ICAM, and other therapeutic targets. In
consideration for the licenses, we are obligated to make certain milestone
payments to the University of Pennsylvania. We also agreed to pay the University
of Pennsylvania ea
rned
royalties based on the number of products we sell that use the inventions
claimed in the licensed patents. We agreed to use commercially reasonable
efforts to develop, commercialize, market, and sell such products covered by
the
license agreements.
The
term
of the agreements is for the later of the expiration or abandonment of the
last
patent or ten years after the first commercial sale of the first licensed
product. We may terminate either of the agreements upon 60 days’ prior written
notice. The University of Pennsylvania may terminate either of the agreements
if
we are more than 90 days late in a payment owed to the University of
Pennsylvania, we breach the agreements and do not cure within 90 days after
receiving written notice from the University of Pennsylvania, if we become
insolvent, or we are involved in bankruptcy proceedings.
Intradigm
Corporation
In
June
2005, we entered into a license and collaboration agreement with Intradigm
Corporation, or Intradigm, for intellectual property covering the treatment
of
ophthalmic diseases characterized by excessive neovascularization, angiogenesis,
or leakage. Under the terms of the agreement, we have agreed to jointly develop
a topical siRNA compound. After selection the topical siRNA compound, we
are
obligated to use commercially reasonable efforts to market, distribute, and
sell
the topical siRNA in the United States and any selected foreign country.
We have
agreed to pay to Intradigm certain milestone payments upon the achievement
of
specified milestones and royalty payments on all net sales of the topical
siRNA
and other licensed products.
The
term
of the agreement is 20 years, unless earlier terminated in accordance with
the
agreement. Either party may terminate upon mutual written consent, upon written
notice by a party if the other party dissolves or enters into bankruptcy
or
insolvency proceedings, or upon 90 days prior written notice of a material
breach of the agreement without cure.
The
Board of Trustees of the University of Illinois
In
August
2006, we entered into an exclusive worldwide license agreement with The Board
of
Trustees of the University of Illinois to commercialize intellectual property
related to ophthalmic siRNA targeting TGF-bRII for the treatment of ophthalmic
disease. In September 2007, the license was amended to include all other fields
of use beyond the treatment of ophthalmic disease. The license agreement
obligates us to pay to the University of Illinois certain milestone payments
and
royalty payments on all net sales of licensed products and an annual license
fee
payment.
University
of Florida Research Foundation
In
April
2006, we entered into three world-wide exclusive license agreements with the
University of Florida Research Foundation. The license agreements obligate
us to
pay to University of Florida Research Foundation royalty payments on all net
sales of licensed products. We agreed to use our commercially reasonable
activities to commercialize products. The term of each of the agreements
is for the earlier of the date that no licensed patent remains an enforceable
patent or the payment of earned royalties under the agreement once begun, ceases
for more than two calendar quarters. We may terminate any of the agreements
upon
60 days’ prior written notice. The University of Florida Research Foundation may
terminate any of the agreements if we are more than 60 days late, after written
demand, for a payment owed to the University of Florida Research Foundation,
if
we breach the agreements and do not cure within 60 days after receiving written
notice from the University of Florida Research Foundation, or if we become
involved in bankruptcy proceedings.
Civamide
License
In
September 2007, we entered into an exclusive worldwide license to commercialize
intellectual property related to pharmaceutical compositions or preparations
containing civamide for the treatment of ophthalmic conditions in humans,
particularly dry eye. The license agreement obligates us to pay the licensor
certain milestone payments and royalty payments on all net sales of licensed
products thereunder and all costs of research and development necessary to
obtain marketing authorizations for such licensed products.
Wound
Dressing
In
October 2007, we entered into an exclusive worldwide license to commercialize
intellectual property related to a novel ocular product for use following
invasive retinal procedures to prevent the development of endophthalmitis,
a
devastating complication that can lead to blindness and loss of the affected
eye. The license agreement obligates us to make royalty payments on all net
sales of licensed products thereunder and all costs of research and development
necessary to obtain marketing authorizations for such licensed products.
Pathogenics
In
April
2006, we entered into a license agreement with Pathogenics, Inc. (“Pathogenics”)
under which we were granted an exclusive, irrevocable license, with the right
to
sublicense, under Pathogenics intellectual property to make, have made, use,
sell, offer for sale, import, or otherwise commercialize N-chlorotaurine and
licensed products for the treatment of ophthalmic disease or infection in any
territory. We were also granted non-exclusive rights to all data resulting
from
a phase I clinical trial with N-chlorotaurine in Austria. We are obligated
to
use commercially reasonable efforts to develop and commercialize the licensed
product, including commercially reasonable efforts to initiate pre-clinical
activities necessary to file an IND with the FDA to initiate a phase I clinical
trial for N-chlorotaurine for an ophthalmic indication. Pathogenics will have
a
non-exclusive right to such information for the treatment of non-ophthalmic
diseases or infections.
We
are
obligated to pay to Pathogenics certain milestone payments upon the achievement
of specified milestones and royalty payments on all net sales of licensed
products. We are also obligated to pay Pathogenics an annual minimum payment
if
the total payments made for such year are less than a specified minimum amount.
The term of the agreement is for the shorter of twenty years or the last to
expire of the Pathogenics intellectual property. We may terminate the agreement
for any reason upon written notice. The agreement may be terminated upon mutual
written consent of the parties, by either party upon written notice if either
party dissolves or is involved in a bankruptcy or insolvency proceeding or
upon
ninety days prior written notice if the other party is in material breach and
fails to cure.
Note
15 Leases
We
conduct certain of our operations under operating lease agreements. Rent expense
was approximately $0.3 million for the year ended December 31, 2007. We did
not
have any lease expense from the period from inception (June 23, 2006) through
December 31, 2006.
As
of
December 31, 2007, the aggregate future minimum lease payments under all
non-cancelable operating leases with initial or remaining lease terms in excess
of one year are as follows:
Year
Ending
|
|
(in
thousands)
|
|
2008
|
|
$
|
333
|
|
2009
|
|
|
351
|
|
2010
|
|
|
338
|
|
2011
|
|
|
350
|
|
2012
|
|
|
226
|
|
Total
minimum lease commitments
|
|
$
|
1,598
|
|
Year
Ending
|
|
(in
thousands)
|
|
2008
|
|
|
9
|
|
2009
|
|
|
6
|
|
2010
|
|
|
2
|
|
Total
minimum lease payments
|
|
|
17
|
|
Less
imputed interest
|
|
|
(2
|
)
|
Present
value of minimum lease payments
|
|
|
15
|
|
Current
portion
|
|
|
9
|
|
Long-term
portion
|
|
$
|
6
|
|
Note
16 Selected Quarterly Financial Data (Unaudited)
|
|
For
the 2007 Quarters Ended
|
|
(in
thousands)
|
|
March
31, 2007
|
|
June
30, 2007
|
|
September
30, 2007
|
|
December
31, 2007
|
|
Revenue
|
|
$
|
-
|
|
$
|
-
|
|
$
|
-
|
|
$
|
847
|
|
Gross
margin
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
39
|
|
Net
(loss) income attributable to common shareholders
|
|
|
(249,945
|
)
|
|
(11,086
|
)
|
|
1,440
|
|
|
(9,031
|
)
|
Basic
and diluted (loss) income per share
|
|
$
|
(3.87
|
)
|
$
|
(0.09
|
)
|
$
|
0.01
|
|
$
|
(0.05
|
|
|
For
the 2006 Quarters Ended
|
|
(in
thousands)
|
|
Period
from
inception
(June
23, 2006) to
June
30, 2006
|
|
September
30,
2006
|
|
December
31,
2006
|
|
Revenue
|
|
$
|
-
|
|
$
|
-
|
|
$
|
-
|
|
Gross
margin
|
|
|
-
|
|
|
-
|
|
|
-
|
|
Net
loss attributable to common shareholders
|
|
|
(250
|
)
|
|
(7
|
)
|
|
(620
|
)
|
Basic
and diluted loss per share
|
|
$
|
(3.68
|
)
|
$
|
(0.00
|
)
|
$
|
(0.01
|
)
|
Due
to
rounding, the quarterly per share amounts may not mathematically compute to
the
annual amount.
Until
our
acquisition of OTI on November 28, 2007, we did not record any revenue or gross
margin. The net loss for the first quarter of 2007 includes in-process research
and development expense of $243.7 million related to the acquisition of Acuity.
The third quarter of 2007 reflects the reversal of $8.1 million of equity-based
compensation expense due to the termination of a consulting agreement prior
to
the shares vesting. The equity-based compensation expense had previously been
recorded as follows: $7.8 million during the first six months of 2007, and
$0.3
million during 2006. Our inception was on June 23, 2006, and as a
result, there was no activity in the first quarter of 2006, and only
eight days of activity in the second quarter of 2006.
Note
17 Subsequent Events
On
March
25, 2008, OTI received a warning letter in connection with a FDA inspection
of
OTI’s facilities in July and August of 2007. The warning letter cited
several deficiencies in OTI’s quality, record keeping, and reporting systems
relating to certain of OTI’s products, including the OTI Scan 1000, OTI Scan
2000, and OTI OCT/SLO combination imaging system. Based upon the
observations noted in the warning letter, OTI is not currently in compliance
with cGMP. The FDA indicated that it has issued an Import Alert and may refuse
admission of these products. As a result, we will not be permitted to sell
these devices in the United States, and the pre-market approval application
for
the Company’s OCT/SLO product will be delayed until the violations have been
corrected.
We
plan
to cooperate fully with the FDA, and upon receipt of the warning letter,
we
immediately began to take corrective action to address the FDA’s concerns and to
assure the quality of OTI’s products. We are committed to providing high
quality products to our customers, and we plan to meet this commitment by
working diligently to remedy these deficiencies and to implement updated
and
improved quality systems and concepts throughout the OTI organization.
|
CHANGES
IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE.
|
None.
Disclosure
Controls and Procedures
The
Company’s management, under the supervision and with the participation of the
Company’s Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”),
has evaluated the effectiveness of the Company’s disclosure controls and
procedures as defined in Securities and Exchange Commission (“SEC”) Rule
13a-15(e) as of December 31, 2007. Based on that evaluation, management has
concluded that the Company’s disclosure controls and procedures are effective to
ensure that information the Company is required to disclose in reports that
it
files or submits under the Securities Exchange Act is communicated to
management, including the CEO and CFO, as appropriate, to allow timely decisions
regarding required disclosure and is recorded, processed, summarized, and
reported within the time periods specified in the SEC’s rules and
forms.
Management’s
Annual Report on Internal Control Over Financial Reporting
Our
management is responsible for establishing and maintaining adequate internal
control over financial reporting, as such term is defined in Rule 13a-15(f)
under the Securities Exchange Act of 1934, as amended. All internal control
systems, no matter how well designed, have inherent limitations. Therefore,
even
those systems determined effective could provide only reasonable assurance
with
respect to financial statement preparation and presentation.
Under
the
supervision and with the participation of our management, including our Chief
Executive Officer and Chief Financial Officer, we conducted an evaluation
of the
effectiveness of our internal control over financial reporting as of December
31, 2007, based on the framework in Internal Control - Integrated Framework
issued by the Committee of Sponsoring Organizations of the Treadway Commission.
As
permitted, our management’s assessment of and conclusion on the effectiveness of
our internal control over financial reporting did not include the internal
controls of Ophthalmic Technologies, Inc., because it was acquired by us
in a
purchase business combination during the fourth quarter of fiscal 2007. OTI
constituted
approximately 15% of our consolidated total assets at December 31, 2007 and
100%
of consolidated revenues for the year then ended.
Based
on
our evaluation under the framework in Internal Control - Integrated Framework,
our management concluded that our internal control over financial reporting
was
effective as of December 31, 2007.
This
annual report does not include an auditors report of Ernst & Young, LLP, our
independent registered public accounting firm, regarding internal control
over
financial reporting as of December 31, 2007 pursuant to temporary rules of
the
Securities and Exchange Commission that permit the Company to provide only
management’s report in this annual report.
Pursuant
to Item 308T(a) of Regulation S-K, this Management’s Report on Internal Control
Over Financing Reporting shall not be deemed filed for purposes of Section
18 of
the Exchange Act or otherwise subject to the liabilities of that
section.
Changes
to the Company’s Internal Control Over Financial Reporting
Beginning
in the fourth quarter of 2007, we began designing and implementing standards
and
procedures at OTI, upgrading and establishing controls over accounting systems,
and adding employees who are trained and experienced in the preparation of
financial statements in accordance with U.S. GAAP to ensure that we have
in
place appropriate internal control over financial reporting at OTI.
Other
than as set forth above with respect to OTI, there have been no changes to
the
Company’s internal control over financial reporting that occurred during the
Company’s fourth fiscal quarter that have materially affected, or are reasonably
likely to materially affect, the Company’s internal control over financial
reporting.
Effective
as of March 28, 2008, the Company’s Board of Directors approved amendments to
the Company’s Amended and Restated Bylaws primarily to remove the requirements
that the Company’s annual stockholders’ meeting be held in Delaware within five
months of the end of the fiscal year. In addition, the Company made the
appointment of certain officers discretionary, whereas, the Amended and Restated
Bylaws as in effect prior to these amendments made such appointments
mandatory.
PART
III
(a)
(1)
|
Financial
Statements: Consolidated Financial Statements filed as part of this
report
are set forth under Part II, Item 8 of this
report.
|
|
(2)
|
Financial
Statement Schedules
|
|
(3)
|
Exhibits:
Each management contract or compensatory plan listed below is identified
with an asterisk. The Exhibits listed in the accompanying index are
filed
as part of this report
|
Exhibit
Number
|
|
Description
|
2.1
(2)
|
|
Amended
and Restated Certificate of Incorporation.
|
|
|
|
2.2
|
|
Amended
and Restated By-Laws.
|
|
|
|
2.3
(1)
|
|
Merger
Agreement and Plan of Reorganization, dated as of March 27, 2007,
by and
among Acuity Pharmaceuticals, Inc., Froptix Corporation, eXegenics,
Inc.,
e-Acquisition Company I-A, LLC, and e-Acquisition Company II-B,
LLC.
|
|
|
|
4.1
(1)
|
|
Form
of Common Stock Warrant.
|
|
|
|
10.1
(1)
|
|
Form
of Lockup Agreement.
|
|
|
|
10.2
(1)
|
|
License
Agreement, dated as March 31, 2003, by and between the Trustees of
the University of Pennsylvania and Acuity Pharmaceuticals, Inc.
(Reich/Tolentino).
|
|
|
|
10.3
(1)
|
|
License
Agreement, dated as March 31, 2003, by and between the Trustees of
the University of Pennsylvania and Acuity Pharmaceuticals, Inc.
(Reich/Gewirtz).
|
|
|
|
10.4
(1)
|
|
First
Amendment to License Agreement, dated as August 1, 2003, by and between
the Trustees of the University of Pennsylvania and Acuity Pharmaceuticals,
Inc. (Reich/Tolentino).
|
|
|
|
10.5
(1)
|
|
First
Amendment to License Agreement, dated as August 1, 2003, by and between
the Trustees of the University of Pennsylvania and Acuity Pharmaceuticals,
Inc. (Gewirtz).
|
|
|
|
10.6
(1)
*
|
|
Employment
Agreement, dated as of September 25, 2004, by and between Dale R.
Pfost and Acuity Pharmaceuticals, Inc.
|
|
|
|
10.7
(1)
*
|
|
Employment
Letter, dated April 9, 2007, between Dale R. Pfost and eXegenics,
Inc.
|
|
|
|
10.8
(1)
|
|
Credit
Agreement, dated as of March 27, 2007, by and among eXegenics, Inc.,
The Frost Group, LLC, and Acuity Pharmaceuticals, LLC.
|
|
|
|
10.9
(1)
|
|
Amended
and Restated Venture Loan and Security Agreement, dated as March 27,
2007, by and among Horizon Technology Funding Company LLC, Acuity
Pharmaceuticals, LLC and eXegenics, Inc.
|
|
|
|
10.10
(1)
|
|
Amended
and Restated Subordination Agreement, dated as of March 27, 2007, by
and among The Frost Group, LLC, Horizon Technology Funding Company
LLC,
Acuity Pharmaceuticals, LLC, and eXegenics,
Inc.
|
10.11
|
|
Share
Purchase Agreement, dated April 11, 2007, by and between Ophthalmic
Technologies, Inc. and eXegenics, Inc.
|
|
|
|
10.12
(3)
|
|
Lease
Agreement dated November 13, 2007, by and between Frost Real Estate
Holdings, LLC and the Company.
|
|
|
|
10.13
|
|
Share
Purchase Agreement, dated as of November 28, 2007, by and among Ophthalmic
Technologies, Inc., OTI Holdings Limited, and the Shareholders named
therein.
|
|
|
|
10.14
|
|
Exchange
and Support Agreement, dated as of November 28, 2007, by and among
OPKO
Health, Inc. and OTI Holdings Limited and the holders of exchangeable
shares named therein.
|
|
|
|
10.15
|
|
Securities
Purchase Agreement, dated December 4, 2007, by and between members
of The
Frost Group, LLC and the Company.
|
|
|
|
10.16
|
|
OPKO
Health, Inc. 2007 Equity Incentive Plan.
|
|
|
|
21
|
|
Subsidiaries
of the Company.
|
|
|
|
23.1
|
|
Consent
of Ernst & Young LLP.
|
|
|
|
31.1
|
|
Certification
by Phillip Frost, Chief Executive Officer, pursuant to Exchange Act
Rules
13a-14 and 15d-14.
|
|
|
|
31.2
|
|
Certification
by Rao Uppaluri, Chief Financial Officer, pursuant to Exchange Act
Rules 13a-14 and 15d-14.
|
|
|
|
32.1
|
|
Certification
by Phillip Frost, Chief Executive Officer, pursuant to 18 U.S.C.
Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of
2002.
|
|
|
|
32.2
|
|
Certification
by Rao Uppaluri, Chief Financial Officer, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of
2002.
|
*
|
|
Denotes
management contract or compensatory plan or
arrangement.
|
|
|
|
(1)
|
|
Filed
with the Company’s Current Report on Form 8-K filed with the Securities
and Exchange Commission on April 2, 2007, and incorporated herein
by
reference.
|
|
|
|
(2)
|
|
Filed
with the Company’s Current Report on Form 8-A filed with the Securities
and Exchange Commission on June 11, 2007, and incorporated herein
by
reference.
|
|
|
|
(3)
|
|
Filed
with the Company’s Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission on November 14, 2007 for the Company’s three-month
period ended September 30, 2007, and incorporated herein by
reference.
|
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, OPKO Health, Inc. has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
|
OPKO
HEALTH, INC.
|
|
|
|
|
By:
|
/s/ Dr. Phillip Frost
|
|
Dr.
Phillip Frost,
|
|
Chairman
of the Board and
Chief
Executive Officer
|
Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of
1934, this report has been signed by the following persons on behalf of OPKO
Health, Inc. in the capacities indicated below.
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
/s/
Dr. Phillip
Frost, M.D.
|
|
|
|
|
Dr. Phillip
Frost, M.D.
|
|
Chairman
of the Board and Chief Executive Officer
(Principal
Executive Officer)
|
|
March 31, 2008
|
|
|
|
|
|
/s/
Dr. Jane
H. Hsiao
|
|
|
|
|
Dr. Jane
H. Hsiao
|
|
Vice
Chairman and Chief Technical Officer
|
|
|
|
|
|
|
|
/s/
Steven
D. Rubin
|
|
|
|
|
Steven
D. Rubin
|
|
Director
and Executive Vice President - Administration
|
|
|
|
|
|
|
|
/s/
Rao
Uppaluri
|
|
|
|
|
Rao
Uppaluri
|
|
Senior
Vice President and Chief Financial Officer
(Principal
Financial Officer)
|
|
|
|
|
|
|
|
/s/
Adam
Logal
|
|
|
|
|
Adam
Logal
|
|
Executive
Director of Finance, Chief Accounting Officer and Treasurer
(Principal
Accounting Officer)
|
|
|
|
|
|
|
|
/s/
Robert
Baron
|
|
|
|
|
Robert
Baron
|
|
Director
|
|
|
|
|
|
|
|
/s/
Thomas
E. Beier
|
|
|
|
|
Thomas
E. Beier
|
|
Director
|
|
|
|
|
|
|
|
/s/
Pascal
J. Goldschmidt, M.D.
|
|
|
|
|
Pascal
J. Goldschmidt, M.D.
|
|
Director
|
|
|
|
|
|
|
|
/s/
Richard
A. Lerner, M.D.
|
|
|
|
|
Richard
A. Lerner, M.D.
|
|
Director
|
|
|
|
|
|
|
|
/s/
John
A. Paganelli
|
|
|
|
|
John
A. Paganelli
|
|
Director
|
|
|
|
|
|
|
|
/s/
Richard
C. Pfenniger, Jr.
|
|
|
|
|
Richard
C. Pfenniger, Jr.
|
|
Director
|
|
|
|
|
|
|
|
/s/
Michael Reich
|
|
|
|
|
Michael
Reich
|
|
Director
|
|
|
EXHIBIT
INDEX
Exhibit
Number
|
|
Description
|
2.1
|
|
Amended
and Restated Bylaws
|
|
|
|
10.11
|
|
Share
Purchase Agreement, dated April 11, 2007, by and between Ophthalmic
Technologies, Inc. and eXegenics, Inc.
|
|
|
|
10.13
|
|
Share
Purchase Agreement, dated as of November 28, 2007, by and among Ophthalmic
Technologies, Inc., OTI Holdings Limited, and the Shareholders named
therein.
|
|
|
|
10.14
|
|
Exchange
and Support Agreement, dated as of November 28, 2007, by and among
OPKO
Health, Inc. and OTI Holdings Limited and the holders of exchangeable
shares named therein.
|
|
|
|
10.15
|
|
Securities
Purchase Agreement, dated December 4, 2007, by and between members
of The
Frost Group, LLC and the Company.
|
|
|
|
10.16
|
|
OPKO
Health, Inc. 2007 Equity Incentive Plan.
|
|
|
|
21
|
|
Subsidiaries
of the Company.
|
|
|
|
23.1
|
|
Consent
of Ernst & Young LLP.
|
|
|
|
31.1
|
|
Certification
by Phillip Frost, Chief Executive Officer, pursuant to Exchange Act
Rules
13a-14 and 15d-14.
|
|
|
|
31.2
|
|
Certification
by Rao Uppaluri, Chief Financial Officer, pursuant to Exchange Act
Rules 13a-14 and 15d-14.
|
|
|
|
32.1
|
|
Certification
by Phillip Frost, Chief Executive Officer, pursuant to 18 U.S.C.
Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of
2002.
|
|
|
|
32.2
|
|
Certification
by Rao Uppaluri, Chief Financial Officer, pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act
of
2002.
|
AMENDED
AND RESTATED BYLAWS
OF
OPKO
HEALTH, INC.
(A
DELAWARE CORPORATION)
Effective:
March 28, 2008
Article
I.
OFFICES
Section
1.1
Registered
Office
.
The
registered office of OPKO Health, Inc. (the “Corporation”) shall be in the City
of Wilmington, County of New Castle, State of Delaware. Notwithstanding the
foregoing, the registered office may be changed at any time upon a resolution
adopted by the Corporation’s Board of Directors (the “Board’’).
Section
1.2
Other
Offices
.
The
Corporation may also have offices at such other places within or without the
State of Delaware as the Board may from time to time determine or the business
of the Corporation may require.
Article
II.
MEETINGS
OF STOCHOLDERS
Section
2.1
Place
.
All
meetings of the stockholders shall be held at such place within or without
the
State of Delaware as shall be designated from time to time by the Board and
stated in the notice of the meeting or in a duly executed waiver thereof.
Section
2.2
Annual
Meetings
.
An
annual meeting of the stockholders shall be held on such day at such time and
place (within or without the State of Delaware) as the Board shall fix, at
which
time the stockholders shall elect a Board and transact such other business
as
may properly be brought before the meeting. Any business may be transacted
at
the meeting, irrespective of whether the notice of such meeting contains a
reference thereto, except as otherwise provided in these Bylaws, or by
statute.
Section
2.3
Special
Meetings
.
Special
meetings of stockholders may be called at any time, but only by the chairman
of
the Board (the “Chairman of the Board”), the Chief Executive Officer of the
Corporation (the “CEO”), or upon a resolution adopted upon the affirmative vote
of a majority of the whole Board, and not by the stockholders.
Section
2.4
Notice
Of Meetings
.
Notice
of all stockholders’ meetings stating the time, place and the objects for which
such meetings are called shall be given by the Chairman of the Board, the CEO,
or any vice-president (a “
Vice
President
”)
or the
Secretary (the “
Secretary
”)
or any
assistant secretary (an “
Assistant
Secretary
”)
of the
Corporation to each stockholder of record entitled to vote at such meeting
not
less than ten (10) days or more than sixty (60) days prior to the date of the
meeting by written notice delivered personally, by electronic transmission,
mailed or delivered via overnight courier to each stockholder. If delivered
personally, such notice shall be deemed to be delivered when received. If mailed
or delivered via overnight courier service, such notice shall be deemed to
be
delivered when deposited in the United States Mail in a sealed envelope with
postage thereon prepaid, or deposited with the overnight courier service, as
the
case may be, addressed to the stockholder at his address as it appears on the
stock record books of the Corporation, unless he shall have filed with the
Secretary a written request that notice intended for him be mailed to some
other
address, in which case it shall be mailed to the address designated in such
request. If delivered by electronic transmission, such notice shall be sent
consistent with Article X hereof.
Any
meeting at which all stockholders entitled to vote have waived or at any time
shall waive notice shall be a legal meeting for the transaction of business,
notwithstanding that notice has not been given as herein before provided. The
waiver must be in writing, signed by the stockholder entitled to the notice,
and
be delivered to the Corporation for inclusion in the minutes or filing with
the
corporate records.
Section
2.5
Notice
for Nominations and Proposals
.
2.5.1
Annual
Meetings
.
(a)
Nominations for the election of directors and proposals for any new business
to
be taken up at any annual meeting of stockholders may be made by the Board
or,
as provided in this
Section
2.5
,
by any
stockholder of the Corporation entitled to vote generally in the election of
directors, subject to the rights of the holders of preferred stock, if
applicable. For nominations or other business to be properly brought before
an
annual meeting by a stockholder, the stockholder must have given timely notice
thereof in writing to the Secretary of the Corporation and such other business
must otherwise be a proper matter for stockholder action. To be timely, a
stockholder’s notice with respect to any annual meeting must be received by the
Secretary at the principal executive offices of the Corporation not later than
the 60th day nor earlier than the 90th day prior to the first anniversary of
the
preceding year’s annual meeting; provided, however, that in the event that the
date of the annual meeting is more than sixty (60) days before or more than
sixty (60) days after such anniversary date, notice by the stockholder must
be
so received not earlier than the 90th day prior to the annual meeting and not
later than the later of the 60th day prior to the annual meeting or the 15th
day
following the day on which public announcement of the date of the meeting is
first made by the Corporation; provided further that with respect to the annual
meeting to be held in 2008, notice by the stockholder must be so received,
not
earlier than March 31, 2008 and not later than the later of April 30, 2008
or
the 15th day following the day on which public announcement of the date of
the
meeting is first made by the Corporation. In no event shall the public
announcement of an adjournment or postponement of an annual meeting commence
a
new time period for the giving of a stockholder’s notice as described above. A
stockholder’s notice shall set forth:
(i)
as to
each person whom the stockholder proposes to nominate for election or reelection
as a director, (A) all information relating to such person that is required
to
be disclosed in solicitations of proxies for election of directors in an
election contest, (B) a description of all relationships between the proposed
nominee and the recommending stockholder and any agreements or understandings
between the recommending stockholder and the nominee regarding the nomination,
and (C) a description of all relationships between the proposed nominee and
any
of the Corporation’s competitors, customers, suppliers, labor unions (if any)
and any other persons with special interests regarding the
Corporation;
(ii)
as
to any other business that the stockholder proposes to bring before the meeting,
a brief description of the business desired to be brought before the meeting,
the reasons for conducting such business at the meeting and any material
interest in such business of such stockholder and the beneficial owner, if
any,
on whose behalf the proposal is made; and
(iii)
as
to the stockholder giving the notice and the beneficial owner, if any, on whose
behalf the nomination or proposal is made, (A) the name and address of such
stockholder, as they appear on the Corporation’s books, the telephone number of
such stockholder, and the name, address and telephone number of such beneficial
owner,
(B)
the
class and number of shares of the Corporation which are owned of record by
such
stockholder and beneficially by such beneficial owner and the time period such
shares have been held, (C) a representation that such stockholder and beneficial
owner intend to appear in person or by proxy at the meeting, and (D) a
representation that such stockholder and such beneficial owner intend to
continue to hold the reported shares through the date of the Corporation’s next
annual meeting of stockholders. For purposes of satisfying the requirements
of
clause
(B)
of this
paragraph with respect to a beneficial owner, the beneficial owner shall supply
to the Corporation either (1) a statement from the record holder of the shares
verifying the holdings of the beneficial owner and indicating the length of
time
the shares have been held by such beneficial owner, or (2) a current Schedule
13D, Schedule 13G, Form 3, Form 4 or Form 5 filed with the Securities and
Exchange Commission reflecting the holdings of the beneficial owner, together
with a statement of the length of time that the shares have been
held.
(iv)
If a
recommendation is submitted by a group of two or more stockholders, the
information regarding the recommending stockholders and beneficial owners,
if
any, must be submitted with respect to each stockholder in the group and any
beneficial owners.
(b)
Notwithstanding anything in paragraph (a) of this Section
2.5.1
to the
contrary, in the event that the number of directors to be elected to the Board
at the annual meeting is increased pursuant to an act of the Board and there
is
no public announcement by the Corporation naming all of the nominees for
director or specifying the size of the increased Board on or before the date
which is 15 days before the latest date by which a stockholder may timely notify
the Corporation of nominations or other business to be brought by a stockholder
in accordance with paragraph (a) of this Section
2.5.1
,
a
stockholder’s notice required by this Section
2.5.1
shall
also be considered timely, but only with respect to nominees for any new
positions created by such increase, if it shall be received by the Secretary
at
the principal executive offices of the Corporation not later than the 15th
day
following the day on which such public announcement is first made by the
Corporation.
2.5.2
Special
Meetings
.
Only
such business shall be conducted at a special meeting of stockholders as shall
have been brought before the meeting pursuant to the Corporation’s notice of
meeting. Nominations of persons for election to the Board at a special meeting
of stockholders at which directors are to be elected pursuant to the
Corporation’s notice of meeting may be made (i) by or at the direction of the
Board or (ii) provided that the Board has determined that directors shall be
elected at such meeting, by any stockholder of the Corporation who is a
stockholder of record at the time of giving of notice provided for in this
Section
2.5
,
who
shall be entitled to vote at the meeting and who complies with the notice
procedures set forth in this
Section
2.5
.
In the
event the Corporation calls a special meeting of stockholders for the purpose
of
electing one or more directors to the Board, any such stockholder may nominate
a
person or persons (as the case may be), for election to such position(s) as
specified in the Corporation’s notice of meeting for inclusion in the
stockholder’s notice required by Section
2.5.1
of these
Bylaws if such nomination shall be delivered to the Secretary at the principal
executive offices of the Corporation not earlier than the close of business
on
the 90th day prior to such special meeting and not later than the close of
business on the later of the 60th day prior to such special meeting or the
15th
day following the day on which public announcement is first made of the date
of
the special meeting and of the nominees proposed by the Board to be elected
at
such meeting. In no event shall the public announcement of an adjournment of
a
special meeting commence a new time period for the giving of a stockholder’s
notice as described above.
2.5.3
General
.
Only
such persons who are nominated in accordance with the procedures set forth
in
this
Section
2.5
shall be
eligible to stand for election to the Board at a meeting of stockholders, and
only such business shall be conducted at a meeting of stockholders as shall
have
been brought before the meeting in accordance with the procedures set forth
in
this
Section
2.5
.
Except
as otherwise provided by law, the Certificate of Incorporation of the
Corporation as amended and restated (the “
Certificate
of Incorporation
”)
or
these Bylaws, the Chairman of the Board shall have the power and duty to
determine whether a nomination or any business proposed to be brought before
the
meeting was made or proposed, as the case may be, in accordance with the
procedures set forth in this bylaw and, if any proposed nomination or business
is not in compliance with this
Section
2.5
,
to
declare that such defective proposal or nomination shall be
disregarded.
2.5.4
Public
Announcement
.
For
purposes of this
Section
2.5
,
“public
announcement” shall mean disclosure in a press release reported by the Dow Jones
News Service, Associated Press or comparable national news service or in a
document publicly filed by the Corporation with the Securities and Exchange
Commission pursuant to Section 13, 14 or 15(d) of the Securities Exchange Act
of
1934 as amended (the “
Exchange
Act
”).
2.5.5
Non-Exclusivity
.
If the
Corporation is required under Rule 14a-8 under the Exchange Act to include
a
stockholder’s proposal in its proxy statement, such stockholder shall be deemed
to have given timely notice for purposes of this
Section
2.5
with
respect to such proposal. Nothing in this
Section
2.5
shall be
deemed to affect any rights of the holders of any series of preferred stock
of
the Corporation to elect directors.
Section
2.6
Quorum
.
Except
as may be otherwise provided by law, a majority of the voting power of all
the
outstanding shares of tile Corporation entitled to vote, represented in person
or by proxy, shall constitute a quorum at a meeting of stockholders. In the
event that the voting power of a majority of the outstanding shares are
represented at any meeting, action on a matter is approved if the votes cast
favoring the action exceed the votes cast opposing the action, unless the
question is one upon which by express provision of law or of the Certificate
of
Incorporation or of these Bylaws a larger or different vote is required, in
which case such express provision shall govern and control the decision of
each
question. If a quorum of the shares entitled to vote shall fail to be obtained
at any meeting, or in the event of any other proper business purpose, the chair
of the meeting or the holders of a majority of the shares present, in person
or
by proxy, may adjourn the meeting to another place, date or time by announcement
to stockholders present in person at the meeting and no other notice of such
place, date or time need be given.
Section
2.7
Organization
.
At
every meeting of the stockholders the Chairman of the Board, or, in his absence,
the CEO, or in the absence of the Chairman of the Board and the CEO, a director
or an officer of the Corporation designated by the Board shall act as chairman.
The Secretary, or, in his absence, an Assistant Secretary, shall act as
secretary at all meetings of the stockholders. In the absence from any such
meeting of the Secretary and any Assistant Secretary, the chairman may appoint
any person to act as secretary of the meeting.
Section
2.8
Closing
of Transfer Books or Fixing of Record Date
.
For the
purpose of determining the stockholders entitled to notice of or to vote at
any
meeting of stockholders or any adjournment thereof, the Board may fix in advance
a date as the record date for any such determination of stockholders, such
date
in any case to be not more than sixty (60) days and not less than ten (10)
days
prior to the date on which the particular action requiring such determination
of
stockholders is to be taken. If the stock transfer books are not closed and
no
record date is fixed for the determination of stockholders entitled to notice
of
or to vote at a meeting of stockholders, or stockholders entitled to receive
payment of a dividend, the date on which notice of the meeting is mailed or
the
date on which the resolution of the Board declaring such dividend is adopted,
as
the case may be, shall be the record date for such determination of
stockholders. When a determination of stockholders entitled to vote at any
meeting of stockholders has been made as provided in this
Section
2.8
,
such
determination shall apply to any adjournment thereof.
Section
2.9
Voting
Lists
.
The
officer or agent having charge of the stock transfer books for common shares
of
the Corporation shall make available, within two (2) business days after notice
of a meeting is given, a complete list of the stockholders entitled to vote
at
such meeting or any adjournment thereof, arranged in alphabetical order, with
the address of and the number of shares held by each stockholder, which list,
for a period beginning within two (2) business days after notice of such meeting
is given, shall be subject to inspection by any stockholder at any time either
(a) on a reasonably accessible electronic network, provided that the information
required to gain access to such list is provided with the notice of the meeting,
or (b) during ordinary business hours, at the principal place of business of
the
Corporation. If the meeting is to be held at a place, then the list shall be
produced and kept at the time and place of the meeting during the whole time
thereof and may be inspected by any stockholder who is present. If the meeting
is to be held solely by means of remote communication, then the list shall
also
be open to the examination of any stockholder during the whole time of the
meeting on a reasonably accessible electronic network, and the information
required to access such list shall be provided with the notice of the meeting.
In the event of any challenge to the right of any person to vote at the meeting,
the presiding officer at such meeting may rely on said list as proper evidence
of the right of parties to vote at such meeting.
Section
2.10
Proxies
.
Stockholders of record who are entitled to vote may vote at any meeting either
in person or by written proxy, which shall be filed with the secretary of the
meeting before being voted. Such proxy shall entitle the holders thereof to
vote
at any adjournment of such meeting, but shall not be valid after the final
adjournment thereof. No proxy shall be valid after the expiration of eleven
(11)
months from the date of its execution unless the stockholder executing it shall
have specified therein the length of time it is to continue in force, which
shall be for some limited period. A proxy is revocable by the stockholder unless
it conspicuously states that it is irrevocable and the appointment of the proxy
is coupled with an interest.
Section
2.11
Voting
of Shares
.
Except
as otherwise provided in the Certificate of Incorporation or these Bylaws,
each
share of Common Stock shall have all voting rights accorded to holders of Common
Stock pursuant to the Delaware General Corporation Law (“DGCL’’), at the rate of
one vote per share.
Section
2.12
Business
and Order of Business
.
At each
meeting of the stockholders such business may be transacted as may properly
be
brought before such meeting, except as otherwise provided by law or in these
Bylaws. The order of business at all meetings of the stockholders shall be
as
determined by the Chairman of the Board, unless otherwise determined by a
majority in interest of the stockholders present in person or by proxy at such
meeting and entitled to vote thereat.
Article
III.
BOARD
OF DIRECTORS
Section
3.1
Number
.
The
number of directors of the Corporation shall be such number, neither fewer
than
three (3) nor more than fifteen (15) (exclusive of directors, if any, to be
elected by holders of any class or series of preferred stock of the Corporation,
voting separately as a class), as determined from time to time by the Board.
The
Board has the power to fix or change the number of directors, including an
increase or decrease in the number of directors, from time to time as
established by the Board. A director need not be a stockholder or a resident
of
the State of Delaware.
Section
3.2
Powers
of Directors
.
The
Board shall have the entire management of the business of the Corporation.
In
the management and control of the property, business and affairs of the
Corporation, the Board is hereby vested with all the powers possessed by the
Corporation itself, so far as this delegation of authority is not inconsistent
with the laws of the State of Delaware, the Certificate of Incorporation, or
these Bylaws. The Board shall have the power to determine what constitutes
net
earnings, profits, and surplus, respectively, what amount shall be reserved
for
working capital and to establish reserves for any other proper purpose, and
what
amount shall be declared as dividends, and such determination by the Board
shall
be final and conclusive. The Board shall have the power to declare dividends
for
and on behalf of the Corporation, which dividends may include or consist of
stock dividends.
Section
3.3
Regular
Meetings of the Board
.
Immediately after the annual election of directors, the newly elected directors
may meet at the same place for the purpose of organization, the election of
corporate officers and the transaction of other business; if a quorum of the
directors is then present, no prior notice of such meeting shall be required.
Other regular meetings of the Board shall be held at such times and places
as
the Board by resolution may determine and specify, and if so determined no
notice thereof need be given, provided that, unless all the directors are
present at the meeting at which said resolution is passed, the first meeting
held pursuant to said resolution shall not be held for at least five (5) days
following the date on which the resolution is passed.
Section
3.4
Special
Meetings
.
Special
meetings of the Board may be held at any time or place whenever called by the
Chairman of the Board, the CEO, the Chief Financial Officer or the Secretary,
or
by written request of at least two directors, notice thereof being given to
each
director by the Secretary or other officer calling the meeting, or they may
be
held at any time without formal notice provided all of the directors are present
or those not present shall at any time waive or have waived notice thereof.
Section
3.5
Notice
.
Notice
of any special meetings shall be given at least two (2) days previously thereto
by written notice delivered personally, by telegram, by overnight courier
service, by facsimile communication or by electronic transmission, or at least
five (5) days previously thereto by written notice sent by mail. The time when
such notice is received, if delivered personally, or when such notice is
dispatched, if delivered through the mail, by overnight courier service, by
facsimile telecommunication or by electronic transmission, shall be the time
of
the giving of the notice.
Section
3.6
Quorum
.
A
majority of the members of the Board, as constituted for the time being, shall
constitute a quorum for the transaction of business, but a lesser number may
adjourn any meeting and the meeting may be held as adjourned without further
notice. If a quorum is present when a vote is taken, the affirmative vote of
a
majority of the directors present is the act of the Board, except as otherwise
provided by law or by these Bylaws. The fact that a director has an interest
in
a matter to be voted on by the meeting shall not prevent his being counted
for
purposes of a quorum.
Section
3.7
Informal
Action by Directors
.
Any
action required to be taken at a meeting of the Board, or any other action
which
may be taken at a meeting of the Board, may be taken without a meeting if all
directors consent to taking such action without a meeting. The action must
be
evidenced by one or more written consents describing the action taken, signed
by
each director, and shall be included in the minutes or filed with the corporate
records reflecting the action taken.
Section
3.8
Meetings
by any Form of Communication
.
The
Board shall have the power to permit any and all directors to participate in
a
regular or special meeting by, or conduct the meeting through the use of any
means of communication by which all directors participating may simultaneously
hear each other during the meeting. A director participating in a meeting by
this means is deemed to be present in person at the meeting.
Section
3.9
Organization
.
At each
meeting of the Board, the Chairman of the Board, or in the absence of the
Chairman of the Board, a director designated by the Board shall act as chairman.
The Secretary, or, in the Secretary’s absence, any person appointed by the
chairman, shall act as secretary of the meeting.
Section
3.10
Resignations
.
A
director may resign at any time by delivering written notice to the Board,
the
Chairman of the Board or the CEO. Resignation is effective when the notice
is
delivered, unless the notice specifies a later effective date.
Section
3.11
Removal
of Directors
.
Subject
to the rights of the holders of one or more series of Preferred Stock, any
director or the entire board of directors may be removed from the office by
the
affirmative vote of the holders of least a majority of the voting power of
the
then outstanding capital stock of the Corporation entitled to vote generally
in
the election of directors, voting together as a single class.
Section
3.12
Vacancies
.
Any
vacancy occurring in the Board, including vacancies resulting from an increase
in the number of directors, may be filled solely by the affirmative vote of
a
majority of the remaining directors, though less than a quorum, and unless
the
Board of Directors determines otherwise (and subject to the rights of the
holders or any series of preferred stock), vacancies shall not be filled by
stockholders. A director elected to fill any vacancy shall hold office for
a
term expiring at the annual meeting of stockholders at which the term of the
class to which he or she has been elected expires, and until such director’s
successor shall have been duly elected and qualifies or until his or her earlier
death, resignation or removal.
Section
3.13
Compensation
.
By
resolution of the Board, the directors may be paid their expenses, if any,
of
attendance at each meeting of the Board. No such payment shall preclude any
director from serving the Corporation in any other capacity and receiving
compensation therefor.
Article
IV.
COMMITTEES
Section
4.1
Appointment
and Powers
.
The
Board may create one or more committees, each committee to consist of two or
more directors of the Corporation, which, to the extent provided in said
resolution or in these Bylaws and not inconsistent with the DGCL, shall have
and
may exercise the powers of the Board in the management of the business and
affairs of the Corporation, and may authorize the seal of the Corporation to
be
affixed to all papers which may require it. Such committee or committees shall
have such name or names as may be determined from time to time by resolution
adopted by the Board. The Board may abolish any such committee at any time.
Section
4.2
Term
of Office and Vacancies
.
Each
member of a committee shall continue in office until a director to succeed
him
shall have been elected and shall have qualified, or until he ceases to be
a
director or until he shall have resigned or shall have been removed in the
manner hereinafter provided. Any vacancy in a committee shall be filled by
the
Board.
Section
4.3
Organization
.
Unless
otherwise provided by the Board, each committee shall appoint a chairman. Each
committee shall keep a record of its acts and proceedings and report the same
from time to time to the Board as the Board may require.
Section
4.4
Resignations
.
Any
member of a committee may resign from the committee at any time by giving
written notice to the Chairman of the Board, the CEO, or the Secretary. Such
resignation shall take effect at the time of the receipt of such notice or
at
any later time specified therein, and, unless otherwise specified therein,
the
acceptance of such resignation shall not be necessary to make it effective.
Section
4.5
Removal
.
Any
member of a committee may be removed from the committee with or without cause
at
any time by resolution of the Board.
Section
4.6
Meetings
.
Regular
meetings of each committee, of which no notice shall be required, shall be
held
on such days and at such places as the chairman of the committee shall determine
or as shall be fixed by a resolution passed by a majority of all the members
of
such committee. Special meetings of each committee will be called by the
Secretary at the request of any two (2) members of such committee, or in such
other manner as may be determined by the committee. Notice of any special
meetings shall be given at least two (2) days previously thereto by written
notice delivered personally, by telegram, by overnight courier service, by
facsimile communication or by electronic transmission, or at least five (5)
days
previously thereto by written notice sent by mail. Every such notice shall
state
the date, time and place of the meeting, but need not state the purposes of
the
meeting. No notice of any meeting of a committee shall be required to be given
to any alternate. The time when such notice is received, if delivered
personally, or when such notice is dispatched, if delivered through the mail,
by
overnight courier service, by facsimile telecommunication or by electronic
transmission, shall be the time of the giving of the notice.
Section
4.7
Quorum
and Manner of Acting
.
Unless
otherwise provided by resolution of the Board, a majority of a committee shall
constitute a quorum for the transaction of business and the act of a majority
of
those present at a meeting at which a quorum is present shall be the act of
such
committee, except as otherwise provided by law or by these Bylaws. The members
of each committee shall act only as a committee and the individual members
shall
have no power as such. Actions taken at a meeting of any committee shall be
reported to the Board at its next meeting following such committee meeting;
provided that, when the meeting of the Board is held within two (2) days after
the committee meeting, such report may be made to the Board at its second
meeting following such committee meeting.
Section
4.8
Compensation
.
Each
member of a committee shall be paid such compensation, if any, as shall be
fixed
by the Board.
Article
V.
WAIVER
OF NOTICE
Whenever
any notice is required to be given by these Bylaws, the Certificate of
Incorporation, or any laws of the State of Delaware, a waiver thereof in writing
signed by the person or persons entitled to such notice and filed with the
minutes or corporate records, whether before or after the time stated therein,
shall be deemed equivalent thereto. Where the person or persons entitled to
such
notice sign the minutes of any stockholders’ or directors’ meeting, which
minutes contain the statement that said person or persons have waived notice
of
the meeting, then such person or persons are deemed to have waived notice in
writing. A stockholder’s attendance at a meeting waives objection to lack of
notice or defective notice of the meeting, unless the stockholder at the
beginning of the meeting (or promptly upon the stockholder’s arrival) objects to
holding the meeting or transacting business at the meeting, and also waives
objection to consideration of a particular matter at the meeting that is not
within the purpose or purposes described in the meeting notice, unless the
stockholder objects to considering the matter when it is presented. A director’s
attendance at or participation in a meeting waives any required notice to the
director of the meeting unless the director at the beginning of the meeting
(or
promptly upon the director’s arrival) objects to holding the meeting or
transacting business at the meeting and does not thereafter vote for or assent
to action taken at the meeting.
Article
VI.
OFFICERS
Section
6.1
Number
.
The
officers of the Corporation shall be a Chairman of the Board, CEO, , Chief
Financial Officer, one or more Vice-Presidents (the number thereof to be
determined by the Board), a Secretary, and a Treasurer, each of whom shall
be
elected by the Board. Such other officers and assistant officers as may be
deemed necessary may be elected or appointed by the Board. Any two or more
offices may be held by the same person, except the offices of CEO and Secretary.
Section
6.2
Election
and Term of Office
.
The
officers of the Corporation to be elected by the Board shall be elected annually
by the Board at the first meeting of the Board held after each annual meeting
of
the stockholders. If the election of officers shall not be held in such meeting,
such election shall be held as soon thereafter as conveniently may be. Each
officer shall hold office until his successor is duly elected and is qualified
or until his death or until he resigns or is removed in the manner hereinafter
provided.
Section
6.3
Removal
.
Any
officer or agent elected or appointed by the Board may be removed by the Board
whenever in its judgment the best interests of the Corporation would be served
thereby, but such removal shall be without prejudice to the contract rights,
if
any, of the person so removed.
Section
6.4
Vacancies
.
A
vacancy in any office because of death, resignation, removal, disqualification
or otherwise, may be filled by the Board for the unexpired portion of the term.
Section
6.5
Chairman
of the Board
.
The
Chairman of the Board shall preside at all meetings of the stockholders and
the
directors. The Chairman of the Board shall represent the Corporation in all
matters involving the stockholders of the Corporation. He shall also perform
such other duties the Board may assign to him from time to time.
Section
6.6
Chief
Executive Officer
.
The CEO
shall in general supervise and control all of the business and affairs of the
Corporation. He shall, in the absence of the Chairman of the Board, preside
at
all meetings of the stockholders and shall enforce the observance of the Bylaws
and the roles of order for the meetings of the Board and the stockholders.
He
shall keep the Board appropriately informed on the business and affairs of
the
Corporation. He may sign, either alone or with the Secretary, an Assistant
Secretary or any other proper officer of the Corporation thereunto authorized
by
the Board, certificates for shares of the Corporation, any deed, mortgages,
bonds, contracts, or other instruments which the Board has authorized to be
executed, except in cases where the signing and execution thereof shall be
expressly delegated by the Board or by these Bylaws to some other officer or
agent of the Corporation, or shall be required by law to be otherwise signed
or
executed, and in general shall perform all duties incident to the office of
CEO
and such other duties as may be prescribed by the Board from time to time.
Section
6.7
President
.
The
President, if any, shall see that all orders and resolutions of the Board are
carried into effect and shall have general and active management of the business
of the Corporation. He or she shall have the authority to execute bonds,
mortgages and other contracts requiring a seal, under the seal of the
Corporation, except where required or permitted by law to be otherwise signed
and executed arid except where the signing and execution thereof shall be
expressly delegated by the Board to some other officer or agent of the
Corporation. If, for any reason, the Corporation does not have a Chairman or
CEO, or such officers are unable to act, the President, if any, shall assume
the
duties of those officers as well.
Section
6.8
Chief
Financial Officer or Chief Accounting Officer and Treasurer
.
The
Chief Financial Officer or Chief Accounting Officer, as the case may be, shall
also serve as the Treasurer of the Corporation and shall arrange for the keeping
of adequate records of all assets, liabilities and transactions of the
corporation. He shall provide for the establishment of internal controls and
see
that adequate audits are currently and regularly made. He shall submit to the
CEO, the President, if any, the Chief Operating Officer, the Chairman of the
Board and the Board timely statements of the accounts of the corporation and
the
financial results of the operations thereof.
Section
6.9
Assistant
Treasurers
.
The
Assistant Treasurer or if there shall be more than one, the Assistant Treasurers
in the order determined by the Board (or if there be no such determination,
then
in the order of their election), shall, in the absence of the Treasurer or
in
the event of his inability or refusal to act, perform the duties and exercise
the powers of the Treasurer and shall perform such other duties and have such
other powers as the Board may from time to time prescribe.
Section
6.10
Chief
Operating Officer
.
If a
Chief Operating Officer is elected, the Chief Operating Officer shall supervise
the operation of the Corporation, subject to the policies and directions of
the
Board. He shall provide for the proper operation of the Corporation and oversee
the internal interrelationship amongst any and all departments of the
Corporation. He shall submit to the CEO, the President, if any, and the Board
timely reports on the operations of the Corporation.
Section
6.11
The
Vice-Presidents
.
In the
absence of the CEO and the President, if any, or in the event of their death,
inability or refusal to act, the Vice-President (or in the event there be more
than one Vice-President, the Vice-Presidents in the order designated at the
time
of their election, or in the absence of any designation, then in the order
of
their election) shall perform the duties of the CEO and the President, if any,
and when so acting, shall have all the powers of and be subject to all the
restrictions upon the CEO and the President, if any. Any Vice-President may
sign, either alone or with the Secretary or an Assistant Secretary, certificates
for shares of the Corporation any deed, mortgages, bonds, contracts or other
instruments which the Board has authorized to be executed, except in cases
where
the signing and execution thereof shall be expressly delegated, by the Board
or
by these bylaws to some other officer or agent of the Corporation, or shall
be
required by law to be otherwise signed or executed, and shall perform such
other
duties as from time to time may be assigned to him by the CEO, the President,
if
any, or by the Board.
Section
6.12
The
Secretary
.
The
Secretary shall: (a) prepare and keep the minutes of the stockholders’ and of
the Boards’ meetings in one or more books provided for that purpose; (b) see
that all notices are duly given in accordance with the provisions of these
bylaws or as required by law; (c) be custodian of the corporate records and
of
the seal (if any) of the Corporation and see that said seal is affixed to all
documents, the execution of which on behalf of the Corporation under its seal
is
duly authorized; (d) keep a register of the post office address of each
stockholder which shall be furnished to the Secretary by such stockholder;
(e)
sign with the CEO, the President, if any, or a Vice-President certificates
for
shares of the Corporation, the issuance of which shall have been authorized
by
resolution of the Board; (f) have general charge of the stock transfer books
of
the Corporation; and (g) in general perform all duties as from time to time
may
be assigned to him by the CEO, the President, if any, or by the Board.
Section
6.13
Assistant
Secretaries
.
The
Assistant Secretaries, when authorized by the Board, may sign with the CEO,
the
President, if any, or a Vice-President certificates for shares of the
Corporation the issuance of which shall have been authorized by a resolution
of
the Board. The Assistant Secretaries, in general, shall perform such duties
as
shall be assigned to them by the Secretary, or by the CEO, the President, if
any, or the Board.
Section
6.14
Registered
Agent
.
The
Board shall appoint a Registered Agent for the Corporation in accordance with
the DGCL and may pay the agent such compensation from time to time as it may
deem appropriate.
Article
VII.
INDEMNIFICATION
AND INSURANCE
Section
7.1
Indemnification
by Corporation
.
The
Corporation shall indemnify to the fullest extent permitted by applicable law
as
the same exists or may hereafter be in effect, any person who was or is a party
or is threatened to be made a party to any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or
investigative (other than an action by or in the right of the Corporation)
by
reason of the fact that he or she is or was a director, officer, employee or
agent of the Corporation, or is or was serving at the request of the Corporation
as a director, officer, employee or agent of another Corporation, partnership,
joint venture, trust or other enterprise, against expenses including attorneys’
fees), judgments, fines and amounts paid in settlement actually and reasonably
incurred by him or her in connection with such action, suit or proceeding if
he
or she acted in good faith and in a manner he or she reasonably believed to
be
in or not opposed to the best interests of the Corporation, and, with respect
to
any criminal action or proceeding, had no reasonable cause to believe his or
her
conduct was unlawful. The termination of any action, suit or proceeding by
judgment, order, settlement, conviction, or upon a plea of
nolo
contendere
or its
equivalent, shall not, of itself; create a presumption that the person did
not
act in good faith and in a manner which he or she reasonably believed to be
in
or not opposed to the best interests of the Corporation, and, with respect
to
any criminal action or proceeding, had reasonable cause to believe that his
or
her conduct was unlawful
.
Section
7.2
Suit
by or in the Right of the Corporation
.
The
Corporation shall indemnify any person who was or is a party, or is threatened
to be made a party to any threatened, pending or completed action or suit by
or
in the right of the Corporation to procure a judgment in its favor by reason
of
the fact that he or she is or was a director, officer, employee or agent of
the
Corporation, or is or was serving at the request of the Corporation as a
director, officer, employee or agent of another Corporation, partnership, joint
venture, trust or other enterprise against expenses (including attorneys’ fees)
actually and reasonably incurred by him or her in connection with the defense
or
settlement of such action or suit if he or she acted in good faith and in a
manner he or she reasonably believed to be in or not opposed to the best
interests of the Corporation and except that no indemnification shall be made
in
respect of any claim, issue or matter as to which such person shall have been
adjudged to be liable to the Corporation unless and only to the extent that
the
Court of Chancery or the court in which such action or suit was brought shall
determine upon application that, despite the adjudication of liability but
in
view of all the circumstances of the case, such person is fairly and reasonably
entitled to indemnity for such expenses which the Court of Chancery or such
other court shall deem proper
.
Section
7.3
Success
on the Merits
.
To the
extent that a director, officer, employee or agent of the Corporation has been
successful on the merits or otherwise in defense of any action, suit or
proceeding referred to in
Section
7.1
or
Section
7.2
of this
Article, or in defense of any claim, issue or matter therein, he or she shall
be
indemnified against expenses (including attorneys’ fees) actually and reasonably
incurred by him or her in connection therewith.
Section
7.4
Determination
that Indemnification is Proper
.
Any
indemnification under
Section
7.1
or
Section
7.2
of this
Article (unless ordered by a court) shall be made by the Corporation only as
authorized in the specific case upon a determination that indemnification of
the
director, officer, employee or agent is proper in the circumstances because
he
or she has met the applicable standard of conduct set forth in such section.
Such determination shall be made:
(a)
by
the Board by a majority vote of a quorum consisting of directors who were not
parties to such action, suit or proceeding; or
(b)
if
such a quorum is not obtainable, or, even if obtainable a quorum, of
disinterested directors so directs, by independent legal counsel in a written
opinion; or
(c)
by
the stockholders.
Section
7.5
Expenses
.
Expenses (including attorneys’ fees) incurred by an officer or director in
defending a civil, criminal, administrative or investigative action, suit or
proceeding may be paid by the Corporation in advance of the final disposition
of
such action, suit or proceeding upon receipt of an undertaking by or on behalf
of such director or officer to repay such amount if it shall ultimately be
determined that he or she is not entitled to be indemnified by the Corporation
as authorized in this
Article
VII
.
Such
expenses (including attorneys’ fees) incurred by other employees and agents may
be so paid upon such terms and conditions, if any, as the Board deems
appropriate.
Section
7.6
Non-Exclusivity
of Indemnification Rights
.
The
indemnification and advancement of expenses provided by or granted pursuant
to
the other sections of this
Article
VII
shall
not be deemed exclusive of any other rights to which those seeking
indemnification or advancement of expenses may be entitled under any bylaw,
agreement, vote of stockholders or disinterested directors or otherwise, both
as
to action in his or her official capacity and as to action in another capacity
while holding such office.
Section
7.7
Insurance
.
The
Corporation shall have power to purchase and maintain insurance on behalf of
any
person who is or was a director, officer, employee or agent of the Corporation,
or is or was serving at the request of the Corporation as a director, officer,
employee or agent of another Corporation, partnership, joint venture, trust
or
other enterprise against any liability asserted against him or her and incurred
by him or her in any such capacity, or arising out of his or her status as
such,
whether or not the Corporation would have the power to indemnity him or her
against such liability under the provisions of this
Article
VII
.
Section
7.8
Continuance
of Indemnification
.
The
indemnification and advancement of expenses provided by or granted pursuant
to
this
Article
VII
shall,
unless otherwise provided when authorized or ratified, continue as to a person
who has ceased to be a director, officer, employee or agent and shall inure
to
the benefit of the heirs, executors and administrators of such a person. The
rights to indemnification and advancement of expenses provided by or granted
pursuant to this
Article
VII
shall
constitute a contract between the Corporation and each director, officer,
employee or agent of the Corporation in each circumstance, and each such person
shall have all rights available in law or equity to enforce such contract rights
against the Corporation. Any repeal or modification of any provision of this
Article
VII
shall
not adversely affect or deprive any director, officer, employee or agent of
any
right or protection offered by such provision prior to such repeal or
modification.
Section
7.9
Definition
of “the Corporation”
.
For
purposes of this
Article
VII
,
references to ‘‘the Corporation” shall include, in addition to the resulting
Corporation, any constituent corporation (including any constituent of a
constituent) absorbed in a consolidation or merger which, if its separate
existence had continued, would have had power and authority to indemnify its
directors, officers, and employees or agents, so that any person who is or
was a
director, officer employee or agent of such constituent Corporation, or is
or
was serving at the request of such constituent Corporation as a director,
officer, employee or agent of another Corporation, partnership, joint venture,
trust or other enterprise, shall stand in the same position under this
Article
VII
with
respect to the resulting or surviving Corporation as he or she would have with
respect to such constituent Corporation of its separate existence bad continued.
Section
7.10
Definition
of “Other Enterprises”
.
For
purposes of this
Article
VII
,
references to “other enterprises” shall include employee benefit plans;
references to “fines” shall include any excise taxes assessed on a person with
respect to any employee benefit plan; and references to “serving at the request
of the Corporation” shall include any service as a director, officer, employee
or agent of the Corporation which imposes duties on, or involves services by,
such director, officer, employee, or agent with respect to an employee benefit
plan, its participants or beneficiaries; and a person who acted in good faith
and in a manner he or she reasonably believed to be in the interest of the
participants and beneficiaries of an employee benefit plan shall be deemed
to
have acted in a manner “not opposed to the best interests of the Corporation” as
referred to in this
Article
VII
.
Article
VIII.
CONTRACTS,
LOANS, CHECKS AND DEPOSITS
Section
8.1
Contracts
.
The
Board may authorize any officer or officers, agent or agents, to enter into
any
contract or execute and deliver any instrument in the name of and on behalf
of
the Corporation, and such authority may be general or confined to specific
instances.
Section
8.2
Loans
.
The
Corporation shall not make any loan other than a sale on credit in the ordinary
course of business or a life insurance policy loan, either directly or
indirectly, to any director or officer of the Corporation except with the
consent of the holders of a majority of all the outstanding shares owned or
controlled by stockholders other than a stockholder for whose benefit such
action is being taken, or if the Board determines that the loan benefits the
Corporation and approves the transaction.
Section
8.3
Checks,
Drafts, etc
.
All
checks, drafts, or other orders for the payment of money, notes or other
evidences of indebtedness issued in the name of the Corporation, shall be signed
by such officer or officers, agent or agents of the Corporation and in such
manner as shall from time to time be determined by resolution of the Board.
Section
8.4
Deposits
.
All
funds of the Corporation not otherwise employed shall be deposited from time
to
time to the credit of the Corporation in such banks, trust companies or other
depositories as the Board may select.
Article
IX.
CERTIFICATES
OF STOCK
Section
9.1
Right
to Certificate
.
Every
holder of stock in the Corporation shall be entitled to have a certificate,
signed by or in the name of the Corporation by the Chairman or Vice-Chairman
of
the Board, or the CEO, or the President, if any, or a Vice-President and the
Treasurer or an Assistant Treasurer or the Secretary or an Assistant Secretary
of the Corporation, certifying the number of shares owned by him in the
Corporation.
Section
9.2
Statements
Setting Forth Rights
.
If the
Corporation shall be authorized to issue more than one class of stock or more
than one series of any class, the designations, preferences and relative,
participating, optional or other special rights of each class of stock or series
thereof and the qualifications, limitations or restrictions of such preferences
and rights shall be set forth in full or summarized on the face or back of
the
certificate which the Corporation shall issue to represent such class or series
of stock, provided that, except as otherwise provided in Section 202 of the
DGCL, in lieu of the foregoing requirements, there may be set forth on the
face
or back of the certificate which the Corporation shall issue to represent such
class or series of stock; a statement that the Corporation will furnish without
charge to each stockholder who so requests the designations, preferences and
relative, participating, optional or other special rights of each class of
stock
or series thereof and the qualifications, limitations or restrictions of such
preferences and rights.
Section
9.3
Facsimile
Signature
.
Where a
certificate is countersigned (a) by a transfer agent other than the Corporation
or its employee, or, (b) by a registrar other than the Corporation or its
employee, the signatures of the officers of the Corporation may be facsimiles.
In case any officer who has signed or whose facsimile signature has been placed
upon a certificate shall have ceased to be such officer before such certificate
is issued, it may be issued by the Corporation with the same effect as if he
were such officer at the date of issue.
Section
9.4
Lost
Certificates
.
The
Board may delegate to its transfer agent the authority to issue without further
action or approval of the Board, a new certificate or certificates in place
of
any certificate or certificates theretofore issued by the Corporation alleged
to
have been lost, stolen or destroyed, upon the receipt by the transfer agent
of
an affidavit of that fact by the person claiming the certificate of stock to
be
lost, stolen or destroyed, and upon the receipt from the owner of such lost,
stolen or destroyed certificate, or certificates, or his legal representative
of
a bond as indemnity against any claim that may be made with respect to the
certificate alleged to have been lost, stolen or destroyed.
Section
9.5
Transfers
of Stock
.
Upon
surrender to the Corporation or the transfer agent of the Corporation of a
certificate for shares duly endorsed or accompanied by proper evidence of
succession, assignment or authority to transfer, and if such shares are not
restricted as to transfer, it shall be the duty of the Corporation to issue
a
new certificate to the person entitled thereto, cancel the old certificate
and
record the transaction upon its books.
Section
9.6
Transfer
Agents and Registrars
.
The
Board may appoint one or more corporate transfer agents and registrars.
Section
9.7
Registered
Ownership of Shares
.
The
Corporation shall be entitled to treat the person in whose name any share of
its
stock is registered as the owner thereof for all purposes and shall not be
bound
to recognize any equitable or other claim to, or interest in, such share on
the
part of any other person, whether or not the Corporation shall have notice
thereof: except as expressly provided by applicable law.
Article
X.
NOTICE
BY ELECTRONIC TRANSMISSION
Section
10.1
Notice
by Electronic Transmission
.
Without
limiting the manner by which notice otherwise may be given effectively to
stockholders pursuant to the DGCL, the Certificate of Incorporation or these
Bylaws, any notice to stockholders given by the Corporation under any provision
of the DGCL, the Certificate of Incorporation or these Bylaws shall be effective
if given by a form of electronic transmission consented to by the stockholder
to
whom the notice is given. Any such consent shall be revocable by the stockholder
by written notice to the Corporation. Any such consent shall be deemed revoked
if: (a) the Corporation is unable to deliver by electronic transmission two
(2)
consecutive notices given by the Corporation in accordance with such consent;
and (b) such inability becomes known to the secretary or an assistant secretary
of the Corporation or to the transfer agent, or other person responsible for
the
giving of notice. However, the inadvertent failure to treat such inability
as a
revocation shall not invalidate any meeting or other action. Any notice given
pursuant to
Section
10.1
shall be
deemed given: (i) if by facsimile telecommunication, when directed to a number
at which the stockholder has consented to receive notice; (ii) if by electronic
mail, when directed to an electronic mail address at which the stockholder
has
consented to receive notice; (iii) if by a posting on an electronic network
together with separate notice to the stockholder of such specific posting,
upon
the later of (A) such posting and (B) the giving of such separate notice; and
(iv) if by any other form of electronic transmission, when directed to the
stockholder. An affidavit of the Secretary or an Assistant Secretary or of
the
transfer agent or other agent of the Corporation that the notice has been given
by a form of electronic transmission shall in the absence of fraud, be prima
facie evidence of the facts stated therein
.
Section
10.2
Definition
of Electronic Transmission
.
An
“electronic transmission” means any form of communication, not directly
involving the physical transmission of paper, that creates a record that may
be
retained, retrieved, and reviewed by a recipient thereof, and that may be
directly reproduced in paper form by such a recipient through an automated
process. Any requirement in these Bylaws for a written or signed document from
any person shall be deemed to be satisfied by an electronic transmission from
such person.
Article
XI.
GENERAL
PROVISIONS
Section
11.1
Dividends
.
Dividends upon the capital stock of the Corporation, subject to the provisions
of the Certificate of Incorporation, if any, may be declared by the Board,
subject to applicable legal requirements. Dividends may be paid in cash, in
property, or in shares of the capital stock, subject to the provisions of the
Certificate of Incorporation.
Section
11.2
Reserves
.
Before
payment of any dividend, there may be set aside out of any funds of the
Corporation available for dividends such sum or sums as the directors from
time
to time, in their absolute discretion, think proper as a reserve or reserves
to
meet contingencies, or for equalizing dividends, or for repairing or maintaining
any property of the Corporation, or for such other purpose as the directors
shall think conclusive to the interest of the Corporation, and the directors
may
modify or abolish any such reserve in the manner in which it was created.
Section
11.3
Fiscal
Year
.
The
fiscal year of the Corporation shall be fixed by resolution of the Board.
Section
11.4
Seal
.
This
Corporation may or may not have a seal and in any event the failure to affix
a
corporate seal to any instrument executed by the Corporation shall not affect
the validity thereof. If a seal is adopted, the seal of this Corporation shall
include the following letters cut or engraved thereon: OPKO HEALTH, INC.
Article
XII.
AMENDMENTS
Section
12.1
Amendments
.
The
Board is expressly authorized to repeal, alter, amend or rescind these Bylaws.
Notwithstanding any other provision of these Bylaws (and notwithstanding some
lesser percentage that may be specified by law), the Bylaws may be repealed,
altered, amended or rescinded by the stockholders of the Corporation as
described in the Certificate of Incorporation or in accordance with the DGCL
only upon the affirmative vote of at least sixty-six and two thirds percent
(66.66%) of the voting power of the then outstanding capital stock of the
Corporation entitled to vote thereon, voting together as a single class.
OPHTHALMIC
TECHNOLOGIES INC.
SHARE
PURCHASE AGREEMENT
April 11,
2007
OPHTHALMIC
TECHNOLOGIES INC
SHARE
PURCHASE AGREEMENT
This
Share Purchase Agreement
(the
“
Agreement
”)
is
made and entered into as of April 11, 2007, by and among
Ophthalmic
Technologies, Inc.
,
an
Ontario corporation (the “
Company
”);
and
Exegenics Inc., a Delaware corporation (the “
Investor
”).
Recitals
Whereas,
|
the
Company has authorized the issuance from treasury of an aggregate
of 67.94
common shares (the “
Shares
”);
and
|
Whereas,
|
the
Investor desires to purchase the Shares on the terms and conditions
set
forth herein; and
|
Whereas,
|
the
Company desires to issue the Shares to Investor on the terms and
conditions set forth herein.
|
Now
Therefore
,
in
consideration of the foregoing recitals and the mutual promises,
representations, warranties, and covenants hereinafter set forth, the parties
hereto agree as follows:
1.
|
Agreement
to Sell and Purchase
|
1.1
|
Issuance
and Purchase
.
Subject
to the terms and conditions hereof, at the Closing (as hereinafter
defined) the Company hereby agrees to issue to the Investor, and
the
Investor agrees to purchase from the Company, that number of common
shares
of the Company equivalent to, but not exceeding, one-third (1/3)
of the
Company’s issued and outstanding share capital, for an aggregate purchase
price of US$5 million (the “Investment Amount”), constituting, at the
Closing, 67.94 Shares at a purchase price of US $73,594.35 per
Share.
|
1.2
|
Authorization
of Shares
.
The Shares, when issued and allotted in accordance herewith: (a)
will be
duly authorized, validly issued, fully paid, non-assessable and free
of
pre-emptive or similar rights; (b) shall have the rights, preferences
and
privileges as set forth in the Articles of Incorporation of the Company
attached hereto as
Exhibit
1.2
(the “
Articles
”);
and (c) will be free and clear of any liens, security interests or
third
party rights created by the
Company.
|
1.3
|
Investor’s
Proportion of Company Share Capital.
As
stated in Section 1.1 above, the Shares shall constitute on the Closing
Date (as defined below), one-third (1/3) of the Company’s issued and
outstanding share capital on a fully diluted basis, after giving
effect to
the consummation of all transactions contemplated at the Closing,
subject
to Section 1.4 below, and treating all options, warrants, convertible
securities and rights to purchase securities of the Company, on an
as-exercised and as-converted basis (“
Fully
Diluted Basis
”),
all as reflected in the Company’s capitalization table attached hereto as
Exhibit
1.3.
|
1.4
|
Cancellation
of Impugned Shareholder Shares.
Notwithstanding
Section 1.3 above, the Parties acknowledge that it is their present
intention that for the purposes of resolving certain issues as between
the
Company and any Impugned Shareholders (as defined below) which will
result
in the purchase for cancellation (“Cancellation”) by the Company, of all
or part of the share capital of the Company held by such Impugned
Shareholders, that if, as a consequence of any such Cancellation,
the
shareholding of the Investor then exceeds one-third (1/3) of the
share
capital of the Company taken as a proportion to the holdings of the
shareholders remaining after such Cancellation (the “Original
Shareholders”, which term
expressly
excludes
any Impugned Shareholder), then, in each such instance, the Investor
shall
sell, for nominal consideration, and the Original Shareholders shall
purchase, in their Pro-Rata Proportions (as defined below), that
number of
the Shares held by the Investor necessary to adjust the proportionate
shareholding of the Investor so that it constitutes only one-third
(1/3)
of the fully-diluted issued and outstanding share capital of the
Company
as at the date of each such Cancellation.
|
1.5
|
Financing
of Cancellation.
Subject to Section 1.7 below, in the event of any such Cancellation
of
Impugned Shareholder shareholdings as contemplated in Section 1.4
above,
the Company shall pay only a nominal amount of the aggregate consideration
payable in respect of all such Cancellations taken together. Any
additional funds required, to the extent such required funds exceed
nominal amounts, shall be borne by the Original Shareholders (as
defined
in Section 1.4) in their Pro-Rata Proportions, or in such proportions
as
the Original Shareholders may agree, in writing, as at the time of
such
Cancellation. Alternatively, and in the sole discretion of the Original
Shareholders, where the Original Shareholders are required to bear
the
cost of any such Cancellation of Impugned Shareholder shareholdings,
the
Original Shareholders may elect instead to purchase such shareholdings
from the Impugned Shareholder, at the transfer price determined under
the
relevant dispute settlement agreement, in their Pro-Rata Proportions,
or
in such proportions as the Original Shareholders may agree, in writing,
as
at the time of such purchase provided, however, that any such purchase
shall not have the effect of reducing the proportionate shareholding
of
the Investor so that it constitutes less than one-third (1/3) of
the
fully-diluted issued and outstanding share capital of the Company
as at
the date of each such purchase.
|
1.6
|
Defined
Terms.
For the purposes of Sections 1.4 and 1.5 above, “Pro-Rata Proportion”
means, with respect to any Original Shareholder as at the date of
each
such Cancellation, the percentage of Shares it owned directly or
indirectly as at the Closing is of the total number of the issued
and
outstanding Shares of the Company as at the Closing time, without
taking
into account the shareholdings of any Impugned Shareholder. For greater
certainty, the Pro-Rata Proportion with respect to any Original
Shareholder will be the fraction that has as its numerator the total
number of issued and outstanding Shares of the Company held by such
Original Shareholder as at the Closing time and as its denominator
the
total number of all issued and outstanding Shares of the Company
held by
all
Original
Shareholders as at the Closing time. For the purposes Sections 1.4
and 1.5
above, “Impugned Shareholder” means each of Nidek Co. Ltd. (“Nidek”) and
Jean-Paul Chaduc (“Chaduc”).
|
1.7
|
Special
Provisions - Nidek Cancellation.
Notwithstanding
Section 1.5 above, the Parties acknowledge that it is their present
intention that, for the purposes of financing a Cancellation of Nidek
shares, the Company shall pay the purchase price of the shares up
to the
amount otherwise paid to the Company by Nidek as part of any settlement
agreement. Any funds required in excess of this amount, to the extent
such
required funds exceed nominal amounts, shall be borne by the Original
Shareholders in accordance with the provisions of Section 1.5 above.
|
2.
|
Closing,
Registration and Payment
|
2.1
|
Closing
.
The closing of the sale and purchase of the Shares under this Agreement
(the “
Closing
”)
shall take place at 10:00 a.m. on April 11, 2007, at the Company's
offices or at such other time or place as the Company and Investor
may
mutually agree (such date is hereinafter referred to as the “
Closing
Date
”).
|
2.2
|
Transactions
at Closing
.
At the Closing, the following transactions and actions shall be taken, and
all such transactions and actions shall be deemed to take place
simultaneously:
|
2.2.1
The
Investor shall pay to the Company the sum of US $5 million, by way of wire
or
electronic transfer of immediately available funds to the Company’s bank account
or by such other form of payment acceptable to the Company;
2.2.2
The
Company shall issue to the Investor 67.94 Shares.
2.2.3
The
Company shall further deliver to the Investor the following
documents:
(a)
Validly
executed share certificate, issued in the name of Exegenics Inc., and
representing the Shares issued to the Investor at the Closing;
(b)
A
copy of
the resolutions of the Board of Directors of the Company, approving: (i) the
execution, delivery and performance of this Agreement; and (ii) the issuance
of
the Shares to the Investor at the Closing, against and subject to payment of
the
Investment Amount;
(c)
Any
other
document or instrument to be provided by the Company reasonably necessary or
expedient to give full effect to the sale and purchase of the Shares and
otherwise to the consummation of all the transactions contemplated
herein.
2.3
|
Conditions
to Closing by the Investor
.
The obligations of the Investor to take any action required of it
hereunder to be taken at the Closing are subject to the fulfillment
at or
before the Closing of the following conditions precedent, any one
or more
of which may be waived in whole or in part by the Investor in its
sole
discretion:
|
2.3.1
Representations
and Warranties
.
The
representations and warranties made by the Company in this Agreement shall
have
been true and correct in all material respects when made, and shall be true
and
correct in all material respects as of the Closing as if made on the date of
the
Closing.
2.3.2
Covenants
.
All
covenants, agreements, and conditions contained in this Agreement to be
performed or complied with by the Company prior to or at the Closing shall
have
been performed or complied with in all material respects, prior to or at the
Closing.
2.3.3
Consents
etc
.
The
Company shall have secured all permits, consents, approvals, resolutions and
authorizations that shall be necessary or required lawfully for the Company
to
consummate this Agreement and to issue the Shares to be purchased by the
Investor at the Closing.
2.3.4
Delivery
of Documents
.
All the
documents to be delivered by the Company to the Investor at the Closing shall
be
in form and substance reasonably satisfactory to the Investor.
2.3.5
Proceedings
and Documents
.
All
corporate and other proceedings in connection with the transactions contemplated
by this Agreement and all documents and instruments incident to such
transactions shall be reasonably satisfactory in substance and form to the
Investor, and the Investor shall have received all such counterpart originals
or
certified or other copies of such documents as the Investor may reasonably
request.
2.3.6
No
Judgment or Order
.
There
shall not be on the date of the Closing any judgment or order of a court of
competent jurisdiction or any ruling, regulation or order of any authority
which
would prohibit or have the effect of preventing consummation of the transactions
contemplated by this Agreement.
2.4
|
Conditions
to Closing by the Company
.
The obligations of the Company to take any action required of the
Company
hereunder to be taken at the Closing are subject to the fulfillment
at or
before the Closing of the following conditions, which conditions
may be
waived in whole or in part by the Company, and which waiver shall
be at
the sole discretion of the Company:
|
2.4.1
Covenants
.
All
covenants, agreements and conditions contained in this Agreement to be
performed, or complied with, by the Investor prior to or at the Closing shall
have been performed or complied with by the Investor prior to or at the
Closing.
2.4.2
Representations
and Warranties
.
The
representations and warranties made by the Investor in this Agreement shall
have
been true and correct when made, and shall be true and correct as of the date
of
the Closing.
2.4.3
Consents,
etc
.
The
Company shall have secured all consents and approvals, as provided in Section
2.3.3 above.
2.4.4
No
Judgment or Order
.
There
shall not be on the date of the Closing any judgment or order of a court of
competent jurisdiction or any ruling, regulation or order of any authority
which
would prohibit or have the effect of preventing consummation of the transactions
contemplated by this Agreement.
3.
|
Representations
and Warranties of the
Company
|
Except
as
set forth on a Schedule of Exceptions delivered by the Company to the Investor
at the Closing, which is attached hereto as
Exhibit 3
,
the
Company hereby represents and warrants to the Investor as of the date of this
Agreement as set forth below.
3.1
|
Organization,
and Qualification
.
The Company is a Company duly organized and validly existing under
the
laws of Ontario, Canada. The Company has all requisite corporate
power and
authority to own and operate its properties and assets, to issue
and sell
the Shares, and to carry out the provisions of this Agreement and
to carry
on its business as presently conducted.
|
3.2
|
Subsidiaries
.
The Company does not own or control any equity security or other
interest
of any other corporation, limited partnership or other business
entity.
|
3.3
|
Capitalization;
Voting Rights
.
|
|
(a)
|
The authorized share capital of the Company, immediately
prior to the Closing, consists of (i) an unlimited number of shares
of Common Stock with no par value (“
Common
Stock
”),
of which 132.48 shares are issued and outstanding;
|
|
|
(b)
|
Other than as set forth on the Schedule of Exceptions
and
in Note 8 of the Financial Statements, there are no outstanding
options, warrants, rights (including conversion or preemptive rights
and
rights of first refusal), proxy or shareholder agreements, or agreements
of any kind for the purchase or acquisition from the Company of any
of its
securities.
|
|
|
(c)
|
All issued and outstanding shares of the Company’s Common
Stock (i)
have
been duly authorized and validly issued and are fully paid and
non-assessable, and (ii) were issued in compliance with all applicable
Canadian laws concerning the issuance of such securities.
|
|
|
(d)
|
The
rights, preferences, privileges and restrictions of the Shares are
as
stated in
the
Articles. The consummation of the transactions contemplated hereunder
will
not result in any anti-dilution adjustment or other similar adjustment
to
any outstanding securities or instruments of the Company. When issued
in
compliance with the law, the provisions of this Agreement and the
Articles, the Shares will be validly issued, fully paid and
non-assessable, and will be free of any liens or encumbrances other
than
liens and encumbrances created by or imposed upon the Investor;
provided,
however
,
that the Shares may be subject to restrictions on transfer under
U.S.,
Canadian or any applicable state or provincial securities laws as
set
forth herein, or as otherwise required by such laws at the time a
transfer
is proposed.
|
|
|
(e)
|
Exhibit
1.3 describes the capitalization of the Company immediately prior
to the
Closing.
|
3.4
|
Authorization
.
The Company has the full power and authority to execute, enter into
and
perform its obligations under this Agreement. The Agreement has been
duly
authorized by all of the necessary corporate actions, and the same
constitute or will constitute (as applicable) valid and legally binding
obligations of the Company, enforceable against it in accordance
with
their respective terms, all except as may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance,
and any other laws of general application affecting enforcement of
creditors' rights generally, and as limited by laws relating to the
availability of specific performance, injunctive relief or other
equitable
remedies.
|
3.5
|
Financial
Statements
.
The Company has made available to the Investor its Financial Reports
as of
April 30, 2006 (the “
Financial
Statements
”
and the “
Financial
Statement Date
”
respectively), copies of which are attached hereto as
Exhibit
3.5
.
The Financial Statements, together with the notes thereto, are complete
and correct in all material respects, have been prepared in accordance
with generally accepted accounting principles in Canada, applied
on a
consistent basis throughout the periods indicated, except as disclosed
therein.
|
3.6
|
Liabilities
.
Except as set forth in the Schedule of Exceptions, the Company has
no
debts and, to the best of its knowledge, knows of no contingent
debts,
not
disclosed in the financial statements, except current debts incurred
in
the ordinary course of business which have not been, either in any
individual case or in the aggregate, materially adverse.
|
3.7
|
Agreements;
Action
.
Except as set forth in the Schedule of Exceptions, there are no
agreements, understandings, instruments, contracts, proposed transactions,
judgments, orders, writs or decrees to which the Company is a party
or to
its knowledge by which it is bound which may involve (i) obligations
(contingent or otherwise) of, or payments to, the Company in excess
of
$10,000, or (ii) the transfer or license of any patent, copyright,
trade
secret or other proprietary right to or from the Company (other than
licenses arising from the purchase of “off the shelf” or other standard
products).
|
3.8
|
Obligations
to Related Parties
.
Except as set forth in the Schedule of Exceptions or the Financial
Statements, there are no obligations of the Company to officers,
directors, shareholders, or employees of the Company other than (a)
for
payment of salary for services rendered and (b) reimbursement for
reasonable expenses incurred on behalf of the Company. No officer,
director or shareholder, or any member of their immediate families,
is,
directly or indirectly, interested in any material contract with
the
Company (other than such contracts as relate to any such person’s
ownership of shares or other securities of the Company). The Company
is
not a guarantor or indemnitor of any indebtedness of any other person
or
corporation.
|
3.9
|
Changes
.
Except as set forth in the Schedule of Exceptions, since the Financial
Statement Date, there has not been to the Company’s knowledge:
|
|
(a)
|
Any
change in the assets, liabilities or operations of the Company from
that
reflected in the Financial Statements, other than changes in the
ordinary
course of business, none of which individually or in the aggregate
has had
a material adverse effect
on
such assets, liabilities or operations of the Company; Since the
date of
the Financial statements it is expected that sales will decrease
for
fiscal 2007 as a result of ongoing supply issues with the Company’s major
supplier for the OCT/SLO product, Newport Corporation. The Company’s
payable to Newport Corporation has also increased. Both these issues
have
been addressed to the satisfaction of Newport and the Company in
a
purchase order, a draft of which is attached hereto, which deals
with both
supply and payable issues.
|
|
(b)
|
Any damage, destruction or loss whether
or not
covered by insurance, materially and adversely affecting the properties,
business or prospects or financial condition of the Company;
|
|
(c)
|
Any change, except in the ordinary
course of
business, in the contingent obligations of the Company by way of guaranty,
endorsement, indemnity, warranty or otherwise;
|
|
(d)
|
Any waiver by the Company of a valuable
right
or of a material debt owed to it;
|
|
(e)
|
Any direct or indirect loans by the
Company to
any shareholder, employee, officer or director of the
Company,
|
|
(f)
|
Any material change in any compensation
arrangement or agreement with any employee, officer, director or
shareholder;
|
|
(g)
|
Any declaration or payment of any dividend
or
other distribution of the assets of the Company;
|
|
(h)
|
Any
debt, obligation or liability incurred, assumed or guaranteed by
the
Company, except those for immaterial amounts and for other liabilities
incurred in the ordinary course of
business;
|
|
(i)
|
Any sale, assignment or transfer of
any
patent, trademarks, copyrights, trade secret or other intangible assets;
or
|
|
(j)
|
Any change in any material agreement
to which
the Company is a party or by which it is
bound.
|
3.10
|
Title
to Properties and Assets; Liens, Etc.
The Company has good and marketable title to its properties and assets,
including the properties and assets reflected in the Financial Statements,
and good title to its leasehold estates, in each case subject to
no
mortgage, pledge, lien, lease, encumbrance or charge (a “Lien”), other
than (a) those resulting from taxes which have not yet become delinquent,
(b) minor liens and encumbrances which do not materially detract
from the
value of the property subject thereto or materially impair the operations
of the Company, and (c) those that have otherwise arisen in the ordinary
course of business. The Company is in compliance with all material
terms
of each agreement to which it is a party or is otherwise bound.
|
3.11
|
Intellectual
Property
.
|
|
(a)
|
To
the best of its knowledge the Company owns or possesses sufficient
legal
rights to all patents, trademarks, service marks, trade names, copyrights,
trade secrets, licenses, information and other proprietary rights
and
processes necessary for its business as now conducted and as presently
proposed to be conducted, without any known infringement of the rights
of
others. There are no outstanding options, licenses or agreements
of any
kind relating to the foregoing proprietary rights, nor is the Company
bound by or a party to any options, licenses or agreements of any
kind
with respect to the patents, trademarks, service marks, trade names,
copyrights, trade secrets, licenses, information and other proprietary
rights and processes of any other person or entity other than such
licenses or agreements arising from the purchase of “off the shelf” or
standard products.
|
|
(b)
|
Except with respect to the Zeiss
letters,
which have been disclosed to the Investor, the Company has not received
any communications alleging that the Company has violated by conducting
its business as presently proposed, would violate any of the patents,
trademarks, service marks, trade names, copyrights or trade secrets
or
other proprietary rights of any other person or entity, nor is the
Company
aware of any basis therefore.
|
|
(c)
|
None of the key employees of the Company
(as
named in Section 3.16 hereto) is obligated under any contract (including
licenses, covenants or commitments of any nature) or other agreement,
or
subject to any judgment, decree or order of any court or administrative
agency, that would interfere with their duties to the Company or that
would conflict with the Company’s business as presently proposed to be
conducted. Each former and current employee, officer and consultant
of the
Company has executed a proprietary information and inventions agreement.
No former and current employee, officer or consultant of the Company
has
excluded works or inventions made prior to his or her employment with
the
Company from his or her assignment of inventions pursuant to such
employee, officer or consultant’s proprietary information and inventions
agreement.
|
3.12
|
Compliance
with Other Instruments
.
The Company is not in violation or default of any term of its current
Articles, or of any provision of any mortgage, indenture, contract,
agreement or instrument to which it is party or by which it is bound,
or
of any judgment, decree, order, writ. The execution, delivery, performance
of, and compliance with this Agreement, and the issuance and sale
of the
Shares pursuant hereto, will not, with or without the passage of
time or
giving of notice, result in any such violation, or be in conflict
with or
constitute a default under any such term, or result in the creation
of any
mortgage, pledge, lien, encumbrance or charge upon any of the properties
or assets of the license, authorization or approval applicable to
the
Company, it business or operations or any of its assets or properties.
|
3.13
|
Litigation
.
Except as set forth in the Schedule of Exceptions, there is no
action,
suit, proceeding or investigation pending or, to the Company’s knowledge,
currently threatened against the Company that questions the validity
of
this Agreement, or the right of the Company to enter into any of
such
agreements, or to consummate the transactions contemplated hereby
or
thereby, or which would reasonably be expected to result, either
individually or in the aggregate, in any material adverse change
in the
assets, conditions, affairs or prospects of the Company, financially
or
otherwise, or any change in the current equity ownership of the
Company,
nor is the Company aware that there is any basis for any of the
foregoing.
|
3.14
|
Tax
Returns and Payments
.
The Company has filed all tax returns required to be filed by it.
All
taxes shown to be due and payable on such returns, any assessments
imposed, and to the Company’s knowledge all other taxes due and payable by
the Company on or before the Closing, have been paid or will be
paid prior
to the time they become delinquent. The Company has no knowledge
of any
liability of any tax to be imposed upon its properties or assets
as of the
date of this Agreement that is not adequately provided for.
|
3.15
|
Employees
.
The Company has no collective bargaining agreements with any of
its
employees.
|
3.16
|
Obligations
of Key Employees
.
Each Key employee of the Company is currently devoting substantially
all
of his or her business time to the conduct of the business of the
Company.
The Company is not aware that any key employee of the Company is
planning
to work less than full time at the Company in the future. No Key
Employee
is currently working or, to the Company’s knowledge, plans to work for a
competitive enterprise, whether or not such key employee is or
will be
compensated by such enterprise. The Company’s Key Employees have executed
with the Company employment agreements that include a non-competition
and
confidentiality provisions. For the purpose of this Section, the
term “Key
Employee” shall refer to Richard Weitz, Gerald Weiss and Justin Pedro.
Gerald Weiss is also involved in a property management company
that
manages amongst other, family controlled real estate. Gerald Weiss
is not
involved in the day to day management of the property management
company.
|
3.17
|
Registration
Rights and Voting Rights
.
T
he
Company has not agreed to grant any registration rights, including
piggyback rights, to any person or
entity.
|
3.18
|
Compliance
with Laws; Permits
.
The Company is not aware of any violation of any applicable statute,
rule,
regulation, order or restriction of any domestic or foreign government
or
any instrumentality or agency thereof in respect of the conduct of
its
business or the ownership of its properties which violation would
materially and adversely affect the business, assets, liabilities,
financial condition, operations or prospects of the Company No
governmental orders, permissions, consents, approvals or authorizations
are required to be obtained and no registrations or declarations
are
required to be filed in connection with the execution and delivery
of this
Agreement and the issuance of the Shares, except such as has been
duly and
validly obtained or filed, or with respect to any filings that must
be
made, or tax to be paid, after the Closing, as will be filed in a
timely
manner. The Company has all franchises, permits, licenses and any
similar
authority necessary for the conduct of its business as now being
conducted
by it, the lack of which could materially and adversely affect the
business, properties or financial condition of the Company and believes
it
can obtain, without undue burden or expense, any similar authority
for the
conduct of its business as planned to be conducted
.
|
3.19
|
Full
Disclosure
.
The Company has provided the Investor with all information requested
by
the Investor in connection with its decision to purchase the Shares
including all information reasonably necessary to make such investment
decision. To the Company’s knowledge, neither
this
Agreement, the exhibits and schedules hereto nor any other document
delivered by the Company to Investor or their attorneys or agents
in
connection herewith or therewith or with the transactions contemplated
hereby or thereby, contain any untrue statement of a material fact
nor, to
the best of the Company’s knowledge, omit to state a material fact
necessary in order to make the statements contained herein or therein
not
misleading
|
3.20
|
Insurance
.
The Company has general commercial, product liability, fire and casualty
insurance, with coverage customary for companies similarly situated
to the
Company.
|
4.
|
Representations
and Warranties of the Investor
|
|
The Investor hereby represents and
warrants to
the Company as follows (such representations and warranties do not
lessen
or obviate the representations and warranties of the Company set forth
in
this Agreement).
|
4.1
|
Requisite
Power and Authority
.
Investor has all necessary power and authority under all applicable
provisions of law to execute and deliver this Agreement and to
carry out
its provisions. All action on Investor’s part required for the lawful
execution and delivery of this Agreement has been or will be effectively
taken prior to the Closing. Upon its execution and delivery, this
Agreement will be a valid and binding obligation of Investor, enforceable
in accordance with its terms, except (a) as limited by applicable
bankruptcy, insolvency, reorganization, moratorium or other laws
of
general application affecting enforcement of creditors’ rights, and (b) as
limited by general principles of equity that restrict the availability
of
equitable remedies.
|
4.2
|
Investment
Representations
.
Investor hereby represents and warrants as follows:
|
|
(a)
|
Investor
Bears Economic Risk
.
Investor has substantial experience in evaluating and investing
in private
placement transactions of securities in companies similar to
the Company
so that it is capable of evaluating the merits and risks of its
investment
in a development-stage company and has the capacity to protect
its own
interests. Investor must bear the economic risk of this investment
indefinitely. Investor understands that the Company has no present
intention to offer to the public or register the Shares or any
of its
Common Stock. Investor is aware that its investment should be
regarded as
highly speculative and may cause it substantial or total loss
of its
investment.
|
|
(b)
|
Entirely
for own Account; Accredited Investor.
Investor
is purchasing the Shares for investment for its account, not as
nominee or
agent, and not with the current view to, or for resale in connection
with,
any distribution thereof. It is an “accredited investor” within the
meaning of (i) Rule 501 of Regulation D promulgated under the U.S.
Securities Act of 1933, as amended; and (ii) National Instrument
45-106 -
Prospectus and Registration Exemptions. It is able to bear the
economic
risks of the investment in the Company and, consequently, without
limiting
the generality of the foregoing, is able to hold the Shares for
an
indefinite period of time and has a sufficient net worth to sustain
a loss
of its entire investment in the Company in the event such loss
should
occur.
|
|
(c)
|
Investor
Can
Protect Its Interest
.
Investor represents that by reason of its, or its management’s, business
or financial experience, Investor has the capacity to protect its
own
interests in connection with the transactions contemplated in the
Agreement. Further, Investor is aware of no publication of any
advertisement or promotion in connection with the transactions
contemplated in the Agreement.
|
|
(d)
|
Company
Information
.
Investor has received and reviewed such data provided to it by
the Company
regarding the Company as it deemed appropriate and has had an opportunity
to discuss the Company’s business, management and financial affairs with
directors, officers and management of the Company and has had the
opportunity to review the Company’s operations and facilities. Investor
has also had the opportunity to ask questions of and receive answers
from,
the Company and its management regarding the terms and conditions
of this
investment.
|
|
(e)
|
No
Public
Market
.
Investor understands that the Shares that it is purchasing are
characterized as “restricted securities” inasmuch as they are being
acquired from the Company in a transaction not involving a public
offering. Investor acknowledges that the Shares may be held indefinitely
and understands that no public market now exists for any of the
Shares
issued by the Company and that the Company has made no assurances
that a
public market will ever exist for the Company’s shares.
|
|
(f)
|
Legend
.
Investor acknowledges that the certificates evidencing the Shares
will
bear the following legend:
|
“UNLESS
PERMITTED
UNDER SECURITIES LEGISLATION, THE HOLDER OF THIS SECURITY MUST NOT TRADE
THE
SECURITY BEFORE AUGUST 12, 2007.”
6.
OPTION
ARRANGEMENTS
6.1
For
and
in consideration of the Closing of the purchase and sale transaction
contemplated herein, each of the Company shareholders listed on the signature
page hereto hereby grant to the Investor an options (collectively, the
“Options”), granting it the irrevocable right to purchase from such shareholder
all of such shareholder’s right, title and interest in and to the capital stock
of the Company (the “Selling Shareholders”). The Company undertakes to dedicate
best efforts to procure, within four (4) weeks from the date hereof, Options
from any other shareholders of the Company not executing this agreement. The
aforesaid options shall extend for the greater of a period of (i) six (6) months
from the date of this Agreement and (ii) three (3) months after completion
of
the audits described in clause (c) below and shall vest effective the date
hereof, at an exercise price per share to be determined in accordance with
the
following formula. The exercise price per share for each option shall be payable
in shares of the common stock of the Investor, par value $0.01 per share (the
“eXeg Common Stock”), and shall be equal to the Aggregate Exercise Price divided
by 135.88. The Aggregate Exercise Price shall be equal to a number of shares
of
eXeg Common Stock determined by dividing the sum of US $10 million by the eXeg
Share Price. eXeg Share Price shall be equal to the average per share closing
price of eXeg Common Stock for the ten (10) trading days ended on the second
business day prior to the exercise of the Option; provided, however, that
notwithstanding the foregoing, the eXeg Share Price shall not exceed US $3.55
nor be less than US $3.20.
The
Options shall be predicated on the understanding that:
|
(a)
|
the
share purchase transaction to be effected by the exercise of the
Option
shall be structured so as to be tax neutral to the Selling Shareholders
and the Investor (which structure may include the transfer of shares
through a Nova Scotia unlimited liability corporation, or such other
mechanism as may be approved by the tax advisors of the parties;
|
|
(b)
|
the
Options shall be subject to compliance with applicable law in Ontario
respecting shareholders’ rights;
|
|
(c)
|
the
Company shall dedicate its best efforts to arranging for audits to
be
conducted in a timely fashion respecting the Company’s fiscal years 2006
and 2007. The audits shall be prepared in accordance with generally
accepted accounting principles in Canada (GAAP).
|
6.2
Conduct
of the Company Prior to the Option Closing Date
.
Unless
the Investor otherwise agrees in writing and except as otherwise set forth
in
this Agreement, between the date of this Agreement and the closing or expiration
of the Options (the “Option Closing Date”), the Company will: (i) conduct its
business only in the ordinary course of business, (ii) use its reasonable
efforts to keep available the services of its present officers and employees
material to its business operations and (iii) use its reasonable efforts to
preserve its current relationships with its customers, suppliers, distributors,
licensors, officers and other key employees and other persons with which it
has
significant business relationships.
|
(a)
|
Between
the date of this Agreement and the Option Closing Date, the Company
shall
confer with the Investor from time to time as reasonably requested
by the
Investor to discuss any material changes or developments in the
operational matters of the
Company.
|
|
(b)
|
Except
as expressly provided in this Agreement, between the date of this
Agreement and the Option Closing Date, the Company will not do
any of the
following without the prior written consent of the
Investor:
|
|
(i)
|
create
any Lien on any of its properties or assets (whether tangible or
intangible),
|
|
(ii)
|
sell,
assign, transfer, lease or otherwise dispose of or agree to sell,
assign,
transfer, lease or otherwise dispose of any its fixed assets or cancel
any
indebtedness owed to it.
|
|
(iii)
|
change
any method of accounting or accounting practice used by it, other
than
such changes required by GAAP.
|
|
(iv)
|
issue
or sell any additional shares of the capital stock of, or other equity
interests in it, or securities convertible into or exchangeable for
such
shares or equity interests, or issue or grant any options, warrants,
calls, subscription rights or other rights of any kind to acquire
additional shares of such capital stock, such other equity interests
or
such securities.
|
|
(v)
|
amend
the Company’s Articles.
|
|
(vi)
|
declare,
set aside or pay any dividend or distribution with respect to any
share of
its capital stock or declare or effectuate a stock dividend, stock
split
or similar event.
|
|
(vii)
|
issue any note, bond, or other debt security or
create,
incur,
assume,
or guarantee any indebtedness for borrowed money or capitalized lease
obligation.
|
|
(viii)
|
make
any capital investment in, make any loan to, or acquire the securities
or
assets of any other person or
entity.
|
|
(ix)
|
enter
into any new or additional agreements or materially modify any existing
agreements relating to the employment of any officer or any written
agreements of any of its employees, except in the ordinary course
of
business.
|
|
(x)
|
make
any payments outside of the ordinary course of business to any of
the its
officers, directors, employees or stockholders. or
|
|
(xi)
|
agree
to take any of the actions specified in this Section
6.2.
|
7.1
|
Entire
Agreement.
This Agreement and the Schedules and Exhibits attached hereto
fully
embraces the legal relationship between the Parties, and no previous
agreements, memoranda of agreements, letters, negotiations, promises,
consents, undertakings, representations, warranties or documents
which
were applied, exchanged, or signed by or between any of the Parties
prior
to the signing of this Agreement shall have any force or effect
with
respect to the subject matter
hereof.
|
7.2
|
Survival
.
The representations, warranties, covenants and agreements made herein
shall survive any investigation made by the Investor and the closing
of
the transactions contemplated hereby for a period of two years following
the Closing. All statements as to factual matters contained in any
certificate or other instrument delivered by or on behalf of the
Company
pursuant hereto in connection with the transactions contemplated
hereby
shall be deemed to be representations and warranties by the Company
hereunder solely as of the date of such certificate or
instrument.
|
7.3
|
Reports.
Within
90 (ninety) days after the end of each quarter and fiscal year, the
Company shall deliver to the Investor a cop of: (i) a balance sheet
of the
Company as at the end of such period, and (ii) statement of income,
consolidated statements of shareholders' equity and cash flows and
consolidating schedule of investment activities for purchases of
property
and equipment of the Company for such period, all in reasonable detail,
prepared in accordance with generally accepted accounting practices
in
Canada, consistently applied (“GAAP”), and fairly presenting, in all
material respects, the financial position of the Company on and its
results of operations and cash flows, subject to changes resulting
from
normal year-end adjustments that will not be material in amount or
effect.
In the case of the annual reports, such reports shall set forth in
comparative form the figures for the prior fiscal year and the
corresponding figures from the consolidated plan and financial forecast
for the current fiscal year described below. As soon as practicable
but in
any event no later than the last day of each fiscal year, the Company
shall deliver to the Investor a forecast and budget for each of the
next
succeeding 12 (twelve) months of the consolidated balance sheet and
the
statements of income, cash flows and stockholders' equity of the
Company
together with an outline of the major assumptions upon which the
forecast
is based.
|
7.4
|
Successors
and Assigns
.
The Company shall not sell, assign, transfer, or otherwise convey
any of
its rights or delegate any of its duties under this Agreement, except
to a
company which has succeeded to substantially all of the business
and
assets of the Company in compliance with this Agreement and has assumed
in
writing its obligations under this Agreement. Except as otherwise
provided
herein, the terms and conditions of this Agreement shall inure to
the
benefit of and be binding upon the respective successors, assigns,
executors and administrators of the Parties. Nothing in this Agreement,
express or implied, is intended to confer upon any party other than
the
Parties or their respective successors and permitted assigns any
rights,
obligations, or liabilities under or by reason of this
Agreement.
|
7.5
|
Governing
Law; Jurisdiction
.
This Agreement shall be governed by and construed according to the
laws of
the State of Florida, without regard to the conflict of laws provisions
thereof.
|
7.6
|
Severability
.
If one or more provisions of this Agreement is held to be illegal,
invalid
or unenforceable under applicable law, such provision shall be excluded
from this Agreement, and the balance of the Agreement shall be interpreted
as if such provision were so excluded and shall be enforceable in
accordance with its terms; provided, however, that in such event
this
Agreement shall be interpreted so as to give effect, to the greatest
extent consistent with and permitted by applicable law, to the meaning
and
intention of the excluded provision as determined by such court of
competent jurisdiction.
|
7.7
|
Amendment
and Waiver
.
The
failure of any Party at any time or times to require performance
of any
provision hereof or to enforce any right with respect thereto, shall
in no
manner affect the right of such Party at a later time to enforce
the same
and shall in no way be construed to be a waiver of such provision
or
right
.
Any term of this Agreement may be amended only with the written consent
of
the Company and the Investor.
|
7.8
|
Delays
or Omissions
.
It is agreed that no delay or omission to exercise any right, power
or
remedy accruing to any party, upon any breach, default or non-compliance
by another party under this Agreement, or the Articles, shall impair
any
such right, power or remedy, nor shall it be construed to be a waiver
of
any such breach, default or non-compliance, or any acquiescence therein,
or of or in any similar breach, default or non-compliance thereafter
occurring. It is further agreed that any waiver, permit, consent
or
approval of any kind or character on the Investor’s part of any breach,
default, or non-compliance under this Agreement, or under the Articles
or
any waiver on such party’s part of any provisions or conditions of the
Agreement or Articles must be in writing and shall be effective only
to
the extent specifically set forth in such writing. All remedies,
either
under this Agreement, the Articles, by law, or otherwise afforded
to any
party, shall be cumulative and not alternative.
|
7.9
|
Notices
.
All notices required or permitted hereunder shall be in writing and
shall
be deemed effectively given: (a) upon personal delivery to the party
to be
notified, (b) when sent by confirmed telex or facsimile if sent during
normal business hours of the recipient, if not, then on the next
business
day, (c) three (3) business days after having been sent by registered
or
certified mail, return receipt requested, postage prepaid, or (d)
one (1)
business day after deposit with a nationally recognized overnight
courier,
specifying next day delivery, with written verification of receipt.
All
communications shall be sent to the Company and to the Investor at
their
respective addresses as set forth on the signature page hereof or
at such
other address as the Company or Investor may designate by written
notice
to the other parties hereto.
|
7.10
|
Expenses
.
The Company shall pay all costs and expenses that it incurs with
respect
to the negotiation, execution, delivery and performance of the Agreement,
including the reasonable fees and disbursements of counsel to the
Investor, which fees and disbursements shall not exceed
$40,000
.
|
7.11
|
Titles
and Subtitles
.
The titles of the sections and subsections of the Agreement are for
convenience of reference only and are not to be considered in construing
this Agreement.
|
7.12
|
Counterparts
and Facsimile Signature
.
This Agreement may be executed in any number of counterparts and
by means
of facsimile signature, each of which shall be an original, but all
of
which together shall constitute one
instrument.
|
7.13
|
Confidentiality
.
The parties hereto agree that, except with the prior written consent
of
the Company, it shall at all times keep confidential and not divulge,
furnish or make accessible to anyone any confidential information,
knowledge or data concerning or relating to the business or financial
affairs of the Company to which the Investor has been or shall become
privy by reason of this Agreement, discussions or negotiations relating
to
this Agreement, the performance of its obligations hereunder or the
ownership of the Shares purchased hereunder. The provisions of this
Section shall be in addition to, and not in substitution for, the
provisions of any separate non-disclosure agreement which may have
been
executed by the parties hereto.
|
7.14
|
Pronouns
.
All pronouns contained herein, and any variations thereof, shall
be deemed
to refer to the masculine, feminine or neutral, singular or plural,
as to
the identity of the parties hereto may require.
|
7.15
|
Further
Assurances.
From
time to time after the Closing Date, each party shall, at the request
of
the other party, execute and deliver such additional conveyances,
transfers and other assurances as may be reasonably required to
effectively transfer the Shares to the Investor and the adjustments
provided for in subsection 1.4 hereof and otherwise to carry out
the
intent of this Agreement.
|
[The
remainder of this page intentionally left blank]
In
Witness Whereof
,
the
parties have executed this
Share
Purchase Agreement
as of
the date set forth in the first paragraph hereof.
Ophthalmic
Technologies Inc.
By:
_______________________________
Name:
_____________________________
Address:
37
Kodiak Crescent,
Unit
16
Toronto,
Ontario M3J 3E5
CANADA
Fax:
(416) 631-6932
|
|
Exegenics
Inc.
By:
_______________________________
Name:
_____________________________
Address:
Fax:
|
The
following constitute the Selling Shareholders referenced in Article 6 hereof
and, by their execution below, agree to the provisions of Article
6.
|
|
1161983
ONTARIO LIMITED
|
|
|
Per:
|
|
|
|
|
Name:
|
|
|
|
Title:
|
|
|
GRALL
CORPORATION LIMITED
|
|
|
Per:
|
|
|
|
|
Name:
|
|
|
|
Title:
|
|
|
|
Witness
Name:
|
Rishard
Weitz
|
|
|
|
|
|
Witness
Name:
|
Carolyn
Weiss
|
|
|
|
Witness
Name:
|
Gerald
Weiss
|
SHARE
PURCHASE AGREEMENT
November
28, 2007
ARTICLE
1 INTERPRETATION
|
2
|
1.1
|
DEFINITIONS
|
2
|
1.2
|
RULES
OF INTERPRETATION
|
6
|
IN
THIS AGREEMENT:
|
6
|
1.3
|
ENTIRE
AGREEMENT
|
7
|
1.4
|
TERMINATION
|
7
|
ARTICLE
2 PURCHASE AND SALE OF SHARES
|
7
|
2.1
|
PURCHASE
AND SALE OF SHARES
|
7
|
2.2
|
PAYMENT
OF PURCHASE PRICE
|
7
|
2.3
|
ESCROW
|
7
|
ARTICLE
3 REPRESENTATIONS AND WARRANTIES
|
8
|
3.1
|
REPRESENTATIONS
AND WARRANTIES OF THE SELLERS
|
8
|
3.1.1
|
ORGANIZATION
AND QUALIFICATION OF THE CORPORATION
|
8
|
3.1.2
|
ORGANIZATION
AND QUALIFICATION OF THE SELLERS
|
8
|
3.1.3
|
SUBSIDIARIES
|
8
|
3.1.4
|
CAPITALIZATION
AND TITLE
|
8
|
3.1.5
|
AUTHORIZATION
OF THE CORPORATION
|
9
|
3.1.6
|
AUTHORIZATION
OF THE SELLERS
|
9
|
3.1.7
|
FINANCIAL
STATEMENTS
|
9
|
3.1.8
|
LIABILITIES
|
10
|
3.1.9
|
AGREEMENTS
AND ACTIONS
|
10
|
3.1.10
|
OBLIGATIONS
TO RELATED PARTIES
|
10
|
3.1.11
|
CHANGES
|
10
|
3.1.12
|
TITLE
TO PROPERTIES AND ASSETS; LIENS, ETC.
|
11
|
3.1.13
|
INTELLECTUAL
PROPERTY
|
11
|
3.1.14
|
COMPLIANCE
WITH OTHER INSTRUMENTS- CORPORATION.
|
12
|
3.1.15
|
COMPLIANCE
WITH OTHER INSTRUMENTS-SELLERS.
|
12
|
3.1.16
|
LITIGATION
|
12
|
3.1.17
|
TAX
RETURNS AND PAYMENTS
|
13
|
3.1.18
|
EMPLOYEES
|
13
|
3.1.19
|
OBLIGATIONS
OF KEY EMPLOYEES
|
13
|
3.1.20
|
REGISTRATION
RIGHTS AND VOTING RIGHTS
|
13
|
3.1.21
|
COMPLIANCE
WITH LAWS; PERMITS
|
13
|
3.1.22
|
FULL
DISCLOSURE
|
14
|
3.1.23
|
INSURANCE
|
14
|
3.1.24
|
SECURITIES
LEGISLATION
|
14
|
3.1.25
|
SECTION
6.2 OF THE SHARE PURCHASE AGREEMENT
|
14
|
3.1.26
|
ACKNOWLEDGEMENT
OF EXCHANGE AGREEMENT
|
14
|
3.2
|
REPRESENTATIONS
AND WARRANTIES OF THE BUYER
|
14
|
3.2.1
|
ORGANIZATION
AND QUALIFICATION
|
14
|
3.2.2
|
SUBSIDIARIES
|
15
|
3.2.3
|
CAPITALIZATION
OF THE BUYER
|
15
|
3.2.4
|
CAPITALIZATION
OF THE HOLDCO
|
15
|
3.3
|
NON-WAIVER/SCHEDULE
OF EXCEPTIONS
|
15
|
3.3.1
|
NON-WAIVER
|
15
|
3.3.2
|
SCHEDULE
OF EXCEPTIONS
|
15
|
3.4
|
TAX
COVENANTS
|
15
|
3.5
|
SURVIVAL
OF REPRESENTATIONS AND WARRANTIES
|
16
|
3.6
|
KNOWLEDGE
OF THE SELLERS
|
16
|
ARTICLE
4 NON-SOLICITATION AND NON-COMPETE
|
17
|
4.1
|
NON
- COMPETITION
|
17
|
4.2
|
NON
-SOLICITATION OF EMPLOYEES OR CONSULTANT.
|
17
|
4.3
|
NON-SOLICITATION
OF CLIENTS.
|
17
|
4.4
|
RESTRICTIONS
REASONABLE
|
17
|
4.5
|
INJUNCTIVE
RELIEF
|
18
|
ARTICLE
5 INDEMNIFICATION
|
18
|
5.1
|
INDEMNIFICATION
BY THE SELLERS
|
18
|
5.2
|
INDEMNIFICATION
BY THE BUYER
|
19
|
5.3
|
DEFENCE
OF CLAIMS
|
19
|
ARTICLE
6
|
20
|
6.1
|
CLOSING
DELIVERIES OF THE SELLER
|
20
|
6.2
|
CLOSING
DELIVERIES OF THE BUYER
|
21
|
6.3
|
PAYMENT
OF SHAREHOLDER AND RELATED PARTY LOANS
|
22
|
6.4
|
CLOSING
PAYMENTS
|
22
|
ARTICLE
7 GENERAL
|
22
|
7.1
|
EXPENSES
|
22
|
7.2
|
ENUREMENT
|
22
|
7.3
|
NOTICES
TO PARTIES
|
22
|
7.4
|
AMENDMENT
|
25
|
7.5
|
ASSIGNMENT
|
25
|
7.6
|
FURTHER
ASSURANCES
|
25
|
7.7
|
PUBLIC
ANNOUNCEMENTS
|
25
|
7.8
|
REMEDIES
CUMULATIVE
|
25
|
7.9
|
LIMITATION
OF LIABILITY
|
25
|
7.10
|
EXECUTION
AND DELIVERY
|
26
|
SHARE
PURCHASE AGREEMENT
THIS
AGREEMENT made as of the
28
th
day of
November
,
2007,
BETWEEN:
Ophthalmic
Technologies Inc.
a
corporation incorporated under the laws of Ontario
(
the
"Corporation")
-
and
-
OTI
Holdings Limited
a
corporation incorporated under the laws of Ontario
(the
"Buyer" or “Newco”)
-
and
-
1161983
Ontario Limited,
a
corporation incorporated under the laws of Ontario
("1161983")
-
and
-
Grall
Corporation Limited,
a
corporation incorporated under the laws of Ontario
("Grall")
-
and
-
Triple
Net Properties Limited
a
corporation incorporated under the laws of Ontario
(“3Net”)
-
and
-
Rishard
Weitz
("Weitz")
-
and
-
Carolyn
Weiss
("Weiss")
-
and
-
Shane
Dunne
("Dunne")
-
and
-
Gerald
Weiss, in trust for Marie-Helene Weiss and Gerald Weiss
("Gerald")
-
and -
Gerald
Weiss
RECITALS:
1.
|
On
April 11, 2007, Exegenics Inc. entered into a share purchase agreement
with the Corporation (the "Share Purchase Agreement") pursuant to
which it
was granted an option to purchase shares of the Corporation from
1161983,
Grall, Weitz, Weiss, and Gerald and pursuant to which the Corporation
undertook to dedicate its best efforts to procure options from the
other
shareholders of the Corporation who had not already granted such
options.
|
|
|
2.
|
Opko
Health, Inc. (“Opko”), a Delaware Corporation is the successor to
Exegenics Inc.
|
|
|
3.
|
On
November 9, 2007, Opko incorporated a wholly owned subsidiary, Ophthalmic
Technologies Holdings Limited (“Holdco”).
|
|
|
4.
|
On
November 9, 2007, Holdco incorporated a wholly owned subsidiary,
Newco for
the purpose of implementing the exercise of the Option.
|
|
|
5.
|
1161983,
Grall, 3Net, Weitz, Weiss, Dunne and Gerald (collectively, the "Sellers"
and each a "Seller"), are, as of the date hereof, the legal and beneficial
owner of all of the issued and outstanding shares of the Corporation,
other than the shares of the Corporation held by Opko Inc. in accordance
with the Capitalization Table attached as Schedule "A" hereto.
|
|
|
6.
|
The
Buyer wishes to purchase all, but not less than all, of the issued
and
outstanding shares of the Corporation held by the Sellers and each
Seller
wishes to sell all, but not less than all, of the issued and outstanding
shares of the Corporation such Seller holds.
|
|
|
7.
|
Opko,
the Buyer and the Seller are parties to that certain Exchange and
Support
Agreement of even date (the “Exchange
Agreement”).
|
IN
CONSIDERATION
of the
premises and the mutual agreements in this Agreement, and of other consideration
(the receipt and sufficiency of which are acknowledged by each of the Parties),
the Parties agree as follows:
ARTICLE
1
INTERPRETATION
In
this
Agreement,
“Affiliate”
means,
with respect to any Person, (i) any other Person directly or indirectly
controlling, controlled by, or under common control with such Person, (ii)
any
Person owning or controlling ten percent or more of the outstanding voting
interests of such Person, (iii) any officer, director, or general partner of
such Person, (iv) any family member of such Person or any trust, family limited
partnership or other similar entity controlled by such Person or his or her
family members, or (v) any Person who is an officer, director, general partner,
trustee, or holder of ten percent or more of the voting interests of any Person
described in clauses (i) through (iv). For purposes of this definition, the
terms “
controlling
”,
“
controlled
by
,”
or
“
under
common control with
”
shall
mean the possession, direct or indirect, of the power to direct or cause the
direction of the management and policies of a Person, whether through the
ownership of voting securities, by contract or otherwise;
“Agreement”
means
this agreement, including all schedules, and all amendments or restatements
as
permitted, and references to “
Article
”,
“
Section
”
or
“
Schedule
”
mean
the specified Article, Section or Schedule of this Agreement;
"
Articles
"
means
the articles of incorporation of the Corporation dated April 16, 1993, and
as
may be amended or restated from time to time;
"
Business
"
means
the business of providing ophthalmic ultrasound and optical coherence tomography
(OCT) equipment for ophthalmology;
“
Business
Day
”
means
any day except a Saturday, Sunday or any day on which banks are generally not
open for business in either of the Cities of Toronto, Ontario and New York,
New
York;
“
Canadian
Dollar Equivalent
”
means,
in respect of an amount expressed in a currency other than Canadian dollars
(the
“
Foreign
Currency Amount
”)
at any
date, the product obtained by multiplying:
(A)
the
Foreign Currency Amount; by
(B)
the
noon spot exchange rate on such date for such foreign currency expressed in
Canadian dollars as reported by the Bank of Canada or, if such spot exchange
rate is not available, such exchange rate on such date for such foreign currency
expressed in Canadian dollars as may be deemed by the Board of Directors in
good
faith to be appropriate for such purpose.
"
Claim
"
means
any demand, action, suit, proceeding, claim, assessment, judgment or settlement
or compromise relating thereto which may give rise to a right to
indemnification;
"
Closing
"
means
the completion of the sale to, and purchase by, the Buyer of the Shares on
the
date hereof and the completion of all other transactions contemplated by this
Agreement which are to occur contemporaneously with the purchase and sale of
the
Shares;
"
Closing
Document
"
means
any document delivered at or subsequent to the Closing as provided in or
pursuant to, this Agreement;
"
Competitive
Business
"
means
the business of any Person that is similar to or competes with the
Business;
"
Corporation
"
means
Ophthalmic Technologies Inc.;
“
Dunne
Escrow Shares
”
means
10,323.94 Exchangeable Shares;
"
Employment
Contracts
"
means
employment agreements with the Key Employees to be delivered as a condition
precedent to Closing;
"Escrow
Shares"
has
the
meaning set out in Section
2.3
;
“
Exchangeable
Shares
”
means
the exchangeable shares in the capital of the Buyer;
“
Financial
Statements
”
means
the financial statements set out in Section
3.1.7
hereto;
“
Financial
Statement Date
”
means
April 30, 2007;
"
including"
means
"
including
without limitation''
and the
term "
including
"
shall
not be construed to limit any general statement which it follows to the specific
or similar items or matters immediately following it;
“
Law
”
means
any federal, state, provincial, municipal, local or foreign statute, law,
by-law, ordinance, regulation, rule, code, order or rule of or duty under common
law, including any statute, law, by-law, ordinance, regulation, rule, code,
order or rule of or duty under common law in Canada, the United States, any
province or territory of Canada or any state or territory of the United
States.
"
Loss
"
and
"
Losses
"
have
the meaning set out in
ARTICLE
5
;
"
ordinary
course
"
when
used in relation to the conduct of the Business means any transaction which
constitutes an ordinary day-to-day business activity of the Corporation
conducted in a commercially reasonable and businesslike manner consistent with
the Corporation's past practices;
"
Parties
"
means
the Buyer and the Sellers, collectively, and "Party" means any one of
them;
“
Person
”
means
any individual, sole proprietorship, partnership, firm, entity, unincorporated
association, unincorporated syndicate, unincorporated organization, trust,
body
corporate, government, government regulatory authority, governmental department,
agency, commission, board, tribunal, dispute settlement panel or body, bureau
or
court, and where the context requires, any of the above when they are acting
as
trustee, executor, administrator or other legal representative;
"
Purchase
Price
"
shall
be equal to the number of Exchangeable Shares granted to all of the Sellers
pursuant to Section
2.2
multiplied by US$3.55;
"
Representative
"
means
each director, officer, employee, agent, solicitor, accountant, professional
advisor and other representative of an Indemnified Party;
"
Restricted
Period
"
means
the later of the last day of:
(i)
the
period commencing on the Closing and ending 3 years after the Closing; and
(ii)
(a)
if
Weitz or Gerald Weiss ceases to be an employee of the Corporation at any time
during the first three years following the Closing, the period commencing on
the
date Weitz or Gerald Weiss, as the case may be, ceases to be an employee of
the
Corporation and ending 2 years after such date; and
(b)
if
Weitz
or Gerald Weiss ceases to be an employee of the Corporation at any time after
the first three years following the date of Closing, the period commencing
on
the date Weitz or Gerald Weiss, as the case may be, ceases to be an employee
of
the Corporation and ending 6 months after such date, provided that the
restricted period may be extended by the Corporation for a further 18 months
in
accordance with the terms of the non-competition agreement dated as of the
date
hereof, between Rishard Weitz or Gerald Weiss, as the case may be and the
Corporation.
“
Schedule
of Exceptions
”
means
the schedule so named and attached to this Agreement.
"
Tax
"
and
"
Taxes
"
mean,
with respect to any Person:
|
(a)
|
all
income taxes (including any tax on or based upon net income, gross
income,
income as specially defined, earnings, profits or selected items
of
income) and all capital taxes, gross receipts taxes, environmental
taxes,
sales taxes, use taxes, ad valorem taxes, value added taxes, transfer
taxes, franchise taxes, licence taxes, withholding taxes, payroll
taxes,
employment taxes, Canada Pension Plan premiums, excise, severance,
social
security premiums, workers' compensation premiums, employment insurance
or
compensation premiums, stamp taxes, occupation taxes, premium taxes,
property taxes, windfall profits taxes, alternative or add-on minimum
taxes, goods and services tax, customs duties or other taxes, fees,
imposts, assessments or charges of any kind whatsoever, together
with any
interest and any penalties or additional amounts imposed by any taxing
authority (domestic or foreign) on such Person, and any interest,
penalties, additional taxes and additions to tax imposed with respect
to
the foregoing; and
|
|
(b)
|
any
liability for the payment of any amount of the type described in
the
immediately preceding subsection (a) of another
Person.
|
1.2
|
Rules
of Interpretation
|
In
this
Agreement:
|
(a)
|
Consent
-
Whenever a provision of this Agreement requires an approval or consent
and
such approval or consent is not delivered within the applicable time
limit, then, unless otherwise specified, the Party whose consent
or
approval is required will be conclusively deemed to have withheld
its
approval or consent.
|
|
(b)
|
Currency
-
Unless otherwise specified, all references to money amounts are to
the
lawful currency of the United States of
America.
|
|
(c)
|
Governing
Law
-
This Agreement is a contract made under and is governed by and construed
in accordance with the law of the Province of Ontario and the federal
laws
of Canada applicable in the Province of
Ontario.
|
|
(d)
|
Headings
-
Headings of Articles and Sections are inserted for convenience of
reference only and do not affect the construction or interpretation
of
this Agreement.
|
|
(e)
|
Number
and Gender
-
Unless the context otherwise requires, words importing the singular
include the plural and vice versa and words importing gender include
all
genders.
|
|
(f)
|
Severability
-
If, in any jurisdiction, any provision of this Agreement or its
application to any party or circumstance is restricted, prohibited
or
unenforceable, such provision will, as to such jurisdiction, be
ineffective only to the extent of such restriction, prohibition or
unenforceability without invalidating the remaining provisions of
this
Agreement and without affecting the validity or enforceability of
such
provision in any other jurisdiction or without affecting its application
to other Parties or circumstances.
|
|
(g)
|
Statutory
references
-
A reference to a statute includes all regulations made pursuant to
such
statute and, unless otherwise specified, the provisions of any statute
or
regulation that amends, supplements or supersedes any such statute
or any
such regulation.
|
|
(h)
|
Time
-
Time is of the essence in the performance of the Parties’ respective
obligations.
|
|
(i)
|
Time
Periods
-
Unless otherwise specified, time periods within or following which
any
payment is to be made or act is to be done are calculated by excluding
the
day on which the period commences and including the day on which
the
period ends and by extending the period to the next Business Day
if the
last day of the period is not a Business
Day.
|
This
Agreement together with the Share Purchase Agreement, the Exchangeable Share
Provisions, the Exchange and Support Agreement and the documents delivered
pursuant to such agreements constitutes the entire agreement between the Parties
and sets out all the covenants, promises, warranties, representations,
conditions, understandings and agreements between the Parties pertaining to
the
subject matter of this Agreement and supersedes all prior agreements,
understandings, negotiations and discussions, whether oral or written. There
are
no covenants, promises, warranties, representations, conditions, understandings
or other agreements, oral or written, express, implied or collateral between
the
Parties in connection with the subject matter of this Agreement except as
specifically set forth in this Agreement and the Exchangeable Share
Provisions.
Section
6
of the Share Purchase Agreement is hereby terminated and is of not further
force
or effect.
ARTICLE
2
PURCHASE
AND SALE OF SHARES
2.1
|
Purchase
and Sale of Shares
|
The
Buyer
agrees to purchase the Shares for the Purchase Price and Sellers agrees to
sell
and transfer the Shares to the Buyer for the Purchase Price.
2.2
|
Payment
of Purchase Price
|
The
Purchase Price shall be paid to each Seller by issuing to such Seller on the
date hereof such number of Exchangeable Shares as is equal to the number of
shares of the Corporation owned by such Seller multiplied by
20,730.80
On
the
date hereof,
the
Buyer, the Seller and Opko shall deliver an Exchange and Support Agreement
with
respect to such Exchangeable Shares.
As
security for the obligations of the Sellers, under
ARTICLE
5
,
on the
date hereof, each Seller shall direct that 15% of the Exchangeable Shares issued
to such Seller in satisfaction of the Purchase Price shall be deposited with
Fraser, Milner, Casgrain LLP as escrow agent (the "
Escrow
Agent
"),
who
shall hold such shares (collectively, the "
Escrow
Shares
")
pursuant to the terms of an agreement substantially in the form attached hereto
as Schedule
2.3
hereto
(the "
Escrow
Agreement
").
ARTICLE
3
REPRESENTATIONS
AND WARRANTIES
3.1
|
Representations
and Warranties of the
Sellers
|
Other
than with respect to Shane Dunne whose representations shall be deemed to be
several and separate and not joint and several, Sections
3.1.2
(Organization and Qualification of the Sellers),
3.1.4(b)
(Title),
3.1.6
(Authorization of the Sellers), and
3.1.15
(Compliance with other instruments-Sellers) which representations shall be
deemed to be several and separate and not joint and several, the Sellers jointly
and severally, represent and warrant to the Buyer as set out in the following
Subsections of this Section and acknowledge that the Buyer is relying upon
such
representations and warranties in entering into this Agreement.
3.1.1
|
Organization
and Qualification of the
Corporation
|
The
Corporation is duly organized and validly existing under the laws of Ontario,
Canada. The Corporation has all requisite corporate power and authority to
own
and operate its properties and assets, to issue shares, and to carry out the
provisions of this Agreement and to carry on its business as presently
conducted.
3.1.2
|
Organization
and Qualification of the
Sellers
|
Each
Seller that is a Corporation is a duly organized and validly existing under
the
laws of Ontario, Canada. Each Seller that is a Corporation has all requisite
corporate power and authority to own and operate its properties and assets,
to
issue shares, and to carry out the provisions of this Agreement and to carry
on
its business as presently conducted.
Save
and
except as disclosed in the Schedule of Exceptions, the Corporation does not
own
or control any equity, security or other interest of any other corporation,
limited partnership or other business entity.
3.1.4
|
Capitalization
and Title
|
|
(a)
|
The
authorized share capital of the Corporation consists of an unlimited
number of shares of Common Stock with no par value ("
Common
Stock
"),
of which 200.42 shares are issued and outstanding in accordance with
the
Capitalization Table set out in Schedule "A" hereto (the “
Capitalization
Table
”).
All such Shares have been issued as fully paid and non-assessable.
|
|
(b)
|
Each
Seller is the registered and beneficial owner of the Common Stock
set out
opposite such Sellers name on the Capitalization Table (collectively,
the
“
Purchased
Shares
”)
and has good and marketable title thereto. On Closing, the Buyer
will
acquire good and marketable title to the Purchased Shares. There
are no
restrictions on transfer of the Purchased Shares other than pursuant
to
the Articles of the Corporation.
|
|
(c)
|
Except
for the option to Justin Pedro, as disclosed in the Financial Statements,
there are no outstanding options, warrants, rights (including conversion
or pre-emptive rights and rights of first refusal), proxy or shareholder
agreements, or agreements of any kind for the purchase or acquisition
of
any of the securities of the
Corporation.
|
|
(d)
|
All
issued and outstanding shares of the Corporation's Common Stock (i)
have
been duly authorized and validly issued and are fully paid and
non-assessable, (ii) were issued in compliance with all applicable
Canadian laws concerning the issuance of such securities and (iii)
are
free and clear of any liens or encumbrances, provided, however, that
such
shares may be subject to restrictions on transfer under U.S., Canadian
or
any applicable state or provincial securities laws as set forth herein,
or
as otherwise required by such laws of the time the transfer is
proposed.
|
3.1.5
|
Authorization
of the Corporation
|
The
Corporation has the full power and authority to execute, enter into and perform
its obligations under this Agreement. In the case of the Corporation this
Agreement has been duly authorized by all of the necessary corporate actions.
This Agreement constitutes valid and legally binding obligations of the
Corporation enforceable against it in accordance with its terms, all except
as
may be limited by applicable bankruptcy, insolvency, reorganization, moratorium,
fraudulent conveyance, and other laws of general application affecting
enforcement of creditors' rights generally, and as limited by laws relating
to
the availability of specific performance, injunctive relief or other equitable
remedies.
3.1.6
|
Authorization
of the Sellers
|
Each
Seller has the full power and authority to execute, enter into and perform
its
obligations under this Agreement. In the case of each Seller who is a
Corporation, this Agreement has been duly authorized by all of the necessary
corporate actions. This Agreement constitutes valid and legally binding
obligations of each Seller, enforceable against such Seller in accordance with
its terms, all except as may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, fraudulent conveyance, and other laws of general
application affecting enforcement of creditors' rights generally, and as limited
by laws relating to the availability of specific performance, injunctive relief
or other equitable remedies.
3.1.7
|
Financial
Statements
|
Except
as
set forth in the Schedule of Exceptions, the Audited financial statement of
the
Corporation for the period ended April 30, 2006 and April 30, 2007 and the
unaudited financial statements for the period ended June 30, 2007, copies of
which have been delivered to the Buyer and are attached hereto as Schedule
3.1.7, together with the notes thereto, are complete and correct in all material
respect, have been prepared in accordance with generally accepted accounting
principles in the United States, applied on a consistent basis throughout the
periods indicated and fairly present the financial condition and results of
operations of the Corporation as of the respective dates thereof and for the
respective periods indicated therein.
Except
as
set forth in Schedule of Exceptions and the Financial Statements, the
Corporation has no debts and, to the best of its knowledge, knows of no
contingent debts, not disclosed in the financial statements, except current
debts incurred in the ordinary course if business which have not been, either
in
any individual case or in the aggregate, materially adverse.
3.1.9
|
Agreements
and Actions
|
Except
as
set forth in the Schedule of Exceptions, (i) there are no judgments, orders,
writs or decrees to which the Corporation is a party or to its knowledge by
which it is bound (ii) there are no agreements, instruments, contracts or
proposed transactions, which may involve (a) obligations (contingent or
otherwise) of, or payments to, the Corporation in excess of $15,000, or (b)
the
transfer or license of any patent, copyright, trade secret or other proprietary
right to or from the Corporation (other than licenses arising from the purchase
of "off the shelf" or other standard products).
3.1.10
|
Obligations
to Related Parties
|
Except
as
set forth in the Schedule of Exceptions or the Financial Statements, there
are
no obligations of the Corporation to officers, directors, shareholders, or
employees of the Corporation other than (a) for payment of salary for services
rendered and (b) reimbursement for reasonable expenses incurred on behalf of
the
Corporation. No officer, director or shareholder, or any member of their
immediate families, is, directly or indirectly, interested in any material
contract with the Corporation (other than such contracts as relate to any such
person's ownership of shares or other securities of the Corporation). The
Corporation is not a guarantor or indemnitor of any indebtedness of any other
person or corporation.
Except
as
set forth in Schedule of Exceptions, since the Financial Statement Date, there
has not been to the Corporation's knowledge:
|
(a)
|
any
change in assets, liabilities or operations of the Corporation from
that
reflected in the Financial Statements, other than changes in the
ordinary
course of business, none of which individually or in the aggregate
has had
a material adverse effect on such assets, liabilities or operations
of the
Corporation.
|
|
(b)
|
any
change, except in the ordinary course of business, in the contingent
obligations of the Corporation by way of guaranty, endorsement, indemnity,
warranty or otherwise;
|
|
(c)
|
any
damage, destruction or loss whether or not covered by insurance,
materially and adversely affecting the properties, business or prospects
or financial condition of the
Corporation;
|
|
(d)
|
any
waiver by the Corporation of a valuable right or of a material debt
owed
to it;
|
|
(e)
|
any
direct or indirect loans by the Corporation to any shareholder, employee,
officer or director of the
Corporation;
|
|
(f)
|
any
material change in any compensation arrangement or agreement with
any
employee, officer, director or
shareholder;
|
|
(g)
|
any
declaration or payment of any dividend or other distribution of the
assets
of the Corporation;
|
|
(h)
|
any
debt, obligation or liability incurred, assumed or guaranteed by
the
Corporation, except those for immaterial amounts and for other liabilities
incurred in the ordinary course of
business;
|
|
(i)
|
any
sale, assignment or transfer of any patent, trademarks, copyrights,
trade
secret or other intangible assets;
or
|
|
(j)
|
any
change in any material agreement to which the Corporation is a party
or by
which it is bound.
|
3.1.12
|
Title
to Properties and Assets; Liens, Etc.
|
Except
as
disclosed in the Schedule of Exceptions, the Corporation has good and marketable
title to its properties and assets, including the properties and assets
reflected in the Financial Statements, and good title to its leasehold estates,
in each case subject to no mortgage, pledge, lien, lease, encumbrance or charge
(a “
Lien
”),
other
than (a) those resulting from taxes which have not yet become delinquent, (b)
minor liens and encumbrances which do not materially detract from the value
of
the property subject thereto or materially impair the operations of the
Corporation, and (c) those that have otherwise arisen in the ordinary course
of
business. Except as disclosed in the Schedule of Exceptions, the Corporation
is
in compliance with all material terms of each agreement to which it is a party
or is otherwise bound.
3.1.13
|
Intellectual
Property
|
|
(a)
|
To
the best of the knowledge of the Corporation and the actual knowledge
of
the Sellers, the Corporation owns or possesses sufficient legal rights
to
all patents, trademarks, service marks, trade names, copyrights,
trade
secrets, licenses, information and other proprietary rights and processes
necessary for its business as now conducted, without any known
infringement of the rights of others.
Except
as disclosed in the Schedule of Exceptions, there are no outstanding
options, licenses or agreements of any kind with any third parties
relating to the foregoing proprietary rights, nor is the Corporation
bound
by or a party to any options, licenses or agreements of any kind
with
respect to the patents, trademarks, service marks, trade names,
copyrights, trade secrets, licenses, information and other proprietary
rights and processes of any other person or entity other than such
licenses or agreements arising from the purchase of “off the shelf” or
standard products.
|
|
(b)
|
Except
with respect to the Zeiss letters, which have been disclosed to the
Buyer,
the Corporation has not received any communications alleging that,
by
conducting its business as presently proposed, the Corporation has
violated or would violate any of the patents, trademarks, service
marks,
trade names, copyrights or trade secrets or other proprietary rights
of
any other person or entity, nor is the Corporation aware of any basis
therefor.
|
|
(c)
|
None
of the key employees of the Corporation (as named in Section
3.1.19
hereto) is obligated under any contract (including licenses, covenants
or
commitments of any nature) or other agreement, or subject to any
judgment,
decree or order of any court or administrative agency, that would
interfere with their duties to the Corporation or that would conflict
with
the Corporation’s business as presently proposed to be conducted.
|
3.1.14
|
Compliance
with Other Instruments- Corporation.
|
Except
as
disclosed in the Schedule of Exceptions, the Corporation is not in violation
or
default of any term of its current Articles, or of any provision of any
mortgage, indenture, contract, agreement or instrument to which it is a party
or
by which it is bound, or of any judgment, decree, order, writ. The execution,
delivery, performance of, and compliance with this Agreement, and the sale
of
the Shares pursuant hereto, will not, with or without the passage of time or
giving of notice, result in any violation, or be in conflict with or constitute
a default under any such term, or result in the creation of any mortgage,
pledge, lien, encumbrance or charge upon any of the properties or assets of
the
license, authorization or approval applicable to the Corporation, its business
or operations or any of its assets or properties.
3.1.15
|
Compliance
with Other Instruments-Sellers.
|
Each
Seller that is a corporation is not in violation or default of any term of
its
current Articles. Each Seller is not in violation of any provision of any
mortgage, indenture, contract, agreement or instrument to which it/he is a
party
or by which it is bound, or of any judgment, decree, order, writ.
Except
as
set forth in the Schedule of Exceptions, there is no action, suit, proceeding
or
investigation pending or, to the Corporation’s knowledge, currently threatened
against the Corporation that questions the validity of this Agreement, or the
right of the Corporation to enter into any of such agreements, or to consummate
the transactions contemplated hereby or thereby, or which would reasonably
be
expected to result, either individually or in the aggregate, in any material
adverse change in the assets, conditions, affairs or prospects of the
Corporation, financially or otherwise, or any change in the current equity
ownership of the Corporation, nor is the Corporation aware that there is any
basis for any of the foregoing.
3.1.17
|
Tax
Returns and Payments
|
Subject
to such facts and qualifications as are set forth in the Schedule of Exceptions,
the Corporation has filed all Tax returns required to be filed by it. All Taxes
shown to be due and payable on such returns, any assessments imposed, and to
the
Corporation’s knowledge all other Taxes due and payable by the Corporation on or
before the Closing, have been paid or will be paid on or prior to the time
they
are due. The Corporation has no knowledge of any liability of any Tax to be
imposed upon its properties or assets as of the date of this Agreement that
is
not adequately provided for.
The
Corporation has no collective bargaining agreements with any of its
employees.
3.1.19
|
Obligations
of Key Employees
|
Each
Key
Employee of the Corporation is currently devoting substantially all of his
or
her business time to the conduct of the business of the Corporation. The
Corporation is not aware that any Key Employee of the Corporation is planning
to
work less than full time at the Corporation in the future. No Key Employee
is
currently working or, to the Corporation’s knowledge, plans to work for a
competitive enterprise, whether or not such key employee is or will be
compensated by such enterprise. The Corporation’s Key Employees have executed
with the Corporation employment agreements that include a non-competition and
confidentiality provisions, copies of which have been provided to the Buyer.
For
the purpose of this Section, the term “Key Employee” shall refer to Rishard
Weitz, Gerald Weiss and Justin Pedro. Gerald Weiss is also involved in a
property management company that manages amongst other, family controlled real
estate. Gerald Weiss is not involved in the day to day management of the
property management company.
3.1.20
|
Registration
Rights and Voting Rights
|
The
Corporation has not agreed to grant any registration rights, including piggyback
rights, to any person or entity.
3.1.21
|
Compliance
with Laws; Permits
|
Except
as
disclosed in the Schedule of Exceptions, the Corporation and the Sellers are
not
aware of any violation by the Corporation of any applicable statute, rule,
regulation, order or restriction of any domestic or foreign government or any
instrumentality or agency thereof in respect of the conduct of its business
or
the ownership of its properties which violation would materially and adversely
affect the business, assets, liabilities, financial condition, operations or
prospects of the Corporation. No governmental orders, permissions, consents,
approvals or authorizations are required to be obtained and no registrations
or
declarations are required to be filed in connection with the execution and
delivery of this Agreement, except such as has been duly and validly obtained
or
filed, or with respect to any filings that must be made, or tax to be paid,
after the Closing, as will be filed in a timely manner. The Corporation has
all
franchises, permits, licenses and any similar authority necessary for the
conduct of its business as now being conducted by it, the lack of which could
materially and adversely affect the business, properties or financial condition
of the Corporation and believes it can obtain, without undue burden or expense,
any similar authority for the conduct of its business as planned to be
conducted.
To
the
Seller’s knowledge, neither this Agreement, the exhibits and schedules hereto
nor any other document delivered by the Corporation and the Sellers to the
Buyer
or their attorneys or agents in connection herewith or therewith or with the
transactions contemplated hereby or thereby, contain any untrue statement of
a
material fact nor, to the best of the Seller’s knowledge, omit to state a
material fact necessary in order to make the statements contained herein or
therein not misleading.
The
Corporation’s policies of insurance, as listed on the Schedule of Exceptions,
have been fully disclosed to the Buyer.
3.1.24
|
Securities
Legislation
|
The
Corporation is a private company within the meaning of the Securities Act
(Ontario) and the sale of the Shares by each Seller to the Buyer will be made
in
compliance with the Securities Act (Ontario).
3.1.25
|
Section
6.2 of the Share Purchase
Agreement
|
Except
as
disclosed in the Schedule of Exceptions,
between
the date of the Share Purchase Agreement and the date hereof, the Corporation
has complied with all of the conditions and restrictions set out in Section
6.2
of the Share Purchase Agreement.
3.1.26
|
Acknowledgement
of Exchange Agreement
|
For
purposes of their decision to enter into this Share Purchase Agreement, the
Sellers acknowledge and agree that they are aware of and understand the
provisions in Section 6.3 of the Exchange Agreement relative to the Opko Common
Shares issuable in exchange for the Exchangeable Shares. Capitalized terms
in
this Section
3.1.26
unless
otherwise defined herein have the meanings ascribed to them in the Exchange
Agreement.
3.2
|
Representations
and Warranties of the
Buyer
|
The
Buyer
represents and warrants to the Seller as set out in the following Subsections
of
this Section and acknowledges that the Seller is relying upon such
representations and warranties in entering into this Agreement.
3.2.1
|
Organization
and Qualification
|
Each
of
the Buyer and Holdco are duly organized and validly existing under the laws
of
Ontario, Canada. Each of the Buyer and Holdco have all requisite corporate
power
and authority to own and operate their properties and assets, and to carry
out
the provisions of this Agreement and to carry on its business as presently
conducted. The Buyer has all the requisite corporate power and authority to
issue the Exchangeable Shares
The
Buyer
does not own or control any equity, security or other interest of any other
corporation, limited partnership or other business entity.
3.2.3
|
Capitalization
of the Buyer
|
The
authorized capital of the Buyer consists solely of an unlimited number of common
shares and an unlimited number of Exchangeable Shares, of which 1 common share
is issued and outstanding. All of the outstanding common shares of the Buyer
are
owned by Holdco, have been validly issued and are fully paid and non-assessable.
The Exchangeable Shares, when issued, will be validly issued as fully paid
and
non-assessable. The issuance of the Exchangeable Shares by the Buyer to each
Seller will be made in compliance with all applicable securities
legislation.
3.2.4
|
Capitalization
of the Holdco
|
The
authorized capital of the Holdco consists solely of an unlimited number of
common shares, of which 1 common share is issued and outstanding. All of the
outstanding common shares of Holdco are owned by Opko, have been validly issued
and are fully paid and non-assessable.
3.3
|
Non-waiver/Schedule
of Exceptions
|
No
investigations made by or on behalf of the Buyer at any time shall waive,
diminish the scope of or otherwise affect any representation or warranty made
by
any Seller or the Corporation in this Agreement or in any Closing Document.
No
waiver by the Buyer of any condition, in whole or in part, shall operate as
a
waiver of any other condition.
3.3.2
|
Schedule
of Exceptions
|
Items
set
forth by the Sellers in the Schedule of Exceptions will be considered
disclosures applicable for
the
purposes of all
representations
and warranties of the Sellers given
in
Section
3.1
to which
its relevance is readily apparent.
At
the
option of each Seller, such Seller and the Buyer agree to file a joint election
pursuant to subsection 85(1) of the Income Tax Act (Canada)(the “
Tax
Act
”)
in the
prescribed form and within the prescribed time whereby the elected amount
provided for therein shall be such amount as is determined by such Seller in
accordance with the limits established under the Tax Act. The Buyer and the
Seller agree to jointly make and file elections under the corresponding
provisions of any applicable provincial income tax legislation. Each Seller
shall be responsible to prepare and file all such elections. The sole obligation
of the Buyer shall be to provide any information reasonably requested by the
Sellers to complete the election forms and to execute and return to the Sellers
any properly completed election form within 10 Business Days of receipt of
such
form from the Sellers. The Buyer shall have no liability for any Taxes of the
Seller arising from the sale of the Shares to the Buyer arising as a result
of
the refusal by the Canada Revenue Agency (or any applicable provincial tax
authority) to accept any such election.
3.5
|
Survival
of Representations and Warranties
|
The
representations and warranties contained in this Agreement and in any agreement,
certificate, affidavit, statutory declaration or other document delivered or
given pursuant to this Agreement shall survive the Closing and, notwithstanding
the Closing or any investigation made by or on behalf of the parties hereto
with
respect thereto, shall continue in full force and effect provided, however,
that
no claim in respect thereof shall be valid unless it is made within the
following time periods:
|
(a)
|
in
the case of a claim in respect of the representations and warranties
set
forth in
3.1.1
(Organization and qualification of the Corporation),
3.1.2
(Organization and qualification of the Seller),
3.1.4
(Capitalization and title),
3.1.5
(Authorization of the Corporation),
3.1.6
(Authorization of the Seller),
3.2.1
(Organization and Qualification of the Buyer and Holdco),
3.2.3
(Capitalization of the Buyer) and
3.2.4
(Capitalization of Holdco) there shall be no time limit within which
such
a claim may be made;
|
|
(b)
|
in
the case of a claim in respect of a representation or warranty relating
to
a tax matter, within a period commencing on the date hereof and ending
on
the date on which the last applicable limitation period under any
applicable tax legislation expires with respect to any taxation year
which
is relevant in determining any liability under this Agreement with
respect
to tax matters; and
|
|
(c)
|
in
the case of a claim in respect of any other representation or warranty
within a period of two years from the date
hereof.
|
3.6
|
Knowledge
of the Sellers
|
Where
any
representation or warranty contained in this Agreement is expressly qualified
by
reference to the "knowledge" of the Sellers, it shall be deemed to refer to
the
knowledge of each of the Seller and the Corporation, after having made
reasonable inquiry.
ARTICLE
4
NON-SOLICITATION
AND NON-COMPETE
Each
of
Weitz and Gerald covenants and agrees that during the Restricted Period, he
will
not, either individually or in partnership or jointly or in conjunction with
any
Person as employee, principal, agent, shareholder (other than as a holder of
not
more than five percent (5%) of the total stock of a publicly-traded company)
or
in any other manner whatsoever carry on, be engaged with, or lend his name
to
any Competitive Business in Canada or, the United States.
4.2
|
Non
-Solicitation of Employees or
Consultant.
|
Each
of
Weitz and Gerald further covenants and agrees that during the Restricted Period,
he shall not directly or indirectly, either individually or in partnership
or
jointly or in conjunction with any Person, enter into any agreement with or
solicit the employment or services of employees of or consultants to the
Corporation, including employees and consultants who were employed with or
retained by the Corporation on the Closing.
4.3
|
Non-Solicitation
of Clients.
|
Each
of
Weitz and Gerald further covenants and agrees that during the Restricted Period,
he shall not directly or indirectly, either individually or in partnership
or
jointly or in conjunction with any Person, contact or solicit the business
(of
the type included within the meaning of Competitive Business) of clients of
the
Corporation; any Person who was a client of the Corporation in the two-year
period immediately prior to the Closing Date.
4.4
|
Restrictions
Reasonable
|
Each
of
Weitz and Gerald herby agrees that all of the restrictions in this Agreement
are
reasonable and enforceable, and that the Buyer would not have entered into
this
Agreement unless he provided the covenants in this Agreement. Each of Weitz
and
Gerald further acknowledges and agrees that:
|
(a)
|
the
goodwill associated with the business, clients and assets of the
Corporation as of the Closing is an integral component of the value
of the
Corporation to the Buyer;
|
|
(b)
|
the
covenants set forth herein are necessary to preserve the value of
the
Business for the Buyer following the Closing of the transaction;
and
|
|
(c)
|
the
limitations of time, geography and scope of the Business agreed to
in this
Agreement are reasonable because, among other
things;
|
|
(a)
|
each
of Weitz and Gerald received significant consideration for his shares
in
the Corporation under the Share Purchase Agreement, and each Seller
acknowledges that it would be unfair for him, after having received
this
consideration, to directly or indirectly complete against the Corporation
during the Restricted Period;
|
|
(b)
|
the
Corporation is engaged in a highly competitive industry;
and
|
|
(c)
|
each
of Weitz and Gerald has unique and important relationships with the
clients of the Corporation and significant business reputation on
the
industry.
|
Each
of
Weitz and Gerald recognizes that his covenants in this Agreement are critical
to
the ongoing success of the Business that the buyer is acquiring from the
Corporation. As such, each of Weitz and Gerald agrees that in the event of
an
actual or threatened breach by him of any of the terms of this Agreement, the
Buyer will suffer irreparable harm, and shall be entitled to an interim and/or
permanent injunction against Weitz and/or Gerald, as the case may be,
restraining such actual or threatened breach. The Buyer shall also be entitled
to pursue damages and any and all other remedies available to it at law or
in
equity.
ARTICLE
5
INDEMNIFICATION
5.1
|
Indemnification
by the Sellers
|
Other
than with respect to Shane Dunne whose indemnification shall be deemed to be
several and separate not joint and several, Sections
3.1.2
(Organization and Qualification of the Sellers),
3.1.4(b)
(Title),
3.1.6
(Authorization of the Sellers), and
3.1.15
(Compliance with other instruments-Sellers) which indemnification shall be
deemed to be several and separate and not joint and several, and, subject to
the
limitations set out in Sections
3.5
and
7.9
,
each
Seller shall, jointly and severally, indemnify, defend and save harmless the
Buyer and each of its Representatives from and against any and all Losses
suffered or incurred by them, as a result of:
|
(a)
|
any
misrepresentation or breach of warranty made or given by any of them
in
this Agreement or in any document delivered pursuant to this Agreement
or
any Closing Document ;
|
|
(b)
|
save
and except with respect to covenants of Weitz and Gerald Weiss pursuant
to
ARTICLE
4
and pursuant to the Employment Agreements and the Confidentiality
and
Proprietary Information Agreements and the Non-Competition and
Non-Solicitation Agreements attached thereto (which covenants and
Employment Agreements, Confidentiality and Proprietary Information
Agreements and Non-Competition and Non-Solicitation Agreements shall
be
severally indemnified by Weitz and Gerald Weiss alone, and by no
other
Seller), any failure by any of them to observe or perform any covenant
or
obligation contained in this Agreement, any Closing Document or in
any
document delivered pursuant to any of them, to be observed or performed
by
it; or
|
|
(c)
|
any
Taxes required to be paid by the Corporation relating to any period
ending
on or before the date hereof.
|
5.2
|
Indemnification
by the Buyer
|
Subject
to the limitations set out in Section
3.5
,
the
Buyer shall indemnify, defend and save harmless each of the Sellers and each
of
the Sellers’ Representatives from and against any and all Losses suffered or
incurred by them, as a result of:
|
(a)
|
any
misrepresentation or breach of any warranty made or given by the
Buyer in
this Agreement;
|
|
(b)
|
any
misrepresentation or breach of warranty made or given by the Buyer
in any
Closing Document or in any document delivered pursuant to this Agreement
or any Closing Document; or
|
|
(c)
|
any
failure by the Buyer to observe or perform any covenant or obligation
contained in this Agreement, any Closing Document or in any document
delivered pursuant to any or them, to be observed or performed by
it.
|
|
(a)
|
A
party hereto (the “
Indemnified
Party
”)
who seeks indemnification hereunder from another party (the “
Indemnifying
Party
”)
shall notify the Indemnifying Party in writing as soon as is possible
after being informed that facts exist which may result in a claim
and in
respect of which a right of indemnification given pursuant to this
Article
5 may apply. The failure of any Indemnified Party to give timely
notice
hereunder shall not affect rights to indemnification hereunder, except
and
only to the extent that, the Indemnifying Party demonstrates actual
material damage caused by such
failure.
|
|
(b)
|
In
the case of a claim originating from a Person other than the Indemnified
Party (a “
Third
Party Claim
”),
the Indemnifying Party shall have the right to elect, by written
notice
delivered to the Indemnified Party within thirty (30) days of receipt
by
the Indemnifying Party of the notice from the Indemnified Party in
respect
of the Third Party Claim, at the sole expense, cost and risk of the
Indemnifying Party to participate in or assume control of the defence
of
the Third Party Claim
and
to pursue such defence in good faith by appropriate actions or proceedings
promptly taken or instituted and diligently pursued, including, without
limitation, to employ and engage attorneys of its own choice reasonably
acceptable to the Indemnified Party to defend, compromise or settle
such
claim,
provided
that
the Indemnifying Party shall pay all reasonable out-of-pocket expenses
incurred by the Indemnified Party as a result of such participation
or
assumption,
provided
,
further
,
that
any
compromise or settlement shall be made only with the written consent
of
the Indemnified Party, such consent not to be unreasonably
withheld.
|
|
(c)
|
If
the Indemnifying Party elects to assume control of the Third Party
Claim,
the Indemnifying Party shall keep the Indemnified Party reasonably
informed of the progress of any defence, compromise or settlement
and the
Indemnified Party shall cooperate with the Indemnifying Party and
its
counsel and shall have the right to participate in the defence, compromise
or settlement of such Third Party Claim at its own expense and, in
so
doing, the Indemnified Party shall have the right to retain counsel
to act
on its behalf,
provided
that
the fees and disbursements of such counsel shall be paid by the
Indemnified Party.
|
|
(d)
|
If
the Indemnifying Party does not elect to assume control of the Third
Party
Claim, or if having so
elected
to
assume control, it thereafter fails to proceed with the defence or
settlement of such Third Party Claim in good faith and with reasonable
diligence, then the Indemnified Party shall be entitled to assume
control
of the Third Party Claim at the Indemnifying Party’s sole expense, cost
and risk. An Indemnified Party agreeing to assume control of a claim
shall
use commercially reasonable efforts to deal with the claim reasonably
diligently and in a manner consistent with the manner in which the
Indemnified Party would have acted if there had been no indemnity.
In such
case, the Indemnifying Party shall be kept reasonably informed of
the
progress of any defence, compromise or settlement (and shall be entitled
to participate in at its expense, but not assume control of, such
action).
|
|
(e)
|
The
Indemnifying Party or the Indemnified Party who does not have control
of
the Third Party Claim shall cooperate with the other of them in the
defence thereof (at the cost and expense of the Indemnifying Party),
such
cooperation to include the provision of records and information within
its
control that are relevant to the Third Party Claim and making available
its employees and servants (and those of its affiliates) as are
appropriate and reasonably necessary and relevant to the Third Party
Claim.
|
ARTICLE
6
CLOSING
DELIVERIES
6.1
|
Closing
Deliveries of the Seller
|
At
Closing, in addition to any other documents to be provided or delivered by
the
Sellers to the Buyer at such time pursuant to this Agreement, each Seller will
execute and/or deliver (or cause to be executed and/or delivered) to the Buyer
the following:
|
(a)
|
the
Exchange and Support Agreement;
|
|
(b)
|
a
release from each of the Sellers and the directors and officers of
the
Corporation of all claims such Sellers, officers and directors had
now
have or shall ever have against the Corporation in a form satisfactory
to
the Buyer other than with respect to the subject matter
hereof;
|
|
(c)
|
the
Escrow Agreement;
|
|
(d)
|
a
resignation of all officers and directors of the
Corporation;
|
|
(e)
|
Employment
Agreements between the Corporation and Gerald Weiss and Rishard
Weitz;
|
|
(f)
|
Option
Agreements between Opko Health, Inc. and Gerald Weiss and Rishard
Weitz;
|
|
(g)
|
share
certificates representing the Purchased Shares duly endorsed in blank
for
transfer;
|
|
(h)
|
a
resolution of the Board of Directors of the Corporation authorising
the
transfer of the Purchased Shares;
|
|
(i)
|
an
opinion of the Counsel to the Seller and the Corporation in form
and
substance satisfactory to the Buyer acting reasonably;
|
|
(j)
|
evidence
in form and substance satisfactory to the Buyer, acting reasonably,
that
the shares of the Corporation held by Jean-Paul Chaduc have been
cancelled
and the shares of the Corporation held by Nidek Co., Ltd. have been
purchased by
<>
;
and
|
|
(k)
|
such
other documents as may be reasonably required by the
Buyer.
|
6.2
|
Closing
Deliveries of the Buyer
|
At
Closing, in addition to any other documents to be provided or delivered by
the
Buyer to the Seller at such time pursuant to this Agreement, the Buyer will
execute and/or deliver (or cause to be executed and/or delivered) to the Buyer
the following:
|
(a)
|
the
Exchange and Support Agreement;
|
|
(b)
|
Employment
Agreements between the Corporation and Gerald Weiss and Rishard
Weitz;
|
|
(c)
|
the
Escrow Agreement;
|
|
(d)
|
Exchangeable
Share certificates in the amount of the Purchase Price payable to
each
Seller in the name of such Seller;
|
|
(e)
|
a
resolution of the Board of Directors of Newco authorising the issuance
of
the Exchangeable Shares in payment of the Purchase
Price;
|
|
(f)
|
Option
Agreements between Opko Health, Inc. and Gerald Weiss and Rishard
Weitz;
|
|
(g)
|
an
opinion of the U.S. Counsel to Opko in form and substance satisfactory
to
the Sellers acting reasonably; and
|
|
(h)
|
such
other documents as may be reasonably required by the
Buyer.
|
6.3
|
Payment
of Shareholder and Related Party
Loans
|
It
shall
be a condition precedent of this Agreement that all loans made by the
Corporation, by any shareholder of the Corporation or by any related party
as
set out in the Schedule of Exceptions shall be repaid in full, including
principal and interest, prior to completion of the transaction contemplated
hereby.
Immediately
prior to Closing, the shareholder loans disclosed in Section
3.1.10
shall
have been repaid.
ARTICLE
7
GENERAL
The
Parties agree that OTI shall pay all reasonable costs for representation by
Ogilvy Renault LLP of OTI and the Sellers and for independent legal advice
for
Shane Dunne and Jean-Paul Chaduc, if he becomes a party to this Agreement.
This
Agreement enures to the benefit of and is binding upon the Parties and their
respective successors (including any successor by reason of merger or
amalgamation of any Party) and permitted assigns.
Any
notice, certificate, consent, determination or other communication required
or
permitted to be given or made under this Agreement shall be in writing and
shall
be effectively given and made if (i) delivered personally, (ii) sent by prepaid
courier service or mail, or (iii) sent prepaid by fax or other similar means
of
electronic communication, in each case to the applicable address set out
below:
|
(a)
|
if
to the Corporation:
|
Ophthalmic
Technologies Inc.
37
Kodiak
Crescent
Unit
16
Toronto,
ON M3J 3E5
Attention:
Gerald Weiss
Fax:
with
a
copy to:
Ogilvy
Renault LLP
Suite
3800, Royal Bank Plaza, South Tower
200
Bay
Street, P.O. Box 84
Toronto,
ON M5J 2Z4
Attention:
Peter Newell
Fax:
416.214.3930
c/o
Opko
4400
Biscayne Boulevard
Miami,
Florida 31337
Attention:
Steven
D.
Rubin
Fax:
with
a
copy to:
Fraser
Milner Casgrain
First
Canadian Place
100
King
Street West
P.O.
Box
100
Toronto,
Ontario M5X 1B2
Attention:
Laurence
Geringer
Fax:
416.863.4592
|
(c)
|
and
if to the Sellers:
|
1161983
Ontario Limited
235
Lesmill Road,
Don
Mills, ON M3V 2V1
Attention:
Fax:
Grall
Corporation Limited
Attention:
Fax:
Rishard
Weitz
37
Kodiak
Crescent, Unit 16
Toronto,
ON M3J 3E5
Fax:
(416)
631-6932
Carolyn
Weiss
Fax:
Shane
Dunne
95
Michael Grass Crescent,
Kingston,
ON K7M 2W2
Fax:
Gerald
Weiss
37
Kodiak
Crescent, Unit 16
Toronto,
ON M3J 3E5
Fax:
(416)
631-6932
Triple
Net Propertied Limited
235
Lesmill Road,
Don
Mills, ON M3V 2V1
Fax:
|
(e)
|
Any
such communication so given or made shall be deemed to have been
given or
made and to have been received on the day of delivery if delivered,
or on
the day of faxing or sending by other means of recorded electronic
communication, provided that such day in either event is a Business
Day
and the communication is so delivered, faxed or sent before 4:30
p.m. on
such day. Otherwise, such communication shall be deemed to have been
given
and made and to have been received on the next following Business
Day. Any
such communication sent by mail shall be deemed to have been given
and
made and to have been received on the fifth Business Day following
the
mailing thereof; provided however that no such communication shall
be
mailed during any actual or apprehended disruption of postal services.
Any
such communication given or made in any other manner shall be deemed
to
have been given or made and to have been received only upon actual
receipt.
|
|
(f)
|
Any
Party may from time to time change its address under this Section
by
notice to the other Party given in the manner provided by this
Section.
|
No
consent or approval by any Party will be binding unless delivered in writing
to
the other Parties hereto.
No
party
may assign any rights or obligations under this Agreement.
The
Parties will, with reasonable diligence, do all such things and provide all
such
reasonable assurances as may be required to consummate the transactions
contemplated by this Agreement, and each party will provide such further
documents or instruments required by any other Party as may be reasonably
necessary or desirable to effect the purpose of this Agreement and carry out
its
provisions.
Except
to
the extent required by Applicable Law, each Party agrees that no disclosure
or
public announcement regarding this Agreement or the transactions contemplated
hereby shall be made by either Party without the prior written consent of the
other Party.
The
rights and remedies of the Parties under this Agreement are cumulative and
in
addition to and not in substitution for any rights or remedies provided by
law.
Any single or partial exercise by any Party hereto of any right or remedy for
default or breach of any term, covenant or condition of this Agreement does
not
waive, alter, affect or prejudice any other right or remedy to which such Party
may be lawfully entitled for the same default or breach.
7.9
|
Limitation
of Liability
|
Other
than with respect to Shane Dunne whose liability is set out below, Sections
3.1.2
(Organization and Qualification of the Sellers),
3.1.4(b)
(Title),
3.1.6
(Authorization of the Sellers), and
3.1.15
(Compliance with other instruments-Sellers), fraud and wilful misconduct, for
which there shall be no limitation on liability, the aggregate liability of
the
Sellers shall not exceed the value of the Escrow Shares and recourse with
respect thereto shall be limited to the Escrow Shares.
Other
than with respect Sections
3.1.2
(Organization and Qualification of the Sellers),
3.1.4(b)
(Title),
3.1.6
(Authorization of the Sellers), and
3.1.15
(Compliance with other instruments-Sellers), fraud and wilful misconduct, for
which there shall be no limitation on liability, the aggregate liability of
the
Shane Dunne shall not exceed the value of the Dunne Escrow Shares and recourse
with respect thereto shall be limited to the Dunne Escrow Shares.
7.10
|
Execution
and Delivery
|
This
Agreement may be executed by the Parties in counterparts and may be executed
and
delivered by fax, and all such counterparts and faxes together constitute one
agreement.
TO
WITNESS
their
agreement, the parties have duly executed this Agreement as of the date first
set forth above.
[THE
REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]
|
Ophthalmic
Technologies Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
c/s
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OTI
Holdings Limited
|
|
|
|
|
|
|
|
|
By:
|
|
c/s
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1161983
Ontario Limited
|
|
|
|
|
|
|
|
|
By:
|
|
c/s
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Grall
Corporation Limited
|
c/s
|
|
|
|
|
|
|
|
By:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Triple
Net Properties Limited
|
c/s
|
|
|
|
|
|
|
|
By:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Witness
|
|
Rishard
Weitz
|
|
|
|
|
|
|
Witness
|
|
Carolyn
Weiss
|
|
|
|
|
|
|
Witness
|
|
Shane
dunne
|
|
|
|
|
|
|
Witness
|
|
Gerald
Weiss,
as
trustee for and on behalf of Marie-Helene Weiss and Gerald
Weiss
|
|
|
|
|
|
|
Witness
|
|
Gerald
Weiss
|
OPKO
HEALTH, INC.
-
and
-
OTI
HOLDINGS LIMITED
-
and
-
EACH
HOLDER OF EXCHANGEABLE SHARES
in
the
capital of OTI Holdings Limited
EXCHANGE
AND SUPPORT AGREEMENT
DATED:
November
28
,
2007
|
Page
|
|
|
EXCHANGE
AND SUPPORT AGREEMENT
|
3
|
|
|
ARTICLE
1 DEFINITIONS AND INTERPRETATION
|
4
|
1.1
|
DEFINITIONS
|
4
|
1.2
|
RULES
OF INTERPRETATION
|
7
|
1.3
|
ENTIRE
AGREEMENT
|
8
|
|
|
|
ARTICLE
2 REPRESENTATIONS AND WARRANTIES OF OPKO
|
8
|
2.1
|
REPRESENTATIONS
AND WARRANTIES OF OPKO
|
8
|
|
|
|
ARTICLE
3 EXCHANGE RIGHT
|
10
|
3.1
|
GRANT
OF EXCHANGE RIGHT
|
10
|
3.2
|
EXERCISE
OF EXCHANGE RIGHT
|
10
|
3.3
|
DELIVERY
OF EXCHANGE RIGHT CONSIDERATION
|
11
|
3.4
|
EFFECT
OF EXERCISE
|
11
|
3.5
|
DEEMED
EXERCISE OF EXCHANGE RIGHT SUBSEQUENT TO RETRACTION
|
12
|
3.6
|
NOTICE
OF INSOLVENCY EVENT
|
12
|
|
|
|
ARTICLE
4 AUTOMATIC EXCHANGE RIGHT
|
12
|
4.1
|
NOTICE
OF OPKO LIQUIDATION EVENT
|
12
|
4.2
|
AUTOMATIC
EXCHANGE
|
13
|
4.3
|
CERTIFICATES
|
13
|
|
|
|
ARTICLE
5 ECONOMIC EQUIVALENCE
|
13
|
5.1
|
ECONOMIC
EQUIVALENCE - OPKO OBLIGATIONS
|
|
5.2
|
ECONOMIC
EQUIVALENCE - THE CORPORATION OBLIGATIONS
|
|
5.3
|
COVENANTS
REGARDING EXCHANGEABLE SHARES
|
|
5.4
|
ADDITIONAL
OPKO COVENANTS
|
16
|
5.5
|
DELIVERY
OF OPKO COMMON SHARES
|
16
|
5.6
|
PROVISION
OF FUNDS
|
17
|
5.7
|
OWNERSHIP
OF COMMON SHARES
|
17
|
5.8
|
OPKO
AND AFFILIATES NOT TO VOTE EXCHANGEABLE SHARES
|
17
|
5.9
|
GRANT
OF CALL RIGHTS
|
18
|
5.10
|
NOTIFICATION
OF CERTAIN EVENTS
|
18
|
5.11
|
QUALIFICATION
OF OPKO COMMON SHARES
|
18
|
5.12
|
TENDER
OFFERS
|
19
|
|
|
|
ARTICLE
6 TAX MATTERS
|
19
|
6.1
|
RIGHT
TO WITHHOLD
|
19
|
6.2
|
SECTION
116 CLEARANCE CERTIFICATE FOR NON-RESIDENT HOLDERS
|
19
|
6.3
|
TRANSFER
TAXES
|
21
|
|
|
|
TABLE
OF CONTENTS
(continued)
Page
ARTICLE
7 REGISTRATION
|
21
|
7.1
|
PIGGYBACK
REGISTRATION.
|
|
7.2
|
REGISTRATION
EXPENSES.
|
|
7.3
|
OBLIGATIONS
OF OPKO.
|
22
|
7.4
|
OBLIGATIONS
OF THE HOLDERS.
|
25
|
7.5
|
TERMINATION
OF REGISTRATION RIGHTS.
|
25
|
7.6
|
DISPOSITIONS.
|
25
|
7.7
|
SEC
RULE144 REPORTING.
|
25
|
7.8
|
INDEMNIFICATION
AND CONTRIBUTION.
|
26
|
|
|
|
ARTICLE
8 GENERAL
|
29
|
8.1
|
TRANSFER
AND ISSUANCE RESTRICTIONS
|
29
|
8.2
|
LEGENDS
|
29
|
8.3
|
SELLER
ACKNOWLEDGEMENTS AND AGREEMENTS
|
30
|
8.4
|
COMPLIANCE
WITH OTHER INSTRUMENTS
|
30
|
8.5
|
CHANGES
IN CAPITAL OF OPKO AND THE CORPORATION
|
31
|
8.6
|
TERM
|
31
|
8.7
|
ENUREMENT
|
31
|
8.8
|
NOTICES
TO PARTIES
|
31
|
8.9
|
NOTICE
TO HOLDERS
|
32
|
8.10
|
AMENDMENT
|
32
|
8.11
|
ASSIGNMENT
|
32
|
8.12
|
FURTHER
ASSURANCES
|
32
|
8.13
|
EXECUTION
AND DELIVERY
|
33
|
EXCHANGE
AND
SUPPORT AGREEMENT
THIS
AGREEMENT
is made
November
28
,
2007
AMONG:
OPKO
HEALTH, INC. ,
a
corporation incorporated pursuant to the laws of Delaware
(“
Opko”)
-
and
-
OTI
Holdings Limited
,
a
corporation incorporated under the laws of the Province of Ontario,
(the
“Corporation”
)
-
and
-
EACH
HOLDER OF EXCHANGEABLE SHARES
in the
capital of the Corporation listed in Schedule A to this Agreement, as amended
from time to time
(collectively,
the
“Holders”
).
WHEREAS:
A.
|
The
parties wish to set out their understanding with respect to certain
rights
and obligations in connection with the exchange of shares of the
Corporation for shares of Opko.
|
B.
|
Schedule
A shall be automatically amended by the Corporation to include each
additional investor that executes a counterpart instrument of accession
to
this Agreement in the form attached as Schedule
B.
|
NOW
THEREFORE IN CONSIDERATION
of
the
premises and the mutual covenants and agreements hereinafter contained and
for
other good and valuable consideration (the receipt and adequacy of which are
hereby acknowledged), the Parties agree as follows:
ARTICLE 1
DEFINITIONS
AND INTERPRETATION
Whenever
used in this Agreement, the following words and terms have the meanings set
out
below.
“Affiliate”
means,
with respect to any Person, (i) any other Person directly or indirectly
controlling, controlled by, or under common control with such Person, (ii)
any
Person owning or controlling ten percent or more of the outstanding voting
interests of such Person, (iii) any officer, director, or general partner of
such Person, (iv) any family member of such Person or any trust, family limited
partnership or other similar entity controlled by such Person or his or her
family members, or (v) any Person who is an officer, director, general partner,
trustee, or holder of ten percent or more of the voting interests of any Person
described in clauses (i) through (iv). For purposes of this definition, the
terms “
controlling
”,
“
controlled
by
,”
or
“
under
common control with
”
shall
mean the possession, direct or indirect, of the power to direct or cause the
direction of the management and policies of a Person, whether through the
ownership of voting securities, by contract or otherwise.
“Agreement”
means
this agreement, including all schedules, and all amendments or restatements
as
permitted, and references to “
Article
”,
“
Section
”
or
“
Schedule
”
mean
the specified Article, Section or Schedule of this Agreement.
“
Articles
”
means
the articles of incorporation of the Corporation, as amended by articles of
amendment filed on the date of this Agreement, and as may be amended or restated
from time to time.
“
Automatic
Exchange Right
”
means
the benefit associated with the obligation of Opko or any Permitted Subsidiary
that may be designated by Opko, to effect the automatic exchange of Exchangeable
Shares for Opko Common Shares pursuant to Section
4.2
.
“
Business
Day
”
means
any day except a Saturday, Sunday or any day on which banks are generally not
open for business in either of the Cities of Toronto, Ontario and New York,
New
York.
“
Common
Shares
”
means
the common shares in the capital of the Corporation.
“
Equity
Split
”
and
“
as
adjusted for Equity Splits
”
have
the meanings given to them in the Exchangeable Share Provisions.
“
Exchange
Right
”
has
the
meaning given to it in Section
3.1
.
“
Exchange
Right Consideration
”
means,
in respect of each Exchangeable Share:
|
(a)
|
one Opko Common Share (as adjusted for Equity Splits);
and
|
|
(b)
|
an
amount equal to the Outstanding Dividend Amount on such Exchangeable
Share
on the date of exchange.
|
“
Exchangeable
Share Provisions
”
means
the rights, privileges, restrictions and conditions attaching to the
Exchangeable Shares as set out in the Articles.
“
Exchangeable
Shares
”
means
the exchangeable shares in the capital of the Corporation.
“Opko
Common Shares”
means
the common shares in the capital of Opko and any other securities into which
such shares may be changed.
“
Opko
Liquidation Event
”
has
the
meaning given to it in Section
4.1
.
“
Opko
Liquidation Event Effective Date
”
means
the effective date of a Opko Liquidation Event.
“
Opko
Sale
”
has
the
meaning given to it in the Exchangeable Share Provisions.
“
GAAP
”
means
United States generally accepted accounting principles in effect from time
to
time applied consistently.
“
Holder
”
means
a
registered holder of Exchangeable Shares, other than Opko and its
Affiliates.
“
Insolvency
Event
”
means
the institution by the Corporation of any proceeding to be adjudicated a
bankrupt or insolvent or to be dissolved or wound up, or the consent of the
Corporation to the institution of bankruptcy, insolvency, dissolution or winding
up proceedings against it, or the filing of a petition, answer or consent
seeking dissolution or winding up under any bankruptcy, insolvency or analogous
laws, including without limitation the
Companies
Creditors’ Arrangement Act
(Canada)
and the
Bankruptcy
and Insolvency Act
(Canada), and the failure by the Corporation to contest in good faith any such
proceedings commenced in respect of the Corporation within 15 days of becoming
aware thereof, or the consent by the Corporation to the filing of any such
petition or to the appointment of a receiver, or the making by the Corporation
of a general assignment for the benefit of creditors, or the admission in
writing by the Corporation of its inability to pay its debts generally as they
become due, or the Corporation not being permitted, pursuant to solvency
requirements of applicable law, to redeem any Retracted Shares pursuant to
Section 5.6 of the Exchangeable Share Provisions.
“
Joint
Approval
”
means
the prior approval of the Corporation and the prior approval of the Holders
given in accordance with Section
3.2
of
the
Exchangeable Share Provisions.
“
Law
”
means
any federal, state, provincial, territorial, municipal, local or foreign
statute, law, by-law, ordinance, regulation, rule, code, order or rule of or
duty under common law, including any statute, law, by-law, ordinance,
regulation, rule, code, order or rule of or duty under common law in Canada,
the
United States, any province or territory of Canada or any state or territory
of
the United States.
“
Liquidation
Call Right
”
has
the
meaning given in the Exchangeable Share Provisions.
“
Liquidation
Event
”
has
the
meaning given in the Exchangeable Share Provisions.
“
Outstanding
Dividend Amount
”
has
the
meaning given in the Exchangeable Share Provisions.
“
Parties
”
means
the Corporation, Opko and the Holders; and “
Party
”
means
any one of them.
“Payer”
has the
meaning given to it in Section
6.1
.
“
Permitted
Subsidiary
”
means
Ophthalmic Technologies Holdings Limited, or any Subsidiary of Opko designated
by Opko: (i) to exercise the Liquidation Call Right, Retraction Call Right
or
Redemption Call Right; or (ii) to be subject to the obligations of a Holder’s
Exchange Right.
“
Person
”
means
any individual, sole proprietorship, partnership, firm, entity, unincorporated
association, unincorporated syndicate, unincorporated organization, trust,
body
corporate, government, government regulatory authority, governmental department,
agency, commission, board, tribunal, dispute settlement panel or body, bureau
or
court, and where the context requires, any of the above when they are acting
as
trustee, executor, administrator or other legal representative.
“
Redemption
Call Right
”
has
the
meaning given in the Exchangeable Share Provisions.
“
Redemption
Date
”
has
the
meaning given in the Exchangeable Share Provisions.
“Registrable
Securities”
means
all of the OPKO Common Shares issued pursuant to this Agreement, together with
any securities issued or issuable pursuant to any stock split, dividend or
other
distribution, recapitalization, exchange or similar event with respect to the
foregoing.
“
Retracted
Shares
”
means
the Exchangeable Shares a Holder has required the Corporation to redeem under
the Exchangeable Share Provisions.
“
Retraction
Call Right
”
has
the
meaning given in the Exchangeable Share Provisions.
“
Retraction
Request
”
has
the
meaning given in the Exchangeable Share Provisions.
“
Share
Purchase Agreement
”
means
the share purchase agreement made as of the date hereof among Rishard Weitz,
Carolyn Weiss, 1161983 Ontario Limited, Grall Corporation Limited, Shane Dunne
and Gerald Weiss, in Trust, Triple Net Properties Limited, the Corporation,
and
Opko
“
Subsidiary
”
of
any
Person means a Person Controlled by:
(a)
such
first Person;
(b)
such
first Person and one or more Persons each of which is Controlled by such first
Person; or
(c)
two
or
more Persons each of which is Controlled by such first Person,
and
includes any indirect subsidiaries.
“
Transfer
”
includes any sale, transfer, exchange, assignment, gift, bequest, disposition,
mortgage, charge, pledge, encumbrance, grant of a security interest or other
arrangement by which possession, legal title or beneficial ownership passes
from
one Person to another, or to the same Person in a different capacity, whether
or
not voluntarily and whether or not for value, and any agreement to effect any
of
the above; but does not include the exchange or redemption of any Exchangeable
Shares or Opko Voting Shares
under
the
terms of this Agreement, the Articles or the organizational documents of
Opko.
“
U.S.
Securities Act
”
means
the
United
States Securities Act of 1933
,
as
amended.
1.2
|
Rules
of Interpretation
|
In
this
Agreement:
|
(a)
|
Consent
-
Whenever a provision of this Agreement requires an approval or consent
and
such approval or consent is not delivered within the applicable time
limit, then, unless otherwise specified, the Party whose consent
or
approval is required will be conclusively deemed to have withheld
its
approval or consent.
|
|
(b)
|
Currency
-
Unless otherwise specified, all references to money amounts are to
the
lawful currency of the United States of
America.
|
|
(c)
|
Governing
Law
-
This Agreement is a contract made under and is governed by and construed
in accordance with the law of the Province of Ontario and the federal
laws
of Canada applicable in the Province of
Ontario.
|
|
(d)
|
Headings
-
Headings of Articles and Sections are inserted for convenience of
reference only and do not affect the construction or interpretation
of
this Agreement.
|
|
(e)
|
Including
-
Where the word “including” or “includes” is used in this Agreement, it
means “including (or includes) without
limitation”.
|
|
(f)
|
Number
and Gender
-
Unless the context otherwise requires, words importing the singular
include the plural and vice versa and words importing gender include
all
genders.
|
|
(g)
|
Severability
-
If, in any jurisdiction, any provision of this Agreement or its
application to any party or circumstance is restricted, prohibited
or
unenforceable, such provision will, as to such jurisdiction, be
ineffective only to the extent of such restriction, prohibition or
unenforceability without invalidating the remaining provisions of
this
Agreement and without affecting the validity or enforceability of
such
provision in any other jurisdiction or without affecting its application
to other Parties or circumstances.
|
|
(h)
|
Statutory
references
-
A reference to a statute includes all regulations made pursuant to
such
statute and, unless otherwise specified, the provisions of any statute
or
regulation that amends, supplements or supersedes any such statute
or any
such regulation.
|
|
(i)
|
Time
-
Time is of the essence in the performance of the Parties’ respective
obligations.
|
|
(j)
|
Time
Periods
-
Unless otherwise specified, time periods within or following which
any
payment is to be made or act is to be done are calculated by excluding
the
day on which the period commences and including the day on which
the
period ends and by extending the period to the next Business Day
if the
last day of the period is not a Business
Day.
|
This
Agreement together with the Exchangeable Share Provisions, constitutes the
entire agreement between the Parties and sets out all the covenants, promises,
warranties, representations, conditions, understandings and agreements between
the Parties pertaining to the subject matter of this Agreement and supersedes
all prior agreements, understandings, negotiations and discussions, whether
oral
or written. There are no covenants, promises, warranties, representations,
conditions, understandings or other agreements, oral or written, express,
implied or collateral between the Parties in connection with the subject matter
of this Agreement except as specifically set forth in this Agreement and the
Exchangeable Share Provisions.
ARTICLE 2
Representations
AND WARRANTIES of opko
2.1
|
Representations
and warranties of Opko
|
Opko
represents and warrants to the Holders as set out in the following Subsections
of this Section and acknowledges that the Holders are relying upon such
representations and warranties in entering into this Agreement:
|
(a)
|
Authorized
and Outstanding Capital
-
At October 25, 2007, the authorized capital stock of OPKO consisted
of
500,000,000 shares of common stock, $.01 par value per share, of
which as
of November 9, 2007 163,214,203 shares were issued or outstanding,
fully
paid and non-assessable, and 10,000,000 shares of preferred stock,
$.01
par value per share, of which 869,366 shares were issued or outstanding,
fully paid and non-assessable. OPKO’s common stock has been duly and
validly registered pursuant to Section 12(b) of the Exchange Act
which
registration is in full force and
effect.
|
|
(b)
|
Incorporation
and Organization
-
OPKO is a corporation duly organized, validly existing and in good
standing under the laws of the State of Delaware and has all necessary
corporate power to own all of its property and assets, to incur all
of its
liabilities and to carry on its business as presently conducted.
|
|
(c)
|
Interest
in each Subsidiary
-
All shares of, or interests in, each of OPKO’s wholly-owned subsidiaries,
held directly or indirectly by Opko are owned free and clear of all
mortgages, liens, charges, pledges, security interests, encumbrances,
claims and demands whatsoever and no person has any right, agreement
or
option, present or future, contingent or absolute, or any right capable
of
becoming a right, agreement or option, for the issue or allotment
of any
unissued shares of each of OPKO’s wholly-owned subsidiaries or any other
security convertible into or exchangeable for any shares of each
of OPKO’s
wholly-owned subsidiaries or to require each of OPKO’s wholly-owned
subsidiaries to purchase, redeem or otherwise acquire any of its
issued
and outstanding shares
.
|
|
(d)
|
SEC
Filings
-
Except for the Current Report on form 8-K and certain financial statements
of Ophthalmic Technologies Inc. in connection with the initial investment
in Ophthalmic Technologies Inc., since March 27, 2007, OPKO has filed
all reports, documents and other information required of it to be
filed
with the SEC (the “OPKO
SEC Reports
”).
The OPKO SEC Reports were prepared in accordance with the requirements
of
the Securities Act or the Exchange Act, as the case may be, and the
rules
and regulations of the SEC thereunder applicable to such OPKO SEC
Reports.
No disclosure included in any of the Parent SEC Reports included
any
statement that, when made or, if such Parent SEC Reports were subsequently
amended, when amended, contained an untrue statement of a material
fact or
omitted to state a material fact necessary in order to make the statements
therein, in light of the circumstances in which such statements were
made,
not materially misleading.
|
|
(e)
|
Stock
Exchange Listing
-
The outstanding Common Shares of OPKO are listed for trading on the
American Stock Exchange, and Opko is, and at all times, has been
in
material compliance with the by-laws, rules and regulations of the
American Stock Exchange.
|
|
(f)
|
No
Material Changes
-
Since the date of the latest financial statements included within
a report
filed by OPKO with the Securities and Exchange Commission, and except
as
disclosed in OPKO’s reports filed with the SEC and other than this
transaction, there has not been any material change in the assets,
liabilities or obligations of Opko or any of OPKO’s wholly-owned
subsidiaries, and to OPKO’s knowledge, there has not been any material
adverse change in the business, operations or condition (financial
or
otherwise) or results of the operations of Opko or any of OPKO’s
wholly-owned subsidiaries.
|
ARTICLE 3
EXCHANGE
RIGHT
3.1
|
Grant
of Exchange Right
|
Opko
and
each Permitted Subsidiary grants to each Holder the right (the “
Exchange
Right
”)
to
require Opko or, as designated by Opko, a Permitted Subsidiary, to purchase
from
such Holder all or any part of the Exchangeable Shares held by such Holder
on
the terms set forth herein for the consideration described in
Section
3.3
.
The
Exchange Right may be exercised at any time and from time to time upon the
occurrence and during the continuance of:
|
(b)
|
the
failure of Opko or any Permitted Subsidiary to purchase all or any
part of
the Exchangeable Shares held by such Holder following exercise of
the
Liquidation Call Right as provided in the Exchangeable Share
Provisions;
|
|
(c)
|
subject
to Section
3.1(b)
,
the failure of the Corporation to redeem all the outstanding Exchangeable
Shares following a Liquidation Event as provided in the Exchangeable
Share
Provisions;
|
|
(d)
|
the
failure of Opko or any Permitted Subsidiary to purchase all or any
part of
the Exchangeable Shares held by such Holder following exercise of
the
Redemption Call Right as provided in the Exchangeable Share
Provisions;
|
|
(e)
|
subject
to Section
3.2(d)
,
the failure of the Corporation to redeem all the outstanding Exchangeable
Shares held by such Holder on the Redemption Date as provided in
the
Exchangeable Share Provisions;
|
|
(f)
|
the
failure of Opko or any Permitted Subsidiary to purchase all or any
part of
the Exchangeable Shares held by such Holder following exercise of
the
Retraction Call Right as provided in the Exchangeable Share Provisions;
or
|
|
(g)
|
subject
to Section
3.1(f)
,
the failure of the Corporation to redeem the Retracted Shares under
a
Retraction Request as provided in the Exchangeable Share Provisions.
|
3.2
|
Exercise
of Exchange Right
|
To
exercise the Exchange Right, the Holder must deliver to Opko, in person or
by
certified or registered mail, the certificates representing the Exchangeable
Shares to be exchanged, together with a written notice in the form set out
in
Schedule “C” hereto stating:
|
(a)
|
that
the Holder is exercising the Exchange
Right;
|
|
(b)
|
the
number of Exchangeable Shares in respect of which the Exchange Right
is
being exercised;
|
|
(c)
|
that
the Holder has good title to and owns all the Exchangeable Shares
free and
clear of all encumbrances, other than those stipulated under the
Share
Purchase Agreement or the Articles;
|
|
(d)
|
whether
the Holder is a non-resident of Canada for the purposes of the
Income
Tax Act
(Canada) (the “Tax Act”);
|
|
(e)
|
the
names in which the new certificates representing the Opko Common
Shares
are to be issued; and
|
|
(f)
|
the
name and address of the Person to whom such new certificates are
to be
delivered.
|
If
only a
part of the Exchangeable Shares represented by any certificate or certificates
delivered to Opko are to be purchased by Opko or, as applicable, a Permitted
Subsidiary under the Exchange Right, a new certificate for the balance of such
Exchangeable Shares shall be issued to the Holder at the expense of the
Corporation.
3.3
|
Delivery
of Exchange Right
Consideration
|
Opko
or a
Permitted Subsidiary, as the case may be, will, as soon as reasonably practical
and, in any event, no later than five Business Days following receipt of the
notice of exercise of the Exchange Right and the certificates representing
the
Exchangeable Shares to be exchanged, deliver or cause to be delivered to the
Holder (or any other Persons properly designated by the Holder) the Exchange
Right Consideration for each Exchangeable Share in respect of which the Exchange
Right is exercised (i.e., certificates representing the Opko Common Shares
constituting the Exchange Right Consideration (which Opko Common Shares are
to
be duly issued as fully paid and non-assessable and free and clear of any lien,
claim, encumbrance, security interest or adverse claim) and a cheque of Opko
or,
as applicable, a Permitted Subsidiary, payable at par at any branch of the
bankers of the Corporation totalling the Outstanding Dividend
Amount).
Immediately
upon receipt by Opko of the notice of the exercise of the Exchange Right and
the
certificates representing the Exchangeable Shares to be exchanged, the exchange
is deemed to have occurred, the Holder is deemed to be the holder of the Opko
Common Shares comprising the Exchange Right Consideration and the Holder of
such
Exchangeable Shares shall be deemed to have transferred to Opko or, as
applicable, a Permitted Subsidiary all of its interest in such Exchangeable
Shares and shall cease to be a holder of such Exchangeable Shares and shall
not
be entitled to exercise any of the rights of a holder in respect thereof, other
than the right to receive its proportionate part of the total purchase price
therefor, unless such Exchange Right Consideration is not delivered to the
Holder (or to such other Persons, if any, properly designated by such Holder),
within three Business Days of the date of the giving of such notice by the
Holder, in which case the rights of the Holder shall remain unaffected until
such Exchange Right Consideration is so delivered to the Holder. Concurrently
with such Holder ceasing to be a holder of Exchangeable Shares, the Holder
shall
be considered and deemed for all purposes to be the holder of the Opko Common
Shares delivered to it pursuant to the Exchange Right.
3.5
|
Deemed
Exercise of Exchange Right Subsequent to
Retraction
|
If
a
Holder requires that the Corporation redeem the Holder’s Retracted Shares and is
notified by the Corporation that the Corporation is not permitted, as a result
of solvency requirements or other provisions of applicable Law, to redeem all
such Retracted Shares, then, if the Retraction Call Right has not been exercised
with respect to such Retracted Shares and the Holder has not revoked the
Retraction Request in accordance with the Exchangeable Share Provisions, the
Retraction Request will constitute the exercise of the Exchange Right with
respect to those Retracted Shares that the Corporation is unable to redeem.
In
any such event, the Corporation will immediately notify Opko (with a copy to
the
Holder) of the prohibition against the Corporation redeeming all of the
Retracted Shares and of the exercise of the Exchange Right (which notice will
constitute the notice of exercise of the Exchange Right for purposes of Section
3.2
)
and
forward or cause to be forwarded to Opko all relevant materials delivered by
the
Holder to the Corporation (including without limitation a copy of the Retraction
Request in connection with such proposed redemption of the Retracted Shares)
and
Opko or such Permitted Subsidiary as may be designated by Opko , will thereupon
purchase the Retracted Shares that the Corporation is not permitted to redeem
in
accordance with the provisions of this Article 2.
3.6
|
Notice
of Insolvency Event
|
Immediately
upon the occurrence of an Insolvency Event or any event which with the giving
of
notice or the passage of time or both would be an Insolvency Event, each of
the
Corporation and Opko shall give written notice thereof to the Holders. As soon
as practicable after receiving notice from the Corporation, Opko or from any
other Person of the occurrence of an Insolvency Event, the Corporation will
mail
to each Holder, at the expense of the Corporation, a notice of such Insolvency
Event, which notice shall contain a brief statement of the right of the Holders
with respect to the Exchange Right.
ARTICLE 4
AUTOMATIC
EXCHANGE RIGHT
4.1
|
Notice
of Opko Liquidation Event
|
|
(a)
|
Opko
will give the Holders notice of each of the following events at the
time
set forth below:
|
|
(i)
|
in
the event of any determination by Opko to institute voluntary liquidation,
dissolution or winding-up proceedings with respect to Opko or to
effect
any other distribution of assets of Opko among its shareholders for
the
purpose of winding up its affairs, at least 60 days prior to the
proposed
effective date of such liquidation, dissolution, winding-up or other
distribution; and
|
|
(ii)
|
immediately,
upon the earlier of (A) receipt by Opko of notice of and (B) Opko
otherwise becoming aware of any threatened or instituted claim, suit,
petition or other proceedings with respect to the involuntary liquidation,
dissolution or winding up of Opko or to effect any other distribution
of
assets of Opko among its shareholders for the purpose of winding
up its
affairs.
|
|
(b)
|
Notice
of any event (an "
Opko
Liquidation Event
")
contemplated by Section
4.1(a)(i)
or
4.1(a)(ii)
above shall include a brief description of the automatic exchange
of
Exchangeable Shares for Opko Common Shares provided for in Section
4.2
below.
|
On
the
fifth Business Day prior to the Opko Liquidation Event Effective Date, all
of
the then outstanding Exchangeable Shares held by the Holders shall be
automatically exchanged with Opko or such Permitted Subsidiary as may be
designated by Opko, for the Exchange Right Consideration. To effect such
automatic exchange, effective the fifth Business Day prior to the Opko
Liquidation Event Effective Date:
|
(a)
|
Opko
or such Permitted Subsidiary, as applicable, will deliver or cause
to be
delivered to each Holder the Exchange Right Consideration for each
Exchangeable Share held by the
Holder;
|
|
(b)
|
each
Holder will be deemed to have transferred to Opko or such Permitted
Subsidiary, as applicable, all of the Holder’s interest in the
Exchangeable Shares (which shall be free and clear of all liens and
encumbrances, other than those stipulated under the Share Purchase
Agreement, or the Articles) and will cease to be a Holder of those
Exchangeable Shares;
|
|
(c)
|
the
Holder will be deemed to be the holder of the Opko Common Shares
delivered
to it; and
|
|
(d)
|
the
certificates held by the Holder previously representing the Exchangeable
Shares will be deemed to represent the Opko Common Shares and other
Exchange Right Consideration delivered to the Holder.
|
Upon
the
request of a Holder and the surrender by the Holder of Exchangeable Share
certificates deemed to represent Opko Common Shares as provided in Section
4.2
,
Opko or
the applicable Permitted Subsidiary, as the case may be, will deliver to the
Holder certificates issued by Opko representing the Opko Common
Shares.
ARTICLE 5
ECONOMIC
EQUIVALENCE
5.1
|
Economic
Equivalence - Opko
Obligations
|
Opko
will
not, without Joint Approval:
|
(a)
|
declare
or pay or make any distribution (other than a distribution consisting
of
an issuance referred to in Section
5.1(b)
)
on the Opko Common Shares unless the Corporation forthwith declares,
pays
or makes, as the case may be, the same per share dividend or distribution
on the Exchangeable Shares as provided in Section
4.1
of
the Exchangeable Share Provisions;
|
|
(b)
|
issue
or distribute to all of the Holders of the then outstanding Opko
Common
Shares in respect of the Opko Common Shares held by such
holders:
|
|
(i)
|
Opko
Common Shares (or securities exchangeable for or convertible into
or
carrying rights to acquire Opko Common Shares) by way of a share
distribution or other distribution;
or
|
|
(ii)
|
rights,
options or warrants entitling them to subscribe for or to purchase
Opko
Common Shares (or securities exchangeable for or convertible into
or
carrying rights to acquire Opko Common
Shares),
|
unless
the economic equivalent on a per share basis of such rights, options, securities
or shares, is issued or distributed forthwith by the Corporation to Holders
(as
determined in good faith by the board of directors of the Corporation);
or
|
(i)
|
a
subdivision or change of the then outstanding Opko into a greater
number
of Opko Common Shares;
|
|
(ii)
|
a
reduction, combination, consolidation or change of the then outstanding
Opko Common Shares into a lesser number of Opko Common
Shares;
|
|
(iii)
|
a
reclassification or other change of the Opko Common Shares;
or
|
|
(iv)
|
an
amalgamation, merger, reorganization or other transaction affecting
the
Opko Common Shares, other than in the event of an Opko Sale pursuant
to
which a Redemption right is exercised,
|
unless
the same or an economically equivalent change is forthwith made by the
Corporation to the Exchangeable Shares, or to the rights of the Holders (if
any
such change is necessary to retain economic equivalence), as determined in
good
faith by the board of directors of the Corporation.
5.2
|
Economic
Equivalence - the Corporation
Obligations
|
The
Corporation will not, without Joint Approval:
|
(a)
|
declare
or pay any dividend or make any other distribution (other than a
dividend
or distribution consisting of an issuance referred to in Section
5.2
(b))
on the Exchangeable Shares unless Opko forthwith declares, pays or
makes,
as the case may be, the same per unit distribution on the Opko Common
Shares;
|
|
(b)
|
issue
to all of the Holders in respect of the Exchangeable Shares held
by such
Holders:
|
|
(i)
|
Exchangeable
Shares (or securities exchangeable for or convertible into or carrying
rights to acquire Exchangeable Shares) by way of stock dividend or
other
distribution; or
|
|
(ii)
|
rights,
options or warrants entitling them to subscribe for or to purchase
Exchangeable Shares (or securities exchangeable for or convertible
into or
carrying rights to acquire Exchangeable
Shares),
|
unless
the economic equivalent on a per unit basis of such rights, options, or in
the
rights of the holders of, securities or shares, is issued or distributed
forthwith by the Corporation to holders of Opko Common Shares (as determined
in
good faith by Opko ); or
|
(iii)
|
a
subdivision or change of the then outstanding Exchangeable Shares
into a
greater number of Exchangeable
Shares;
|
|
(iv)
|
a
reduction, combination, consolidation or change of the then outstanding
Exchangeable Shares into a lesser number of Exchangeable
Shares;
|
|
(v)
|
a
reclassification or other change of the Exchangeable Shares;
or
|
|
(vi)
|
an
amalgamation, merger, reorganization or other transaction affecting
the
Exchangeable Shares, other than in the event of an Opko Sale pursuant
to
which a Redemption right is
exercised,
|
unless
the same or an economically equivalent change is forthwith made to the Opko
Common Shares (if any such change is required to retain economic equivalence),
as determined in good faith by Opko .
5.3
|
Covenants
Regarding Exchangeable
Shares
|
Opko
and
the Corporation will:
|
(a)
|
ensure
that the declaration date, record date and payment date for a dividend
on
the Exchangeable Shares will be the same as the declaration date,
record
date and payment date for the corresponding dividend on Opko Common
Shares;
|
|
(b)
|
advise
each Holder sufficiently in advance of any Company Sale or Liquidation
Event to allow each Holder to exercise its rights of retraction pursuant
to the Exchangeable Share Provisions to receive Opko Common Shares
immediately prior to any such event or date;
|
|
(c)
|
duly
and timely perform all of their respective obligations, and take
all
actions and do all things as are necessary or desirable to enable
and
permit each other to perform their respective obligations, under
the
Exchangeable Share Provisions; and
|
|
(d)
|
ensure
that any redemption of Exchangeable Shares of a Holder in connection
with
a Company Sale, if requested by such Holder, shall be effective only
upon,
and will be conditional upon, the closing of the Company Sale.
|
5.4
|
Additional
Opko Covenants
|
Opko
will:
|
(a)
|
not
exercise its vote as a shareholder of the Corporation, nor allow
any
direct or indirect Subsidiary to exercise its own vote as a shareholder
of
the Corporation, to initiate the voluntary liquidation, dissolution
or
winding-up of the Corporation nor take any action or omit to take
any
action that is designed to result in the liquidation, dissolution
or
winding-up of the Corporation, other than in circumstances where
such vote
is necessary in order to enable the Corporation to fulfill its obligations
under this Agreement or pursuant to the Exchangeable Share Provisions;
and
|
|
(b)
|
take
all such commercially reasonable actions and do all such commercially
reasonable things as are necessary or desirable to enable and permit
Opko,
the Corporation, or a Permitted Subsidiary, as applicable, in accordance
with applicable law, to perform its obligations arising upon the
exercise
by it of the Liquidation Call Right, the Retraction Call Right or
the
Redemption Call Right, including without limitation all such actions
and
all such things as are necessary or desirable to enable and permit
Opko,
the Corporation, or a Permitted Subsidiary, as applicable, to cause
to be
delivered Opko Common Shares to the holders of Exchangeable Shares
in
accordance with the provisions of the Liquidation Call Right, the
Retraction Call Right or the Redemption Call Right, as the case may
be.
|
5.5
|
Delivery
of Opko Common Shares
|
Upon
notice from a Holder, the Corporation or a Permitted Subsidiary of any event
that requires the Corporation or such Permitted Subsidiary to deliver Opko
Common Shares to any Holder of Exchangeable Shares, Opko will, within five
(5)
Business Days, or upon the automatic exchange of Opko Common Shares for
Exchangeable Shares pursuant to Section
4.2
,
Opko
will on the fifth Business Day prior to the Opko Liquidation Event Effective
Date, issue and deliver or cause the delivery of the requisite number of Opko
Common Shares Holder or to the former Holder of the surrendered Exchangeable
Shares, as the Corporation or such Permitted Subsidiary directs. All such Opko
Common Shares will be, when issued and delivered, duly issued, fully paid and
non-assessable, and will be free and clear of any lien, claim, encumbrance,
security interest or adverse claim (other than resale restrictions arising
under
applicable securities Laws.)
Opko
shall provide, or cause the provision of, the Corporation and each Permitted
Subsidiary with sufficient funds, assets or other property as and when necessary
to enable the Corporation and each such Permitted Subsidiary to pay or otherwise
satisfy its obligations under the Exchangeable Share Provisions and this
Agreement, including without limitation, the payment of dividends by the
Corporation and any and all obligations arising under the exercise by a
Permitted Subsidiary of the Liquidation Call Right, the Retraction Call Right,
the Redemption Call Right or under Articles 2 and 3 hereof.
5.7
|
Ownership
of Common Shares
|
Opko,
or
one of its wholly-owned Subsidiaries, will be and will remain the direct or
indirect beneficial owner of all issued and outstanding voting shares in the
capital of the Corporation (including without limitation, the Common Shares),
except: (i) any change in ownership in connection with a transaction that
constitutes a Company Sale; or (ii) with Joint Approval and the prior written
approval of Opko.
5.8
|
Opko
and Affiliates Not to Vote Exchangeable
Shares
|
|
(a)
|
Subject
to Section
5.4
,
Section
5.8(b)
and Section
5.8(c)
,
Opko will appoint and cause to be appointed proxyholders with respect
to
all Exchangeable Shares from time to time held by it and its Affiliates
for the sole purpose of attending each meeting of Holders in order
to be
counted as part of the quorum for each
meeting.
|
|
(b)
|
Opko
will not, and will cause its Affiliates not to, exercise any voting
rights
that may be exercisable by holders of the Exchangeable Shares from
time to
time in respect of any matter considered at any meeting of Holders
of
Exchangeable Shares.
|
|
(c)
|
Where
Holders (excluding Opko and its Affiliates) of more than two-thirds
of the
Exchangeable Shares approve the adding to or changing of restrictions
or
conditions, or the removing or changing of rights or privileges,
attaching
to the Exchangeable Shares, and such Holders of the Exchangeable
Shares do
not hold a sufficient number of Exchangeable Shares to cause such
action
to be approved by written consent of such Holders (as prescribed
by
applicable Law), Opko will, if it is a holder of Exchangeable Shares,
and
will cause its Affiliates who are holders of Exchangeable Shares,
to
execute any resolutions in writing which are executed by such other
Holders or to exercise its votes in the same manner as exercised
by the
Holders of more than two-thirds of the Exchangeable Shares (excluding
Opko
and its affiliates).
|
The
Corporation and each Holder grants to Opko and each Permitted Subsidiary, the
Liquidation Call Right, the Redemption Call Right and the Retraction Call
Right.
5.10
|
Notification
of Certain Events
|
In
order
to assist Opko to comply with its obligations hereunder, the Corporation will
give Opko notice of each of the following events set forth below:
|
(a)
|
in
the event of any determination by the board of directors of the
Corporation to institute voluntary liquidation, dissolution or winding
up
proceedings with respect to the Corporation or to effect any other
distribution of the assets of the Corporation among its shareholders
for
the purpose of winding up its affairs, at least 60 days prior to
the
proposed effective date of such liquidation, dissolution, winding
up or
other distribution;
|
|
(b)
|
immediately,
upon the earlier of (i) receipt by the Corporation of notice of,
and (ii)
the Corporation otherwise becoming aware of, any threatened or instituted
claim, suit, petition or other proceedings with respect to the involuntary
liquidation, dissolution or winding up of the Corporation or to effect
any
other distribution of the assets of the Corporation among its shareholders
for the purpose of winding up its
affairs;
|
|
(c)
|
immediately,
upon receipt by the Corporation of a Retraction Request;
and
|
|
(d)
|
as
soon as practicable upon the issuance by the Corporation of any
Exchangeable Shares or rights to acquire Exchangeable
Shares.
|
5.11
|
Qualification
of Opko Common
Shares
|
If
any
Opko Common Shares (or other shares or securities into which Opko Common Shares
may be reclassified or changed) to be issued and delivered hereunder or pursuant
to the Exchangeable Share Provisions require registration or qualification
with
or approval of or the filing of any document, including any prospectus or
similar document, with or the taking of any proceeding with or the obtaining
of
any order, ruling or consent from, any governmental or regulatory authority
under any Canadian or United States federal, provincial or state securities
or
other law or regulation or pursuant to the rules and regulations of any
securities or other regulatory authority or the fulfillment of any other United
States or Canadian legal requirement before such shares (or such other shares
or
securities) may be issued by Opko and delivered by Opko at the direction of
a
Permitted Subsidiary or the Corporation, if applicable, to the holders of
surrendered Exchangeable Shares, Opko will in good faith and expeditiously
take
all such commercially reasonable actions and do all such commercially reasonable
things as are necessary or desirable to cause such Opko Common Shares (or such
other shares or securities) to be and remain duly registered, qualified or
approved under United States and/or Canadian law, as the case may
be.
In
the
event that a tender offer, share exchange offer, issuer bid, take-over bid
or
similar transaction with respect to Opko Common Shares (an "Offer") is proposed
by Opko or otherwise occurs and the Exchangeable Shares are not purchased by
a
Permitted Subsidiary pursuant to the Redemption Call Right, Opko will use
commercially reasonable efforts and expeditiously and in good faith to take
all
such commercially reasonable actions and do all such things as are necessary
or
desirable to enable and permit the Holders (other than Opko and its Affiliates)
to participate in such Offer to the same extent and on an economically
equivalent basis as the holders of Opko Common Shares, without discrimination.
Without limiting the generality of the foregoing, Opko will use commercially
reasonable efforts and expeditiously and in good faith to ensure that Holders
may participate in all such Offers without being required to retract
Exchangeable Shares as against the Corporation.
ARTICLE 6
TAX
MATTERS
The
Corporation, Opko and each Permitted Subsidiary (each, as the case may be,
a
“Payer”
)
may
deduct and withhold from any amount otherwise payable to any Holder such amounts
as the Payer is required to deduct and withhold with respect to such payment
under the
Tax
Act
,
the
United
States Internal Revenue Code of 1986
or any
provision of provincial, state, territorial, municipal, local or foreign tax
Law, in each case as amended or succeeded. To the extent that amounts are so
withheld, such withheld amounts are to be treated for all purposes as having
been paid to the Holder of the shares or shares in respect of which such
deduction and withholding was made, provided that such withheld amounts are
actually remitted to the appropriate taxing authority. To the extent that the
amount so required or permitted to be deducted or withheld from any payment
to a
Holder exceeds the cash portion of the amounts otherwise payable to the Holder,
the Holder will be notified in writing thereof by the Payer, and the Holder
must
pay the difference (up to the amount required to be withheld by the Payer)
in
cash to the Payer; failing payment of such difference within five Business
Days
after notice is provided to the Holder, the Payer is hereby authorized to sell
or otherwise dispose of such portion of the amounts otherwise payable to the
Holder as is necessary to provide sufficient funds to the Payer to enable it
to
comply with such deduction or withholding requirement, and the Payer will notify
the Holder thereof and remit to such Holder any unapplied balance of the net
proceeds of such sale. The Payer shall endeavour in good faith to maximize
the
proceeds realized from any such sale or disposition of the
consideration.
6.2
|
Section
116 Clearance Certificate for Non-Resident
Holders
|
|
(a)
|
Each
Holder that is a non-resident of Canada for purposes of the Tax Act
(a
“
Non-resident
Holder
”)
and to whom the Exchangeable Shares are “taxable Canadian property” and
not “excluded property” for purposes of the Tax Act must, prior to a
disposition of such shares to the Corporation, Opko or any Permitted
Subsidiary as may be designated by Opko, deliver to the Payer an
amount in
Canadian dollars equal to 25% of the fair market value of the Exchangeable
Shares to be disposed of, as determined on the date of disposition
(the
“
Up-front
Amount
”).
The Up-front Amount shall be released by the Payer or remitted to
the
Canada Revenue Agency (the “
CRA
”)
as set forth below.
|
|
(b)
|
If
the Up-front Amount has not been delivered to the Payer on, or prior
to,
the date of disposition of the Exchangeable Shares (the “
Effective
Date
”),
the Non-resident Holder must, prior to a disposition of such shares
to the
Corporation, Opko or any Permitted Subsidiary as may be designated
by
Opko, deliver a section 116 clearance certificate (a “
Clearance
Certificate
”)
to the Payer.
|
|
(c)
|
If
a Clearance Certificate having a certificate limit
as
defined in subsection 2 of Section 116 of the Tax Act (the “
Certificate
Limit
”)
at least equal to the fair market value for the Exchangeable Shares
being
disposed of has not been delivered to the Payer on or prior to the
Effective Date, the Payer shall withhold 50%
of
the proceeds of disposition otherwise deliverable to the
Non-resident
Holder. If a Clearance Certificate has been delivered to the Payer
on or
before the Effective Date and the Certificate Limit is less than
the 50%
of the fair market value of the Exchangeable Shares being disposed
of, the
Payer shall withhold 50% of the amount by which the proceeds of
disposition otherwise payable to the Non-resident Holder exceeds
the
Certificate Limit.
Any
amount so withheld (the “
Withheld
Amount
”)
shall be released by the Payer or remitted to the Canada Revenue
Agency
(the “
CRA
”)
as set forth below.
|
|
(d)
|
If
on or before the 27th day of the month following the calendar month
which
includes the Effective Date (the “
Remittance
Date
”),
the Payer receives from the Non-resident Holder a Clearance Certificate
with a Certificate Limit
at
least equal to the fair market value of the Exchangeable Shares disposed
of, the Payer shall, promptly after receipt of such Clearance Certificate,
deliver to the Non-resident Holder the Withheld Amount or the Up-front
Amount, as may be applicable, plus any interest earned thereon (less
any
applicable withholding taxes).
|
|
(e)
|
If
on or before the Remittance Date, the Payer does not receive from
the
Non-resident Holder a Clearance Certificate, or receives a Clearance
Certificate with a Certificate Limit that is less than the fair market
value of the Exchangeable Shares being disposed of, then, unless
the CRA
has issued a letter confirming that the CRA will not enforce the
remittance of funds as is normally required under subsection 116(5)
of the
Tax Act and that the Payer will not be charged interest or penalties
if it
delays the remittance of amounts in respect of the disposition of
the
Exchangeable Shares until further instructed by the CRA (a “
Comfort
Letter
”),
the Payer shall remit to the Receiver General for Canada (the
“
Receiver
General
”)
from the Withheld Amount or the Up-front Amount, as may be applicable,
an
amount equal to 25% of the fair market value of the Exchangeable
Shares
disposed of (or, if a Clearance Certificate is received but with
a
Certificate Limit less than the fair market value of the Exchangeable
Shares disposed of, an amount equal to 25% of the difference between
the
fair market value of the Exchangeable Shares disposed of and the
Certificate Limit) and shall remit to the Non-resident Holder such
portion
of the Withheld Amount or the Up-front Amount, as may be applicable,
not
required to be remitted to CRA (if any), together with any interest
earned
thereon (less applicable withholding taxes).
|
|
(f)
|
If
the CRA has issued a Comfort Letter, the Payer shall not make any
remittance to the Receiver General on the date that would otherwise
be the
Remittance Date and if a Clearance Certificate is subsequently received
while the Comfort Letter remains in effect, with a Certificate Limit
at
least equal to the fair market value of the Exchangeable Shares being
disposed of, the Payer shall, promptly after receipt of such certificate,
remit to the Non-resident Holder the Withheld Amount or the Up-front
Amount, as may be applicable, together with any interest earned thereon,
less any applicable withholding taxes. If notification from the CRA
is
received that the Comfort Letter is no longer in effect, the date
of
receipt of such notification shall be deemed to be the Remittance
Date for
the purposes of this section.
|
|
(g)
|
Any
amount that the Payer withholds from the proceeds of disposition
otherwise
payable to the Non-resident Holder pursuant to the provisions hereof
shall
be treated as having been paid to the Non-resident Holder on account
of
the proceeds of disposition on the date of
disposition.
|
Each
Holder will pay any documentary, stamp, transfer or other similar taxes that
may
be payable in respect of any Transfer involved in the issuance or delivery
of
Opko Common Shares.
ARTICLE 7
REGISTRATION
7.1
|
Piggyback
Registration.
|
|
(a)
|
Beginning
on the date of this Agreement, OPKO will notify all Holders of Registrable
Securities in writing at least 10 days prior to the filing of any
registration statement under the Securities Act for purposes of a
public
offering of OPKO Common Shares by OPKO (including, but not limited
to,
registration statements relating to secondary offerings of OPKO Common
Shares, but excluding registration statements relating to employee
benefit
plans or with respect to corporate reorganizations or other transactions
under SEC Rule 145) and will afford each such Holder an opportunity
to
include in such registration statement up to 100% of such Registrable
Securities held by such Holder, subject to Section
7.1(b)
.
Each Holder desiring to include in any such registration statement
part of
the Registrable Securities held by it will, within 5 days after the
above-described notice from OPKO (the “Holder Notice Period”), so notify
OPKO in writing. Such notice will state the intended method of disposition
of the Registrable Securities by such Holder as well as the number
of
Registrable Securities proposed by such Holder to be included in
such
registration statement.
|
|
(b)
|
If
the registration statement under which OPKO gives notice under this
Section
7.1(b)
is
for an underwritten offering, OPKO will so advise the Holders of
Registrable Securities as a part of such notice. In such event, the
right
of any Holder to be included in a registration pursuant to this
Section
7.1(b)
will be conditioned upon such Holder’s participation in such underwriting
and the inclusion of such Holder’s Registrable Securities in the
underwriting to the extent provided herein. All Holders proposing
to
distribute their Registrable Securities through such underwriting
will
enter into an underwriting agreement in customary form with the
underwriter or underwriters selected for such underwriting by OPKO.
Notwithstanding any other provision of this
Section
7.1(b)
,
if
the underwriter determines that marketing factors require a limitation
of
the number of shares to be underwritten, the number of shares that
may be
included in the underwriting will be allocated first to OPKO.
|
|
(c)
|
OPKO
will have the right to terminate or withdraw any registration initiated
by
it under this Section
7.1
prior to the effectiveness of such registration whether or not any
Holder
has elected to include securities in such registration.
|
7.2
|
Registration
Expenses.
|
OPKO
shall pay all fees and expenses incident to the performance of or compliance
with this
ARTICLE 7
including
without limitation: (a) all registration and filing fees and expenses,
including without limitation those related to filings with the SEC, and in
connection with applicable state securities or Blue Sky Laws, (b) printing
expenses (including without limitation expenses of printing certificates for
Registrable Securities), (c) messenger, telephone and delivery expenses,
(d) fees and disbursements of counsel for OPKO, (e) fees and expenses
of all other Persons retained by OPKO in connection with a registration
statement and (f) all listing fees to be paid by OPKO. Holders shall pay
all fees and disbursements of counsel retained for Holders in connection with
a
registration statement as well as all underwriter discounts associated with
any
public offering conducted on such Holder’s behalf.
Whenever
required to effect the registration of any Registrable Securities, OPKO will,
as
soon as practicable:
|
(a)
|
prepare
and file with the SEC a registration statement with respect to such
Registrable Securities and use its reasonable efforts to cause such
registration statement to become effective and keep such registration
statement effective for at least 180 days or, if earlier, until
(i) the participating Holder or Holders have completed the
distribution related thereto or (ii) the Registrable Securities are
no longer required to be
registered;
|
|
(b)
|
prepare
and file with the SEC such amendments and supplements to such registration
statement and the prospectus used in connection with such registration
statement as may be necessary to comply with the provisions of the
Securities Act with respect to the disposition of all securities
covered
by such registration statement;
|
|
(c)
|
in
the event of any underwritten public offering, enter into and perform
its
obligations under an underwriting agreement, in usual and customary
form,
with the managing underwriter or underwriters of such offering. Each
Holder participating in such underwriting will also enter into and
perform
its obligations under such an agreement;
|
|
(d)
|
promptly
notify each Holder of Registrable Securities covered by such registration
statement at any time when a prospectus relating thereto is required
to be
delivered under the Securities Act upon learning of the happening
of any
event as a result of which the prospectus included in such registration
statement, as then in effect, includes an untrue statement of a material
fact or omits to state a material fact required to be stated therein
or
necessary to make the statements therein not misleading and, at the
request of the Holders, OPKO shall prepare a supplement or amendment
to
such prospectus so that, as thereafter delivered to the purchasers
of such
Registrable Securities, such prospectus shall not contain an untrue
statement of a material fact or omit to state any fact necessary
to make
the statements therein not misleading in the light of the circumstances
then existing;
|
|
(e)
|
furnish
to each Holder and to each underwriter such number of copies of the
registration statement and the prospectus included therein (including
each
preliminary prospectus) as such Persons reasonably may request in
order to
facilitate the intended disposition of the Registrable Securities
covered
by such registration statement;
|
|
(f)
|
use
its best efforts (
i
) to
register or qualify the Registrable Securities covered by such
registration statement under the securities or “blue sky” laws of such
jurisdictions as the sellers of Registrable Securities or, in the
case of
an underwritten public offering, the managing underwriter reasonably
shall
request, (
ii
) to
prepare and file in those jurisdictions such amendments (including
post
effective amendments) and supplements, and take such other actions,
as may
be necessary to maintain such registration and qualification in effect
at
all times for the period of distribution contemplated thereby and
(
iii
) to
take such further action as may be necessary or advisable to enable
the
disposition of the Registrable Securities in such jurisdictions,
provided,
that OPKO shall not for any such purpose be required to qualify generally
to transact business as a foreign corporation in any jurisdiction
where it
is not so qualified or to consent to general service of process in
any
such jurisdiction;
|
|
(g)
|
permit
a single firm of counsel designated as selling stockholders' counsel
by
the Holders to review the registration statement and all amendments
and
supplements thereto for a reasonable period of time prior to their
filing.
|
|
(h)
|
if
such registration involves an underwritten offering, furnish a legal
opinion of the Corporation’s counsel, dated the date of the closing under
the underwriting agreement, with respect to the registration statement,
each amendment and supplement thereto, the prospectus included therein
(including the preliminary prospectus) and other documents relating
thereto, in customary form and covering such matters as are customarily
covered by legal opinions of issuers’ counsel in such public
offerings.
|
|
(i)
|
if
such registration involves an underwritten offering, furnish a legal
opinion of the Corporation’s counsel, dated the date of the closing under
the underwriting agreement, with respect to the registration statement,
each amendment and supplement thereto, the prospectus included therein
(including the preliminary prospectus) and other documents relating
thereto, in customary form and covering such matters as are customarily
covered by legal opinions of issuers’ counsel in such public
offerings
|
|
(j)
|
make
available for inspection by each seller of Registrable Securities,
any
underwriter participating in any distribution pursuant to such
registration statement, and any attorney, accountant or other agent
retained by such seller or underwriter, all relevant financial and
other
records, pertinent corporate documents and properties of OPKO, and
cause
OPKO's officers, directors and employees to supply all information
reasonably requested by any such seller, underwriter, attorney, accountant
or agent in connection with such registration statement;
|
|
(k)
|
provide
a transfer agent and registrar, which may be a single entity for
the
Registrable Securities not later than the effective date of the
Registration Statement;
|
|
(l)
|
take
all actions reasonably necessary to facilitate the timely preparation
and
delivery of certificates (not bearing any legend restricting the
sale or
transfer of such securities) representing the Registrable Securities
to be
sold pursuant to the Registration Statement and to enable such
certificates to be in such denominations and registered in such names
as
the Sellers or any underwriters may reasonably
request;
|
|
(m)
|
take
all other reasonable actions necessary to expedite and facilitate
the
registration of the Registrable Securities pursuant to the Registration
Statement; and
|
|
(n)
|
advise
each Holder of Registrable Securities covered by such registration
statement and, if requested by any such Holder, confirm such advice
in
writing:
|
|
(i)
|
when
such registration statement, and any amendment thereto, has been
filed
with the SEC and when the registration statement or any post-effective
amendment thereto has become effective;
|
|
(ii)
|
of
any request by the SEC for amendments or supplements to such registration
statement or the prospectus included therein or for additional
information;
|
|
(iii)
|
of
the issuance by the SEC of any stop order suspending effectiveness
of the
registration statement or the initiation of any proceedings for that
purpose; and
|
|
(iv)
|
of
the receipt by OPKO of any notification with respect to the suspension
of
the qualification of the securities included in the registration
statement
for sale in any jurisdiction or the initiation of any proceeding
for such
purpose.
|
7.4
Obligations
of the Holders.
Each
Holder desiring to include in any such registration statement all or any part
of
the Registrable Securities held by such Holder will reasonably cooperate with
OPKO in connection with the preparation and filing of any registration statement
and each amendment thereof and, upon OPKO’s reasonable request, will in a timely
manner furnish in writing to OPKO accurate and complete information regarding
the Holder, the distribution of the Registrable Securities and other matters
as
may be required by applicable Law, rule or regulation for inclusion in the
registration statement and each amendment; the provision of such information
by
such Holders to OPKO shall be a condition precedent to OPKO’s obligations under
ARTICLE 7
hereof.
7.5
Termination
of Registration Rights.
All
registration rights granted under this
ARTICLE 7
will
terminate and be of no further force and effect as to any Holder on the earlier
of (a) five years from the date hereof and (b) such time as all of
the Registrable Securities held by such Holder (together with its affiliates,
partners and former partners) may be sold under SEC Rule 144 during any
90-day period.
7.6
Dispositions.
Each
Holder agrees that it will comply with the prospectus delivery requirements
of
the Securities Act as applicable to it in connection with sales of Registrable
Securities pursuant to a registration statement.
7.7
SEC
Rule 144 Reporting.
With
a
view to making available to the Holders the benefits of certain rules and
regulations of the SEC that may permit the sale of the Registrable Securities
to
the public without registration, OPKO will use its reasonable best efforts
to:
|
(a)
|
Make
and keep public information available, as those terms are understood
and
defined in SEC Rule 144 or any similar or analogous rule promulgated
under the Securities Act.
|
|
(b)
|
File
with the SEC, in a timely manner, all reports and other documents
required
of OPKO under the Exchange Act;
|
|
(c)
|
As
long as a Holder owns any Registrable Securities, furnish to such
Holder
promptly upon request: a written statement by OPKO as to its compliance
with the reporting requirements of SEC Rule 144, the Securities Act,
and the Exchange Act, a copy of the most recent annual or quarterly
report
of OPKO and such other reports and documents so filed by OPKO; and
such
other reports and documents as a Holder may reasonably request in
availing
itself of any rule or regulation of the SEC allowing it to sell any
such
securities without registration.
|
7.8
Indemnification
and Contribution.
|
(a)
|
In
the event of a registration of any of the Registrable Securities
under the
Securities Act pursuant to Section
7.1
,
OPKO will indemnify and hold harmless each seller of such Registrable
Securities thereunder, any underwriter (as defined in the Securities
Act)
for such seller, and each other Person, if any, who controls such
seller
or underwriter within the meaning of the Securities Act or the Exchange
Act, from and against, and pay or reimburse them for, any losses,
claims,
reasonable expenses, damages or liabilities to which such seller,
underwriter or controlling Person may become subject under the Securities
Act, the Exchange Act or otherwise, insofar as such losses, claims,
expenses, damages or liabilities (or actions in respect thereof)
arise out
of or are based upon any untrue statement or alleged untrue statement
of
any material fact contained in any registration statement under which
such
Registrable Securities were registered under the Securities Act pursuant
to Section
7.1
,
any preliminary prospectus or final prospectus contained therein,
or any
amendment or supplement thereof, or arise out of or are based upon
the
omission or alleged omission to state therein a material fact required
to
be stated therein or necessary to make the statements therein not
misleading, or any violation or alleged violation of the Securities
Act,
the Exchange Act, any state securities or blue sky laws and specifically
will reimburse each such seller, underwriter and controlling Person
for
any legal or other expenses reasonably incurred by it in connection
with
investigating or defending any such loss, claim, damage, liability
or
action;
provided
,
that OPKO will not be liable in any such case if and to the extent
that
any such loss, claim, expense, damage or liability arises out of
or is
based upon OPKO's reliance on an untrue statement or alleged untrue
statement or omission or alleged omission so made in conformity with
information furnished by any such seller, underwriter or controlling
Person in writing specifically for use in such registration statement
or
prospectus; and
provided
further
,
that OPKO shall not be liable to the extent that any such loss, claim,
expense, damage or liability (or action in respect thereof) arises
out of
or is based upon an untrue statement or alleged untrue statement
or
omission in such registration statement corrected in an amendment
or
supplement to the registration statement, such amendment or supplement
was
delivered to the indemnified party in sufficient quantities and a
reasonable period of time prior to the closing of any offering and
the
indemnified party failed to deliver or failed to cause to be delivered
such registration statement as so amended or supplemented to the
Person
asserting such loss, claim, expense, damage or
liability.
|
|
(b)
|
In
the event of a registration of any of the Registrable Securities
under the
Securities Act pursuant to Section
7.1
,
each seller of such Registrable Securities thereunder, severally
and not
jointly, will indemnify and hold harmless OPKO, each Person, if any,
who
controls OPKO within the meaning of the Securities Act, each officer
of
OPKO who signs the registration statement, each director of OPKO
and any
underwriter and any controlling Person of such underwriter from and
against all losses, claims, reasonable expenses, damages or liabilities,
joint or several, to which OPKO or such officer, director,
underwriter
or
controlling Person may become subject under the Securities Act, Exchange
Act or otherwise, insofar as such losses, claims, expenses, damages
or
liabilities (or actions in respect thereof) arise out of or are based
upon
reliance on any untrue statement or alleged untrue statement of any
material fact contained in the registration statement under which
such
Registrable Securities were registered under the Securities Act,
any
preliminary prospectus or final prospectus contained therein, or
any
amendment or supplement thereof, or arise out of or are based upon
the
omission or alleged omission to state therein a material fact required
to
be stated therein or necessary to make the statements therein not
misleading, and will reimburse OPKO and each such officer, director,
underwriter and controlling Person for any legal or other expenses
reasonably incurred by them in connection with investigating or defending
any such loss, claim, expense, damage, liability or action;
provided
,
that such seller will be liable hereunder in any such case if and
only to
the extent that any such loss, claim, expense, damage or liability
arises
out of or is based upon an untrue statement or alleged untrue statement
or
omission or alleged omission made in reliance upon and in conformity
with
information pertaining to such seller, as such, furnished in writing
to
OPKO by such seller specifically for use in such registration statement
or
prospectus; and
provided
,
further
,
that the liability of each seller hereunder shall be limited to the
proportion of any such loss, claim, expense, damage or liability
which is
equal to the proportion that the public offering price of the Registrable
Securities sold by such seller under such registration statement
bears to
the total public offering price of all securities sold
thereunder
|
|
(c)
|
Notwithstanding
the foregoing, the indemnity provided in this
ARTICLE 7
shall not apply to amounts paid in settlement of any such loss, claim,
expense, damage or liability if such settlement is effected without
the
consent of such seller;
|
|
(d)
|
Promptly
after receipt by an indemnified party hereunder of notice of the
commencement of any action (including any governmental action), such
indemnified party shall, if a claim in respect thereof is to be made
against the indemnifying party hereunder, notify the indemnifying
party in
writing thereof, but the delay so to notify the indemnifying party
shall
not relieve it from any liability which it may have to such indemnified
party other than under this Section
7.8
and shall only relieve it from any liability which it may have to
such
indemnified party under this Section
7.8
if
and to the extent the indemnifying party is materially prejudiced
by such
delay. In case any such action shall be brought against any indemnified
party and it shall notify the indemnifying party of the commencement
thereof, the indemnifying party shall be entitled to participate
in and,
to the extent it shall wish, to jointly with any other indemnifying
party
similarly notified, assume and undertake the defence thereof with
counsel
satisfactory to such indemnified party, and, after notice from the
indemnifying party to such indemnified party of its election so to
assume
and undertake the defence thereof, the indemnifying party shall not
be
liable to such indemnified party under this Section
7.8
for any legal expenses subsequently incurred by such indemnified
party in
connection with the defence thereof
provided
,
that if the defendants in any such action include both the indemnified
party and the indemnifying party and the indemnified party shall
have
reasonable defences available to it which are different from or additional
to those available to the indemnifying party or if the interests
of the
indemnified party reasonably may be deemed to conflict with the interests
of the indemnifying party, the indemnified party shall have the right
to
select a separate counsel and to assume such legal defences and otherwise
to participate in the defence of such action, with the reasonable
expenses
and fees of such separate counsel and other expenses related to such
participation to be reimbursed by the indemnifying party as incurred.
|
|
(e)
|
If
the indemnification provided for in this Section
7.8
is
held by a court of competent jurisdiction to be unavailable to an
indemnified party with respect to any loss, claim, expense, damage
or
liability referred to therein, then the indemnifying party, in lieu
of
indemnifying such indemnified party hereunder, shall contribute to
the
amount paid or payable by such indemnified party as a result of such loss,
claim, expense, damage or liability in such proportion as is appropriate
to reflect the relative fault of the indemnifying party on the one
hand
and of the indemnified party on the other in connection with the
untrue
statement or alleged untrue statement or omission or alleged omission
or
violation or alleged violation that resulted in such loss, claim,
expense,
damage or liability as well as any other relevant equitable
considerations. The relative fault of the indemnifying party and
of the
indemnified party shall be determined by reference to, among other
things,
whether the untrue statement or alleged untrue statement or omission
or
alleged omission or violation or alleged violation relates to information
supplied or acts or omissions by the indemnifying party or by the
indemnified party and the parties’ relative intent, knowledge, access to
information, and opportunity to correct or prevent such statement,
omission or violation;
provided
further
,
that, in no event shall any contribution of a holder or Registrable
Securities under this Section
7.8
exceed the net proceeds from the offering received by such holder.
|
|
(f)
|
(e)
The obligations of the Parties under this Section
7.8
shall survive the completion of any offering of Registrable Securities
in
a registration statement under Section
7.1
;
provided
that any such indemnification obligations shall not extend beyond
the
period proscribed by the applicable statute of limitations (and all
extensions thereof) with respect to such action or claim; and
provided
further
,
that if notice is given under this Section
7.8
with respect to any matter entitling a party to indemnification hereunder
prior to the applicable expiration date, such indemnification obligation
shall continue indefinitely in respect of the applicable claim until
it is
finally resolved.
|
ARTICLE 8
GENERAL
8.1
|
Transfer
and Issuance Restrictions
|
Notwithstanding
any of other provision of this Agreement:
|
(a)
|
no
Exchangeable Shares may be Transferred unless, in addition to such
Transfer complying with all provisions related to Transfers set forth
in
this Agreement and in the constating documents of the Corporation,
concurrently with such transfer the transferee enters into this Agreement
by executing a counterpart instrument of accession in the form attached
as
Schedule B; and
|
|
(b)
|
no
additional Exchangeable Shares may be issued by the Corporation to
any
Person who is not a Holder without Joint Approval, and if Joint Approval
is obtained unless, concurrently with such issuance, the Person to
whom
such shares are issued enters into this Agreement by executing a
counterpart instrument of accession in the form attached as Schedule
B.
|
The
Corporation will cause each certificate representing its Exchangeable Shares
to
bear the following language either as an endorsement or on the face of such
share certificate:
The
shares represented by this certificate are subject to all the terms and
conditions of an exchange and support agreement made _______,
______________
,
2007
as it
may be amended, which agreement contains, among other things, restrictions
on
the right of the holder hereof to transfer or sell the shares. A copy of such
exchange and support agreement is on file at the registered office of the
Corporation.
8.3
|
Seller
Acknowledgements and
Agreements
|
Each
Holder hereby acknowledges, certifies and agrees that:
(a)
The
Opko
Common Shares contained in the Exchange Right Consideration have not been and
will not be registered under the US Securities Act of 1933, as amended (the
“U.S. Securities Act”);
(b)
Such
Holder shall not sell, transfer or otherwise dispose of such Opko Common Shares
unless in accordance with Regulation S under the US Securities Act (“Regulation
S”), pursuant to registration under the U.S. Securities Act or pursuant to an
applicable exemption from the registration requirement of the US Securities
Act
and any applicable state securities law, and shall not engage in any hedging
transactions with regard to the Opko Common Shares unless in compliance with
the
US Securities Act;
(c)
The
Opko
Common Shares constitute “restricted securities,” as defined in Rule 144 under
the U.S. Securities Act (“Rule 144”), and, accordingly, will be subject to the
holding period, volume limitations, manner of sale, notice of proposed sale
and
other compliance requirements, as applicable, of Rule 144 for purposes of any
resale of the Opko Common Shares into the U.S. public securities markets;
(d)
Any
certificate representing Opko Common Shares shall bear a transfer restriction
legend referring to the U.S. Securities Act, including a reference to Regulation
S, and applicable state securities law;
(e)
Such
Holder has such knowledge and experience in financial and business matters
that
such Holder is capable of evaluating the risks of an investment an Opko Common
Shares and for purposes of the investment decision from time to time related
to
any exercise of the Exchange Right is relying solely on the reports and other
information filed by Opko with the U.S. Securities and Exchange Commission
and
not on any material nonpublic information about Opko;
(f)
Such
Holder as of the date hereof and the date of exercise of the Exchange Right,
is
not a “distributor” (as defined in Regulation S) and is not exercising the
Exchange Right with an intent to effect, and will not undertake, a distribution
of the Exchange Right Consideration; and
(g)
Such
Holder at the time of the exercise the Exchange Right is not a U.S. person
(as
defined in Regulation S), is outside the United States, and is not acquiring
the
Exchange Right Consideration for the account or benefit of a U.S.
person.
8.4
|
Compliance
with other Instruments
|
Each
Party confirms that it will comply, and Opko will cause each Permitted
Subsidiary to comply, with the Exchangeable Share Provisions and this
Agreement.
8.5
|
Changes
in Capital of Opko and the
Corporation
|
At
all
times after the occurrence of any event as a result of which the Opko Common
Shares or the Exchangeable Shares are in any way changed, this Agreement will
be
amended and modified as necessary in order that it will apply with full force
and effect to all new securities into which the Opko Common Shares or the
Exchangeable Shares are so changed.
This
Agreement is effective as of the date of this Agreement and terminates when
no
Exchangeable Shares (or securities or rights convertible into or exchangeable
for or carrying rights to acquire Exchangeable Shares) are held by any Person
(other than Opko and its Affiliates).
This
Agreement enures to the benefit of and is binding upon the Parties and their
respective successors (including any successor by reason of merger or
amalgamation of any Party) and permitted assigns as contemplated in Section
8.10
.
Any
notice, certificate, consent, determination or other communication required
or
permitted to be given or made under this Agreement shall be in writing and
shall
be effectively given and made if (i) delivered personally, (ii) sent by prepaid
courier service or mail, or (iii) sent prepaid by fax or other similar means
of
electronic communication, in each case to the applicable address set out
below:
|
(a)
|
if
to the Corporation, to Opko, any Permitted Subsidiary, or their
Affiliates, to:
|
4400
Biscayne Boulevard
Miami,
Florida 31337
Attention:
Steven
D.
Rubin
Fax:
<>
with
a
copy to:
Fraser
Milner Casgrain
First
Canadian Place
100
King
Street West
P.O.
Box
100
Toronto,
Ontario M5X 1B2
Attention:
Laurence
Geringer
Fax:
416.863.4592
|
(b)
|
and
if to the Holders in accordance with Section
8.9
.
|
|
(c)
|
Any
such communication so given or made shall be deemed to have been
given or
made and to have been received on the day of delivery if delivered,
or on
the day of faxing or sending by other means of recorded electronic
communication, provided that such day in either event is a Business
Day
and the communication is so delivered, faxed or sent before 4:30
p.m. on
such day. Otherwise, such communication shall be deemed to have been
given
and made and to have been received on the next following Business
Day. Any
such communication sent by mail shall be deemed to have been given
and
made and to have been received on the fifth Business Day following
the
mailing thereof; provided however that no such communication shall
be
mailed during any actual or apprehended disruption of postal services.
Any
such communication given or made in any other manner shall be deemed
to
have been given or made and to have been received only upon actual
receipt.
|
|
(d)
|
Any
Party may from time to time change its address under this Section
by
notice to the other Party given in the manner provided by this
Section.
|
Any
and
all notices to be given and any documents to be sent to any Holder shall be
given or sent to such Holder at its address as shown on the register of holders
of Exchangeable Shares (or, if not available, on the register of holders of
Opko
Common Shares or as provided by the Holder) in any manner permitted by the
by-laws of the Corporation from time to time in force in respect of notices
to
shareholders (with a copy to each of the persons set out in Section
8.8
)
and
shall be deemed to be received (if given or sent in such manner) at the time
specified in such by-laws, the provisions of which by-laws shall apply
mutatis
mutandis
to
notices or documents as aforesaid sent to such Holders.
No
amendment, supplement, modification, waiver or termination of this Agreement
is
binding without Joint Approval and the prior written approval of Opko and no
consent or approval by any Party will be binding unless delivered in writing
to
the other Parties hereto. The Corporation, at the request of Opko , shall call
a
meeting or meetings of the Holders for the purpose of considering any proposed
amendment or modification requiring approval pursuant to this Section
8.10
.
Any
such meeting or meetings shall be called and held in accordance with the by-laws
of the Corporation, the Exchangeable Share Provisions and all applicable
Laws.
Any
Holder may assign its rights and obligations under this Agreement to any
permitted transferee of any of such Holder’s Exchangeable Shares. Otherwise, no
party may assign any rights or obligations under this Agreement without Joint
Approval.
The
Parties will, with reasonable diligence, do all such things and provide all
such
reasonable assurances as may be required to consummate the transactions
contemplated by this Agreement, and each party will provide such further
documents or instruments required by any other Party as may be reasonably
necessary or desirable to effect the purpose of this Agreement and carry out
its
provisions.
8.13
|
Execution
and Delivery
|
This
Agreement may be executed by the Parties in counterparts and may be executed
and
delivered by fax, and all such counterparts and faxes together constitute one
agreement.
[THE
REMAINDER OF THIS PAGE HAS BEEN INTENTIONALLY LEFT BLANK]
IN
WITNESS OF WHICH
the
Parties have duly executed this Exchange and Support Agreement.
Opko:
OPKO
HEALTH, INC.
By:_______________________________
Name:
Title:
The
Corporation:
OTI
Holdings Limited
By:______________________________
Name:
Title:
IN
WITNESS OF WHICH
the
Parties have duly executed this Exchange and Support Agreement.
Holders:
SIGNED
IN THE PRESENCE OF:
|
)
|
|
|
)
|
|
|
)
|
|
|
)
|
|
Witness
|
)
|
RISHARD
WEITZ
|
|
)
|
|
|
)
|
|
|
)
|
|
Witness
|
)
|
CAROLYN
WEISS
|
|
)
|
|
|
)
|
|
|
)
|
|
|
)
|
|
|
)
|
|
Witness
|
)
|
GERALD
WEISS, IN TRUST
|
|
)
|
|
|
)
|
|
|
)
|
|
|
)
|
|
Witness
|
)
|
SHANE
DUNNE
|
1161983
ONTARIO LIMITED.
By:____________________________
Name:
Title:
GRALL
CORPORATION LIMITED.
By:____________________________
Name:
Title:
TRIPLE
NET PROPERTIES LIMITED.
By:______________________________
Name:
Title:
STOCK
PURCHASE AGREEMENT
This
Stock Purchase Agreement is dated as of December 4, 2007 (this "
Agreement
"),
between OPKO Health, Inc., a Delaware corporation (the "
Company
"),
and
the members of The Frost Group, LLC, as listed on
Annex
A
hereto
(collectively, the "
Purchasers
").
WHEREAS,
the Company desires to sell to Purchasers, and Purchasers desire to purchase
from the Company, shares of the Company's common stock, par value $.01 per
share
(the "
Common
Stock
"),
on
the terms and subject to the conditions set forth in this
Agreement.
WHEREAS,
the Purchase Price and the Shares issued shall be allocated among the Purchasers
in accordance with
Annex
A.
NOW,
THEREFORE, in consideration of the premises and the mutual covenants contained
in this Agreement and for other good and valuable consideration, the receipt
and
sufficiency of which are hereby acknowledged, and intending to be legally bound,
the parties agree as follows:
Article
1
Purchase
and Sale of Common Stock
1.1
Purchase
and Sale of the Shares
.
Subject
to the terms and conditions hereof, the Company hereby agrees to issue and
sell
to Purchasers, and Purchasers hereby agree to purchase from the Company,
10,869,565
shares of Common Stock (the "Shares") at a purchase price of $1.84 per share
for
an aggregate purchase price of $20 million (the "
Purchase Price
").
1.2
Closing
.
The
closing of the issuance and sale of the Shares (the "
Closing
")
shall
take place at the Company’s offices in Miami, Florida concurrently with the
execution of this Agreement. As payment in full for the Shares being purchased
by them at the Closing, Purchasers shall pay to the Company the Purchase Price
by wire transfer no later than December 7, 2007. Upon the receipt of the
Purchase Price, the Company shall instruct the Company’s transfer agent to issue
and deliver to Purchasers, stock certificates in definitive form, registered
in
the names of Purchasers, representing the number of Shares purchased at the
Closing in accordance with
Annex
A
.
Article
2
Additional
Agreements
The
Company and Purchasers shall cooperate with each other and use their respective
commercially reasonable best efforts to take or cause to be taken all actions,
and do or cause to be done all things, necessary, proper or advisable under
this
Agreement and applicable laws and regulations to consummate and make effective
the sale of the Shares (the "
Sale
")
and
the other transactions contemplated by this Agreement as soon as practicable,
including preparing and filing as promptly as practicable all documentation
to
effect all necessary applications, notices, petitions, filings and other
documents and to obtain as promptly as practicable all permits, consents,
approvals and authorizations necessary or advisable to be obtained from any
third party and/or any governmental entity in order to consummate the Sale
or
any of the other transactions contemplated by this Agreement.
Article
3
Representations
and Warranties of the Company
The
Company represents and warrants to Purchasers as of the date hereof as
follows:
3.1
Authorization
of Agreements, etc
.
The
execution and delivery by the Company of this Agreement, the performance by
the
Company of its obligations hereunder, and the issuance, sale and delivery of
the
Shares have been duly authorized by all requisite corporate action and will
not
result in any violation of, be in conflict with, or constitute a default under,
with or without the passage of time or the giving of notice: (a) any provision
of the Company's Certificate of Incorporation, as amended, or Bylaws, as
amended; (b) any provision of any judgment, decree or order to which the Company
is a party or by which it is bound; (c) any material contract or agreement
to
which the Company is a party or by which it is bound; or (d) any statute, rule
or governmental regulation applicable to the Company, except where such
violation, conflict, or default would not have a material adverse effect on
the
Company.
3.2
Valid
Issuance of Common Stock
.
The
Shares have been duly authorized and, when issued, sold and delivered in
accordance with this Agreement for the consideration expressed herein will
be
validly issued, fully paid and nonassessable with no personal liability
attaching to the ownership thereof and will be free and clear of all liens,
charges and encumbrances of any nature whatsoever except for restrictions on
transfer under this Agreement and under applicable Federal and state securities
laws.
3.3
Validity
.
This
Agreement has been duly executed and delivered by the Company and constitutes
the legal, valid and binding obligation of the Company, enforceable in
accordance with its terms except (i) as limited by applicable bankruptcy,
insolvency, reorganization, moratorium, and other laws of general application
affecting enforcement of creditors' rights generally, and (ii) as limited by
laws relating to the availability of specific performance, injunctive relief,
or
other equitable remedies.
3.4
Brokers
and Finders
.
Neither
the Company nor any of its subsidiaries, officers, directors or employees has
employed any broker or finder or incurred any liability for any brokerage fees,
commissions or finders' fees in connection with the Sale or the other
transactions contemplated by this Agreement.
Article
4
Representations
and Warranties of Purchasers
Each
of
the Purchasers hereby severally and not jointly represents and warrants to
the
Company as of the date hereof as follows:
4.1
Validity
.
This
Agreement has been duly executed and delivered by Purchaser and constitutes
the
legal, valid and binding obligation of Purchaser, enforceable in accordance
with
its terms except:
(a)
as
limited by applicable bankruptcy, insolvency, reorganization, moratorium, and
other laws of general application affecting enforcement of creditors' rights
generally; and
(b)
as
limited by laws relating to the availability of specific performance, injunctive
relief, or other equitable remedies.
4.2
Investment
Representations
.
(a)
Purchaser
is an "accredited investor" within the meaning of Rule 501 of Regulation D
under
the Securities Act of 1933, as amended (the "
Securities
Act
")
and
was not organized for the specific purpose of acquiring the Shares;
(b)
Purchaser
has sufficient knowledge and experience in investing in companies similar to
the
Company in terms of the Company's stage of development so as to be able to
evaluate the risks and merits of its investment in the Company and it is able
financially to bear the risks thereof;
(c)
it
is the
present intention that the Shares being purchased by Purchaser are being
acquired for Purchaser's own account for the purpose of investment and not
with
a present view to or for sale in connection with any distribution
thereof;
(d)
Purchaser
understands that:
(i)
the
Shares have not been registered under the Securities Act by reason of their
issuance in a transaction exempt from the registration requirements of the
Securities Act pursuant to Section 4(2) thereof or Rule 505 or 506 promulgated
under the Securities Act;
(ii)
the
Shares must be held indefinitely unless a subsequent disposition thereof is
registered under the Securities Act or is exempt from such
registration;
(iii)
the
Shares will bear a legend to such effect; and
(iv)
the
Company will make a notation on its transfer books to such effect;
and
(e)
the
Company has made available to Purchaser all documents and information that
the
Purchaser has requested relating to an investment in the Company.
4.3
Brokers
and Finders
.
The
Purchaser has not employed any broker or finder or incurred any liability for
any brokerage fees, commissions or finders' fees in connection with the Sale
or
the other transactions contemplated by this Agreement.
Article
5
Miscellaneous
5.1
Lock-Up
.
Each of
the Purchasers hereby irrevocably agrees that until the second anniversary
of
the date of this Agreement, he she or it will not, without the prior written
consent of the Company, directly or indirectly:
(a)
Offer
for
sale, sell, pledge or otherwise dispose of (or enter into any transaction or
device that is designed to, or could be expected to, result in the disposition
by any person at any time in the future, of any of the Shares;
(b)
Enter
into any swap or other derivatives transaction that transfers to another, in
whole or in part, any of the economic benefits or risks of ownership of the
Shares, or
(c)
Publicly
disclose the intention to do any of the foregoing, for a period commencing
on
the date hereof and ending on the second anniversary of the date hereof.
5.2
Legend
.
Each
certificate that represents Shares shall have conspicuously endorsed thereon
the
following legends:
THIS
STOCK HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE
"SECURITIES ACT"), OR ANY STATE SECURITIES LAWS. THIS STOCK MAY NOT BE OFFERED
OR TRANSFERRED BY SALE, ASSIGNMENT, PLEDGE OR OTHERWISE UNLESS (A) A
REGISTRATION STATEMENT FOR THE STOCK UNDER THE SECURITIES ACT IS IN EFFECT
OR
(B) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL, WHICH OPINION IS
SATISFACTORY TO THE COMPANY, TO THE EFFECT THAT SUCH REGISTRATION IS NOT
REQUIRED UNDER THE SECURITIES ACT OR THE RELEVANT STATE SECURITIES
LAWS.
THIS
STOCK IS SUBJECT TO RESTRICTIONS ON RESALE PURSUANT TO THAT CERTAIN STOCK
PURCHASE AGREEMENT WITH THE COMPANY DATED DECEMBER 4, 2007 AND MAY NOT BE
OFFERED OR TRANSFERRED BY SALE, ASSIGNMENT, PLEDGE OR OTHERWISE UNTIL DECEMBER
4, 2009, WITHOUT THE PRIOR WRITTEN CONSENT OF THE COMPANY.
5.3
Brokerage
.
Each
party hereto will indemnify and hold harmless the other against and in respect
of any claim for brokerage or other commissions relative to this Agreement
or to
the transactions contemplated hereby, based in any way on agreements,
arrangements or understandings made or claimed to have been made by such party
with any third party.
5.4
Parties
in Interest
.
All
representations, covenants and agreements contained in this Agreement by or
on
behalf of any of the parties hereto shall bind and inure to the benefit of
the
respective successors and assigns of the parties hereto whether so expressed
or
not.
5.5
Notices
.
All
notices, requests, consents, demands, and other communications under this
Agreement shall be in writing and shall be deemed to have been duly given on
the
date of service if served personally on the party to whom notice is to be given,
on the date of transmittal of services via telecopy to the party to whom notice
is to be given (with a confirming copy delivered within 24 hours thereafter),
or
on the third day after mailing if mailed to the party to whom notice is to
be
given, by first class mail, registered or certified, postage prepaid, or
overnight mail via a nationally recognized courier providing a receipt for
delivery and properly addressed as follows:
If
to the Company:
|
OPKO
Health, Inc.
|
4400
Biscayne Blvd.
Suite
1180
Miami,
FL
33137
Attn:
Kate Inman, Esq.
If
to any of the Purchasers:
|
The
Frost Group, LLC
|
4400
Biscayne Blvd.
Suite
1500
Miami,
FL
33137
Attn:
Steven Rubin
Any
party
may change its address for purposes of this paragraph by giving notice of the
new address to each of the other parties in the manner set forth
above.
5.6
Governing
Law
.
This
Agreement shall be governed by and construed in accordance with the laws of
the
State of Florida for all purposes and in all respects, without regard to the
conflict of law provisions of such state.
5.7
Entire
Agreement
.
This
Agreement constitutes the sole and entire agreement of the parties with respect
to the subject matter hereof.
5.8
Counterparts
.
This
Agreement may be executed in two or more counterparts (including facsimiles),
each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.
5.9
Amendments
and Waivers
.
This
Agreement may be amended or modified, and provisions hereof may be waived,
only
with the written consent of the Company and the Purchasers.
5.10
Severability
.
If any
provision of this Agreement shall be declared void or unenforceable by any
judicial or administrative authority, the validity of any other provision and
of
the entire Agreement shall not be affected thereby.
5.11
Titles
and Subtitles
.
The
titles and subtitles used in this Agreement are for convenience only and are
not
to be considered in construing or interpreting any term or provision of this
Agreement.
NOW
THEREFORE, the Company and Purchasers have executed this Stock Purchase
Agreement as of the date first above written.
OPKO
HEALTH, INC.
By:_________________________________
Name:
Title:
FROST
GROUP, LLC
By:_________________________________
Its:
FROST
GAMMA INVESTMENTS TRUST,
Member
of
the Frost Group, LLC
By:_________________________________
Name:
Title:
_______________________________
Jane
Hsiao
,
Member
of the Frost Group, LLC
_______________________________
Steven
Rubin, Member of the Frost Group, LLC
_______________________________
Rao
Upp
aluri
,
Member
of the Frost Group, LLC
ANNEX
A
Member
|
Investment
|
Number
of Shares
|
|
|
|
Jane
Hsiao
|
$7,500,000
|
4,076,087
|
Steve
Rubin
|
$25,000
|
13,587
|
Rao
Uppaluri
|
$25,000
|
13,587
|
Frost
Gamma Investments Trust
|
$12,450,000
|
6,766,304
|
Total
|
|
|
OPKO
HEALTH, INC.
2007
EQUITY INCENTIVE PLAN
1.
DEFINITIONS
The
following terms shall have the following meanings unless the context indicates
otherwise:
1.1.
“
Affiliate
”
and
“
Associate
”
shall
have the respective meanings given to such terms under Rule 12b-2 under the
Exchange Act.
1.2.
“
Award
”
shall
mean either a Stock Option, an SAR, a Stock Award, a Stock Unit, a Performance
Share, a Performance Unit, or a Cash Award.
1.3.
“
Award
Agreement
”
shall
mean a written agreement between the Company and the Participant that
establishes the terms, conditions, restrictions and/or limitations applicable
to
an Award in addition to those established by the Plan and by the Committee’s
exercise of its administrative powers.
1.4.
“
Beneficial
Owner
”
shall
have the meaning given to such term under Rule 13d-3 under the Exchange
Act.
1.5.
“
Board
”
shall
mean the Board of Directors of the Company.
1.6.
“
Cash
Award
”
shall
mean the grant by the Committee to a Participant of an award of cash as
described in Section 11 below.
1.7.
“
Cause
”
shall
mean (i) willful malfeasance or willful misconduct by the Employee in
connection with his/her employment, (ii) continuing failure to perform such
duties as are requested by the Company and/or its subsidiaries,
(iii) failure by the Employee to observe material policies of the Company
and/or its subsidiaries applicable to the Employee, (iv) material breach of
any agreement with or duty owed to the Company and/or its subsidiaries
applicable to the Employee, or (v) the commission by the Employee of
(x) any felony or (y) any misdemeanor involving moral turpitude.
1.8.
“
Change
in Control of the Company
”
or
“
Change
in Control
”
shall
mean the occurrence of any of the following events:
(a) any
Person, as such term is used for purposes of Section 13(d) or 14(d) of the
Exchange Act, or any successor section thereto, (other than (i) the
Company, (ii) any trustee or other fiduciary holding securities under an
employee benefit plan of the Company, (iii) any Subsidiaries of the
Company, (iv) any company owned, directly or indirectly, by the
shareholders of the Company in substantially the same proportions as their
ownership of stock of the Company), or (v) the Frost Group, LLC or any of
its Affiliates becomes, either alone or together with such Person’s Affiliates
and Associates, the Beneficial Owner, directly or indirectly, of securities
of
the Company representing 50% or more of the combined voting power of the
Company’s then-outstanding securities.
(b) during
any period of twenty-four months, individuals who at the beginning of such
period constitute the Board, and any new directors whose election by the Board
or nomination for election by the Company’s shareholders was approved by a vote
of at least two-thirds of the directors then still in office who either were
directors at the beginning of the period or whose election or nomination for
election was previously so approved, cease for any reason to constitute at
least
a majority thereof;
(c) the
effective date or date of consummation of any transaction or series of
transactions (other than a transaction to which only the Company and one or
more
of its subsidiaries are parties) under which the Company is merged or
consolidated with any other company, other than a merger or consolidation which
would result in the voting securities of the Company outstanding immediately
prior thereto continuing to represent (either by remaining outstanding or by
being converted into voting securities of the surviving entity) 50% or more
of
the combined voting power of the voting securities of the Company or such
surviving entity outstanding
immediately after such merger or consolidation; or
(d) the
shareholders of the Company approve a plan of complete liquidation of the
Company or an agreement for the sale or disposition by the Company of all or
substantially all of the Company’s assets.
1.9.
“
Code
”
shall
mean the Internal Revenue Code of 1986, as amended from time to time.
1.10.
“
Committee
”
shall
mean the Board’s Compensation Committee or any other committee of the Board
appointed to administer this Plan.
1.11.
“
Common
Stock
”
shall
mean the common stock of the Company.
1.12.
“
Company
”
shall
mean OPKO Health, Inc., a Delaware Corporation.
1.13.
“
Disability
”
shall
mean the inability to engage in any substantial gainful activity by reason
of a
medically determinable physical or mental impairment which constitutes a
permanent and total disability, as defined in Section 22(e) (3) of the
Code (or any successor section thereto) and has applied for and been granted
Long Term Disability under the Company’s Long Term Disability Plan. The
determination whether a Participant has suffered a Disability shall be made
by
the Committee, in its sole discretion, based upon such evidence as it deems
necessary and appropriate, and shall be conclusive and binding on the
Participant. A Participant shall not be considered disabled unless he or she
furnishes such medical or other evidence of the existence of the Disability
as
the Committee, in its sole discretion, may require.
1.14.
“
Dividend
Equivalent Right
”
shall
mean the right to receive an amount equal to the amount of any dividend paid
with respect to a share of Common Stock multiplied by the number of shares
of
Common Stock underlying or with respect to a Stock Option, a SAR, a Stock Unit
or a Performance Unit, and which shall be payable in cash, in Common Stock,
in
the form of Stock Units or Performance Units, or a combination of any or all
of
the foregoing.
1.15.
“
Effective
Date
”
shall
mean the date on which the Board adopts the Plan.
1.16.
“
Employee
”
shall
mean an employee of the Company or any Subsidiary as described in Treasury
Regulation Section 1.421-7(h).
1.17.
“
Exchange
Act
”
shall
mean the Securities Exchange Act of 1934, as amended from time to time,
including applicable regulations thereunder.
1.18.
“
Fair
Market Value
”
shall,
unless otherwise required by any applicable provision of the Code or any
Treasury Regulations, mean:
(a) if
a security is listed or trading on a national securities exchange or other
market system, the closing price of such security on the date of calculation
(or
on the last preceding trading date if such security was not traded on such
date), or
(b) if
such security is not listed or trading on a national securities exchange or
other market system, as determined in good faith by the Board or the Committee.
1.19.
“
Family
Members
”
shall
mean a Participant’s spouse, parents, children, and siblings, whether by blood,
marriage or adoption.
1.20.
“
Independent
Contractor
”
shall
mean a Person (other than a Person who is an Employee or a Nonemployee Director)
or an entity that renders services to the Company or any Subsidiary.
1.21.
“
ISO
”
shall
mean an “incentive stock option” as such term is used in Code Section 422.
1.22.
“
Nonemployee
Director
”
shall
mean a member of the Board or the board of directors of a Subsidiary who is
not
an Employee.
1.23.
“
Nonqualified
Stock Option
”
shall
mean a Stock Option that is not an ISO.
1.24.
“
Participant
”
shall
mean any Employee, Nonemployee Director or Independent Contractor to whom an
Award has been granted by the Committee under the Plan.
1.25.
“
Performance-Based
Award
”
shall
mean an Award subject to the achievement of certain performance goal or goals
as
described in Section 12 below.
1.26.
“
Performance
Share
”
shall
mean the grant by the Committee to a Participant of an Award as described in
Section 10.1 below.
1.27.
“
Performance
Unit
”
shall
mean the grant by the Committee to a Participant of an Award as described in
Section 10.2 below.
1.28.
“
Person
”
shall
mean any person, entity or “group” (within the meaning of Section 13(d)(3)
or Section 14(d)(2) of the Exchange Act).
1.29.
“
Plan
”
shall
mean the OPKO Health, Inc. 2007 Equity Incentive Plan, as it may be amended
from
time to time.
1.30.
“
Retirement
”
shall
mean the termination of the employment, other than for Cause or due to death
or
Disability, of a Participant who; (i) has reached the age of 65;
(ii) has reached the age of 62 and has completed 5 years of service
with the Company; or (iii) has reached the age of 60 and has completed
10 years of service with the Company.
1.31.
“
SAR
”
shall
mean the grant by the Committee to a Participant of a stock appreciation right
as described in Section 8 below.
1.32.
“
Stock
Award
”
shall
mean the grant by the Committee to a Participant of an Award of Common Stock
as
described in Section 9.1 below.
1.33.
“
Stock
Option
”
shall
mean the grant by the Committee to a Participant of an option to purchase Common
Stock as described in Section 7 below.
1.34.
“
Stock
Unit
”
shall
mean the grant by the Committee to a Participant of an Award as described in
Section 9.2 below.
1.35.
“
Subsidiary
”
shall
mean a corporation of which the Company is the Beneficial Owner, directly or
indirectly, of more than 50% of the Voting Stock or any other business entity
in
which the Company is the Beneficial Owner, directly or indirectly, of more
than
50% or any other business venture designated by the Committee in which the
Company has a significant interest, as determined in the discretion of the
Committee.
1.36.
“
Treasury
Regulations
”
shall
mean the regulations promulgated under the Code by the United States Department
of the Treasury, as amended from time to time.
1.37.
“
Vest
”
shall
mean:
(a) with
respect to Stock Options and SARs, when the Stock Option or SAR (or a portion
of
such Stock Option or SAR) first becomes exercisable and remains exercisable
subject to the terms and conditions of such Stock Option or SAR; or
(b) with
respect to Awards other than Stock Options and SARs, when the Participant has:
(i) an
unrestricted right to receive the compensation (whether payable in Common Stock,
cash or a combination of both) attributable to such Award (or a portion of
such
Award) or to otherwise enjoy the benefits underlying such Award; and
(ii) a
right to transfer an Award subject to no Company-imposed restrictions or
limitations other than restrictions and/or limitations imposed by
Section 14 below
1.38.
“
Vesting
Date
”
shall
mean the date or dates on which an Award Vests.
1.39.
“
Voting
Stock
”
shall
mean the capital stock of any class or classes having general voting power
under
ordinary circumstances, in the absence of contingencies, to elect the directors
of a corporation.
2.
PURPOSE AND TERM OF PLAN
2.1.
Purpose
.
The
purpose of the Plan is to motivate certain Employees, Nonemployee Directors
and
Independent Contractors to put forth maximum efforts toward the growth,
profitability, and success of the Company and Subsidiaries by providing
incentives to such Employees, Nonemployee Directors and Independent Contractors
either through cash payments and/or through the ownership and performance of
the
Common Stock. In addition, the Plan is intended to provide incentives which
will
help the Company attract and retain highly qualified individuals as Employees
and Nonemployee Directors and to assist in aligning the interests of such
Employees and Nonemployee Directors with those of its shareholders.
2.2.
Term
.
The
Plan shall be effective as of the Effective Date; provided, however, that the
Plan shall be approved by the shareholders of the Company at an annual meeting
or any special meeting of shareholders of the Company within 12 months
before or after the Effective Date, and such approval by the shareholders of
the
Company shall be a condition to the right of each Participant to receive Awards
hereunder. Any Award granted under the Plan prior to the approval by the
shareholders of the Company shall be effective as of the date of grant (unless
the Committee specifies otherwise at the time of grant), but no such Award
may
Vest, be paid out, or otherwise be disposed of prior to such shareholder
approval. If the shareholders of the Company fail to approve the Plan in
accordance with this Section 2.2, any Award granted under the Plan shall be
automatically cancelled without payment of any consideration to the recipient
of
such Award. The Plan shall remain in effect for ten years or until earlier
terminated by the Board and no Award may be granted under the Plan on a date
that is more than ten years from the Effective Date; provided, however, that
in
the event of Plan termination or expiration, the provisions of the Plan shall
remain in effect as to any Awards which remain outstanding until all such Awards
have been satisfied or are terminated under the terms of this Plan or under
the
applicable Award Agreement.
3.
ELIGIBILITY AND PARTICIPATION
3.1.
Eligibility
.
All
Employees, all Nonemployee Directors and all Independent Contractors shall
be
eligible to participate in the Plan and to receive Awards. An individual’s
status as a member of the Committee will not affect his eligibility to
participate in the Plan.
3.2.
Participation
.
Participants shall consist of such Employees, Nonemployee Directors and
Independent Contractors as the Committee in its sole discretion designates
to
receive Awards under the Plan. Subject to Section 7.1, an Award may also be
granted to an Employee, in connection with hiring, retention or otherwise prior
to the date the Employee first performs services for the Company or any
Subsidiary, provided that such Awards shall not become Vested prior to the
date
the Employee first performs such services. Designation of a Participant in
any
year shall not require the Committee to designate such Person to receive an
Award in any other year or, once designated, to receive the same type or amount
of Award as granted to the Participant in any other year. The Committee shall
consider such factors as it deems pertinent in selecting Participants and in
determining the type and amount of their respective Awards.
4.
ADMINISTRATION
4.1.
Responsibility
.
The
Committee shall have the responsibility, in its sole discretion, to control,
operate, manage and administer the Plan in accordance with its terms; provided,
however, that the Board may in any instance perform any of the functions of
the
Committee hereunder.
4.2.
Award
Agreement
.
Each
Award granted under the Plan shall be evidenced by an Award Agreement which
shall be signed by the Company and the Participant; provided, however, that
in
the event of any conflict between a provision of the Plan and any provision
of
an Award Agreement, the provision of the Plan shall prevail.
4.3.
Authority
of the Committee
.
The
Committee shall have all the discretionary authority that may be necessary
or
helpful to enable it to discharge its responsibilities with respect to the
Plan,
including but not limited to the following:
(a) to
determine eligibility for participation in the Plan and to select Participants;
(b) to
determine eligibility for and the type and size of an Award granted under the
Plan;
(c) to
make Awards in accordance with the terms of the Plan and to determine the terms
and conditions of each Award;
(d) to
supply any omission, correct any defect, or reconcile any inconsistency in
the
Plan in such manner and to such extent as it shall deem appropriate in its
sole
discretion to carry the same into effect;
(e) to
issue administrative guidelines as an aid to administer the Plan and make
changes in such guidelines as it from time to time deems proper;
(f) to
make rules for carrying out and administering the Plan and make changes in
such
rules as it from time to time deems proper;
(g) to
the extent permitted under the Plan, grant waivers of Plan terms, conditions,
restrictions, and limitations and to vary the terms of Awards
(h) to
take account of tax, securities law and other regulatory requirements of foreign
jurisdictions;
(i) to
accelerate the Vesting of any Award when such action or actions would be in
the
best interest of the Company;
(j) to
grant Awards in replacement of Awards previously granted under this Plan or
any
other executive compensation plan of the Company; and
(k) to
take any and all other actions it deems necessary or advisable for the proper
operation or administration of the Plan.
4.4.
Action
by the Committee
.
The
Committee may act only by a majority of its members. Any determination of the
Committee may be made, without a meeting, by a writing or writings signed by
all
of the members of the Committee. In addition, the Committee may authorize any
one or more of its members or, subject to Section 4.5 below, one or more
agents to execute and deliver documents on behalf of the Committee.
4.5.
Delegation
of Authority
.
To the
extent permitted by applicable law, the Committee may delegate to one or more
of
its members, or to one or more officers of the Company, such administrative
duties as it may deem advisable; provided, however, that any such delegation
shall be in writing and, provided, further, that the Committee may not delegate
its authority (a) to make Awards to Participants or (b) under
Sections 4.3 (a), (b), (c), (d), (e), (f), (g), (h), (i) or
(j) or Section 16 of the Plan. Any action undertaken by any such
member or agent in accordance with the Committee’s delegation of authority shall
have the same force and effect as if undertaken directly by the Committee,
and
any reference in the Plan to the Committee shall, to the extent consistent
with
the terms and limitations of such delegation, be deemed to include a reference
to such members or agents. In addition, the Committee, or any Person to whom
it
has delegated duties under this Section 4.5, may employ one or more Persons
to render advice with respect to any responsibility the Committee or such Person
may have under the Plan. The Committee may employ such legal or other counsel,
consultants and agents as it may deem desirable for the administration of the
Plan. Expenses incurred by the Committee in the engagement of such counsel,
consultant or agent shall be paid by the Company, or the Subsidiary whose
employees have benefited from the Plan, as determined by the Committee. In
the
performance of its functions, the Committee shall be entitled to rely upon
information, opinions, computations and advice furnished by the Company’s
officers, any counsel, consultant or agent retained by the Committee, and any
other party the Committee deems necessary, and no member of the Committee shall
be liable for any action taken or not taken in reliance upon any such advice.
4.6.
Determinations
and Interpretations by the Committee
.
All
determinations and interpretations made by the Committee shall be binding and
conclusive on all Participants and their heirs, successors, and legal
representatives.
4.7.
Liability
.
No
member of the Board, no member of the Committee and no Employee shall be liable
for any act or failure to act hereunder, except in circumstances involving
his
or her willful misconduct, or for any act or failure to act hereunder by any
other member or Employee or by any agent to whom duties in connection with
the
administration of the Plan have been delegated.
4.8.
Indemnification
.
The
Company shall indemnify members of the Board, members of the Committee and
any
agent of the Committee who is an Employee, against any and all liabilities
or
expenses to which they may be subjected (including, without limitation, the
reasonable fees and expenses of counsel) by reason of any act or failure to
act
with respect to their duties on behalf of the Plan, except in circumstances
involving such Person’s willful misconduct.
5.
SHARES SUBJECT TO PLAN
5.1.
Available
Shares
.
Subject
to the provisions of Section 5.2 below, the aggregate number of shares of
Common Stock which shall be available for grants or payments of Awards under
the
Plan during its term shall be 35,000,000 shares (the “
Total
Plan Shares
”).
In
the event that (i) an Award (or portion thereof) lapses, expires or is
otherwise terminated without the issuance of the shares subject to such Award
or
is settled by the delivery of consideration other than shares, (ii) shares
are tendered to pay the exercise price of a Stock Option or other Award or
(iii) shares are withheld from any award to satisfy a Participant’s tax
withholding obligations or, if applicable, to pay the exercise price of a Stock
Option or other Award, such shares shall again become available for grants
or
Awards hereunder. Such shares of Common Stock available for issuance under
the
Plan may be either authorized but unissued shares, shares of issued stock held
in the Company’s treasury, or both, at the discretion of the Company. Awards
that are payable only in cash are not subject to this Section 5.1.
5.2.
Adjustment
to Shares
.
The
existence of the Plan, the Award Agreements and the Awards granted hereunder
shall not affect or restrict in any way the right or power of the Company or
the
shareholders of the Company to make or authorize any adjustment,
recapitalization, reorganization or other change in the Company’s capital
structure or its business, any merger or consolidation of the Company, any
issue
of stock or of options, warrants or rights to purchase stock or of bonds,
debentures, preferred or prior preference stocks whose rights are superior
to or
affect the Common Stock or the rights thereof or which are convertible into
or
exchangeable for Common Stock, or the dissolution or liquidation of the Company,
or any sale or transfer of all or any part of its assets or business, or any
other corporate act or proceeding, whether of a similar character or otherwise.
If there is any change in the Common Stock of the Company, through merger,
consolidation, reorganization, recapitalization, stock dividend, stock split,
reverse stock split, split-up, split-off, spin-off, combination of shares,
exchange of shares, dividend in kind or other like change in capital structure
or distribution to shareholders of the Company in the nature of a liquidating
distribution or a distribution pursuant to a plan of dissolution, the Committee
may, in its discretion, make a proportionate adjustment to each outstanding
Award that the Committee considers appropriate so that thereafter each such
Award shall be with respect to or exercisable for such securities, cash and/or
other property as would have been received in respect of the Common Stock
subject to such Award had such Award been paid, distributed or exercised in
full
immediately prior to such change or distribution. In addition, in the event
of
any such change or distribution, in order to prevent dilution or enlargement
of
Participants’ rights under the Plan, the Committee shall have the authority to
adjust, in an equitable manner as it deems appropriate, the number and kind
of
shares that may be received in respect of any Award, the number and kind of
shares subject to outstanding Awards, the exercise price applicable to
outstanding Stock Options, and the Fair Market Value of the Common Stock and
other value determinations applicable to outstanding Awards. Appropriate
adjustments may also be made by the Committee in the terms of any Awards granted
under the Plan to reflect such changes or distributions and to modify any other
terms of outstanding Awards on an equitable basis, including modifications
of
performance goals and changes in the length of performance periods; provided,
however, that with respect to Performance-Based Awards, such modifications
and/or changes do not disqualify compensation attributable to such Awards as
“performance-based compensation” under Code Section 162(m). In addition,
the Committee is authorized to make adjustments to the terms and conditions
of,
and the criteria included in, Awards in recognition of unusual or nonrecurring
events affecting the Company or the financial statements of the Company, or
in
response to changes in applicable laws, regulations, or accounting principles.
The Committee’s determination of what, if any, adjustments shall be made shall
be final and binding on the Company and all Participants.
5.3.
No
Repricing
.
Absent
shareholder approval, neither the Committee nor the Board shall have the
authority, with or without the consent of the affected holders of the Awards,
to
“reprice” an Award after the date of its initial grant with a lower exercise
price in substitution for the original exercise price. Adjustments in accordance
with Section 5.2 above shall not be deemed “repricings” for purposes of
this Section 5.3. This Section 5.3 may not be
amended,
altered or repealed by the Committee or the Board without the approval of the
shareholders of the Company.
6.
MAXIMUM INDIVIDUAL AWARDS
6.1.
Maximum
Aggregate Number of Shares Underlying Stock-Based Awards Granted Under the
Plan to Any Single Participant
.
The
maximum aggregate number of shares of Common Stock underlying all Awards
measured in shares of Common Stock (whether payable in Common Stock, cash or
a
combination of both) that may be granted to any single Participant in respect
of
any fiscal year of the Company shall be 2,000,000 shares, subject to
adjustment as provided in Section 5.2 above.
6.2.
Maximum
Dollar Amount Underlying Cash-Based Awards Granted Under the Plan to Any Single
Participant
.
The
maximum dollar amount that may be paid to any single Participant with respect
to
all Awards measured in cash (whether payable in Common Stock, cash or a
combination of both) in respect of any fiscal year of the Company shall be
$2,000,000.
7.
STOCK OPTIONS
7.1.
In
General
.
The
Committee may, in its sole discretion, grant Stock Options to Employees,
Nonemployee Directors and Independent Contractors on or after the Effective
Date, subject, in all cases to Section 2.2 of the Plan. The Committee
shall, in its sole discretion, determine the Employees, the Nonemployee
Directors and Independent Contractors who will receive Stock Options and the
number of shares of Common Stock underlying each Stock Option. Each Stock Option
shall be subject to such terms and conditions consistent with the Plan set
forth
in the applicable Award Agreement and such other terms and conditions consistent
with the Plan and the applicable Award Agreement as the Committee may impose
from time to time. In addition, each Stock Option shall be subject to the
following terms and conditions set forth in Sections 7.2 through 7.8 below.
7.2.
Exercise
Price
.
The
Committee shall specify the exercise price of each Stock Option in the Award
Agreement; provided, however, that the exercise price of any Nonqualified Stock
Option shall not be less than 100% of the Fair Market Value of the Common Stock
on the date of grant.
7.3.
Term
of Stock Option
.
The
Committee shall specify the term of each Stock Option in the Award Agreement
shall terminate as set forth in Section 14 below or at such earlier times
and upon such conditions or circumstances as the Committee shall, in its sole
discretion, set forth in the Award Agreement.
7.4.
Vesting
Date
.
The
Committee shall specify the Vesting Date with respect to each Stock Option
in
the Award Agreement; provided, that the Committee may provide in the applicable
Award Agreement that any Stock Option shall Vest in such portions or
installments as the Committee may, in its sole discretion, determine. The
Committee may grant Stock Options that are Vested, either in whole or in part,
on the date of grant. If the Committee fails to specify a Vesting Date in the
Award Agreement, 25% of such Stock Option shall become exercisable on each
of
the first four anniversaries of the date of grant and shall remain exercisable
following such anniversary date until the Stock Option expires in accordance
with its terms under the Award Agreement or under the terms of the Plan. The
Vesting of a Stock Option may be subject to such other terms and conditions
as
shall be determined by the Committee, including, without limitation,
accelerating the Vesting if certain performance goals are achieved.
7.5.
Exercise
of Stock Options
.
The
Stock Option exercise price may be paid in cash or, in the sole discretion
of
the Committee, by the delivery of shares of Common Stock or other securities
of
the Company then owned by the Participant, by the withholding of shares of
Common Stock for which a Stock Option is exercisable, or by a combination of
these methods. In the sole discretion of the Committee, and subject to all
applicable laws, rules and regulations, payment may also be made by delivering
a
properly executed exercise notice to the Company together with a copy of
irrevocable instructions to a broker to deliver promptly to the Company the
amount of sale proceeds to pay the exercise price. To facilitate the foregoing,
the Company may enter into agreements for coordinated procedures with one or
more brokerage firms. The Committee may prescribe any other method of paying
the
exercise price that it determines to be consistent with applicable law and
the
purpose of the Plan, including, without limitation, in lieu of the exercise
of a
Stock Option by delivery of shares of Common Stock then owned by a Participant,
providing the Company with a notarized statement attesting to the number of
shares owned by the
Participant,
where upon verification by the Company, the Company would issue to the
Participant only the number of incremental shares to which the Participant
is
entitled upon exercise of the Stock Option. In determining which methods a
Participant may utilize to pay the exercise price, the Committee may consider
such factors as it determines are appropriate; provided, however, that any
method approved by the Committee shall comply with applicable securities laws.
When payment of the exercise price for a Stock Option consists of shares of
the
Company’s capital stock or other securities of the Company, such securities will
not be accepted as payment unless the Participant has held such shares for
the
requisite period necessary to avoid a charge to the Company’s earnings for
financial reporting purposes.
7.6.
Additional
Terms and Conditions
.
The
Committee may, by way of the Award Agreements or otherwise, establish such
other
terms, conditions, restrictions and/or limitations, if any, of any Stock Option,
as they may determine in their sole discretion; provided, they are not
inconsistent with the Plan, including, without limitation, any requirement
that
the Participant not engage in competition with the Company or any Subsidiary.
7.7.
Conversion
Stock Options
.
The
Committee may, in its sole discretion and upon such terms and conditions as
it
deems appropriate, grant a Stock Option to any holder of an option (hereinafter
referred to as an “Original Option”) to purchase shares of the stock of any
corporation:
(a) the
stock or all or substantially all of the assets of which were acquired, directly
or indirectly, by the Company or any Subsidiary, or
(b) which
was merged with and into the Company or a Subsidiary, so that the Original
Option is converted into a Stock Option (hereinafter referred to as a
“Conversion Stock Option”); provided, however, that such Conversion Stock Option
as of the date of its grant (the “
Conversion
Stock Option Grant Date
”)
shall
have substantially the same economic value as the Original Option as of the
Conversion Stock Option Grant Date.
8.
STOCK APPRECIATION RIGHTS
8.1.
In
General
.
The
Committee may, in its sole discretion, grant SARs to Employees, Nonemployee
Directors, and/or Independent Contractors. An SAR is a right to receive a
payment in cash, Common Stock or a combination of both, in an amount equal
to
the excess of (x) the Fair Market Value of the Common Stock, or other
specified valuation, of a specified number of shares of Common Stock on the
date
the SAR is exercised over (y) the Fair Market Value of the Common Stock, or
other specified valuation (which shall be no less than the Fair Market Value
of
the Common Stock), of such shares of Common Stock on the date the SAR is
granted, all as determined by the Committee. If a SAR is granted retroactively
in tandem with or in substitution for a Stock Option, the designated Fair Market
Value of the Common Stock in the Award Agreement shall be the Fair Market Value
of the Common Stock on the date such Stock Option was granted, the SAR shall
cover the same number of shares of Common Stock as covered by the Stock Option
(or such lesser number of shares as the Committee may determine) and the SAR
shall be exercisable only at such time or times and to the extent the related
Stock Option shall be exercisable, and shall have the same term and exercise
price as the related Stock Option. Upon exercise of a Stock Appreciation Right
granted in tandem with a Stock Option, the related Stock Option shall be
cancelled automatically to the extent of the number of shares covered by such
exercise; conversely, if the related Stock Option is exercised as to some or
all
of the shares covered by the tandem grant, the tandem Stock Appreciation Right
shall be cancelled automatically to the extent of the number of shares covered
by the Stock Option exercised. Each SAR shall be subject to such terms and
conditions, including, but not limited to, a provision that automatically
converts a SAR into a Stock Option on a conversion date specified at the time
of
grant, as the Committee shall impose from time to time in its sole discretion
and subject to the terms of the Plan.
9.
STOCK AWARDS AND STOCK UNITS
9.1.
Stock
Awards
.
The
Committee may, in its sole discretion, grant Stock Awards to Employees,
Nonemployee Directors, and/or Independent Contractors as additional compensation
or in lieu of other compensation for services to the Company. A Stock Award
shall consist of shares of Common Stock which shall be subject to such terms
and
conditions as the Committee in its sole discretion determines appropriate,
including, without limitation, restrictions on the sale or other
disposition
of such
shares, the Vesting
Date
with
respect to such shares, and the right
of
the
Company to reacquire such shares for no consideration upon termination of the
Participant’s employment within specified periods. With respect to the shares of
Common Stock subject to a Stock Award, the Participant shall have all of the
rights of a holder of shares of Common Stock, including the right to receive
dividends and to vote the shares, unless the Committee determines otherwise
on
the date of grant. The Committee may require the Participant to deliver a duly
signed stock power, endorsed in blank, relating to the Common Stock covered
by
such Stock Award. As a condition to any Stock Award, the Participant may be
required to deliver to the Company a share power, endorsed in blank, relating
to
the Shares covered by such Award. Any share certificate issued in connection
with a Stock Award may be held in the custody of the Company and will bear
the
following legend and/or any other legend required by this Plan, the applicable
Award Agreement or applicable law:
THE
TRANSFERABILITY OF THIS CERTIFICATE AND THE SHARES REPRESENTED HEREBY ARE
SUBJECT TO THE TERMS AND CONDITIONS OF THE OPKO HEALTH, INC. 2007 EQUITY
INCENTIVE PLAN AND AN AGREEMENT ENTERED INTO BETWEEN THE PARTICIPANT AND OPKO
HEALTH, INC. (WHICH TERMS AND CONDITIONS MAY INCLUDE, WITHOUT LIMITATION,
CERTAIN TRANSFER RESTRICTIONS AND FORFEITURE CONDITIONS). COPIES OF THAT PLAN
AND AGREEMENT ARE ON FILE IN THE PRINCIPAL OFFICES OF EXEGENICS INC. AND WILL
BE
MADE AVAILABLE TO THE HOLDER OF THIS CERTIFICATE WITHOUT CHARGE UPON REQUEST
TO
THE SECRETARY OF OPKO HEALTH, INC.
9.2.
Stock
Units
.
The
Committee may, in its sole discretion, grant Stock Units to Employees,
Nonemployee Directors, and/or Independent Contractors as additional compensation
or in lieu of other compensation for services to the Company. A Stock Unit
is a
hypothetical share of Common Stock represented by a notional account established
and maintained (or caused to be established or maintained) by the Company for
such Participant who receives a grant of Stock Units. Stock Units shall be
subject to such terms and conditions as the Committee, in its sole discretion,
determines appropriate including, without limitation, determinations of the
Vesting Date with respect to such Stock Units and the criteria for the Vesting
of such Stock Units. A Stock Unit granted by the Committee shall provide for
payment in shares of Common Stock at such time or times as the Award Agreement
shall specify. The Committee shall determine whether a Participant who has
been
granted a Stock Unit shall also be entitled to a Dividend Equivalent Right.
9.3.
Payout
of Stock Units
.
Subject
to a Participant’s election to defer in accordance with Section 17.3 below,
upon the Vesting of a Stock Unit, the shares of Common Stock representing the
Stock Unit shall be distributed to the Participant, unless the Committee, in
its
sole discretion, provides for the payment of the Stock Unit in cash (or partly
in cash and partly in shares of Common Stock) equal to the value of the shares
of Common Stock which would otherwise be distributed to the Participant.
10.
PERFORMANCE SHARES AND PERFORMANCE UNITS
10.1.
Performance
Shares
.
The
Committee may, in its sole discretion, grant Performance Shares to Employees,
Nonemployee Directors, and/or Independent Contractors as additional compensation
or in lieu of other compensation for services to the Company. A Performance
Share shall consist of a share or shares of Common Stock which shall be subject
to such terms and conditions as the Committee, in its sole discretion,
determines appropriate, including, without limitation, determining the
performance goal or goals which, depending on the extent to which such goals
are
met, will determine the number and/or value of the Performance Shares that
will
be paid out or distributed to the Participant who has been granted Performance
Shares. Performance goals may be based on, without limitation, Company-wide,
divisional and/or individual performance, as the Committee, in its sole
discretion, may determine, and may be based on the performance measures listed
in Section 12.3 below. With respect to the Performance Shares, the
Participant shall have none of the rights of a holder of shares of Common Stock,
including the right to receive dividends and to vote the shares, unless and
until such Performance Shares shall have been Vested and distributed to the
Participant.
10.2.
Performance
Units
.
The
Committee may, in its sole discretion, grant Performance Units to Employees,
Nonemployee Directors, and/or Independent Contractors as additional compensation
or in lieu of other compensation for services to the Company. A Performance
Unit
is a hypothetical share or shares of Common Stock represented by a notional
account which shall be established and maintained (or caused to be established
or
maintained)
by the Company for such Participant who receives a grant of Performance Units.
Performance Units shall be subject to such terms and conditions as the
Committee, in its sole discretion, determines appropriate, including, without
limitation, determining the performance goal or goals which, depending on the
extent to which such goals are met, will determine the number and/or value
of
the Performance Units that will be accrued with respect to the Participant
who
has been granted Performance Units. Performance goals may be based on, without
limitation, Company-wide, divisional and/or individual performance, as the
Committee, in its sole discretion, may determine, and may be based on the
performance measures listed in Section 12.3 below.
10.3.
Payout
of Performance Shares or Performance Units
.
Subject
to a Participant’s election to defer in accordance with Section 17.3 below,
upon the Vesting of a Performance Share or a Performance Unit, the shares of
Common Stock representing the Performance Share or the Performance Unit shall
be
distributed to the Participant, unless the Committee, in its sole discretion,
provides for the payment of the Performance Share or a Performance Unit in
cash
(or partly in cash and partly in shares of Common Stock) equal to the value
of
the shares of Common Stock which would otherwise be distributed to the
Participant.
11.
CASH AWARDS
11.1.
In
General
.
The
Committee may, in its sole discretion, grant Cash Awards to Employees,
Nonemployee Directors, and/or Independent Contractors as additional compensation
or in lieu of other compensation for services to the Company. A Cash Award
shall
be subject to such terms and conditions as the Committee, in its sole
discretion, determines appropriate, including, without limitation, determining
the Vesting Date with respect to such Cash Award, the criteria for the Vesting
of such Cash Award, and the right of the Company to require the Participant
to
repay the Cash Award (with or without interest) upon termination of the
Participant’s employment within specified periods.
12.
PERFORMANCE-BASED AWARDS
12.1.
In
General
.
The
Committee, in its sole discretion, may designate Awards granted under the Plan
as Performance-Based Awards (as defined below) if it determines that such
compensation might not be tax deductible by the Company due to the deduction
limitation imposed by Code Section 162(m). Accordingly, an Award granted
under the Plan may be granted in such a manner that the compensation
attributable to such Award is intended by the Committee to qualify as “qualified
performance-based compensation” (as such term is used in Code
Section 162(m) and the Treasury Regulations thereunder) and thus be exempt
from the deduction limitation imposed by Code Section 162(m)
(“Performance-Based Awards”).
12.2.
Qualification
of Performance-Based Awards
.
Awards
shall only qualify as Performance-Based Awards under the Plan if:
(a) at
the time of grant the Committee is comprised solely of two or more “outside
directors” (as such term is used in Code Section 162(m) and the Treasury
Regulations thereunder);
(b) with
respect to either the granting or Vesting of an Award (other than (i) a
Nonqualified Stock Option or (ii) a SAR, which are granted with an exercise
price at or above the Fair Market Value of the Common Stock on the date of
grant), such Award is subject to the achievement of a performance goal or goals
based on one or more of the performance measures specified in Section 12.3
below;
(c) the
Committee establishes in writing (i) the objective performance-based goals
applicable to a given performance period and (ii) the individual employees
or class of employees to which such performance-based goals apply no later
than
90 days after the commencement of such performance period (but in no event
after 25 percent of such performance period has elapsed);
(d) no
compensation attributable to a Performance-Based Award will be paid to or
otherwise received by a Participant until the Committee certifies in writing
that the performance goal or goals (and any other material terms) applicable
to
such performance period have been satisfied; and
(e) after
the establishment of a performance goal, the Committee shall not revise such
performance goal (unless such revision will not disqualify compensation
attributable to the Award as “performance-based
compensation”
under Code Section 162(m)) or increase the amount of compensation payable
with respect to such Award upon the attainment of such performance goal.
12.3.
Performance
Measures
.
The
Committee shall use the following performance measures (either individually
or
in any combination) to set performance goals with respect to Awards intended
to
qualify as Performance-Based Awards: net sales; pretax income before allocation
of corporate overhead and bonus; budget; cash flow; earnings per share; net
income; financial goals; return on shareholders’ equity; return on assets;
attainment of strategic and operational initiatives; appreciation in and/or
maintenance of the price of the Common Stock or any other publicly-traded
securities of the Company; market share; gross profits; earnings before interest
and taxes; earnings before interest, taxes, depreciation and amortization;
economic value-added models; comparisons with various stock market indices;
and/or reductions in costs.
13.
CHANGE IN CONTROL
13.1.
Accelerated
Vesting
.
Notwithstanding any other provision of this Plan to the contrary, and without
limiting the powers of the Committee under Section 4.3 of the Plan, if
there is a Change in Control of the Company, the Vesting Date and/or payout
of
each outstanding Award shall be accelerated so that each such Award shall,
immediately prior to the effective date of the Change in Control, become fully
vested with respect to the total number of shares of Common stock subject to
such Award. Upon the consummation of any Change of Control, all outstanding
Awards under the Plan shall, to the extent not previously exercised, either
be
assumed by any successor corporation or parent thereof or be replaced with
a
comparable Award with respect to shares of common stock of such successor
corporation or parent thereof.
13.2.
Cashout
.
The
Committee, in its sole discretion, may determine that, upon the occurrence
of a
Change in Control of the Company, all or a portion of certain outstanding Awards
shall terminate within a specified number of days after notice to the holders,
and each such holder shall receive an amount equal to the value of such Award
on
the date of the Change in Control, and with respect to each share of Common
Stock subject to a Stock Option or SAR, an amount equal to the excess of the
Fair Market Value of such shares of Common Stock immediately prior to the
occurrence of such Change in Control (or such other greater amount as the
Committee may determine in its sole and absolute discretion to be equitable
to
prevent dilution or enlargement of Participants’ rights under the Plan) over the
exercise price per share of such Stock Option or SAR. Such amount shall be
payable in cash, in one or more kinds of property (including the property,
if
any, payable in the transaction) or in a combination thereof, as the Committee,
in its sole discretion, shall determine.
13.3.
Assumption
or Substitution of Awards
.
Notwithstanding anything contained in the Plan to the contrary, the Committee
may, in its sole discretion, provide that an Award may be assumed by any entity
which acquires control of the Company or may be substituted by a similar award
under such entity’s compensation plans.
14.
TERMINATION OF EMPLOYMENT IF PARTICIPANT IS AN EMPLOYEE
14.1.
Termination
of Employment Due to Death
.
Subject
to the terms of the Plan, any written agreement between the Participant and
the
Company, and the applicable Award Agreement, if a Participant’s employment is
terminated due to death:
(a) all
non-Vested portions of Awards held by the Participant on the date of the
Participant’s death shall immediately be forfeited by such Participant as of
such date; and
(b) all
Vested portions of Stock Options and SARs held by the Participant on the date
of
the Participant’s death shall remain exercisable until the earlier of:
(i) the
end of the 12-month period following the date of the Participant’s death, or
(ii) the
date the Stock Option or SAR would otherwise expire.
14.2.
Termination
of Employment for Cause
.
Subject
to the terms of the Plan, any written agreement between the Participant and
the
Company, and the applicable Award Agreement, if a Participant’s employment is
terminated by the Company for Cause, all Awards held by a Participant on the
date of the termination of his or her employment for Cause, whether Vested
or
non-Vested, shall immediately be forfeited by such Participant as of such
date.
If
a Participant’s employment is terminated for Cause during the six months
following any exercise, payment or delivery pursuant to an Award, such exercise,
payment or delivery may be rescinded within two years thereafter. In the event
of any such rescission, the Participant shall pay to the Company the amount
of
any gain realized or payment received as a result of the rescinded exercise,
payment or delivery, in such manner and on such terms and conditions as may
be
required, and the Company shall be entitled to set-off against the amount of
any
such gain any amount owed to the Participant by the Company.
14.3.
Termination
of Employment Due to Retirement or Disability
.
Subject
to the terms of the Plan, any written agreement between the Participant and
the
Company, and the applicable Award Agreement, if a Participant’s employment is
terminated due to Retirement or Disability of the Participant:
(a) all
non-Vested portions of Awards held by the Participant on the date of the
Participant’s Retirement or the date of the termination of his or her
employment, as the case may be, shall immediately be forfeited by such
Participant as of such date; and
(b) all
Vested portions of Stock Options and SARs held by the Participant on the date
of
the Participant’s Retirement or the date of the termination of his or her
employment, as the case may be, shall remain exercisable until the earlier
of:
(i) the
end of the 36-month period following the date of the Participant’s Retirement or
the date of the termination of his or her employment, as the case may be, or
(ii) the
date the Stock Option or SAR would otherwise expire.
14.4.
Other
Terminations of Employment
.
Subject
to the terms of the Plan, any written agreement between the Participant and
the
Company, and the applicable Award Agreement, if a Participant’s employment is
terminated for any reason other than for Cause, retirement or due to death
or
Disability:
(a) all
non-Vested portions of Awards held by the Participant on the date of the
termination of his or her employment shall immediately be forfeited by such
Participant as of such date; and all Vested portions of Stock Options and/or
SARs held by the Participant on the date of the termination of his or her
employment shall remain exercisable until the earlier of;
(i) the
end of the 12-month period following the date of the termination of the
Participant’s employment, or
(ii) the
date the Stock Option or SAR would otherwise expire.
14.5.
Change
in Status
.
Notwithstanding anything to the contrary set forth in the Plan, if any Employee
ceases for any reason to be an Employee but continues to perform services for
the Company (whether as a Nonemployee Director, consultant, agent, Independent
Contractor or otherwise), such Participant shall retain his or her Awards upon
the original terms and conditions thereof; provided, however, that if such
Participant thereafter ceases to perform services for the Company then the
provisions of this Section 14.4 shall no longer apply and such Award shall
thereafter be subject to the provisions of Section 14.1, 14.2 or 14.3, as
applicable.
14.6.
Committee
Discretion
.
Notwithstanding anything contained in the Plan to the contrary, and without
limiting the powers of the Committee under Section 4.3 of the Plan, the
Committee may, in its sole discretion, provide that:
(a) any
or all non-Vested portions of Stock Options and/or SARs held by the Participant
on the date of the Participant’s death and/or the date of the termination of his
or her employment shall immediately become exercisable as of such date and
shall
remain exercisable until a date that occurs on or prior to the date the Stock
Option or SAR is scheduled to expire;
(b) any
or all Vested portions of Nonqualified Stock Options and/or SARs held by the
Participant on the date of the Participant’s death and/or the date of the
termination of his or her employment shall remain exercisable until a date
that
occurs on or prior to the date the Stock Option or SAR is scheduled to expire;
and/or
(c) any
or all non-Vested portions of Stock Awards, Stock Units, Performance Shares,
Performance Units, and/or Cash Awards held by the Participant on the date of
the
Participant’s death and/or the date of the termination of his or her employment
shall immediately Vest or shall become Vested on a date that occurs on or prior
to the date the Award is scheduled to vest.
(d) Cancellation
and Rescission of Awards Due to Detrimental Activity. Unless the Award Agreement
specifies otherwise, and regardless of whether the Participant’s employment or
engagement with the Company is terminated (whether for Cause or otherwise),
the
Committee may cancel, rescind, or otherwise withhold any Awards held by a
Participant, whether Vested or non-Vested, and any such Awards shall immediately
be forfeited by such Participant at any time that the Participant is not in
compliance with all applicable provisions of the Award Agreement and the Plan,
or if the Participant engages in any “Detrimental Activity.” For purposes of
this Section 14.6, “Detrimental Activity” shall include: (i) the
rendering of services, directly or indirectly, to or for the benefit of any
organization or engaging directly or indirectly in any business which is
competitive with the Company, or which organization or business, or the
rendering of services to or for the benefit of such organization, is prejudicial
to or in conflict with the interests of the Company; (ii) the disclosure to
anyone outside the Company, or the use in other than the Company’s business,
without prior written authorization from the Company, of any “confidential
information,” as defined in the Company’s Employee Handbook, acquired by the
Participant either during or after employment with the Company; (iii) the
failure or refusal to disclose promptly and to assign exclusively to the
Company, all right title and interest in any invention or idea, patentable
or
not, made or conceived by the Participant during employment with the Company,
relating in any manner to the actual or anticipated business, research or
development work of the Company or the failure or refusal to do anything
reasonably necessary to enable the Company to secure a patent where appropriate
in the United States and in other countries; (iv) a violation of any rule,
policy, procedure or guideline of the Company, including but not limited to
the
Company’s Code of Conduct; (v) any attempt, directly or indirectly, to
induce any employee of the Company to be employed or render services other
than
for the Company, or any attempt directly or indirectly to solicit the trade
or
business of any current or prospective customer, supplier, or partner of the
Company, other than in connection with the Company’s business; (vi) the
Participant being convicted of, or entering a guilty plea with respect to a
crime, whether or not connected with the Company; (vii) any other conduct
or act determined to be injurious, detrimental or prejudicial to any interest
of
the Company or (viii) any agreement, whether or not in writing, to do any
of the foregoing. Upon exercise, payment or delivery pursuant to an Award,
the
Participant may be required to certify, in a manner acceptable to the Committee,
that he or she is in compliance with all of the terms and conditions of the
Plan
and is not and has not engaged in any Detrimental Activity. In the event a
Participant fails to comply with the provisions of this Section 14.6 after
the grant of the Award and prior to, or during the six months after any
exercise, payment or delivery pursuant to an Award, such exercise, payment
or
delivery may be rescinded within two years thereafter. In the event of any
such
rescission, the Participant shall pay to the Company the amount of any gain
realized or payment received as a result of the rescinded exercise, payment
or
delivery, in such manner and on such terms and conditions as may be required,
and the Company shall be entitled to set-off against the amount of any such
gain
any amount owed to the Participant by the Company.
15.
TAXES
15.1.
Withholding
Taxes
.
With
respect to Employees, the Company, or the applicable Subsidiary, may require
a
Participant whose Stock Award, Stock Unit, Performance Share or Performance
Unit
granted hereunder has Vested, or who exercises a Stock Option or SAR granted
hereunder to reimburse the Company or the Subsidiary which employs such
Participant for any taxes required by any governmental regulatory authority
to
be withheld or otherwise deducted and paid by such corporation or entity in
respect of the issuance or disposition of such shares or the payment of any
amounts. In lieu thereof, the Company or the Subsidiary which employs such
Participant, shall have the right to withhold the amount of such taxes from
any
other sums due or to become due from the Company or the Subsidiary, as
applicable, to the Participant upon such terms and conditions as the Committee
shall in its sole discretion prescribe. The Company or the Subsidiary that
employs such Participant may, in its discretion, hold the stock certificate
to
which such Participant is entitled upon the Vesting of a Stock Award, Stock
Unit, Performance Share or Performance Unit or the exercise of a Stock Option
or
SAR as security for the payment of such withholding
tax
liability, until cash sufficient to pay that liability has been accumulated
by
or paid to the Company or such Subsidiary.
15.2.
Use
of Common Stock to Satisfy Withholding Obligation
.
With
respect to Employees, at any time that the Company, Subsidiary or other entity
that employs such Participant becomes subject to a withholding obligation under
applicable law with respect to the vesting of a Stock Award, Stock Unit,
Performance Share or Performance Unit or the exercise of a Nonqualified Stock
Option (the “Tax Date”), except as set forth below, a holder of such Award may,
subject to the approval of the Committee, elect to satisfy, in whole or in
part,
the holder’s related personal tax liabilities (an “Election”) by
(i) directing the Company, Subsidiary or other entity that employs such
Participant to withhold from shares issuable in the related vesting or exercise
either a specified number of shares or shares of Common Stock having a specified
value (in each case equal to the related minimum statutory personal withholding
tax liabilities with respect to the applicable taxing jurisdiction in order
to
comply with the requirements for a “fixed plan” under Accounting Principals
Board Opinion No. 25), (ii) tendering shares of Common Stock or other
securities of the Company previously issued pursuant to the exercise of a Stock
Option or other shares of the Common Stock owned by the holder, or
(iii) combining any or all of the foregoing Elections in any fashion. The
foregoing notwithstanding, however, when previously issued shares of Common
Stock or other securities of the Company are tendered pursuant to an Election,
such tender of shares will not be accepted unless the Participant has held
such
shares for the requisite period necessary to avoid a charge to the Company’s
earnings for financial reporting purposes. An Election shall be irrevocable.
The
withheld shares and other shares of Common Stock or other securities tendered
in
payment shall be valued at their Fair Market Value on the Tax Date. The
Committee may in its sole discretion disapprove of any Election, suspend or
terminate the right to make Elections or provide that the right to make
Elections shall not apply to particular shares or exercises. The Committee
may
impose any additional conditions or restrictions on the right to make an
Election as it shall deem appropriate, including conditions or restrictions
with
respect to Section 16 of the Exchange Act.
15.3.
No
Guarantee of Tax Consequences
.
No
Person connected with the Plan in any capacity, including, but not limited
to,
the Company and any Subsidiary and their respective directors, officers, agents
and employees makes any representation, commitment, or guarantee that any tax
treatment, including, but not limited to, federal, state and local income,
estate and gift tax treatment, will be applicable with respect to amounts
deferred under the Plan, or paid to or for the benefit of a Participant under
the Plan, or that such tax treatment will apply to or be available to a
Participant on account of participation in the Plan.
16.
AMENDMENT AND TERMINATION
16.1.
Termination
of Plan
.
The
Board or the Committee may suspend or terminate the Plan at any time with or
without prior notice; provided, however, that no action authorized by this
Section 16.1 shall reduce the amount of any outstanding Award or adversely
change the terms and conditions thereof without the Participant’s consent.
16.2.
Amendment
of Plan
.
Provided that no amendment may adversely affect the rights of any Participant
under any outstanding Award without the Participant’s consent; and, provided
further, that no such amendment shall be effective without shareholder approval
if such approval is required to comply with any applicable law or the rules
of
any national securities exchange or other market system on which the Company’s
securities are then listed or traded; and, provided further, that the Board
or
the Committee may not, without shareholder approval, increase the maximum number
of shares issuable under the Plan, the Board or the Committee may amend the
Plan
at any time with or without prior notice. Notwithstanding any provision herein
to the contrary, the Board or the Committee shall have broad authority to amend
the Plan or any Award to take into account changes in applicable tax laws,
securities laws, accounting rules and other applicable state and federal laws.
16.3.
Amendment
or Cancellation of Award Agreements
.
Without
limitation to the rights of the Committee under Sections 4.3 and 14.6 of
the Plan, the Committee may amend or modify any Award Agreement at any time
by
mutual agreement between the Committee and the Participant or such other Persons
as may then have an interest therein. In addition, by mutual agreement between
the Committee and a Participant or such other Persons as may then have an
interest therein, Awards may be granted to an Employee, Nonemployee Director
or
Independent Contractor in substitution and exchange for, and in cancellation
of,
any Awards previously granted to such Employee, Nonemployee Director or
Independent Contractor under the Plan, or any award previously
granted
to
such
Employee, Nonemployee Director or Independent Contractor under any other present
or future plan of the Company or any present or future plan of an entity which
(i) is purchased by the Company, (ii) purchases the Company, or
(iii) merges into or with the Company.
17.
MISCELLANEOUS
17.1.
Other
Provisions
.
Awards
granted under the Plan may also be subject to such other provisions (whether
or
not applicable to the Award granted to any other Participant) as the Committee
determines in its sole discretion on the date of grant to be appropriate,
including, without limitation, for the installment purchase of Common Stock
under Stock Options, to assist the Participant in financing the acquisition
of
Common Stock, for the forfeiture of, or restrictions on resale or other
disposition of, Common Stock acquired under any Stock Option, for the
acceleration of Vesting of Awards in the event of a Change in Control of the
Company, for the payment of the value of Awards to Participants in the event
of
a Change in Control of the Company, or to comply with federal and state
securities laws, or understandings or conditions as to the Participant’s
employment in addition to those specifically provided for under the Plan.
17.2.
Transferability
.
Each
Award granted under the Plan to a Participant shall not be transferable
otherwise than by will or the laws of descent and distribution or pursuant
to a
“qualified domestic relations order” as defined in the Code or Title I of
the Employee Retirement Income Security Act of 1974, as amended, and the rules
and regulations adopted thereunder and Stock Options and SARs shall be
exercisable, during the Participant’s lifetime, only by the Participant;
provided, however, that the Committee may in its sole discretion permit the
transfer of an Award to a Participant’s Family Members or to one or more trusts
established in whole or in part for the benefit of one or more such Family
Members In the event of the death of a Participant, each Stock Option or SAR
theretofore granted to him or her shall be exercisable during such period after
his or her death as the Committee shall, in its sole discretion, set forth
in
the Award Agreement on the date of grant and then only by the executor or
administrator of the estate of the deceased Participant or the Person or Persons
to whom the deceased Participant’s rights under the Stock Option or SAR shall
pass by will or the laws of descent and distribution.
17.3.
Election
to Defer Compensation Attributable to Award
.
The
Committee may, in its sole discretion, allow a Participant to elect to defer
the
receipt of any compensation attributable to an Award under guidelines and
procedures to be established by the Committee after taking into account the
advice of the Company’s tax counsel.
17.4.
Listing
of Shares and Related Matters
.
If at
any time the Committee shall determine that the listing, registration or
qualification of the shares of Common Stock subject to any Award on any
securities exchange or under any applicable law, or the consent or approval
of
any governmental regulatory authority, is necessary or desirable as a condition
of, or in connection with, the granting of an Award or the issuance of shares
of
Common Stock thereunder, such Award may not be exercised, distributed or paid
out, as the case may be, in whole or in part, unless such listing, registration,
qualification, consent or approval shall have been effected or obtained free
of
any conditions not acceptable to the Committee. The Committee may require each
Participant purchasing or acquiring shares of Common Stock pursuant to a Stock
Option or other Award under the Plan to represent to and agree with the Company
in writing that such Participant is acquiring the shares for investment and
not
with a view to the distribution thereof. All certificates for shares of Common
Stock delivered under the Plan shall be subject to such stock-transfer orders
and other restrictions as the Committee may deem advisable under the rules,
regulations, and other requirements of the Securities and Exchange Commission
or
any national securities exchange or other market system on which the Company’s
securities are listed or traded, and any applicable federal or state securities
law, and the Committee may cause a legend or legends to be put on any such
certificates to make appropriate reference to such restrictions.
17.5.
No
Right, Title, or Interest in Company Assets
.
Participants shall have no right, title, or interest whatsoever in or to any
investments which the Company may make to aid it in meeting its obligations
under the Plan. Nothing contained in the Plan, and no action taken pursuant
to
its provisions, shall create or be construed to create a trust of any kind,
or a
fiduciary relationship between the Company and any Participant, beneficiary,
legal representative or any other Person. The Plan is intended to constitute
an
unfunded plan for incentive compensation. To the extent that any Person acquires
a right to receive payments from the Company under the Plan, such right shall
be
no greater than the right of an unsecured general creditor of the Company.
All
payments to be made hereunder
shall
be
paid from the general funds of the Company and no special or separate fund
shall
be established and no segregation of assets shall be made to assure payment
of
such amounts except as expressly set forth in the Plan. The Plan is not intended
to be subject to the Employee Retirement Income Security Act of 1974, as
amended.
17.6.
No
Right to Continued Employment or Service or to Grants
.
The
Participant’s rights, if any, to continue to serve the Company as a director,
officer, employee, independent contractor or otherwise, shall not be enlarged
or
otherwise affected by his or her designation as a Participant under the Plan,
and the Company or the applicable Subsidiary reserves the right to terminate
the
employment of any Employee or the services of any Independent Contractor or
director at any time. The adoption of the Plan shall not be deemed to give
any
Employee, Nonemployee Director, Independent Contractor or any other individual
any right to be selected as a Participant or to be granted an Award.
17.7.
Awards
Subject to Foreign Laws
.
The
Committee may grant Awards to individual Participants who are subject to the
tax
laws of nations other than the United States, and such Awards may have terms
and
conditions as determined by the Committee as necessary to comply with applicable
foreign laws. The Committee may take any action, which it deems advisable to
obtain approval of such Awards by the appropriate foreign governmental entity;
provided, however, that no such Awards may be granted pursuant to this
Section 17.7 and no action may be taken which would result in a violation
of the Exchange Act or any other applicable law.
17.8.
Governing
Law
.
The
Plan, all Awards granted hereunder, and all actions taken in connection herewith
shall be governed by and construed in accordance with the laws of the State
of
Florida without reference to principles of conflict of laws, except as
superseded by applicable federal law or as otherwise provided in any Award
Agreement.
17.9.
Other
Benefits
.
No
Award granted under the Plan shall be considered compensation for purposes
of
computing benefits under any retirement plan of the Company or any Subsidiary
nor affect any benefits or compensation under any other benefit or compensation
plan of the Company or any Subsidiary now or subsequently in effect.
17.10.
No
Fractional Shares
.
No
fractional shares of Common Stock shall be issued or delivered pursuant to
the
Plan or any Award. The Committee shall determine in its sole discretion whether
cash, Common Stock, Stock Options, or other property shall be issued or paid
in
lieu of fractional shares or whether such fractional shares or any rights
thereto shall be forfeited or otherwise eliminated.
17.11.
Authority
of the Company and Shareholders
.
The
existence of the Plan, the Award Agreements and the Awards granted hereunder
shall not affect or restrict in any way the right or power of the Company or
the
shareholders of the Company to make or authorize any adjustment,
recapitalization, reorganization or other change in the Company’s capital
structure or its business, any merger or consolidation of the Company, any
issue
of stock or of options, warrants or rights to purchase stock or of bonds,
debentures, preferred or prior preference stocks whose rights are superior
to or
affect the Common Stock or the rights thereof or which are convertible into
or
exchangeable for Common Stock, or the dissolution or liquidation of the Company,
or any sale or transfer of all or any part of its assets or business, or any
other corporate act or proceeding, whether of a similar character or otherwise.
17.12.
Other
Compensation Plans
.
The
adoption of the Plan shall not affect any other stock option, incentive or
other
compensation plans in effect for the Company or any Subsidiary, nor shall the
plan preclude the Company from establishing any other forms of incentive or
other compensation for Employees and Nonemployee Directors of the Company or
any
Subsidiary.
Exhibit
21
SUBSIDIARIES
OF OPKO HEALTH, INC.
NAME
|
|
JURISDICTION
OF INCORPORATION
|
OPKO
Instrumentation, LLC
|
|
Delaware
|
OPKO
Ophthalmics, LLC
|
|
Delaware
|
Froptix
LLC
|
|
Florida
|
Ophthalmics
Technology, Inc.
|
|
Ontario,
Canada
|
Exhibit
23.1
Consent
of Independent Registered Public Accounting Firm
We
consent to the incorporation by reference in the Registration Statement (Form
S-8 No. 333-144040) pertaining to the OPKO Health, Inc. 2007 Equity Incentive
Plan of our report dated March 28, 2008, with respect to the consolidated
financial statements of OPKO Health, Inc. in this Annual Report (Form 10-K)
for
the year ended December 31, 2007.
|
|
|
|
|
/s/
Ernst & Young LLP
|
|
Certified
Public Accountants
|
Miami,
Florida
March
28,
2008
Exhibit
31.1
I,
Phillip Frost, certify that:
|
(1)
|
I
have reviewed this Annual Report on Form 10-K of OPKO Health, Inc.;
|
|
(2)
|
Based
on my knowledge, this report does not contain any untrue statement
of a
material fact or omit to state a material fact necessary to make
the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this
report;
|
|
(3)
|
Based
on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects
the
financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report;
|
|
(4)
|
The
registrant's other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
|
|
(a)
|
Designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure
that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is
being
prepared;
|
|
(b)
|
Designed
such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision,
to
provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
|
|
(c)
|
Evaluated
the effectiveness of the registrant's disclosure controls and procedures
and presented in this report our conclusions about the effectiveness
of
the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation;
and
|
|
(d)
|
(d)
Disclosed
in this report any change in the registrant's internal control over
financial reporting that occurred during the registrant's most recent
fiscal quarter (the registrant's fourth fiscal quarter in the case
of an
annual report) that has materially affected, or is reasonably likely
to
materially affect, the registrant's internal control over financial
reporting; and
|
|
(5)
|
The
registrant's other certifying officer(s) and I have disclosed, based
on
our most recent evaluation of internal control over financial reporting,
to the registrant's auditors and the audit committee of the registrant's
board of directors (or persons performing the equivalent functions):
|
|
(a)
|
All
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to
record,
process, summarize and report financial information; and
|
|
(b)
|
Any
fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
control
over financial reporting.
|
|
|
|
Date: March 31, 2008
|
|
/s/
Phillip Frost
|
|
Phillip
Frost, M.D.
|
Exhibit
31.2
CERTIFICATIONS
I,
Rao
Uppaluri, certify that:
|
(1)
|
I
have reviewed this Annual Report on Form 10-K of OPKO Health, Inc.;
|
|
(2)
|
Based
on my knowledge, this report does not contain any untrue statement
of a
material fact or omit to state a material fact necessary to make
the
statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this
report;
|
|
(3)
|
Based
on my knowledge, the financial statements, and other financial information
included in this report, fairly present in all material respects
the
financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report;
|
|
(4)
|
The
registrant's other certifying officer(s) and I are responsible for
establishing and maintaining disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules
13a-15(f) and 15d-15(f)) for the registrant and have:
|
|
(a)
|
Designed
such disclosure controls and procedures, or caused such disclosure
controls and procedures to be designed under our supervision, to
ensure
that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is
being
prepared;
|
|
(b)
|
Designed
such internal control over financial reporting, or caused such internal
control over financial reporting to be designed under our supervision,
to
provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles;
|
|
(c)
|
Evaluated
the effectiveness of the registrant's disclosure controls and procedures
and presented in this report our conclusions about the effectiveness
of
the disclosure controls and procedures, as of the end of the period
covered by this report based on such evaluation;
and
|
|
(d)
|
(d)
Disclosed
in this report any change in the registrant's internal control over
financial reporting that occurred during the registrant's most recent
fiscal quarter (the registrant's fourth fiscal quarter in the case
of an
annual report) that has materially affected, or is reasonably likely
to
materially affect, the registrant's internal control over financial
reporting; and
|
|
(5)
|
The
registrant's other certifying officer(s) and I have disclosed, based
on
our most recent evaluation of internal control over financial reporting,
to the registrant's auditors and the audit committee of the registrant's
board of directors (or persons performing the equivalent functions):
|
|
(a)
|
All
significant deficiencies and material weaknesses in the design or
operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant's ability to
record,
process, summarize and report financial information; and
|
|
(c)
|
Any
fraud, whether or not material, that involves management or other
employees who have a significant role in the registrant's internal
control
over financial reporting.
|
|
|
|
Date: March 31, 2008
|
|
/s/
Rao Uppaluri
|
|
Rao
Uppaluri
Chief
Executive Officer
|
Exhibit
32.1
CERTIFICATION
PURSUANT TO
18
U.S.C. SECTION 1350,
AS
ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the Annual Report of OPKO Health, Inc. (the “Company”) on Form
10-K for the year ending December 31, 2007 (the “Report”), and pursuant to
pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley
Act of 2002, I, Phillip Frost, Chief Executive Officer of the Company, certify
that to the best of my knowledge:
|
(1)
|
The
Report fully complies with the requirements of section 13(a) or 15(d)
of
the Securities Exchange Act of 1934; and
|
|
(2)
|
The
information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the
Company.
|
|
|
|
|
|
/s/
Phillip Frost
|
|
Phillip
Frost, M.D.
Chief
Executive Officer
March
31, 2008
|
Exhibit
32.2
CERTIFICATION
PURSUANT TO
18
U.S.C. SECTION 1350,
AS
ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the Annual Report of OPKO Health, Inc. (the “Company”) on Form
10-K for the year ending December 31, 2007 (the “Report”), and pursuant to
pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley
Act of 2002, I, Rao Uppaluri, Chief Financial Officer of the Company, certify
that to the best of my knowledge:
|
(1)
|
The
Report fully complies with the requirements of section 13(a) or 15(d)
of
the Securities Exchange Act of 1934; and
|
|
(2)
|
The
information contained in the Report fairly presents, in all material
respects, the financial condition and result of operations of the
Company.
|
|
|
|
|
|
|
|
Rao
Uppaluri
Chief
Financial Officer
March
31, 2008
|